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Abstract 
Extracellular signal-regulated kinase 5 (ERK5) is a member of the protein kinase 
superfamily, which plays an essential role in the transduction of extracellular signals to 
intracellular effectors. Activation of the ERK5 signalling pathway is associated with cell 
survival, proliferation, and differentiation, and thus ERK5 over-expression may have 
implications in carcinogenesis. Therefore, the discovery and development of small molecule 
inhibitors of ERK5 may offer a novel therapeutic intervention for cancer. 
High throughput screening (HTS) of chemical libraries, conducted by Cancer Research 
Technology, revealed three distinct chemical series as moderate inhibitors of ERK5. Two of 
these series are described herein i.e.: 3-cyanopyridines (IC50 = 0.5 – 31.3 µM); and pyrrole-
carboxamides (IC50 = 0.66 – 3.5 µM). 
Two 3-cyanopyridine based hits (2-(2-((3-cyano-4-(4-fluorophenyl)-6-phenylpyridin-2-
yl)thio)acetamido)acetic acid, 68 and 2-((3-cyano-4-(4-fluorophenyl)-6-phenylpyridin-2-
yl)thio)-N-(2-oxopropyl)acetamide, 67; IC50 values = 1.6 and 0.5 µM, respectively) were 
resynthesised and were slightly less active at 4.9 and 20.5 µM. The 3-cyanopyridine scaffold 
was deemed a valid starting point for initiating structure activity relationship (SAR) studies. 
Three areas were identified for further investigation i.e.: modification to the thioether side-
chain; modification to the aryl substituent; and isosteric replacement of the 3-cyano motif. 
Structure-activity studies did not result in improved potency over the initial hits.  
 
Previously, the pyrrole-carboxamide series has been validated successfully. Hit-to-lead 
studies around the aroyl ring highlighted the importance of substitution pattern for potency, 
with 2,6-difluoro (or 2,3-dichloro) substituents conferring the greatest potency (4-(2,6-
difluorobenzoyl)-N-(pyridin-4-ylmethyl)-1H-pyrrole-2-carboxamide, 144; IC50 = 2.3 µM) 
initially. Truncation of the carboxamide side-chain resulted in improved activity (IC50 = 0.9 
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µM) and crucially, ≥100-fold selectivity for ERK5 over the closely related kinase p38α was 
also achieved e.g. 4-(2,6-difluorobenzoyl)-N-(pyridin-4-yl)-1H-pyrrole-2-carboxamide, 256.. 
Tuning of the aroyl substituents and pyridyl groups resulted in discovery of 4-(2-bromo-6-
fluorobenzoyl)-N-(pyridin-3-yl)-1H-pyrrole-2-carboxamide, 278 a potent and selective ERK5 
inhibitor with excellent drug-like properties (i.e.: MW = 388; cLogP = 3.2; LE = 0.35; 
Aqueous solubility = >100 µM; PPB = 94%). Preliminary in vivo studies of lead compound 
4-(2-bromo-6-fluorobenzoyl)-N-(pyridin-3-yl)-1H-pyrrole-2-carboxamide have confirmed 
efficacy in xenograft tumour models, and satisfactory pharmacokinetic properties in mice. 
The pyrrole-carboxamide series has now entered the lead optimisation phase of drug 
discovery, focussing on improvement of cellular activity, and eliminating CYP inhibition, 
with the aim of providing compounds with suitable potency and properties for clinical trials. 
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Chapter 1: Overview of Modern Chemotherapy 
1.1 Introduction to Cancer 
Cancer is an illness characterized by the uncontrolled growth of cells in the body, as a result 
of mutation in one or more genes. Cells which are free from the usual constraints of 
proliferation, growth and apoptosis arise through a variety of factors; through complex 
biological mechanisms, as a result of genetic malfunctions.
1
 In 2009, approximately 320,500 
new cases of cancer were diagnosed in the UK.
2
 There are over 200 classifications of cancer, 
with breast, lung, colorectal and prostate cancers accounting for 54% of newly diagnosed 
cases each year (Figure 1). Advances in cancer research and the development of new 
treatments have enabled the ten year survival rate to double over the past thirty years. 
Overall, cancer survival statistics are improving, with around half of people diagnosed with 
cancer passing the five year survival point, and the cancer death rate has fallen by 10% over 
the last decade overall in the UK.
3
 Despite this improvement, there are still a number of 
specific cancers where the survival rate is particularly low, and therefore on-going research 
into new effective chemotherapeutic agents is essential in this disease area.  
 
Figure 1: The 20 most commonly diagnosed cancers (excluding non-melanoma skin cancer) 
in the UK, 2009. * Bowel cancer including anal cancer; ** 4% of female cancers and 3% of male cancers are 
registered without specification of the primary site. From ref 
4
. 
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1.2 The History of Chemotherapy 
Until the 1960s the most common treatments for cancer were surgery and radiotherapy, but 
development of untraced metastases from the primary tumour  meant that the overall cure rate 
was low (33%) following local treatments.
5
 The twentieth century saw the beginning of drug 
development for the treatment of cancer. Investigation into the use of nitrogen mustards 
began following World War 2, following the observation that levels of bone marrow and 
lymph tissue were significantly reduced in men who had been exposed to the toxic gases. 
Pioneering treatment of patients suffering from lymphoma revealed that clinical use of 
nitrogen mustards was an effective treatment for the disease. Based on this research, DNA 
alkylating agents such as chlorambucil, 1 were developed.
5
 In 1948, Farber et al described 
the effects of administering folic acid to children with acute lymphoblastic leukaemia (ALL). 
The observed effect was acceleration of the disease. Farber postulated that ALL may 
therefore be treated using an antagonist of folic acid, aminopterin, which would eventually 
lead to the discovery of methotrexate, 2.
6
 Methotrexate is known to act as an inhibitor of 
dihydrofolate reductase (DHFR), an enzyme involved in the biosynthesis of folic acid. Folic 
acid is required for biosynthesis of thymidine, and therefore the synthesis of DNA. The anti-
folate chemotherapeutic agents were some of the first examples of rationally designed anti-
cancer drugs used in the clinic.
5
 These early discoveries led to the belief that cancer could be 
treated and ultimately cured using synthetically created compounds. 
               
              Chlorambucil, 1                                                 Methotrexate, 2 
1.3 Targeted Drug Discovery 
Until recently, drug discovery for new cancer therapeutics largely centred on the 
development of inhibitors of DNA synthesis, DNA-alkylating agents and anti-metabolites. 
Although efficacious, these drug classes suffered from severe toxicity profiles due to lack of 
selectivity for cancer cells over normal tissue.
7
 The notion of targeted drug discovery was 
first described in 1874, when P. Ehrlich hypothesised that the differences between 
chemoreceptors on microorganisms and cancer cells to those of healthy tissues could be 
22 
 
exploited therapeutically.
8
 Despite this, it would take another 100 years for targeted drug 
discovery to come into practice in cancer treatment. It was not until the early 1980’s, when 
the practice of targeted drug discovery became more prolific, driven by the discovery of 
oncogenes. One of the first targeted agents to be identified was tamoxifen, 3 approved in 
1977 for patients with advanced breast cancer. At the time of its discovery, tamoxifen was 
not acclaimed as a breakthrough drug, as enthusiasm for cytotoxic chemotherapy was still 
prevalent.
9
 The role of oestrogens in the development of breast cancer is well established; 
tamoxifen acts as an antagonist of the oestrogen receptor, preventing oestrogenic signalling. 
Tamoxifen has since become the ‘gold standard’ of care for the treatment of advanced breast 
cancers which are positive for the oestrogen receptor.
9
 Following the success of tamoxifen for 
the treatment of female oestrogen dependent cancer, came the launch of bicalutamide, 4 
(Casodex) in 1995. The use of anti-androgens for the treatment of advanced prostate cancer is 
discussed in further detail in Section 3.1.3. 
                                     
              Tamoxifen, 3                       Bicalutamide, 4 
The development of kinase inhibitors has become a prevalent therapeutic area since the 
discovery of the Bcr-Abl oncogene, which encodes a constitutively active tyrosine kinase in 
patients with chronic myelogenous leukaemia (CML).
7
 The discovery of this oncogene 
ultimately led to the successful development of imatinib, 5 (Glivec), launched in 2005 for the 
treatment for patients with CML. This ground-breaking drug proved that it is possible to 
develop rationally designed, targeted therapeutic agents for the treatment of cancer, where a 
specific oncogene has been implicated in the onset and progression of the disease.
7
 
 
Imatinib, 5 
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1.4 Modern Drug Development 
The modern drug discovery process typically follows the scheme outlined in Figure 2. High-
throughput screening (HTS) of compound collections is used to identify ‘hits’ showing good 
to moderate activity against the biological target. Following hit validation, hit-to-lead studies 
establish structure-activity relationships (SARs) with respect to potency. Physicochemical 
properties, synthetic tractability, selectivity for the target and freedom of intellectual property 
are also considered at this stage. Christopher Lipinski formulated the ‘rule of five’ in 1997, 
setting out distinct physicochemical properties required for the development of an orally 
bioavailable drug. Poor in vivo absorption and/or permeation properties are expected for 
small molecule drugs when one or more of Lipinski’s criteria are not met. A molecular 
weight greater than 500, a logP above 5, and more than 5 H-bond donors/more than 10 H-
bond acceptors present in a molecule are all undesirable features, when considering oral 
bioavailability of a drug.
10
 Since Lipinski’s computational approach to rational drug design 
was first published, early assessment of several other parameters have become commonplace 
in the medicinal chemistry setting. For example topological polar surface area (TPSA) is 
frequently considered, a factor affecting cell permeation. Typically a TPSA below 140Å
2
 is 
required for adequate cell penetration by a compound.
11
 Potent and selective compounds are 
assessed using a range of in vitro ADMET (absorption, distribution, metabolism, elimination, 
toxicology) assays, and successful fulfilment of criteria results in progression to the lead 
optimisation stage of development. Ideally, management of drug absorption, metabolic 
liability and toxicology profile by tuning physicochemical properties should be achieved in 
the hit-to-lead stage. Table 1 summarises the ADMET in vitro techniques typically utilised on 
a drug discovery project, and are currently being used in hit-to-lead assessment of ERK5 
inhibitors.  
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Table 1: Summary of common ADMET in vitro techniques utilised in a drug discovery 
project 
In Vitro Technique Rationale 
Turbidimetric solubility assay 
Aqueous solubility is an important factor 
influencing GI tract absorption and therefore 
oral bioavailability. 
Plasma protein binding (PPB) assay 
The extent of binding to plasma proteins 
influences the degree of drug distribution. 
Extensive PPB also limits the amount of free 
drug, affecting efficacy. 
Microsomal clearance assay 
Gives an estimation of intrinsic clearance, by 
assessing microsomal stability. Excessive 
clearance indicates a high level of 
metabolism by CYP enzymes. 
Caco-2 permeability assay 
Predicts in vivo absorption by measuring the 
rate of transport of drug across the Caco-2 
cell line. Measurement of transport in both 
directions across the cell membrane allows 
measurement of an efflux ratio. A high ratio 
suggests compounds are a substrate for the P-
glycoprotein (P-gp) efflux pump. 
CYP inhibition assay 
Compounds which inhibit CYP isoforms are 
liable to cause drug-drug interactions, by 
preventing the clearance of other compounds. 
This may lead to adverse reactions or 
toxicity. 
hERG inhibition assay 
Inhibition of the hERG current across a 
voltage gated potassium channel in the heart 
causes QT interval prolongation and is 
associated with cardiotoxicity. 
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During lead optimisation, proof-of-concept (POC) studies in a preclinical disease model are 
initiated, which confirm drug efficacy. Optimisation of in vivo drug properties is also 
performed. The predictive in vitro tools outlined in Table 1 minimise the risk of progressing 
compounds which will ultimately fail. However, it is impossible to guarantee success due to 
the complex nature of biological systems. Assessment of DMPK properties (in vivo 
clearance, volume of distribution, bioavailability and half-life) is often performed in mouse or 
rat models in the lead optimisation stage. Medicinal chemistry plays a crucial role in three 
stages of drug discovery; hit validation, hit-to-lead, lead optimisation, prior to candidate 
selection, preclinical development and ultimately, clinical trials. 
 
Figure 2: The drug discovery regime. From ref 
12
. 
1.5 The Role of Protein Kinases  
Protein kinases are one of the largest superfamilies of homologous genes, encoding proteins 
sharing common structural features. There are currently 518 known members, many of which 
whose structures have been elucidated. Protein kinases are structurally related and 
categorized by their catalytic domains which consist of approximately 250-300 amino acids. 
Two main subdivisions exist; protein-tyrosine kinases, and protein-serine/threonine kinases 
of which ERK5 is a member. A third category exists which displays dual functionality, with 
the ability to phosphorylate all three residues. The characteristic activity and specificity of 
26 
 
kinase activation/inhibition arises from the unique pockets which surround the catalytic 
domain. 
Protein kinases transfer the γ-phosphate group of a purine nucleotide triphosphate, usually 
adenosine triphosphate (ATP), to the hydroxyl groups of selected amino acid residues of their 
protein substrates (Figure 3).
13
 Phosphorylation of the substrate results in a functional change, 
such as onset of enzyme activity. This enables transduction of biochemical signals through 
the cell. Receptor kinases contain intracellular protein kinase domains which are linked 
covalently to the ligand binding domain. Upon high affinity binding of a ligand to the 
receptor ligand binding domain, dimerisation occurs which in turn activates the protein 
kinase catalytic domain within the cell. A phosphorylation cascade ensues resulting in signal 
transduction to kinases which control complex cellular processes including progression 
through the cell cycle.
13
 Protein kinases are, therefore, interesting targets for drug discovery, 
due to the presence of mutations or overexpression in kinase signal transduction pathways 
resulting in the onset and progression of several cancers. There are currently a number of 
kinase inhibitors in clinical use for the treatment of several types of human tumours, 
including imatinib, 5. 
 
Figure 3: Phosphorylation of a protein substrate (where R = Serine, Threonine or Tyrosine) 
by a protein kinase. 
1.6 Kinase Inhibitors in the Clinic for the Treatment of Cancer 
Imatinib, 5 was licenced for the treatment of CML in 2001. CML is characterized by 
reciprocal translocation of genetic material from chromosomes 9 and 22. This results in the 
production of a fused Bcr-Abl oncogenic protein which results in unregulated cell 
proliferation and apoptosis as it lacks the auto-inhibition properties of wild-type Abl protein. 
27 
 
Imatinib is a potent ATP competitive inhibitor of the Abl protein kinase and thus is an 
effective treatment for CML. This drug also has applications in treating gastrointestinal 
stromal tumour (GIST) as it was also found to be an inhibitor of c-Kit. Levels of c-kit are 
elevated in GIST due to genetic mutations.
14
 Since the discovery of imatinib, several 
subsequent kinase inhibitors have been developed and licenced for use in various cancer 
types (Table 2).  
Table 2: Licensed kinase inhibitors for the treatment of cancer 
Name Structure 
Year of 
Approval 
Target Clinical Use 
Imatinib, 5 
(Glivec) 
 
2001
15
 
Bcr-Abl 
fusion 
CML, 
GIST
15
 
Gefitinib, 6 
(Iressa) 
 
2003
15
 
EGFR-
TK 
Non-small 
cell lung 
cancer 
(NSCLC)
15
 
Sorafenib,7 
(Nexavar) 
 
2005
15
 
Raf1 
(Multi-
kinase 
inhibitor) 
Renal cell 
carcinoma 
(RCC), 
hepato-
cellular 
carcinoma 
(HCC)
15
 
Sunitinib, 8 
(Sutent) 
 
2006
15
 
Multi-
kinase 
inhibitor 
 RCC, 
imatinib 
resistant 
GIST
15
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Erlotinib, 9 
(Tarceva) 
 
2010
16
 
EGFR-
TK 
Metastatic 
NSCLC
17
 
Dasatinib, 10 
(Sprycel) 
 
2010
18
 
Bcr-Abl 
fusion 
(Multi-
kinase 
inhibitor) 
CML
18
 
Nilotinib, 11 
(Tasigna) 
 
2010
18
 
Bcr-Abl 
fusion 
(Multi-
kinase 
inhibitor) 
CML
18
 
Vandetanib, 
12 
(Caprelsa) 
 
2011
16
 
VEGFR/
EGFR 
Medullary 
thyroid 
cancer
19
 
Vemurafenib, 
13 
(Zelboraf) 
 
2012
18
 
BRaf 
V600E 
Malignant 
melanoma
18
 
Crizotinib, 14 
(Xalkori) 
 
2012 (USA) 
Expected 
2013 
(UK)
18
 
ALK NSCLC
18
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The development of resistance to kinase inhibitors has been reported in the clinic. Gefitinib, 
6, an inhibitor of the epidermal growth factor receptor tyrosine kinase (EGFR-TK) was 
initially found to produce a dramatic response in patients suffering from non-small cell lung 
cancer (NSCLC). However, despite the initial success of the drug, the majority of tumours 
become drug-resistant over the course of treatment. Patients whose tumours initially respond 
to treatment with gefitinib or erlotinib, 9 typically develop resistance within 12 months. 
 In the case of EGFR-TK inhibitors, over 50% of resistant forms of NSCLC contain a single 
secondary mutation in the EGFR, with substitution of a methionine residue at position 790 
for threonine (T790M).
20, 21
 The replacement of the gatekeeper threonine residue has a 
profound effect on small-molecule binding, as it is this residue which typically allows access 
to a lipophilic pocket within the ATP binding site in protein kinases. The development of 
second generation kinase inhibitors which target the T790M variant of the EGFR-TK is in 
progress, for the treatment of patients which no longer respond to gefitinib or erlotinib 
treatment. Canertinib, 15, acts as an irreversible inhibitor of wild type EGFR and EGFR
T790M
 
with in vitro activities of 0.3 and 26.0 nM respectively. In contrast, gefitinib also inhibits wt-
EGFR with an in vitro IC50 of 0.3 nM, but activity is significantly diminished (IC50 = 1013 
nM) in the T790M mutant.
22
 Canertinib is currently being evaluated in Phase II clinical trials. 
 
Canertinib, 15 
Identification of a novel mutation (V600E) in BRaf present in human tumours including 
malignant melanoma has recently led to the development of vemurafenib, 13, which shows 
significant anti-tumour effects in cell lines possessing the V600E mutation, but is inactive in 
wild type BRaf cells.
23
 The ability of cancer cell lines to acquire drug resistance via 
secondary mutations, and the marked effect on drug efficacy as a result of single point 
mutation highlights the necessity for continued genomic investigation and drug discovery for 
the development of new therapeutic agents. 
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Chapter 2: Mitogen-Activated Protein Kinases and Their Role in Cancer 
2.1 Overview of the MAPK Pathways 
The complex process of signal transduction in eukaryotes is mediated via a number of 
pathways. These kinases are responsible for the conversion of extracellular signals to cellular 
responses. Mitogen-activated protein kinase (MAPK) pathways typically consist of a three 
tiered kinase module,
24
 activated following phosphorylation from a kinase further upstream. 
Among these pathways are a series of highly conserved proline directed MAPKs, which 
phosphorylate their substrates at a serine and/or threonine residue.
25
  
Eukaryotes possess 14 highly conserved MAP kinases which are categorised into 7 groups.  
These 7 are further differentiated by the nature of their pathway. Extracellular signal-related 
kinase (ERK) 1/2, the p38 isoforms, c-Jun amino (N)-terminal kinase (JNK) isoforms and 
ERK5 are referred to as conventional MAPKs, whereas ERKs 3, 4, 7 and 8 and Nemo-like 
kinase (NLK) are considered atypical MAPKs. The TXY amino acid sequence present in the 
activation loop of conventional MAPKs varies between the four sub-families (i.e. ERK, TEY; 
p38, TGY; JNK TPY). Of the conventional MAPKs, ERK5 differs most greatly from the 
other members. ERK5, or ‘Big MAP kinase 1’ (BMK-1) contains an N-terminus extension, 
which contains transactivation domain (TAD) and nuclear localisation sequences (NLS).
26
 
There is a high level of sequence homology amongst the members of the MAPK family. 
ERK5 shares 51% and 48% sequence identity with ERK2 and p38α respectively in the kinase 
domain, and increases to 78% and 56% in the active site region. Due to the highly conserved 
nature of the MAPK family members, access to counter-screening assays is essential for a 
project aiming to develop selective ATP-competitive kinase inhibitors. Despite the high 
sequence homology between ERK5 and ERK2 in the ATP binding pocket, their gatekeeper 
residues differ significantly in size (ERK2 = Gln; ERK5 = Leu). The gatekeeper residue plays 
a key role in controlling access to a hydrophobic pocket. This creates an opportunity to 
design selective inhibitors for ERK5 over ERK2. Although p38α has a lower overall 
sequence homology, it was anticipated that designing an inhibitor selective for ERK5 over 
p38α would be more challenging due to the similar sizes of their respective gatekeeper 
residues (p38α = Thr). The gatekeeper residue in the JNK family of enzymes is methionine, 
which is also significantlylarger than that of ERK5.  
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Figure 4: Schematic representation of the structures of conventional and atypical MAPKs. 
From ref 
26
. 
2.2 Signal Transduction in the MAPK family 
The classical Raf/MEK/ERK signal transduction cascade is the most extensively studied of 
all the known MAPK pathways. This pathway is activated in response to extracellular signals 
such as the binding of growth factors (e.g. epidermal growth factor (EGF)) to the epidermal 
growth factor receptor (EGFR).
27
 Following binding of a growth factor, receptor dimerization 
occurs, which results in activation of the intracellular tyrosine kinase. MAPK pathway 
activation may also be initiated by cytokines, or various cellular stresses (e.g. osmotic 
stress).
28
 Following activation of the intracellular receptor tyrosine kinase, signalling via a 
three-tiered kinase module is induced, assisted by adaptor proteins such as growth factor 
receptor-bound protein (Grb2) and SoS (Son of Sevenless) which facilitate activation of GTP 
Ras. A MAPK is activated by a MAPK/ERK kinase (MAPKK, or MEK) which in turn is 
activated by a MEK kinase (MAPKKK or MEKK) (Figure 5).
29
 The first identified MEKKs 
were part of the Raf family of enzymes and A-Raf is known to selectively activate MEK1 
over MEK2, whereas B-raf and Raf-1 are non-specific for MEKs 1 and 2. MEK1/2 are the 
only members of the MAPK signalling pathways which are activated by Raf enzymes.
30
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Figure 5: Signalling cascades for the four conventional MAPK sub-families.
29
 
2.3 The Ras/Raf/MEK/ERK Signalling Pathway 
The activation of ERK1 and 2 proceeds via the aforementioned pathway (Section 2.2), 
following dual sequential phosphorylation of the conserved TEY motif by MEKs 1 and 2. 
Dissociation of activated ERK from MEK results in localisation to the nucleus whereby 
activation of several transcription factors such as c-Ets1, c-Ets-2, MNK1, MNK2, Sp1, E2F, 
Elk1 and AP-1 occurs. Activation of these transcription factors is associated with a number of 
processes including cell proliferation, differentiation and apoptosis. Therefore, deregulation 
of this pathway is associated with the progression of several cancers.
26, 31
 
2.3.1 Targeting the Ras/Raf/MEK/ERK1/2 Pathway for the Treatment of Cancer 
Initial efforts in drug discovery had focussed on inhibition of the Ras/Raf/MEK/ERK 
pathway by targeting the extracellular receptors which promote cancer progression following 
binding of growth factors (e.g. erlotinib, 9). However, drug resistance to inhibitors of the 
EGFR-TK is known, due to redundancy of the inhibited pathway.
32
 Ras oncoproteins are 
known to play a major role in the development of cancers, due to their ability to activate 
signalling pathways such as the MEK/ERK cascade. Ras mutations are present in 
approximately 30% of all human cancers, and in particular, pancreatic cancer and sporadic 
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colorectal carcinoma have high incidence of K-Ras mutation, at 90% and 50% respectively.
33
 
Furthermore, the aberrant overexpression of Raf, MEK and ERK1/2 has proved to be an 
attractive target for therapeutic intervention.  
Several drug discovery groups have embarked upon development of MEK inhibitors for the 
treatment of cancer. The first MEK1 inhibitor to reach the stages of clinical evaluation was 
CI-1040, 16, (PD184352) developed by Pfizer, and was identified following a medicinal 
chemistry program which was led by a high-throughput screening (HTS) campaign.
34
 CI-
1040 has been shown to act as an allosteric inhibitor, which enables high specificity for 
MEK1 over similar kinases such as p38α and JNK2. A Ki of 17 nM was measured for MEK1 
by CI-1040. Following successful completion of Phase I clinical trials, CI-1040 advanced to 
Phase II investigating efficacy in patients with metastatic breast cancer, non-small cell lung 
cancer and pancreatic cancer. Unfortunately, a response was not measured following single 
agent dosing in each of the three tumour types, therefore further investigation into CI-1040 
was terminated.
31
 As a result, the second generation MEK inhibitor PD0325901, 17, was 
developed which displays significantly improved in vivo efficacy and drug-like properties to 
CI-1040, and an in vitro IC50 of 1 nM.
35
 
                                               
                          CI-1040, 16                                            PD0325901, 17               
AZD6244, 18, (also known as ARRY-142886) was developed by AstraZeneca as a second 
generation MEK inhibitor; an analogue of CI-1040, it is a potent and selective inhibitor of 
MEK. AZD6244 has been shown to be particularly effective in cell lines which display 
BRAF or Ras mutations. AZD6244 has an IC50 value of 14 nM against MEK, with an 
improved pharmacological profile to CI-1040, and Phase II clinical trials have recently been 
completed.
36, 37
 A third analogue of CI-1040 is RO4987655, 19, currently in Phase II clinical 
trials for the treatment of advanced solid tumours, following successful Phase I dose 
escalation studies. A safety profile comparable to other MEK inhibitors was reported in Phase 
34 
 
I, and  drug plasma concentrations in the efficacious range as predicted by preclinical models 
were attained.
38
  
                                           
                         AZD6244, 18                                        RO4987655, 19 
Pharmacological inhibition of ERK1/2 by small molecules is also an area of interest, although 
there are far fewer examples of ERK inhibitors described in the literature to date. The 
discovery of FR180204, 20, an ATP competitive inhibitor of ERK was reported in 2005. 
FR180204 inhibits both ERK1 and ERK2 with IC50 values of 0.51 and 0.33 µM, respectively. 
Furthermore, the assessment of 20 in a cell-based functional assay has demonstrated that 
pharmacological inhibition of ERK1/2 results in inhibition of the AP-1 transcription factor, 
which is associated with regulation of gene expression. As AP-1 transactivation is associated 
with the TGF-β pathway, it is suggested that ERKs 1 and 2 play a crucial role in TGF-β 
mediated signalling.
39
  
 
FR180204, 20 
A pyrazolylpyrrole-based hit for ERK1/2, 21 was identified by Vertex pharmaceuticals 
following a HTS campaign, which displayed micromolar activity against ERK2 (21; Ki = 2.3 
µM). 3D-QSAR and in silico ‘side-chain hopping’ approaches led to the discovery of several 
potent ERK inhibitors (summarised in Table 3).
40
 To date, ERK1/2 inhibitors have not 
reached the clinic. 
35 
 
 
Table 3: Optimisation of potency for pyrazolylpyrrole based inhibitors of ERK.
40
 
Compound R
1
 R
2
 R
3
 Ki ERK2 (µM) 
21 H Me Me 2.300 
22 Cl H Benzyl 0.086 
23 Cl H 
(R)-1-Phenyl-2-
hydroxylethyl 
0.035 
24 Cl H 
(R)-1-(3-Cl, 4-FPh)-2-
hydroxylethyl 
0.002 
 
2.4 The p38 and JNK Signalling Pathways 
The p38 subfamily of MAPKs consists of 4 isoforms, α, β, γ and δ. Of these four, p38α is the 
most widely investigated and therefore, well characterised. It is expressed in the majority of 
mammalian cells and is involved in the regulation of cytokine expression. The major role of 
p38α is inactivation and regulation of immune response.41 Also referred to as stress activated 
protein kinase 2 (SAPK2), p38α mediates cellular responses to cellular stress including UV, 
heat, and osmotic shock. Inflammatory cells (e.g. neutrophils, monocytes, and macrophages) 
predominantly synthesise the p38α isoform. Production of pro-inflammatory cytokines (e.g. 
Interleukin-1 (IL-1), tumour necrosis factor and IL-6) following activation of the p38 MAPK 
pathway is associated with the development of inflammatory disease.
42
 The p38 pathway is 
also associated with the regulation of apoptosis, and has recently been identified as a tumour 
suppressor. It has been demonstrated that induction of p38-dependant apoptosis occurs 
following treatment with chemotherapeutic agents (i.e. cisplatin, a DNA damaging agent) in 
different cell lines.
43, 44
 Like p38α, the JNK family of enzymes are SAPKs, activated 
primarily by environmental stress and Figure 5 shows that the MAPKKKs activated in both 
the p38 and JNK pathways are shared. Activation of the JNK pathway has been associated 
with tumour formation via deregulation of cellular growth.
45
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2.4.1 Targeting the p38 and JNK Pathways for the Treatment of Inflammatory Diseases 
and Cancer 
A number of inhibitors of p38α have entered clinical trials for a number of disease areas 
driven by inflammatory response. PH797804, 25, is currently under evaluation in Phase II 
clinical trials for the treatment of rheumatoid arthritis, and neuropathic pain.
46
 Also under 
investigation in Phase II trials include GW856553, 26 (losmapimod) for the treatment of 
chronic obstructive pulmonary disease (COPD) and SB-681323, 27, (dilmapimod) also for 
the treatment of pain.
47
  
 
              PH797804, 25                        GW856553, 26                       SB-681323, 27 
Only one p38α inhibitor to date has been evaluated clinically for the treatment of cancer. 
Talmapimod, 28, (SCIO-469) was reported to be undergoing clinical trials in patients with 
multiple myeloma (MM) in 2009.
48
 It has been reported that talmapimod when dosed as a 
single agent has little effect on cell viability, although when dosed in combination with a 
proteasome inhibitor, Velcade, 29, the reduction in proteasome-induced cell proliferation and 
metabolism is significantly enhanced. Sensitization to proteasome inhibitors by p38 
inhibition is attributed to the reduced activation of MAPK-activated protein kinase-2 
(MAPKAPK-2) and activation of the anti-apoptotic heat shock protein 27 (HSP27).  
Therefore, p38α inhibitors may have a therapeutic application for increasing the sensitivity of  
resistant or unresponsive tumours to existing chemotherapeutic agents.
49
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                    Talmapimod, 28                                                      Velcade, 29 
Several inhibitors of the JNK family of MAP kinases have been reported in the literature for 
use in numerous therapeutic areas. Like p38, JNK is implicated in the progression of 
inflammatory disease and cancer. However, the biological role of JNK in the progression of 
neurodegenerative and metabolic disease is also under investigation. There are currently no 
known clinical candidates whose biological target is the JNK sub-family.
50
 
2.5 Introduction to Extracellular Signal Regulated Kinase 5 (ERK5) 
Also known as ‘Big Map Kinase 1’ (BMK-1), ERK5 is almost twice the size of other 
MAPKs (consisting of 816 amino acids).
51
 Activation of the signalling pathway of which 
ERK5 is a part is associated with cell survival, proliferation, and differentiation, and thus its 
overexpression may have implications in carcinogenesis.
52
 
2.5.1 The MEK5/ERK5 Signalling Pathway 
Signalling through the MEK5/ERK5 pathway is stimulated by binding of growth factors 
EGF, NGF, vascular endothelium growth factor (VEGF) and fibroblast growth factor-2 
(FGF-2) to their receptors found on the cell surface. Activation of the signalling pathway can 
also occur as a result of cellular stresses, or cytokines as is common in the MAPK sub-family 
(Figure 6).
53  
Unlike the conventional linear Ras/Raf/MEK/ERK pathway (outlined in Section 
2.3), the ERK5 signalling cascade occurs independently of Raf.
54
 Cloning of the ERK5 
protein was completed in 1995, which first identified MEK5 as a binding partner. ERK5 is 
activated specifically by MEK5 which is in turn activated by the MAPKKKs, MEKK2/3.
52, 55
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Figure 6: EGF induced signalling cascade through the MEK5/ERK5 pathway to activate 
cytoplasmic and nuclear transcriptional factors c-Fos, c-Jun, MEF2 and c-Myc. 
 
2.5.2 Adaptor and Scaffold Proteins in the ERK5 pathway 
Adaptor and scaffold proteins ensure transmission of the signal to the MAPK, assembling the 
required components of the cascade in multi-enzyme complexes.
52
 An interaction between 
MEKK2 and Lad (Lck-associated adaptor) assists ERK5 activation, by increasing the binding 
affinity between MEKK2 and MEK5.
56
 MEKKs 2/3 contain a Phox/Bem1 (PB1) domain 
which may associate with other PB1 containing proteins via protein-protein interactions, and 
it is this interaction which mediates MEK5 activation. Interestingly, ERK5 is the only MAPK 
to harbour a PB1 domain and it has been demonstrated that MEK5 acts as a scaffold protein 
by tethering MEKK1/2 to ERK5 via its N- and C-terminal regions of the PB1 domain. The 
formation of this three-kinase complex is unique to the MAPK family.
57
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2.5.3 Structure and Functional Domains of ERK5 
The specificity of the activation of ERK-type kinases can be attributed to their unique 
tripeptide motif in the activation loop of the kinase. For activation of ERKs to occur, 
phosphorylation must occur on two sites which are separated by a single amino acid, i.e. in 
ERK5 the tripeptide sequence Thr-Glu-Tyr is phosphorylated. This motif is common to 
ERK5 and ERKs 1 and 2.  However, BMK-1 is structurally different to the other members of 
the ERK sub-families. A unique loop-12 structure and extended C-terminal domain (~400 
amino acids) gives ERK5 its characteristic structure.
52, 53
 The C-terminal extension harbours 
both nuclear localisation (NLS) and export (NES) sequences, two proline rich domains, a 
transcriptional activating domain (TAD) and myocyte enhancer factor 2 (MEF2) interacting 
region.
58
 It has been established that the large C-terminal domain present only in ERK5 is 
auto-phosphorylated at multiple sites, resulting in an increase in transcriptional activity. It is 
also understood that the C-terminus has an auto-inhibitory effect on the ERK5 protein. The 
long C-terminus masks the catalytic domain, thus blocking ERK5 substrates from binding. 
Following activation of ERK5 by MEK5, a conformational change is apparent, allowing 
interaction of ERK5 and its substrates. Deletions in the C-terminal portion of the kinase 
results in an increased level of catalytic activity, which supports the hypothesis of an auto-
inhibitory function.
52
 
 
Figure 7: Unique transcriptional activity of the ERK5 arises from the extended C-terminus 
which does not feature in ERK1/2. From ref 
59
. 
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2.5.4 Downstream Effectors of ERK5 
Activation of ERK5 results in translocation from the cytoplasm to the nucleus and subsequent 
activation of a number of transcription factors including MEF2 which control growth factor 
mediated survival, c-Myc, c-Jun, c-Fos, activating protein 1 (AP-1) and NFκB. Bcl-2 
associated death promoter (Bad) and serine/threonine kinase (SGK) are also implicated as 
ERK5 substrates.
60
 ERK5 also phosphorylates and activates the p90 ribosomal s6 kinase 
(RSK) involved in signal transduction.
61
 RSKs are themselves known to activate several 
cytosolic and nuclear substrates, and are implicated in the regulation of a number of cellular 
processes associated with the onset and progression of cancer, including cell proliferation, 
survival, and motility.
62
 
2.5.5 Interaction of ERK5 with Promyelocytic Leukaemia Protein (PML) 
Investigation into the molecular mechanism by which ERK5 regulates cell proliferation 
revealed an interaction with PML, a tumour suppressor. Western blot analysis showed co-
precipitation of ERK5 and PML, and immunoprecipitation of PML also resulted in isolation 
of ERK5. Furthermore, p21, a downstream effector of PML, was induced following knockout 
of the gene encoding ERK5 (MAPK7) by small interfering RNA (siRNA). These data 
indicate that ERK5 complexes to and phosphorylates PML, resulting in down-regulation of 
the cell cycle regulator, p21. Pharmacological inhibition of ERK5 has proven to be a 
successful strategy for increasing p21 expression. The ERK5 inhibitor XMD8-92 which 
exerts this effect is discussed in more detail in Section 2.5.7.1.
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2.5.6 The Role of ERK5 in the Development of Cancer 
In 2000, Hanahan and Weinberg defined six biological capabilities as the ‘hallmarks’ of 
cancer, differentiating tumours from normal cells. These include; maintenance of 
proliferative signalling, resistance to apoptosis or immortality, induction of angiogenesis, 
activation of invasion and metastasis, and evasion of growth suppressors.
1
 ERK5 is 
implicated in a number of these biological processes as will be discussed in more detail in 
this section. 
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2.5.6.1 Cell Cycle Progression and Cell Survival 
The association of ERK5 overexpression with the activation of several transcription factors 
leading to cell proliferation is clear. Cervical cancer (HeLa) cells transfected with the 
dominant negative ERK5 gene (mutation of residues phosphorylated by MEK5 to 
phenylalanine or alanine) do not undergo cell proliferation, despite stimulation with growth 
factor EGF.
64
 However, the underlying mechanism by which ERK5 controls progression 
through the cell cycle is less well understood. Kato et al suggested in 1998 that ERK5 is 
involved in the regulation of the transition through the G1/S phase of the cell cycle.
64
 This 
hypothesis has been widely disputed, based on the observation that levels of phospho-ERK5 
are scarcely detectable in HeLa cells during G1 or S phase arrest.
65
 In contrast, Cude et al 
suggest that ERK5 activation occurs at a maximum level during the G2/M phase of the cell 
cycle. ERK5 activation was found to be crucial for transition of the cell into mitosis. 
Furthermore, ERK5 was found to activate the transcription factor NFκB, mediated by RSK2 
during the G2/M phase, which is essential for mitotic entry.
65
  
In 2007, it was suggested that ERK5 is activated during mitosis, and phosphorylates Bim (a 
pro-apoptotic BH3-only protein and a member of the Bcl-2 family), thus promoting cell 
survival.
66
 However, in 2012 it was proven by Gilley et al that it is CDK1 that mediates Bim 
phosphorylation rather than ERK5 as previously suggested. Treatment of HeLa cells with 
Paclitaxel, 30, or Nocodazole, 31, results in phosphorylation of Bim, independent of ERK1/2. 
However, activation of Bim proceeded normally in fibroblast cells which were negative for 
ERK5 and treatment of the cells with a dual MEK5/ERK5 inhibitor (BIX02189, discussed in 
further detail in Chapter 4) did not reverse this effect. Conversely, administration of a 
selective CDK1 inhibitor did abolish Bim phosphorylation.
67
 
                                    
                   Paclitaxel, 30                                                       Nocodazole, 31 
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2.5.6.2 Angiogenesis 
Angiogenesis, the formation of new blood vessels from pre-existing vasculature, is 
characterised by the proliferation, reorganisation and stabilisation of endothelial cells. It has 
been established that ERK5 is a regulator of embryonic angiogenesis, and that embryos 
deficient in ERK5 cannot survive. The MAPK p38α, also implicated in angiogenesis, is 
unable to compensate for an ERK5 deficiency due to the requirement of ERK5 at an earlier 
developmental stage than p38.
68
 As tumours depend upon the formation of new blood vessels 
for growth and metastasis, the link between ERK5 mediated angiogenesis and the progression 
of cancer has been made.  
Deletion of the MAPK7 gene which encodes ERK5 in animal studies confirmed that tumour 
volumes were significantly diminished in ERK5 knockout mice compared with their wild-
type counterparts. Furthermore, the vasculature of the tumours was diminished in ERK5-null 
animals. The reduction in angiogenesis was attributed to the correlation between ERK5 
activation and subsequent phosphorylation of ribosomal protein S6 (rpS6), a substrate of 
RSK. The RSK-rpS6 signalling pathway is associated with cell proliferation and survival, key 
processes in tumour vascularisation by endothelial cells.
69
 More recently, ERK5 has been 
shown to induce ‘inhibitor of differentiation’ (Id1), a negative regulator of thrombospondin-1 
(TSP1), a known inhibitor of angiogenesis.
70
  
2.5.6.3 Migration, Invasion and Metastasis 
Metastasis is characterised by the spread of malignant cells from the primary tumour site to 
secondary areas around the body. Degradation of basement membranes surrounding tumours 
by matrix metalloproteinase (MMP) enzymes facilitates tumour invasion and is associated 
with the formation of metastases. As reported previously, ERK5 activates the transcription 
factor AP-1. The promoters of several MMPs (including MMP-1, 3, 7, 9, 11, 13 and 19) share 
consensus sequence with AP-1, thus implicating ERK5 in the development of tumour 
metastases.
71, 72
 Furthermore, immunohistochemical data has confirmed the link between 
MEK5 overexpression and cellular migration and invasion in androgen-sensitive human 
prostate adenocarcinoma (LNCaP) cells via induction of MMP-9.
73
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Focal adhesion kinase (FAK) has been found to activate of ERK2 and ERK5 via an integrin 
mediated pathway. Integrins are a family of receptors implicated in cell attachment and 
motility. Binding of vitronectin to the extracellular integrin stimulates the ERK pathways in 
cancer cells. Transfection of MDA-MB-231 breast cancer cells with a dominant negative 
variant of FAK resulted in ERK5 inhibition and reduced levels of cell adhesion and motility 
when compared to the wild-type cell line.
74
 
2.5.7 Pharmacological Inhibitors of the MEK5/ERK5 Pathway 
There are currently three pharmacological inhibitors of the MEK5/ERK5 pathway described 
in the literature. The first two compounds to be identified are the dual MEK5/ERK5 
inhibitors BIX02188 and BIX02189, discovered by Boehringer Ingelheim Pharmaceuticals. 
These two compounds are described in further detail in Chapter 4, and were resynthesised for 
use as a positive control compound in this project. 
In 2010, the identification of XMD8-92, 33, as a selective inhibitor of ERK5 was reported by 
the Scripps Research Institute. XMD8-92 was discovered serendipitously, following 
screening of a library subset of compounds initially designed as polo-like kinase (PLK) 
inhibitors. Expansion of the 6-membered aliphatic ring present in PLK inhibitor BI-2536, 32, 
abolished PLK activity but screening of the compound against a panel of 402 protein kinases 
revealed ERK5 inhibition. Further structure activity relationship (SAR) studies around this 
scaffold led to the synthesis of XMD8-92. It is reported that XMD8-92 has a dissociation 
constant (KD) of 80 nM for ERK5 in an enzymatic assay. Of the 402 kinases screened, only 
four other kinases were found to be inhibited by 33, i.e. DCAMKL2, TNK1 and PLK4; KDs = 
190, 890 and 600 nM, respectively; KD for DCAMKL1 was not reported, and no inhibition of 
MEK5 was observed up to a 50 µM drug concentration. A cellular IC50 of 1.5 µM in HeLa 
cells was recorded, it is claimed, with approximately 10-fold selectivity against the most 
potent off-targets.
63
  
                
                         BI-2536, 32                 XMD8-92, 33 
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2.5.7.1 Effect of ERK5 Inhibition by XMD8-92  
The biological effects of XMD8-92, have been demonstrated in tumour-bearing mice. 
Following the introduction of HeLa or Lewis lung carcinoma (LL/2) cells to test animals, 33 
was administered intraperitoneally (IP) twice daily at a dose of 50 mg/kg. Tumour growth 
was measured at regular time points. Representative animals from each group are pictured in 
Figure 8, showing the extent of tumour growth at the end of the experiment. Administration 
of the ERK5 inhibitor XMD8-92 results in a significant decrease in mean tumour volume in 
both human tumour xenograft models, when compared to the control. The ability of  
XMD8-92 to prevent the formation of new vasculature was assessed in an angiogenesis 
model, via implantation of a Matrigel plug. Further details of this assay are provided in 
Section 6.7.7.4. A significant decrease in blood vessel formation was detected following 50 
mg/kg IP dosing of XMD8-92 compared with animals receiving vehicle only, via 
quantification of haemoglobin concentrations (Figure 9). The discovery of a novel, selective 
ERK5 inhibitor has assisted in validating that tumour angiogenesis is mediated by MAPK 
signalling, particularly via ERK5, and that pharmacological inhibition of ERK5 may provide 
an opportunity for the treatment of invasive and metastatic cancers where ERK5 is 
deregulated.
63
 
 
Figure 8: Mouse xenograft model; treatment of tumour-bearing mice (HeLa or LL/2 cell 
lines) with 50 mg/kg XMD8-92 twice daily IP. From ref 
63
. 
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Figure 9: Matrigel plug angiogenesis model; 50 mg/kg XMD8-92 twice daily IP for 6 days. 
From ref 
63
. 
2.5.7.2 Hit Identification for Novel Inhibitors of ERK5 
In 2007, a high-throughput screen (HTS) was conducted by Cancer Research Technology 
(CRT) laboratories in order to identify novel chemotypes with good to moderate activity 
against ERK5 as a starting point for drug development. A diverse library of 48,479 
compounds and a kinase focused library of 9138 compounds were screened against ERK5 at 
a concentration of 30 µM. A total of 511 compounds were identified which showed inhibitory 
activity greater than 50%. Of these 511 compounds, 245 were confirmed as inhibitors of 
ERK5 using the Immobilised Metal Affinity Polarization (IMAP
™
) assay format. 
Three distinct compound classes were identified; benzo[d]thiazoles 34, 3-cyanopyridines 35, 
and pyrrole carboxamides 36, which were selected for hit validation.  
 
 34; 0.06-0.09 µM                       35; 0.45-31.3 µM          36; 0.66-3.5 µM 
Benzo[d]thiazole compounds obtained from commercial libraries exhibited excellent 
inhibitory activity against ERK5 (IC50 = 6-9 nM). Research in this series was conducted by 
Dr Ruth Bawn.
75
 Unfortunately, the series was not validated and therefore no further studies 
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around the benzo[d]thiazole scaffold were performed. Hit validation of the 3-cyanopyridine 
and pyrrole carboxamide series are described in Sections 5.2 and 6.2.  
2.5.7.3 IMAP
™
 Assay Format 
All compounds described herein were evaluated for in vitro ERK5 inhibition using the 
IMAP
™
 assay format unless otherwise stated. The IMAP
™
 assay is a generic assay kit 
obtained from Molecular Devices designed for the screening of compounds against kinases, 
phosphatases and phosphodiesterases.
76
  
The assay is based on the fluorescence polarisation (FP) of a labelled peptide substrate 
(Figure 10). Upon phosphorylation by the kinase, the peptide substrate binds to an 
immobilised metal (III) nanoparticle, thus increasing the fluorescence polarisation observed 
by reducing rotational speed of the substrate. When no inhibition of the kinase occurs, a 
maximum amount of FP is observed.
 
Upon inhibition of the kinase by a small molecule the 
level of FP observed will be significantly lower. The Km app of ATP for ERK5 has been 
determined as 350 μM and thus all IC50 determination assays are performed at this 
concentration of ATP.  
 
Figure 10: Schematic diagram of the IMAP
™
 assay.
76
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Chapter 3: Cancer Types Where ERK5 Signalling is De-regulated 
3.1 Prostate cancer 
3.1.1 Introduction to Prostate Cancer 
Prostate cancer typically characterised by abnormal growth of the epithelial cells in the 
prostate tissue, a small walnut shaped organ involved in the male reproductive system. 
According to statistics published by Cancer Research UK, prostate cancer (CaP) is the most 
commonly diagnosed form of cancer in men, with almost 41,000 new cases in the UK in 
2009. In 2008, approximately 900,000 cases of prostate cancer were diagnosed worldwide. 
Fortunately, advances in screening and detection have enabled the majority of patients 
diagnosed with CaP to reach 5 or 10 year survival points (Figure 11). However, prostate 
cancer is still the second leading cause of cancer related deaths, behind lung cancer.
77
 
 
Figure 11: Recent prostate cancer statistics according Cancer Research UK. From ref 
77
. 
There are several risk factors associated with the development of prostate cancer, the most 
prevalent being age. The probability of being diagnosed with prostate cancer increases 
significantly past the age of 50 (Figure 12). Genetic predisposition also plays an important 
role in the development of prostate cancer, and the link between carrying germline mutations 
in the BRCA2 gene (associated with the onset of breast and ovarian cancers in females) has 
been established.
78
 Several other factors including diet, alcohol intake, and bodyweight have 
been investigated, but there is currently no evidence to suggest a link with prostate cancer.
77
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Figure 12: Average number of prostate cancer diagnoses per year, with age-specific 
incidence rates, 2007-2009. From ref 
77
. 
3.1.2 Screening and Detection of Prostate Cancer 
Screening for prostate cancer typically involves a blood test measuring the levels of prostate-
specific antigen (PSA) in the bloodstream. This protein is naturally secreted by the prostate. 
However, elevated levels of this antigen indicates enlargement of the prostate gland. This 
however is not a diagnostic measure, as elevated PSA levels may also be detected in non-
cancerous conditions such as prostatitis, or benign enlargement of the prostate. Paradoxically, 
many men with prostate cancer do not display elevated PSA levels. The PSA blood test, 
however, is a non-invasive indicative test which for many men can provide reassurance or 
lead to early detection of prostate cancer. Should a high PSA level be detected, a 
recommendation for biopsy may be necessary, which gives a definite diagnosis but is 
invasive and often painful. If cancerous cells are detected following a biopsy, they are 
evaluated and graded according to their appearance in terms of abnormality (graded on a 
scale of 1-5) as viewed through a microscope (Figure 13). The complication of multiple 
patterns in one specimen being observed is overcome by using a combined score of the two 
most prevalent tissue patterns. This technique is referred to as the Gleason sum score.
79
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                               1               2                 3                 4              5 
Figure 13: The Gleason grading system. Grade 1 cells are almost ‘normal’ displaying closely 
packed round glands with well-defined edges. Grade 1 cells show no glandular 
differentiation. From ref 
80
. 
3.1.3 Current Treatments for Advanced Prostate Cancer 
Radical prostatectomy is the treatment of choice for patients where their cancer has not 
spread beyond the prostate. This treatment option allows a normal lifestyle following surgery, 
without compromising survival of the patient. Radiotherapy is also a treatment option at this 
stage. For patients with advanced prostate cancer, hormone therapy is usually the first line 
treatment. This may also be used for patients where cancerous cells have returned following 
surgery or radiotherapy, the cancer has already spread to secondary sites around the body, or 
the primary tumour is too large to be treated by surgery or radiotherapy alone.
81
 It is 
estimated that between 80 and 90% of diagnosed prostate cancers are dependent on 
androgens and the androgen receptor for their development, and expression of the androgen 
receptor is maintained during prostate cancer progression.
82
 Blocking the production of 
testosterone is a successful approach towards treating such cancers which are dependent on 
signalling through the androgen receptor. Testosterone is primarily synthesised in the testes, 
therefore androgen ablation may be achieved via orchiectomy; surgical removal of the testes. 
However, there are currently several drug classes which suppress the action of androgens 
either by reducing serum testosterone and 5α-dihydrotestosterone (DHT) levels, or by 
directly inhibiting the androgen receptor (AR), without the need for surgical intervention. 
Androgen receptor antagonists nilutamide, 37 flutamide, 38 and bicalultamide, 4 act in a 
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testosterone/DHT competitive manner at the AR in the prostate gland, directly inhibiting the 
androgen signalling pathway.  
                                                         
                              Nilutamide, 37                                           Flutamide, 38  
In contrast, gonadotropin-releasing hormone (GnRH) agonists Leuprolide and Goserelin, 39 
act upon the anterior pituitary gland, paradoxically decreasing the release of the luteinising 
hormone (LH) when administered in high doses, through down-regulation of GnRH 
receptors. Luteinising hormone stimulates androgen synthesis in the testes, therefore the use 
of a GnRH agonist such as goserelin, reduces testosterone and DHT serum levels to a 
concentration comparable with those following orchiectomy.
83
 GnRH antagonists (e.g. 
Abarelix) have also been used clinically for androgen ablation, which does not result in the 
initial surge in testosterone production which is associated with the GnRH agonists.  
 
Goserelin, 39 
Unfortunately, approximately 20% of patients will not respond at all to hormonal therapy and 
for many patients where a response is observed, it is common for resistance to occur resulting 
in the presence of castrate-resistant tumours.
84
 Typically prostate cancers are responsive to 
hormonal treatments for 12 to 18 months before becoming castrate-resistant and ultimately,  
metastatic.
85
 Once bony metastasis has occurred the survival rate is extremely low, with 
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patients having a 9 to 12 month life expectancy.
84
 At present the treatment of hormone-
refractory metastatic tumours is palliative, intending not to cure the disease, but to improve 
quality of life and relieve pain.
86
 Until recently, the only treatments available for these 
advanced cancers included taxanes, e.g. Docetaxel 40, which increase survival outcome, 
reduce serum PSA levels and improve quality of life when used in conjunction with 
Prednisone, 41, a corticosteroid drug.
86
 In 2011, Abiraterone, 42 was approved as a 17α-
hydroxylase and C17-20 lyase inhibitor, which prevents androgen biosynthesis, and prolongs 
the life of patients suffering from terminal prostate cancer. 
                         
                        Docetaxel, 40                                                   Prednisone, 41 
Despite successful androgen depletion following chemical or surgical castration, 
approximately 10% of baseline testosterone is still present.
87
 Dehydroepiandrostenedione 
(DHEA) and androstenedione are converted into testosterone by enzymes found in the 
prostate and other peripheral tissues (Figure 14). The androgen receptor’s sensitivity to 
testosterone and DHT is often elevated in castrate-resistant prostate cancer. Therefore, the 
prevention of extra-testicular androgen synthesis by Abiraterone has provided a novel therapy 
for patients suffering advanced prostate cancer which is no longer responsive to the 
traditional androgen ablating drugs (i.e. goserelin, nilutamide).
87, 88
  The discovery of  
TAK-700, 43, (orteronel), a potent and selective non-steroidal imidazole-based inhibitor of 
C17-20 lyase has since been reported, which has an IC50 of 28 nM.
89, 90
 Orteronel is currently in 
Phase III clinical trials for the treatment of patients with castrate-resistant metastatic disease.
 
13,14
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                          Abiraterone, 42                                            Orteronel, 43 
 
Figure 14: Steroid biosynthesis pathway. Abiraterone acetate inhibits 17α-hydroxylase and 
C17,20-lyase preventing testosterone synthesis. From ref 
87
. 
The development of second-generation anti-androgen treatments is also in progress. One of 
the known mechanisms of resistance to first-line hormonal therapy is up-regulation of the 
androgen receptor. Furthermore, in cells which over-express the AR, first generation anti-
androgens such as bicalutamide act as partial agonists of the androgen signalling pathway. 
This clinical liability of the first generation anti-androgens highlights the advantage of 
identifying progression to the castrate-resistant stage as soon as possible. MDV3100 
(enzalutamide, 44) was optimised as an inhibitor of the AR following a screen of non-
steroidal compounds and has a binding affinity for the AR between 5 and 8 times that of 
bicalutamide, 4. Enzalutamide also impairs nuclear translocation, and recruitment of co-
activators of the AR ligand-receptor complex,
91
 and is currently in Phase III clinical trials for 
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the treatment of castrate-resistant prostate cancer following encouraging anti-tumour activity 
in Phase II trials.
92
  
 
Enzalutamide, 44 
3.1.4 The Implication of MEK5/ERK5 Pathway Deregulation in the Development of 
Castrate-Resistant Prostate Cancer 
Castrate-resistant tumours arise as a result of mutated androgen receptor overexpression 
which may be activated regardless of anti-androgen therapy by receptor independent 
mechanisms. Mutated androgen receptors may be deemed ‘promiscuous’, allowing activation 
by binding of the anti-androgen drug or other steroid hormones and thirdly, the mutated 
receptor may be hypersensitive, thus allowing activation despite very low concentrations of 
androgen present.
88, 93 
Expression of the anti-apoptotic gene Bcl-2 has been implicated in the 
development of castrate-resistance in tumours. Bcl-2 was found to be below detectable levels 
in androgen dependent cancers. However, high levels of the gene are found in the resistant 
form of the disease. Presence of this gene allows the cells to evade apoptosis generating a 
series of cells unresponsive to hormone therapy. Inhibition of the Bcl-2 mediated pro-
apoptotic pathway is therefore one potential therapeutic strategy for the treatment of castrate-
resistant prostate cancer.
94 
  
Another validated therapeutic strategy is targeting the MEK5/ERK5 pathway. ERK5 
expression is significantly up-regulated in the epithelial cells of advanced prostate cancers 
when compared with those of benign tumours. It is also found that overexpression strongly 
correlates with an elevated Gleason sum score, indicating poorly differentiated tumours 
(Figure 15).
73, 95
 Altered MEK5/ERK5 signalling has also been found to be related to 
increased metastatic potential of prostate cancer cells, which is directly related to the poor 
survival outcome associated with the disease (Figure 16).  The exact pathophysiology of bone 
metastasis is not fully understood although the link between ERK5 overexpression and 
MMP-9 synthesis has been made (Section 2.5.6.3). Elevated cytoplasmic and nuclear levels 
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of ERK5 serve as an independent prognostic marker for advanced prostate cancer, with 
nuclear ERK5 expression present only in malignant cells.
73
 
 
Figure 15: The relationship between ERK5 expression and Gleason sum score.
41
 Staining 
intensity is semi-quantitative, scored as either absent (0), weak (1), moderate (2) or strong 
(3). From ref 
95
. 
  
Figure 16: Left: ERK5 expression in the presence and absence of bone metastases. Black = 
No ERK5 expression detected; White = ERK5 expression detected. Right: Elevated ERK5 
expression correlated with disease specific survival. From ref 
73
.
 
Definitive confirmation of the link between ERK5 overexpression and aggressive metastatic 
prostate cancer has been achieved in vivo, following mouse xenograft studies. Implanted 
LNCaP cells transfected with MAPK7, the gene encoding ERK5, proliferated more rapidly 
when compared those transfected with an empty vector. A significant increase in mean 
tumour volume at 40 days post implantation was measured, and the rate of migration and 
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invasion were also notably elevated (Figure 17), with an increase of 1.8 and 2.1 fold 
respectively.
73
 
 
Figure 17: PC3 cells transfected with the MAPK7 gene show a more aggressive phenotype. 
From ref 
73
.  
3.1.5 The Effects of PD184352 on Prostate Cancer Cell Growth  
The small-molecule inhibitor PD184352, 45, targets MEK1/2 in an allosteric manner. At a 
low concentration of 0.3 µM, inhibition of ERK1/2 mediated by MEK1/2 was achieved with 
no measured effect on cell proliferation in PC3 cells. A higher concentration of drug (3 µM) 
was found to also inhibit ERK5, most likely as a result of action upon MEK5. Treatment of 
PC3 cells with the elevated concentration of 45 also gave a significant reduction in cell 
proliferation. These data suggest that effects once attributed to the ERK1/2 pathway may 
actually be regulated by ERK5, and that clinical inhibition of ERK5 may have a therapeutic 
application for potentiation of cell proliferation, as well as the prevention of tumour 
metastasis and angiogenesis.  
 
PD184352, 45 
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3.2 Breast Cancer 
3.2.1 Introduction to Breast Cancer 
Whereas prostate cancer is the most frequently diagnosed cancer in men, breast cancer is the 
most commonly diagnosed cancer in females with approximately 49,000 new cases in the 
United Kingdom in 2009. Although rare, male breast cancer accounted for approximately 1% 
of UK cancer diagnoses in 2009.
77
 There are several risk factors associated with the onset of 
breast cancer in females. The age of onset is generally lower than that of prostate cancer, and 
the risk of developing breast cancer is strongly associated with production of the female 
hormone oestrogen. Hormonal influences, such as use of the contraceptive pill and 
reproductive history exert a significant effect on the risk of developing breast cancer. 
However, the most influential factor is genetic predisposition, with approximately 10% of 
breast cancers in the Western world resulting from hereditary factors.
96
 For example, 
mutations in the tumour suppressor genes BRCA1 and BRCA2 has been associated with an 
elevated incidence of breast (and to a lesser extent, ovarian) cancer development, increasing 
the lifetime risk to ≥80%.97 
 
Figure 18: Recent breast cancer statistics according Cancer Research UK. 95% LCL and 
UCL are the lower and upper confidence limits around the age-standardised (AS) rate. From 
ref 
77
. 
3.2.2 Influence of Stat3 on the MEK5/ERK5 Pathway 
Stat3 has been classified as an oncogene whose constitutive activation is detected in breast 
cancer cell lines (Stat3-C). Several genes are reported to be up-regulated by Stat3, including 
the members of the matrix metalloproteinase family MMP-1 and MMP-10, vascular 
endothelial growth factor (VEGF), and connective tissue growth factor (CTGF) amongst 
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others in a non-malignant telomerase immortalised breast cancer (TERT) cell line. 
Furthermore, expression of Stat3-C in TERT cells resulted in a 22-fold increase in MEK5 
induction and activation. In MDA-MB-435 Stat3 expressing breast carcinoma cells, MEK5 
expression and activation was inhibited following the use of Stat3 small-interfering RNA 
(siRNA), which suggests that MEK5 may be directly regulated by Stat3 in some breast 
cancers.
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3.2.3 Expression of ERK5 in HER2-positive Breast Cancer 
Overexpression of the HER2 receptor tyrosine kinase oncogene is found in 20-30% of breast 
cancers, and is associated with a more aggressive phenotype, and poor disease specific 
survival. The identification of HER2 (or ErbB2) in the 1980’s resulted in a large amount of 
clinical interest, which eventually led to its validation as an anti-cancer target.
99
 The 
monoclonal antibody trastuzamab (Herceptin) and small-molecule inhibitor lapatanib, 46 
both target the HER2 protein, and are therefore clinically efficacious in patients with 
advanced or metastatic breast cancers which are HER2-positive.  
 
Lapatanib, 46 
The extracellular HER2 receptors mediate signalling via several pathways, including those 
involving the MAPKs, and PI3K (Akt). In breast cancer cells, ERK5 activation is triggered 
by binding of the substrate neuregulin to the HER2 receptor, and in cancer cell lines where 
HER2 is expressed, ERK5 has been found to be constitutively elevated. Most interestingly, 
inhibition of ERK5 in combination with the use of Herceptin appears to sensitize cells to 
treatment.  Furthermore, ERK5 is found to be overexpressed in a number of patients, and 
recent findings illustrate that ERK5 is an independent prognostic measure in breast cancer 
(Figure 19).
100
 Therefore, the clinical development of an ERK5 inhibitor may provide a more 
successful approach for the treatment of advanced breast cancer. 
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Figure 19: Left: Disease-free survival with respect to ERK5 levels in patients with early 
stage breast cancer; Right: Disease-free survival with respect to ERK5 levels in patients with 
HER2 positive early stage breast cancer. From ref 
100
. 
3.3 Hepatocellular Carcinoma (HCC) 
3.3.1 Introduction to HCC 
HCC is the most commonly diagnosed form of liver cancer, and is the fifth most common 
cancer type in the world.
101
 Unlike breast and prostate cancer, liver cancer in adults often has 
a poor prognosis at the time of initial diagnosis. The main risk factors associated with the 
development of liver cancer are exposure to the Hepatitis B and C viruses, and excessive 
consumption of alcohol. Due to the implication of alcohol abuse in HCC, significant liver 
cirrhosis is also present at the time of a cancer diagnosis. At this stage, the tumour is deemed 
inoperable and an average life expectancy of approximately three months is given.
77
 
3.3.2 Gene Amplification of ERK5 in HCC 
Analysis of HCC cell lines revealed DNA copy number abberations, revealing a novel 
amplification at the 17p11 chromosome fragment. Amplification of chromosomal DNA is 
one of the primary mechanisms of protein overexpression associated with the progression of 
cancer.
101
 It is this amplicon at 17p11 which harbours MAPK7, and as a result, cell lines 
where this amplification was apparent did indeed show overexpression of ERK5 (Figure 20). 
A total of 35 of 66 HCC tumours tested contained an increase in MAPK7 copy numbers. 
Based on this observation, siRNA was used to knockdown the MAPK7 gene in proliferating 
SNU449 HCC cells, reported to have the greatest amplification of MAPK7. Down-regulation 
of MAPK7 resulted in a growth inhibitory effect, attributed to prevention of mitotic entry 
regulated by ERK5 (Figure 21).
101
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Figure 20: Amplicon map of the 17p11 chromosome in two HCC cell lines; SNU449 and 
JHH-7. From ref 
101
. 
 
Figure 21: Growth inhibition of SNU449 cells by siRNA knockdown of the MAPK7 gene. 
From ref 
101
. 
3.4 Multiple Myeloma (MM) 
Multiple myeloma (MM) is characterised by the accumulation of neoplastic plasma cells of 
β-lymphocyte origin, associated with the immune system. Accounting for 10% of all 
haematological malignancies, MM results in the overproduction of antibodies which are 
unable to fight infection in the normal fashion.
102, 103
 Often, intensive high-dose 
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chemotherapy is required for treatment, which kills normal and neoplastic cells. The Stat3 
protein discussed in Section 3.2.2 has been implicated in the survival of MM cancer cells, in 
addition to breast cancer cells, and is known to stimulate ERK5 expression. The myeloma 
growth factor, interleukin 6 (IL-6) has been shown to activate ERK5 in MM cell lines, and 
IL-6 dependant cell proliferation is down-regulated via expression of a dominant negative 
form of ERK5. As observed in HER2-positive breast cancer (Section 3.2.3), sensitization to 
pro-apoptotic agents is observed following knockout of ERK5 activity in MM. A novel 
therapeutic route for treatment of patients with MM who do not respond to current 
chemotherapeutic agents is therefore apparent. 
  
61 
 
Chapter 4: Resynthesis of BIX02188 and BIX02189 
4.1 Rationale for the Synthesis of BIX02188 and BIX02189 
In 2008, a new class of pharmacological inhibitors of MEK5 were described. The indolinone 
based inhibitors, BIX02188 (47) and BIX02189 (48), both exhibit low nanomolar potency 
against MEK5 with IC50 values of 4.3 and 1.5 nM respectively, and are also moderately 
active against ERK5, (IC50 values of 810 and 59 nM respectively).
104
 This indolinone class of 
inhibitors developed by Boehringer Ingelheim Pharmaceuticals are dual-inhibitors of the 
MEK5/ERK5 signalling pathway. BIX02188 is shown below, drawn as it is illustrated in the 
literature.
104
 It is clear that there is one atom missing from the structure and for the purposes 
of our investigations it was assumed to be the primary amide. 
 
               BIX02188, 47                                                            BIX02189, 48  
4.2 Cambrex PKLight
™
 Protein Kinase Assay 
The Cambrex PKLight
™
 protein kinase assay was used to determine in vitro IC50 values for 
BIX02188 and BIX02189. During a kinase reaction, the level of free ATP is depleted as the 
γ-phosphate group is transferred to the substrate. The reduction in ATP is accurately 
measured using Cambrex PKLight
™ 
bioluminescent reagents. Upon incubation with an 
inhibitor, the kinase activity decreases, resulting in a higher concentration of free ATP at the 
end of the assay. A luminescent signal is emitted at an intensity proportional to the level of 
ATP present. 
The literature procedure used either GST-MEK5 or GST-ERK5 isolated from baculovirus as 
the kinase, with a 0.75 µM ATP concentration. A 10-point dose titration with a maximum 
concentration of 10 µM of inhibitor was performed (Figure 22). IC50 values were calculated 
from % kinase activity relative to a control (where control activity is 100% in the absence of 
an inhibitor). 
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Figure 22: Dose titration curves for BIX02188 and BIX02189 against MEK5, ERK5, JNK2, 
ERK1, MEK2 and MEK1. Each data point represents an average of two data points. From 
 ref 
104
. 
Importantly, kinase selectivity profiling indicated that 47 and 48 are selective against a range 
of protein kinases, including other members of the MAPK superfamily (Table 4). Activity 
against MEK1/2, ERK1 and JNK2 were all above 6000 nM. Selectivity over the EGF-TK 
was also achieved. Resynthesis of authentic samples of BIX02188 and BIX02189 was 
desirable for a number of reasons. Evaluation of these inhibitors in the IMAP
™
 assay 
established at CRT would assist in validating the assay format currently being used as the 
primary assay for prospective ERK5 inhibitors. Furthermore, these compounds are of great 
interest for the establishment of biomarkers for inhibitors of the MEK5/ERK5 pathway.  
Table 4: Selectivity profile of BIX02188 and BIX02189 against closely related kinases.
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Kinase 
IC50 [nM] 
BIX02188 BIX02189 
MEK5 4.3 1.5 
MEK1 >6300 >6200 
MEK2 >6300 >6200 
ERK5 810 59 
ERK1 >6300 >6200 
JNK2 >6300 >6200 
TGFβR1 1800 580 
EGFR >6300 >6300 
STK16 >6300 >6300 
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4.3 Synthesis of BIX02188 and BIX02189 
BIX02188 and BIX02189 were resynthesised based on the literature protocol published by 
Boehringer Ingelheim pharmaceuticals (Scheme 1).
105
 Esterification of the commercially 
available carboxylic acid 49 was performed using thionyl chloride in methanol. Conversion 
to the corresponding methyl ester was achieved in high yield (85%). Subsequent SNAr of 50 
with dimethyl malonate in the presence of a strong base afforded 51 in 66% yield. 
Synthesis of the indolinone scaffold proceeded via a one-pot, three-step mechanism under 
transfer hydrogenation conditions. Firstly, the nitro group is reduced to the corresponding 
aniline, which cyclises to give dimethyl 2-oxoindoline-3,6-dicarboxylate (not shown). 
Finally, this intermediate undergoes decarboxylation to afford indolinone 52 in almost 
quantitative yield. Protection of the amide with an acetyl group followed by a Knovenagel-
type condensation with triethyl orthobenzoate afforded 53 as a mixture of E- and Z- isomers 
in 79%. Substitution with 3-dimethylamino methylaniline proceeded in moderate yield 
(52%). At this stage only the Z- isomer 54 was observed probably due to the formation of a 
pseudocycle stabilised by intramolecular hydrogen bonding. Problems were encountered in 
the last two steps of the reaction scheme. Hydrolysis of the acetyl protecting group and 
methyl ester were shown to go to completion upon analysis by LCMS and TLC. However, 
the zwitterionic nature of the resulting product led to complications on workup and 
purification. Extraction of the product into an organic solvent was extremely difficult, and 
purification of the carboxylic acid 55 by HPLC was necessary resulting in a low isolated 
yield of 38%. An alternative method was attempted which did not require an aqueous 
workup, using potassium trimethylsilanolate in THF,
106
 (Scheme 2) but cleavage of the N-
acetyl group was detected by LCMS, with no conversion to the corresponding carboxylic 
acid. The deacetylated product 56 was not isolated. 
64 
 
 
Scheme 1: Resynthesis of BIX02188 and BIX02189. Reagents and conditions; i) SOCl2, 
MeOH, 60 
o
C, 16 h; ii) dimethyl malonate, KO
t
Bu, NMP, 75 
o
C, 2h; iii) NH4HCO2, Pd/C, 
AcOH, 100 
o
C, 10 min, MW; iv) acetic anhydride, 130 
o
C, 3 h, then triethyl orthobenzoate 
100 
o
C, 3 h; v) 3-dimethylamino methylaniline, DMF, 80 
o
C, 3 h; vi) LiOH monohydrate, 
H2O, THF, 60 
o
C, 16 h; vii) For R = H; PyBOP, HOBt, Hünig’s base, NH4Cl, DMF, RT, 16 
h; For R = CH3; PyBOP, HOBt, Hünig’s base, dimethylamine hydrochloride, DMF, RT, 16 h. 
 
Scheme 2: Cleavage of the N-Acetyl protecting group. Reagents and conditions; 
 i) potassium trimethylsilanolate, THF, RT, 6 h.
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BIX02188 and BIX02189 were obtained following amide coupling reactions using 
benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate (PyBOP) and 
hydroxybenzotriazole (HOBt) as an additive in the presence of Hünig’s base. Couplings were 
performed with ammonium chloride and dimethylamine hydrochloride which gave 47 and 48 
in 16% and 51% yield, respectively. It is not known why the yield is considerably poorer for 
the primary amide and purification by semi-preparative HPLC was required for both 
compounds. 
4.4 ERK5 Inhibitory Activity of Indolinone Based Inhibitors 
BIX02188 and BIX02189 were submitted for biological evaluation, along with the 
intermediate carboxylic acid 55 (Table 5). The activity observed in the literature varies 
significantly from that measured in the IMAP
™
 assay. The IMAP
™
 assay performed at CRT 
is conducted with an ATP concentration of 350 µM in accordance with the Km of ATP for 
ERK5. This is an unusually high ATP concentration for an in vitro kinase assay and may 
explain the large variation in IC50 values. In the IMAP
™ 
assay, all three indolinone based 
compounds assessed are equipotent. 
 
Table 5: Comparison of reported cellular data with IMAP
™
 assay data 
Compound R 
Lit. ERK5 IC50 
(PKLight
™
, µM) 
Measured ERK5 IC50 
(IMAP
™
, µM) 
55 OH - 11.3 ± 2.9 
47 NH2 0.81 10.5 ± 0.3 
48 N(Me)2 0.06 9.2 ± 0.9 
 
Cellular based assays were performed in collaboration with Professor Hing Leung at the 
Beatson Institute, Glasgow. Treatment of SNU449 cells (a HCC cell line), with BIX02189 
did not show any reduction in the levels of EGF induced autophospho-ERK5 versus controls 
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(as shown by the autophospho-ERK5 immunoprecipitation/western blotting (IP/WB) assay) 
or phospho-ERK5 (as shown by the phospho-ERK5 Western blots, WB), (Figure 23). 
Immunoprecipitation was performed as the autophospho-ERK5 antibody is weak, and binds 
non-specifically to other proteins. This method extracts and concentrates ERK5 protein from 
cell lysates using an ERK5 antibody. A western blot may then be performed using the 
autophospho-ERK5 antibody. The SNU449 cell line was used as it is the only cell line tested 
which has sufficiently high levels of autophosphorylated ERK5 for detection in the IP/WB 
assay. (Assays were conducted by Dr Lesley McPhail). 
 
Figure 23: Autophosphorylation/western blotting assay using SNU449 cells with 48. 
In collaboration with Dr Simon Cook of the Babraham Institute, Cambridge, BIX compounds 
were assessed in a dual-luciferase reporter gene assay. ERK5 IC50 values are determined via 
measurement of phosphorylation levels of the downstream transcription factor MEF2D, 
facilitated by luminescence detection. The dual-luciferase reporter gene assay is described in 
more detail in Section 7.8. Assays were conducted by Dr Pamela Lochhead using material 
resynthesised at Newcastle, and those obtained from Boehringer. 
48 
Control 
Control 
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Figure 24: Effects of BIX inhibitors on ERK5 activity in the dual-luciferase reporter gene 
assay.  
Figure 25: Comparison of BIX02189 resynthesised in-house (NC, red) versus authentic 
material (Babraham, blue). 
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Table 6: IC50 values for BIX02188 and BIX02189 authentic material versus resynthesised 
material.  
Compound 
IC50 (µM) 
Authentic (Babraham) Resynthesised (Newcastle) 
BIX02188 
1.2 Inactive 
1.5 Inactive 
BIX02189 
2 2 
0.5 0.5 
 
A discrepancy was observed when comparing BIX02188 synthesised at Newcastle with that 
of the commercial supplier (Figure 24, Table 6). However, the data obtained for BIX02189 
(NC) correlated extremely well with the authentic material (Figure 25). The MEF2D reporter 
gene assay determined the IC50 for BIX02189 as 1.25 µM as an average of duplicate 
measurements. 
Due to the inactivity of resynthesised BIX02188, 47, quality control studies were initiated. A 
small sample of the authentic material was obtained and analysed by LCMS which confirmed 
a mass difference of 15 amu between the two samples. It was deduced that the correct 
structure of BIX02188 was the mono-methylated amide 57, and not the primary amide 
illustrated in the literature. This demonstrates that the substitution pattern around the amide 
moiety plays a critical role in cellular activity, likely due to differences in cell permeability. 
 
57 
BIX02189 has proved to be a powerful molecular tool in the design and validation of both in 
vitro and cell based assays and is currently used as a positive control in the dual-luciferase 
MEF2D reporter gene assay being conducted at the Babraham Institute.  
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Chapter 5: The 3-Cyanopyridine Series 
5.1 Synthetic Strategy Towards 3-Cyanopyridines 
The first synthetic approach which was considered for the synthesis of 3-cyanopyridines was 
based on the route reported by Shestopalov et al (Figure 26).
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 4,6-Diaryl-3-cyanopyridine-
2(1H)-thiones are key intermediates in the synthesis of hit compounds 67 and 68 and allow 
diversification at the R
1
 position via alkylation of the pyridine-thione motif. Aryl substituted 
pyridine-thiones are accessible from the appropriate α, β-unsaturated ketones.  
 
Figure 26: Retrosynthetic analysis of the 3-cyanopyridine scaffold 
 
Scheme 3: Shestopalov’s synthesis of 58: Reagents and Conditions; i) S8, morpholine, EtOH, 
80 
o
C, 30 min then malononitrile, 80 
o
C, 2 h. 
Shestopalov’s one-pot synthesis begins with a Michael addition of malononitrile on an α, β-
unsaturated ketone (Scheme 3). The next step is less well defined. Elemental sulfur (as the 
allotrope S8) is known to give betaines in the presence of organic bases and ethanol (Scheme 
4). 
 
Scheme 4: Reaction of sulfur S8 with morpholine to give the reactive betaine species.
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Reagents and Conditions; morpholine, EtOH, ∆. 
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The ketonitrile, 62 resulting from Michael addition with malononitrile is subsequently 
thiolated at the C(2)-H bond giving 63, and the transformation which occurs thereafter may 
proceed by two possible mechanisms. The first involves formation of a thiirene ring followed 
by rearrangement and finally cyclization by intramolecular condensation (Scheme 5).  
 
Scheme 5: First possible mechanism for pyridine-thione synthesis. 
The alternative mechanism begins with elimination of hydrogen sulfide, which then may add 
across one of the two nitrile groups to give an unsaturated thioamide. Condensation of the 
thioamide gave the product (Scheme 6). 
 
Scheme 6: Second possible mechanism for pyridine-thione synthesis. 
Pyridine-thiones may exist in equilibrium between two possible tautomers, but generally 
prefer to exist as the thione. However, this may be affected by the various ring substituents. 
This phenomenon has been reported with regards to pyridine-4-thiones, where the presence 
of an electron-withdrawing group or groups, particularly polyhalogenated species, can 
influence the compound to exist predominantly as the thiol.
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 The environment in which the 
pyridine-thiones exist may also dictate their preference for either tautomer. It is generally 
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accepted that in polar solvents the predominant form is the thione, but in non-polar solvents 
and in the gaseous phase the thiol may be preferred.
 
Pyridine-2-thiones also readily dimerise 
via a disulfide bond, due to the equilibrium which exists between the thione moiety and its 
thiophenol tautomer. These properties of the pyridine-thione moiety were considered as 
potential challenges in the synthesis and isolation of these intermediates.  
5.2 Hit Validation of 3-Cyanopyridines 
Resyntheses of the two most potent 3-cyanopyridine hits from the HTS (IC50 range 0.4-1.6 
µM) were performed by Dr Betty Cottyn using the synthetic strategy outlined in Section 
5.4.1. Results of hit validation studies are shown in Table 7. 
 
Table 7: IC50 values for resynthesised hit compounds 
Compound R
1
 IC50 HTS (µM) 
IC50 Resynthesised 
(µM)
a
 
67 
 
0.4 20.5 ± 1.3 
68 
 
1.6 4.9 ± 0.3 
a 
Determinations ± standard deviation (mean of n = 2 unless otherwise stated) 
The results show a significant variation between the initial activity observed by HTS to that 
of the resynthesised material. The reason for the discrepancy between these results has not 
been established. However, trace impurities are well known to be the cause of false positive 
results, highlighting the importance of hit validation by resynthesis, and the limitations of the 
HTS campaign. Despite the diminished activity observed in this series, the 3-cyanopyridine 
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scaffold was deemed a valid starting point for initiating structure activity relationship (SAR) 
studies due to its modest potency, synthetic tractability and novelty.  
5.3 Proposed Libraries for the 3-Cyanopyridine Series 
Following hit validation, areas were identified for further investigation in order to build up 
structure activity relationships (SAR) around the 3-cyanopyridine scaffold. Key areas are 
highlighted in Figure 27. 
 
Figure 27: SAR questions posed following hit validation studies 
It was determined that the majority of these questions could be answered following the 
synthesis of three focussed libraries: 
Library 1 – Modification to the thioether side-chain (R1) 
Library 2 – Modification to the aryl substituent (R2 as shown in Figure 26) 
Library 3 – Isosteric replacement of the 3-cyano motif 
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5.3.1 Library 1 - Modification to the Thioether Side-chain 
 
Table 8: Proposed compounds for Library 1 with rationale 
Compound Side-Chain R
1
 Rationale 
68 
 
Present in hit compound; synthesis to be 
optimised 
67 
 
Present in hit compound; methyl ketone is 
tolerated, indicating carboxylic acid may 
be replaced 
69 
 
Classical isostere for the carboxylic acid; 
can the carboxylic acid be replaced? 
70 
 
Amide removed; is the amide group 
crucial for activity? 
71 
 
Amide removed plus chain length 
truncated by one carbon unit; is chain 
length important? 
72 
 
Carbonyl removed; is the carbonyl acting 
as a H-bond acceptor? 
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5.3.2 Library 2 - Modification to the Aryl Substituent 
 
Table 9: Proposed compounds for Library 2  
Compound 73 74 75 76 77 78 79 
R
2
 
  
  
  
 
 
The compounds selected for synthesis in this series aimed to probe regions of the ERK5 ATP 
binding site around the R
2
 aromatic group. In particular, compounds were chosen to 
investigate the position of the substituent and to compare EWG and EDG properties. Due to 
the large molecular weight of the hit compounds (>450 g/mol), replacement of the aromatic 
rings with methyl groups was desirable (compound 80) in order to establish whether the 
aromatic groups in positions R
2
 and R
3
 were part of the pharmacophore. All compounds in 
this series were synthesised containing the carboxylic acid containing side-chain present in 
the parent, 68 for comparison purposes. Selected compounds with the methyl ketone side-
chain were also synthesised. 
 
80 
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5.3.3 Library 3 – Isosteric Replacement of the 3-Cyano Motif 
 
Table 10: Proposed replacements for the cyano group, X. 
Compound 81 82 83 
X -H -Br -CCH 
 
To determine the nature of the interaction of the nitrile group within the enzyme ATP binding 
site, a series of replacements were considered. The bromo analogue would have a similar size 
and lipophilicity but lacks the H-bond acceptor and EWG character. The alkyne is a more 
classical isostere, occupying the same area of chemical space and possessing sp hybridisation 
character. However, the alkyne is a weak H-bond donor, whereas the nitrile is an acceptor.  
5.4 SAR Studies of the Thioether Side-Chain (R
1
) 
Preliminary SAR studies aimed to investigate the role of the functional groups present in the 
thioether side-chain, while keeping aryl groups R
2
 and R
3
 constant. The first objective was to 
optimise the chemistry utilised for resynthesis of the initial hits. 
5.4.1 Optimisation of the synthesis of 4-(4-fluorophenyl)-6-phenylpyridine-2(1H)-thione 86 
4-Fluorochalcone was obtained via aldol condensation of acetophenone with 4-
fluorobenzaldehyde (Scheme 7). This reaction proceeded cleanly with ease of purification by 
recrystallisation in 75%. The key step towards the synthesis of 86 proved challenging. Low 
isolated yields (≤ 15%) were reported, which have been attributed to the ability of this 
intermediate to tautomerise, and its readiness to oxidise under atmospheric conditions.
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76 
 
 
Scheme 7: Initial synthetic strategy towards 86: Reagents and Conditions; i) acetophenone, 
NaOH, EtOH, RT, 16 h; ii) S8, morpholine, EtOH, 80 
o
C, 30 min then malononitrile, 80 
o
C, 2 
h. 
Generation of the betaine species followed by addition of malononitrile and the relevant 
chalcone, 85 resulted in formation of a complex reaction mixture. The one-pot nature of the 
cyclisation reaction was thought to add unnecessary complexity so the replacement of the 
unusual betaine species with 2-cyanothioacetamide for the Michael addition was investigated. 
Due to the unstable nature of 86 in air, subsequent reactions were performed under an 
atmosphere of nitrogen. Purification difficulties were overcome by reacting the crude 
intermediate directly in the alkylation step, with an excess of sodium methoxide to give 89. 
tert-Butyl 2-(2-bromoacetamido)acetate, 88 was synthesised via an efficient one-step 
procedure, in excellent yield (96%), (Scheme 8). This improved method (Scheme 9) led to 
the isolation of 89 in 54% yield over 2 steps, and the product was easily purified by column 
chromatography. Deprotection of the tert-butyl ester with neat TFA gave acid 68 in near 
quantitative yield (99%). This methodology was used for the synthesis of all subsequent 3-
cyanopyridine compounds.  
 
Scheme 8: Synthesis of tert-butyl 2-(2-bromoacetamido)acetate, 88. Reagents and 
Conditions; i) bromoacetyl chloride, Et3N, DMAP, DCM, 0 
o
C-RT, 3 h. 
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Scheme 9: Optimised synthesis of 68: Reagents and Conditions; i) acetophenone, NaOH, 
EtOH, RT, 16 h; ii) 2-cyanothioacetamide, 1.6M sodium methoxide solution, 80 
o
C, 1.5 h; iii) 
tert-butyl 2-(2-bromoacetamido)acetate, DMF, 100 
o
C, 3-4 h; iv) TFA, RT, 30 min. 
5.4.2 Isosteric Replacement of the Carboxylic Acid 
The most potent compound identified from HTS (68) contains a carboxylic acid moiety at the 
terminus of the thioether side-chain. Replacement of this group was thought to be desirable 
due to the association of carboxylic acids with poor cell permeability. Extension of Scheme 9 
with two further reactions allowed isosteric replacement with an amide (to investigate its 
importance) (Scheme 10). Coupling of p-methoxybenzylamine in the presence of HBTU gave 
amide 90 in a moderate yield of 47%. This intermediate was also sent for biological 
evaluation. Subsequent cleavage of the PMB group was achieved using neat TFA. Reaction 
monitoring by LCMS indicated a slow conversion to the desired primary amide, with a 
reaction time of 48 h necessary to reach completion, giving primary amide 69 in 52% yield 
(unoptimised).  
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Scheme 10: Synthesis of N-(2-amino-2-oxoethyl)-2-((4-(4-fluorophenyl)-6-phenylpyridin-2-
yl)thio)acetamide, 69: Reagents and Conditions; i) p-methoxybenzylamine, HBTU, DIPEA, 
DMF, 60 
o
C, 4.5 h; ii) TFA, 70 
o
C, 48 h. 
5.4.3 Modification to the Secondary Amine 
The amide group provides one potential hydrogen bond donor and one acceptor. Systematic 
removal of one or both of these motifs was performed in order to establish which (if any) 
were involved in key interactions with the binding site of the enzyme. Synthesis of a suitable 
side-chain containing a secondary amine proved to be challenging (Scheme 11). 
Scheme 11: Synthesis of tert-butyl 2-((tert-butoxycarbonyl)(2-
((methylsulfonyl)oxy)ethyl)amino)acetate, 94. Reagents and Conditions; i) ethanolamine, 
RT, 72 h; ii) Boc2O, Et3N, DMAP, DCM, RT, 3 h; iii) MsCl, Et3N, DCM, 0 
o
C-RT, 16 h. 
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SN2 substitution of ethanolamine with tert-butyl 2-bromoacetate gave alcohol 92 in good 
yield (82%). Boc protection of the resulting secondary amine, followed by mesylation gave 
mesylate 94 which was used immediately in the subsequent alkylation with 86 (Scheme 12). 
Purification of intermediates 93 and 94 was not performed, due to concerns of intramolecular 
lactonisation, or polymerisation. As intermediates 93 and 94 both contain a lone pair on their 
respective alcohol and mesylate groups, it was suggested that attack of the lone pair on the 
carbonyl moieties present in the Boc and tert-butyl ester groups may be possible.  
Substitutions of the 3-cyanopyridine scaffold with tert-butyl 5-bromopentanoate and tert-
butyl 4-bromobutanoate proceeded in moderate yields of 34 and 58% over two steps 
respectively but comparable to that of tert-butyl 2-(2-bromoacetamido)acetate (54% over two 
steps). However, the reaction with tert-butyl 2-((tert-butoxycarbonyl)(2-
((methylsulfonyl)oxy)ethyl)amino)acetate afforded 97 in low yield of 12% over 3 steps. 
Deprotection gave products 70, 71 and 72 in 54-91%.  
 
Scheme 12: SN2 substitution and subsequent deprotection of 3-cyanopyridine side-chains. 
Reagents and conditions; i) relevant bromoalkyl/acetyl species, DMF, 100 
o
C, 3-4 h; ii) TFA, 
RT, 30 min. 
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5.4.4 ERK5 Inhibitory Activity of Thioether Analogues 
Biological results from the IMAP
™ 
assay for compounds synthesised in this series are shown 
in Table 11. Results are expressed as IC50 values and as % inhibition at 120 µM. However, it 
was observed that during the assay, a number of the compounds were insoluble at higher 
concentrations (indicated in Table 11) and therefore results for these compounds cannot be 
considered accurate. 
All changes to the thioether side-chain resulted in loss of potency, giving compounds with 
IC50 values greater than 120 µM. Interestingly, the primary amide 69 is much less active than 
its carboxylic acid and methyl ketone counterparts. Conservation of the peptidic features of 
the side-chain appears to be crucial, as removal of the carbonyl or amide (compounds 70, 71 
and 72) appears to abolish activity.  
 
Table 11: SARs for compounds with variation at R
1
. NB: Insoluble = Compound precipitated 
at 1.2 mM in 40% DMSO 
Compound R
1
 IC50 (µM)
a
 
% Inhibition @ 
120 µM
a
 
Solubility 
68 
 
4.9 ± 0.3 89 ± 5.8  
67 
 
20.5 ± 1.3 72.6 ± 0.2  
90 
 
>120 23.6 ± 4.0 Insoluble 
69 
 
>120 37.6 ± 7.5  
81 
 
70  
 
>120 49.0 ± 1.0 Insoluble 
71 
 
>120 40.8 ± 5.6 Insoluble 
72 
 
>120 32.8 ± 1.6  
a 
Determinations ± standard deviation (mean of n = 2 unless otherwise stated) 
5.5 Modification to the R
2
 Aryl Substituent 
Both of the hit compounds identified from HTS contained a 4-fluorophenyl group in the R
2
 
position of the 3-cyanopyridine core. SAR studies were initiated to investigate the importance 
of this moiety and expand the diversity at this position.  
5.5.1 Synthesis of Carboxylic Acid Derivatives 
A small library of compounds was prepared using the optimised synthetic route described in 
Section 5.4.1, via Michael addition of the relevant chalcone with 2-cyanothioacetamide, 
followed by cyclisation, then alkylation of the resulting thione. Preliminary SAR conducted 
by Dr Betty Cottyn had revealed that removal of the fluorine atom abolished activity. Hence, 
replacement with other electron withdrawing groups, and modification to the position of the 
fluorine atom was explored. 
Aldol condensations gave moderate to good yields, with the exception of 4-pyridine 
carboxaldehyde (10% yield). In this case, synthesis of the relevant chalcone, 106 was 
achieved via a Wittig reaction, using (benzoylmethylene)triphenylphosphorane which gave 
(E)-1-phenyl-3-(pyridin-4-yl)prop-2-en-1-one in an improved yield of 78% (Scheme 13). 
Tandem Michael addition/cyclisation and SN2 substitution reactions all proceeded to give the 
desired products in variable yield (20-54%; Table 12). 
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Table 12: Synthesis summary for compounds with variation at R
2
. Reagents and conditions 
are as shown in Scheme 9, page 77 . 
R
2
 
Aldol Condensation 
Yield, i (%) 
Cyclisation/SN2 
Substitution 
Yield, ii/iii (%) 
Deprotection 
Yield, iv (%) 
 
85; 75 89; 54 68; 99 
 
98; 64 99; 46 73; 100 
 
100; 56 101; 20 74; 99 
 
102; 80 103; 41 75; 100 
 
104; 73 105; 28 76; 90 
 
106; 10 - - 
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 Scheme 13: Synthesis of (E)-1-phenyl-3-(pyridin-4-yl)prop-2-en-1-one, 77. Reagents and 
Conditions; i) (benzoylmethylene)triphenylphosphorane, toluene, 110 
o
C, 3 h; ii) 2-
cyanothioacetamide, 1.6M sodium methoxide solution, 80 
o
C, 1.5 h; iii) tert-butyl 2-(2-
bromoacetamido)acetate, DMF, 100 
o
C, 3-4 h; iv) TFA, RT, 30 min. 
5.5.2 Synthesis of Methyl Ketone Derivatives 
Incorporation of the methyl ketone side-chain was performed on selected 3-cyanopyridine 
scaffolds for direct comparison with the carboxylic acid based compounds. 2-Bromo-N-(2-
oxopropyl)acetamide, 113 was synthesised via conversion of 2-((tert-
butoxycarbonyl)amino)acetic acid, 109 to the corresponding Weinreb amide 110, followed by 
reaction with methyl magnesium bromidegiving methyl ketone 111. Hydrolysis of the 
carbamate gave intermediate 112, which was reacted directly as the hydrochloride salt with 
bromoacetyl chloride (Scheme 14). Subsequent alkylations with 2-bromo-N-(2-
oxopropyl)acetamide 113 are summarised in Table 13. 
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Scheme 14: Synthesis of 2-bromo-N-(2-oxopropyl)acetamide, 113, and subsequent coupling. 
Reagents and Conditions; i) CDI, THF, 70 
o
C, 3 h then N,O-dimethylhydroxylamine 
hydrochloride, Et3N, 50 
o
C, 3 h; ii) MeMgCl THF, 0 
o
C-RT, 16 h; iii) 4M HCl in dioxane, 
RT, 12 h; iv) bromoacetyl chloride, Et3N, DMAP, DCM, RT, 12 h, v) Relevant R
2
 substituted 
pyridine-thione (crude mixture), DMF, 100 
o
C, 3-4 h. 
 
Table 13: Synthesis summary for compounds with variation at R
2 
Compound R
2
 
Cyclisation/SN2 Substitution 
Yield, i (%) 
67 
 
36 
114 
 
78 
 
 
85 
 
5.5.3 Investigation of SAR for the Replacement of the 4- and 6- Aromatic Rings 
Substitution of 2-mercapto-4,6-dimethylnicotinonitrile 115 with tert-butyl 2-(2-
bromoacetamido)acetate using KOH as the base proceeded in a typical yield of 52% and 
deprotection was quantitative. The corresponding reaction with 2-bromo-N-(2-
oxopropyl)acetamide, 113 gave 2-((3-cyano-4,6-dimethylpyridin-2-yl)thio)-N-(2-
oxopropyl)acetamide, 117 in 79%. 
 
Scheme 15: Synthesis of 80 and 117. Reagents and Conditions; i) relevant bromoacetyl side-
chain 113 or 88, KOH, DMF, 100 
o
C, 3 h; ii) TFA, RT, 30 min. 
5.5.4 ERK5 Inhibitory Activity of Carboxylic Acid Analogues 
Repositioning the fluorine atom to the 3-position of the aryl ring abolished activity. 
Interestingly, the 2-fluorophenyl analogue showed moderate activity with an IC50 value of 
34.3 µM (and 100% inhibition of the enzyme at 120 µM). This compound was effective only 
at concentrations above 10 µM, but inhibitory activity greatly increased above this 
concentration. At 120 µM, compound 74 is more potent than the initial hit 68, but has a lower 
overall IC50. Combining both fluorine atoms in the 2- and 4- positions does not show an 
additive (or synergistic) effect. Difluoro compound 75 was found to be less active (ERK5 
IC50 = 73 µM) than both mono-fluorinated analogues. However, this compound suffered from 
poor solubility in the assay which may have contributed to lower observed activity. 
Replacement of the 4-fluoro group with a 4-CF3 moiety, 76 also led to a reduction in potency. 
The 4-pyridyl derivative, 77, was also less potent compared to the parent, 68. Removal of the 
aryl groups abolished activity, confirming the requirement for aromatic substituents in the 4- 
and 6-positions of the 3-cyanopyridine scaffold. 
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Table 14: ERK5 inhibitory activity for carboxylic acid analogues 
Compound R
2
 R
3
 IC50 (µM)
a
 
% Inhibition 
@ 120 µM
a
 
Solubility
b
 
68 
 
Ph 4.9 ± 0.3 89 ± 5.8  
73 
 
Ph >120 25.4 ± 2.9  
74 
 
Ph 34.3 ± 6.4 102.1 ± 1.6  
75 
 
Ph 72.9 ± 26.1 66.9 ± 9.3 Insoluble 
76 
 
Ph >120 50.1 ± 15.0  
77 
 
Ph 65.1 ± 12.4 81.7 ± 4.4  
80 Me Me >120 14.0 ± 3.8  
a 
Determinations ± standard deviation (mean of n = 2 unless otherwise stated) 
b
 NB: Insoluble 
= Compound precipitated at 1.2 mM in 40% DMSO 
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5.5.5 ERK5 Inhibitory Activity of Methyl Ketone Analogues 
 
Table 15: ERK5 inhibitory activity of methyl ketone analogues 
Compound R
2
 R
3
 IC50 (µM)
a
 
% Inhibition @ 
120 µM
a
 
67 
 
Ph 20.5 ± 1.3 72.6 ± 0.2 
114 
 
Ph 104.9 ± 6.5 76.1 ± 5.2 
117 Me Me >120 6.0 ± 1.6 
a 
Determinations ± standard deviation (mean of n = 2 unless otherwise stated) 
A 4-fold loss in activity was observed between the parent methyl ketone, 67 and the 4-pyridyl 
and dimethylated derivatives.  
5.6 Isosteric Replacement of the 3-Cyano Motif 
Previous work had shown that removal of the 3-cyano moiety had a detrimental effect on 
activity, e.g pyridine 81 showed weak ERK5 inhibition (50% at 120 µM). Replacement of the 
nitrile with a bromine atom as a steric isostere was performed. It was initially envisaged that 
the incorporation of a halogen at the 3-position would also allow Sonogashira coupling to 
introduce an alkyne as a classical isostere if desired. 
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81; ERK5 IC50 >120 µM; % Inhibition = 50.4% ± 1.2 @ 120 µM 
5.6.1 Synthesis of 3-Bromo and 3-Alkynyl Analogues 
Following a similar procedure to the synthesis of 4-(4-fluorophenyl)-6-phenylpyridine-2(1H)-
thione, 86, 4-(4-fluorophenyl)-6-phenylpyridin-2(1H)-one, 118 was isolated in 34% (Scheme 
16). Bromination of the 3-position of the pyridine was achieved selectively using N-
bromosuccinamide in acetic acid. Selectivity for bromination of the 3-position was confirmed 
by a combination of COSY and NOESY NMR experiments of intermediates 118 and 119. 
The C(3)-H may only show interaction with one aromatic proton through space in the 
NOESY spectrum. When the 3-position was brominated, peaks associated with the 
interaction between C(5)-H and protons present on two different aromatic rings were visible, 
thus confirming the selectivity for the 3-position. Conversion of the pyridone to pyridine-
thione was performed successfully using Lawesson’s reagent. Once again, rapid 
tautomerisation to the thiol form was observed by analysis of the crude mixture by 
1
H NMR 
spectroscopy, and so the mixture was subjected to alkylation without further purification. 
Deprotection of the tert-butyl ester proved trivial and gave 82 in 93% yield. 
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Scheme 16: Synthesis of 2-(2-((3-bromo-4-(4-fluorophenyl)-6-phenylpyridin-2-
yl)thio)acetamido)acetic acid, 82. Reagents and Conditions; i) acetamidoacetamide, Cs2CO3, 
DMF, 100 
o
C, 2.5 h; ii) NBS, AcOH, 60 
oC, 5 h; iii) Lawesson’s reagent, toluene, 100 oC, 20 
h; iv) tert-butyl 2-(2-bromoacetamido)acetate, KOH, DMF, 100 
o
C, 4 h; v) TFA, RT, 30 min. 
Sonogashira couplings were attempted using intermediate 119 as the bromoaryl species 
(Scheme 17). Introduction of the alkyne at this stage would allow continuation of Scheme 16, 
via conversion to the thione, alkylation of the sulphur and deprotection of the tert-butyl ester. 
Finally, deprotection of the silyl protecting group with TBAF would afford the final 
carboxylic acid product. Unfortunately, no conversion to the corresponding alkyne was 
observed. When microwave irradiation was used, reductive dehalogenation occurred (entries 
3 and 4; Table 16).  
 
Scheme 17: Reagents and Conditions; i) TMS acetylene, Pd(PPh3)2Cl2, CuI, Et3N, THF, See 
conditions in Table 16. 
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Table 16: Sonogashira coupling conditions attempted with intermediate 119 
Attempt Temp (
o
C) Time (h) Observation 
1 RT 16 No conversion 
2 80 16 No conversion 
3 100 MW 1 
No conversion; loss 
of bromine 
4 150 MW 1 
No conversion; loss 
of bromine 
 
Synthesis of the corresponding 3-iodo analogue, 123 was performed to enhance reactivity in 
the Sonogashira coupling (Scheme 18). Intermediate 118 was reacted with NIS in 
quantitative yield. Sonogashira couplings were subsequently attempted (Table 17). Reaction 
monitoring by LCMS was used throughout the optimisation process.  No conversion to the 
alkyne was observed with conventional heating, but microwave irradiation at temperatures of 
100 
o
C and 120 
o
C resulted in 18-36% conversion with no reductive dehalogenation. TMS-
alkyne 122 was not isolated during optimisation due to the small scale of the reactions 
undertaken. Further optimisation attempts were to focus on the modification to the catalyst 
employed, and reaction time at a fixed temperature of 120 
o
C (MW). Following optimisation, 
it was planned that TMS-alkyne 122 would be isolated, then scale-up to be performed. 
Unfortunately, SAR data indicated that all other structural modifications to the 3-
cyanopyridine scaffold abolished activity. Due to the extensive optimisation required, 
synthesis of the 3-alkynyl analogue was postponed pending further results in this series. 
 
Scheme 18: Reagents and Conditions; i) NIS, AcOH, 60 
o
C, 5 h; ii) TMS acetylene, 
Pd(PPh3)2Cl2, CuI, Et3N, THF, See conditions in Table 17. 
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Table 17: Sonogashira coupling conditions attempted with intermediate 123 
Attempt Temp (
o
C) Time (h) Observation 
1 RT 16 No conversion 
2 80 16 No conversion 
3 100, MW 1 18% conversion by LCMS 
4 150, MW 1 
32% conversion by LCMS; 
majority –I (m/z 266) 
5 120, MW 1 
36% conversion by LCMS; 
No degredation 
 
5.6.2 SAR for Cyano Group Replacement 
 
Table 18: NB: Insoluble = Compound precipitated at 1.2 mM in 40% DMSO 
Compound X IC50 (µM)
a
 
% Inhibition @ 
120 µM
a
 
Solubility 
68 CN 4.9 ± 0.3 89 ± 5.8  
81 H >120 50.4 ± 1.2  
82 Br 74.3 
b
 53.2 ± 14.5 Insoluble 
a 
Determinations ± standard deviation (mean of n = 2 unless otherwise stated); 
b 
n = 1 
Replacement of the cyano group with a bromine atom acting as a steric isostere did not confer 
any additional potency against ERK5 versus the parent compound. The brominated analogue 
was equipotent with compound 81, suggesting that the nitrile is acting as a hydrogen bond 
acceptor. However, due to the increased lipophilicity of the brominated analogue (clogP = 5.3 
vs 4.3 for X = CN), aqueous solubility of this compound under assay conditions was poor. As 
such, a definite conclusion regarding the role of the cyano moiety could not be reached. 
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5.7 Conclusion 
Hit validation was performed for two 3-cyanopyridines (67 and 68). The resynthesised 
compounds showed a significant decrease in potency following resynthesis, but with 
acceptable variation. Structural modifications focussing around components of the thioether 
side-chain, the R
2
-aryl substituent and the 3-cyano moiety were performed. Structure-activity 
relationships showed that the original hits remained the most potent inhibitors to date (i.e. 68, 
ERK5 IC50 = 4.9 µM). Many of the compounds synthesised displayed poor solubility in the 
IMAP
™ 
assay, rendering biological data for such compounds inaccurate. As a result of the 
limited SARs and poor solubility, further work on this series was discontinued. 
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Chapter 6: The Pyrrole-Carboxamide series 
6.1 Synthetic Strategies Towards Pyrroles 
There are several reported synthetic routes towards substituted pyrrole-based compounds. 
Due the presence of the pyrrole motif in numerous bioactive natural products (e.g. Lamellarin 
O, 124 and Lukianol A, 125; effective cytotoxic agents in leukaemia and lymphoma 
screens)
109
 pyrroles are an attractive target for synthetic research. Three classical methods are 
described herein; the Knorr and Paal-Knorr syntheses, and the Hantzsch pyrrole synthesis.  
 
                Lamellarin O, 124               Lukianol A, 125 
6.1.1 Knorr Pyrrole Synthesis 
In 1884, Knorr published his synthetic route towards pyrrole-3-carboxylate.
110
 An α-
aminoketone is reacted with a β-ketoester in the presence of catalytic zinc and acetic acid. 
Tandem condensation of the amine with the β-ketoester followed by an intramolecular aldol-
type condensation gives the desired pyrrole product. Because α-aminoketones readily self-
condense, this species is usually prepared in situ from the relevant oxime.  
 
Scheme 19: Knorr Pyrrole Synthesis. 
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6.1.2 Paal-Knorr Pyrrole Synthesis 
One year later (1885), the Paal-Knorr synthesis was simultaneously published by the two 
chemists.
111
 Despite widespread use of the Paal-Knorr method, the mechanism was not fully 
elucidated until 1991 (Amarnath et al).
112
 Mechanistic studies revealed that cyclisation 
proceeds via a hemiaminal intermediate, as opposed to an enamine, or imine intermediate. 
The reaction may be conducted under neutral or slightly acidic conditions with an excess of 
the amine. However, care must be taken as excessively acidic reaction conditions (below pH 
3) result in formation of the corresponding furan. 
 
Scheme 20: Paal-Knorr Pyrrole Synthesis. 
6.1.3 Hantzsch Pyrrole Synthesis  
The multicomponent Hantzsch synthesis was described a few years later (1890). Not unlike 
the Knorr synthesis, a β-ketoester is reacted with an amine (in this case ammonia). The 
resulting enamine then reacts with an α-haloketone, followed by cyclisation to give the 
product (Scheme 21). Historically, this reaction has not been as widely used, due to reported 
low yields associated with furan by-products. Solid-phase syntheses have recently been 
developed to improve yields, which utilise acetoacetylated Rink resin, with the relevant α-
haloketone and amine (Scheme 22) under mild conditions. Hydrolysis of the resin is achieved 
via acid hydrolysis.
113
 
 
Scheme 21: Hantzsch pyrrole synthesis. 
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Scheme 22: Hantzsch pyrrole synthesis on solid support.
113
 Reagents and Conditions; i) 
R
1
NH2, trimethylorthoformate, DMF, RT, 48 h; ii) 2, 6-di-tert-butylpyridine, DMF, RT, 17 h; 
iii) 20% TFA/DCM, RT, 30 min. 
6.2 Pyrrole-Carboxamides Identified from HTS 
HTS identified seventeen compounds which fit into the pyrrole-carboxamide class. Of this 
seventeen, seven were shown to inhibit ERK5 at <10 µM. Validation by resynthesis was 
performed for four of the most potent hits (Table 19). 
Two of the four hits were shown to be inactive against ERK5 (139, 140; >120 µM), and 
compound 141 was 10-fold less active. However, the most potent hit identified (138) was 
validated as an inhibitor of ERK5 in the low micromolar range (IC50 = 3.7 ± 0.8 µM). SAR 
studies were initiated following this result. 
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Table 19: IC50 values for resynthesised hit compounds  
Compound R
1
 R
2
 IC50 HTS (µM) 
IC50 
Resynthesised 
(µM)
a
 
138 
 
 
0.7 3.7 ± 0.8 
139 
 
 
1.9 >120 
140 
 
 
3.5 >120 
141 
 
 
4.3 42.0 ± 3.4 
a 
Determinations ± standard deviation (mean of n = 2). 
6.3 Existing SAR Around the Pyrrole-Carboxamide Scaffold 
Preliminary SAR data was generated by Dr Sandrine Vidot and Dr Ruth Bawn. Modification 
to the aroyl ring demonstrated that incorporation of a substituent in the para-position was not 
tolerated (147, Table 20). Dihalogenation (2,3-dichloro or 2,6-difluoro) conferred the best 
potency. N-Methylation of the heterocycle abolished activity (ERK5 >120 µM), indicating 
that the pyrrole NH is acting as a hydrogen bond donor. N-Methylation of the carboxamide 
motif was tolerated, but activity was 5-fold lower than the non-methylated counterpart (145 
versus 146, Table 20). Removal of the ketone or reduction to the corresponding secondary 
alcohol also resulted in loss of activity (ERK5 >120 µM), suggesting presence of a hydrogen 
bond acceptor in this position is crucial. Finally, 3- and 4-pyridyl substituents were found to 
97 
 
be equipotent with the 4-fluorophenyl moiety present in the carboxamide side-chain of hit 
compound 138. 
 
 
Figure 28: SARs for the pyrrole-carboxamide series 
 
Table 20: Preliminary SAR data around the pyrrole-carboxamide core 
Compound R
1
 R
2
 IC50 (µM)
a
 
138 
 
 
3.7 ± 0.8 
142 
 
 
2.0 ± 2.0 
143 
 
 
3.8 ± 3.7 
144 
 
 
2.3 ± 0.1 
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145 
  
1.8 ± 0.6 
146 
  
9.0 ± 0.2 
147 
 
 
>120 
a 
Determinations ± standard deviation (n =2) 
6.4 Hit-to-Lead Development Criteria 
Following successful hit validation and the establishment of clear preliminary SAR, hit-to-
lead studies aimed to develop compounds with improved potency, desirable physicochemical 
and in vitro ADMET properties and finally, in vivo efficacy and a suitable DMPK profile. 
Target parameters identified for a lead compound are shown in Table 21. These criteria were 
utilised throughout the hit-to-lead phase. The primary objective following hit validation was 
to improve ERK5 inhibitory activity (with a target IC50 of less than 1 µM), while maintaining 
drug-like physicochemical properties. Physicochemical property criteria were set according 
to Lipinski’s rule of five; discussed in more detail in Section 6.7.7.1. Ligand efficiency (LE) 
was used as a measurement of overall binding energy per heavy atom, with a value greater 
than 0.3 for LE indicating a high efficiency. Selectivity versus a panel of 131 diverse protein 
kinases was performed at the International Centre for Kinase Profiling, and routine counter-
screening against the closest homologue of ERK5, p38α performed at CRT. An initial target 
of 10-fold selectivity against all other protein kinases was desirable, in order to attribute 
efficacious effects observed in subsequent in vitro and in vivo studies to ERK5, ruling out any 
off-target effects. In addition, cellular activity was measured for compounds displaying 
superior in vitro activity (<1 µM). The dual luciferase reporter gene assay is described in 
further detail in Section 7.8, and is a measure of the ability of the compound to cross cell 
membranes in a HEK293 (human embryonic kidney) cell-line, and cellular ERK5 inhibition. 
An initial cellular IC50 below 10 µM was deemed an acceptable level of permeation 
dependent activity. Undesirable inhibitory effects of CYP isoforms and hERG were also 
monitored, aiming for greater than 10 and 25 µM inhibitory concentrations, respectively, to 
maximise the elimination of drug-drug interaction and cardiotoxicity liability. A high free 
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fraction (<99% in PPB assays), low microsomal clearance in human and mouse liver 
microsomes (<48 µL/min/mg), high aqueous solubility (> 50 µM) and a low efflux ratio in 
the Caco-2 assay (<2) were prioritised to achieve the best chance of good oral bioavailability, 
and an acceptable half-life in vivo. At this stage, research was guided using homology 
modelling due to the lack of a protein crystal structure of ERK5. 
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Table 21: Target criteria for development of a lead compound 
Category Criteria Lead Compound 
Physicochemical 
properties 
Modelling/Crystal Structure Required 
Molecular weight (MW) <500 
sLogP <5 
TPSA 75-100 
H bond donors/acceptors <5/<10 
PKa Salt forming 
In Vitro pharmacology 
ERK5 IC50 (µM) < 1 
LE >0.3 
Selectivity (over other kinases) >10 fold 
Cellular ERK5 IC50 (µM) <10 
hERG IC50 (µM) >25 
In Vitro ADME 
Solubility (µM) >50 
PPB (%) <99 
Mouse liver microsomal (MLM) 
Clearance (µL/min/mg) 
<48 
Human liver microsomal (HLM) 
Clearance (µL/min/mg) 
<48 
Caco-2 A2B Papp (x10
-6
 cm/s) >10 
Efflux Ratio <2 
CYP1A, CYP2C19, CYP2C9, 
CYP2D6, CYP3A4 IC50 (µM) 
All >10 
In Vivo DMPK and 
Efficacy 
Clearance (mL/mg/kg) <30 
Vdss (L/kg) >1 
Bioavailability (F) (%) >30 
t1/2 Mouse (h) >1 
t1/2 Human (h) >1 
Biomarker modulation Required 
Xenograft efficacy Required 
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6.5 Structure-Guided Drug Design 
Modern drug discovery and optimisation efforts, particularly in the area of kinase inhibitors, 
have largely relied on crystallographic methods to aid in the design of novel compounds.
114
 
As a crystal structure was not available for use in structure-guided drug design, the homology 
model was developed by Dr Susan Boyd of CompChem Solutions, on behalf of CRT. 
BLAST (Basic Local Alignment Search Tool) searching identified ERK2 as the closest 
homologue of ERK5, with 51% and 78% sequence identity in the kinase domain and active 
site regions respectively. Therefore, the original homology model was based on ERK2 
(Figure 29). Three key active site differences between ERK2 and ERK5 were identified as 
follows: Ile103 (ERK2)/Val134 (ERK5), Gln105 (ERK2)/Leu136 (ERK5) and Cys164 
(ERK2)/Gly198 (ERK5).  Fus-3, a non-mammalian protein, was identified as the second 
BLAST hit, followed by p38α which has a 56% sequence identity with the ERK5 binding 
site. The highly conserved protein structure amongst the MAPK family was considered to be 
a challenge for the design of selective ERK5 inhibitors. 
 
Figure 29: Homology model of ERK5 based on the structure of ERK2; Green = ERK5 
model; Red = ERK2 template. 
It has been reported that a single mutation of the gatekeeper residue of ERK2 (Gln105) 
results in the susceptibility of the protein to p38α inhibitors, where selectivity was previously 
observed in wild-type ERK2.
115
  Substitution of Gln105 with threonine or alanine results in 
pyridinyl imidazole-based inhibitors of p38α conferring potency against mutant ERK2. 
102 
 
SB202190, 148 binding is 25,000-fold greater following mutation of the binding site (Figure 
30). 
 
SB202190, 148 
 
Figure 30: A closely related analogue of SB202190 148, bound in the mutant ERK2 active 
site (Q105T; blue), versus wild-type ERK2 (red). 
Comparison of the ERK2, ERK5 (modelled) and p38α protein structures revealed that the 
differences in gatekeeper residues could be exploited in order to achieve selectivity. The 
gatekeeper residues in ERK5 and p38α are leucine and threonine respectively. Unfortunately, 
these two residues are similar in size, increasing the difficulty of achieving selectivity. The 
homology model was used to propose a binding mode for the pyrrole-carboxamide series, and 
two potential solutions were found. It is likely that the pyrrole-carboxamide series inhibit 
ERK5 in an ATP competitive manner. Binding mode 1 (Figures 31, 32) suggested that the 
nitrogen atom of the pyridine ring makes an interaction with the salt bridge lysine residue, 
leaving the halogenated aroyl moiety pointing out into solvent. 
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Figure 31: Binding mode 1 prediction; interaction of pyridine with salt bridge lysine residue. 
 
Figure 32: Binding mode 1 prediction; 3D model. 
Binding mode 2 (Figures 33, 34) suggested that the aroyl group is directed into the 
hydrophobic pocket, with the carbonyl group making a key interaction with the salt bridge 
lysine residue. Taking into account the previous SAR data, it is more likely that this is the 
correct binding mode. The sensitivity of the potency to the substitution pattern around the 
aroyl substituent implies that there is a limited amount of space in the hydrophobic pocket. 
For example a loss of activity was observed when para substituents (e.g. 147) were 
incorporated. In this model, when the aroyl ring is di-ortho substituted, steric contacts are 
maximised with the protein. When no ortho-substituent is present, poorer steric contacts and 
some steric clashes at the meta-position are observed. The observed SAR supports the second 
of the two proposed homology models.  
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Figure 33: Binding mode 2 prediction; interaction of carbonyl with salt bridge lysine residue; 
All Cl shown for demonstration purposes. 
 
Figure 34: Binding mode 2 prediction; 3D model; All Cl shown for demonstration purposes. 
6.6 Selectivity Screening for Hit Compounds 
Compound 145 was submitted for selectivity screening against a panel of 63 kinases. Of the 
63 screened, 17 showed some degree of inhibition when treated with 145 at a concentration 
of 10 µM. The majority of kinases were only weakly inhibited. However, six kinases were 
identified with greater than 15% inhibition (Table 22).  
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Table 22: Selectivity data of 145 
Kinase % Inhibition @ 10 µM 
JNK1α1 19 
MAPK1 20 
NEK2 43 
PKA 19 
SAPK2a/p38α 91 
SGK 17 
 
The selectivity data highlighted that pyrrole 145 was active against p38α. An IC50 
determination for 145 against p38α confirmed activity of 0.41 ± 0.2 µM. It was clear that 
implementation of a p38α counter-screen would be required for compounds exhibiting 
significant ERK5 activity. Later in the project, counter-screen data combined with existing 
knowledge of the p38α structure would assist in the development of a more refined homology 
model. 
6.7 Structure-Activity Relationships for Modifications to the Aroyl Moiety 
Preliminary SAR data revealed that the substitution pattern around the aroyl ring (R
1
) was 
crucial for activity. Further investigation of this motif was driven by the ERK2-based 
homology models. 
6.7.1 SAR for Replacement of the Phenyl Ring with Saturated Rings 
6.7.1.1 Proposed Series and Rationale 
 Both binding modes suggested by the homology model indicated that a range of non-
aromatic cyclic systems may be tolerated (Figure 35). The primary objective of the work 
undertaken at this stage was to improve potency for ERK5. It appeared that there was 
sufficient space in the binding pocket to accommodate the geometry of the cyclohexane 
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and/or cyclopentane rings in particular. The incorporation of a non-aromatic ring in the 
binding site potentially enables formation of interactions with amino acid residues which are 
not accessible via decoration of the planar aromatic ring. It was also envisaged that a range of 
amide linked 5- or 6- membered heterocycles may be incorporated. The 4-pyridyl side-chain 
was selected to be incorporated in all target compounds to enable direct comparison of 
analogues synthesised. 
 
Figure 35: Homology modelling of a 4-cyclohexanone analogue. 
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Table 23:  Proposed library of non-aromatic derivatives 
R
1
 
 
149 
 
150 
 
151 
 
152 
 
153 
 
154 
 
155 
 
156 
 
157 
 
158 
 
159 
 
160 
 
161 
 
162 
 
163 
 
The library aimed to incorporate non-aromatic groups with a range of properties (e.g. 
variation of sterics, electronics and polarity). Investigation of unsubstituted 5-, 6- and 7-
membered rings was performed in order to establish the steric availability in the binding 
pocket. Methyl or methoxy groups in the 2-, 3- and 4- positions of the 6-membered ring were 
incorporated to probe the importance of the substitution pattern and whether it was possible 
to make additional interactions with the protein structure (i.e. hydrogen-bond formation via 
the oxygen lone pair of the methoxy substituent). Finally, a range of heterocycles were 
introduced. Replacement of the ketone linker with an amide group aimed to enhance the 
hydrogen bonding capability of the carbonyl via a mesomeric effect.
116
 The incorporation of 
additional heteroatoms into the ring creates the possibility additional interactions in the active 
site. 
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6.7.1.2 Synthesis of Unsubstituted Alkyl Ring Containing Analogues 
Cyclohexane, 149, cyclopentane, 150, and cycloheptane 151 derivatives were synthesised via 
the previously established route (Scheme 24). 
Synthesis of target compounds was achieved via an efficient 3-step strategy. Friedel-Crafts 
acylation of commercially available methyl 1H-pyrrole-2-carboxylate, 166 with the relevant 
acid chloride proceeded in excellent yield (80-98%) in all cases. Selectivity for the 4-position 
is achieved using AlCl3 as the Lewis acid.
117
 If necessary, acid chlorides were synthesised 
from the corresponding carboxylic acid (Scheme 23). Hydrolysis of the methyl ester was 
quantitative in all cases. Coupling of carboxylic acids (i.e. 168) with 4-picolylamine using 
CDI afforded the target compounds 149, 150 and 151 in good to excellent yields (60-98%). 
 
Scheme 23: Reagents and conditions: i) SOCl2, DMF (cat), THF, RT, 3 h. 
 
Scheme 24: Reagents and conditions: i) R
1
COCl, AlCl3, DCM, 0 
o
C-RT, 16 h; ii) LiOH 
monohydrate, H2O, THF, 65 
o
C, 16 h; iii) CDI, THF, 70 
o
C, 3 h, then 4-picolylamine, 50 
o
C, 
3 h.  
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Table 24: Synthesis summary for incorporation of unsubstituted saturated rings 
R
1
 
Friedel-Crafts 
Yield (%) 
Hydrolysis 
Yield (%) 
CDI Coupling 
Yield (%) 
 
170; 81 171; 100 149; 60 
 
172; 80 173; 97 150; 63 
 
174; 98 175; 100 151; 98 
 
6.7.1.3 Synthesis of Substituted Alkyl Ring Containing Analogues 
The importance of substituents around the saturated ring was probed. A methyl group was 
incorporated into the 2-, 3- and 4- positions following Scheme 24, to investigate the steric 
tolerance of the binding pocket. Despite the inactivity of the 4-substituted aryl analogues, 4-
substituents on the saturated rings were included as they occupy different space. During the 
syntheses of these analogues, an interesting phenomenon was observed. Two products were 
isolated following Friedel-Crafts acylation of methyl 1H-pyrrole-2-carboxylate, 166 with 2-, 
and 3-methylcyclohexanecarbonyl chloride. Due to the presence of two chiral centres in these 
molecules, it was initially assumed that the two products isolated were the two pairs of 
diastereoisomers, with cis and trans geometry respectively. Analysis of the 
1
H NMR data 
revealed that the products isolated were the two regioisomers (e.g. 176 and 177). Table 25 
shows a distinctive trend between the proportion of 5-substituted product and position of the 
methyl group. It is likely that the observed effect is due to the steric hindrance exerted on the 
intermediate oxonium ion formed in the Friedel-Crafts reaction, by the adjacent methyl 
group. 
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Table 25: Chemical yield, selectivity and stereochemical outcome for the 4- regioisomer 
versus the 5- regioisomer following Friedel-Crafts acylation of methyl 1H-pyrrole-2-
carboxylate 
R
1
 
4-R
1
 Regioisomer 
Yield (%) 
5-R
1
 Regioisomer 
Yield (%) 
Selectivity 
(4- : 5-) 
Stereochemistry 
 
178/179; 59 180/181; 21 3:1 trans only 
 
182/183; 53 184/185; 6 9:1 cis only 
 
186; 59 0 1.0 
Mixture; 
cis:trans 
 
 
Figure 36: Coupling profile of Ha for compounds 178/179 according to the Karplus equation; 
Hb (Jab ~12 Hz), Hc (Jac ~3 Hz) and Hd (Jad ~12 Hz). 
Use of the Karplus equation allowed elucidation of the stereochemical outcome for the 2-
methyl analogues 178/179 and its regioisomers. (Figure 36).
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 Assignment of the 3-methyl 
compounds 182/183 was more challenging, where in this instance the C-1 proton (Ha) was 
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not unequivocally distinguishable as either cis nor trans by 1D NMR alone. A small-
molecule crystal structure was obtained which confirmed that the thermodynamic cis-product 
had been obtained as a mixture of enantiomers (Figure 37). 
 
Figure 37: Small-molecule crystal structure of 183. 
Sterics are believed to be the main factor influencing stereochemical outcome. The proton 
adjacent to the ketone is enolisable, and equilibration to the most thermodynamically stable 
product is likely to have occurred over the course of the reaction, resulting in the two largest 
groups both being in the equatorial position. Acylation of 166 with 4-
methylcyclohexanecarbonyl chloride proceeded regioselectively for the 4-position of the 
pyrrole. However, 4-methyl compound 186 was obtained as a mixture of cis/trans 
diastereoisomers (Table 25). When the methyl group is in the 4-position of the acid chloride 
the steric effect is less significant, resulting in both regioselectivity for the 4-position and an 
increased proportion of the cis diastereoisomer. 
Hydrolysis and CDI couplings on the 4-substituted pyrrole scaffold all proceeded in good 
yield (81-98% and 68-89% respectively; Table 26). Although initially an undesired reaction 
product, the 5-substituted regioisomer was carried forward into subsequent hydrolysis and 
CDI coupling steps, in order for the resulting amides to act as negative control compounds. 
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Table 26: Synthesis summary for 4-methylcyclohexane derivatives 
R
1
 Hydrolysis Yield (%) 
CDI Coupling 
Yield (%) 
 
187/188; 81 189/190; 76 
 
191/192; 85 193/194; 89 
 
195; 98 154; 68 
 
 
Table 27: Synthesis summary for 5-methylcyclohexane derivatives  
R
1
 Hydrolysis Yield (%) 
CDI Coupling 
Yield (%) 
 
196/197; 75% 198/199; 83 
 
200/201; 86 202/203; 79 
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 The same strategy as for synthesis of the methylated compounds was employed for the 
synthesis of methoxy substituted analogues. Synthesis of the 4-substituted analogue, 155 
proceeded as expected (Scheme 25), although an unusually low yield (28%) was obtained for 
the Friedel-Crafts acylation. Amide 155 was achieved as a mixture of diastereoisomers, in a 
similar ratio to the 4-methyl analogue 154.  
 
Scheme 25: Reagents and Conditions; i) 4-methoxycyclohexanecarbonyl chloride, AlCl3, 
DCM, 0 
o
C-RT, 16 h; ii) LiOH monohydrate, H2O, THF, 65 
o
C, 16 h; iii) CDI, THF, 70 
o
C, 3 
h, then 4-picolylamine, 50 
o
C, 3 h.  
It was noted that Friedel-Crafts acylation of methyl 1H-pyrrole-2-carboxylate, 166 with 3-
methoxycyclohexane carbonyl chloride did not yield the desired product. 
1
H NMR analysis 
revealed the major product to be the corresponding alcohol, indicating loss of the methyl 
group under the reaction conditions. In the presence of a Lewis acid, the nucleophilic lone 
pair of the oxygen atom may attack the carbonyl when both groups are in the axial position, 
liberating a chloride ion. The chloride ion may then demethylate the positively charged 
oxygen atom in an SN2 fashion, similar to that observed in a Krapcho reaction.
119
 This could 
yield a bicyclic lactone, which is able to participate in the Friedel-Crafts acylation of the 
aromatic species (Scheme 26) to give the alcohol product. This phenomenon is not observed 
with the 4-methoxy compound. 
114 
 
 
Scheme 26: Formation of a reactive lactone intermediate to afford the 3-hydroxy by-product  
Following Friedel-Crafts acylation alcohol 206 was achieved in 48% yield as a single 
diastereoisomer with cis geometry (the thermodynamic product). Silyl protection of this 
intermediate was performed in order to achieve selectivity during the CDI coupling. 
Hydrolysis and CDI coupling reactions proceeded well in 80% and 54% respectively. 
Deprotection using TBAF gave alcohol 210 in 80% yield (Scheme 27). 
 
Scheme 27: Reagents and Conditions; i) 3-methoxycyclohexane carbonyl chloride, AlCl3, 
DCM, 0 
o
C-RT, 16 h; ii) TIPSCl, imidazole, DCM, RT, 16 h; iii) LiOH monohydrate, H2O, 
THF, 65 
o
C, 16 h; iv) CDI, THF, 70 
o
C, 3 h, then 4-picolylamine, 50 
o
C, 3 h; v) TBAF, THF, 
RT, 3 h. 
It was envisaged that the target methoxy analogue could be synthesised from intermediate 
209 with cis stereochemistry (Scheme 28). Protection of the pyrrole nitrogen with a Boc 
group was intended to enable selective deprotection of the TIPS group using TBAF and so 
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would allow selective methylation of the alcohol. Unfortunately, upon treatment with TBAF 
in THF, both the TIPS and the N-Boc groups were removed from intermediate 211.  
 
Scheme 28: Reagents and Conditions; i) Boc2O, Et3N, DMAP, DCM, 0 
o
C-RT, 16 h; ii) 
TBAF, THF, 0 
o
C, 2 h; iii) O-methylation; iv) Boc deprotection. 
As it was not possible to synthesise the 3-methoxy analogue 214 via this route, it was 
desirable to synthesise the 4-hydroxy counterpart, 215 so that direct comparisons regarding 
the substitution pattern between these compounds could be made.  
Treatment of the 4-methoxy compound, 155 with BBr3 resulted in consumption of the 
starting material (Scheme 29), but the desired product was not isolated. Two products which 
could not be separated by column chromatography were evident. The major product had 
mass/charge ratios (m/z) of 389 and 391 amu in a 1:1 ratio, indicative of the presence of a 
bromine atom. The minor product had an m/z of 310 and crude 
1
H NMR confirmed the 
presence of an alkene. Structures of these reaction by-products were therefore elucidated as 
4-bromocyclohexane, 216 and 4-cyclohex-3-ene 217 (or its regioisomer) containing 
analogues. As it was not possible to separate these two products, no further action was taken. 
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Scheme 29: Conversion of 4-methoxy analogue, 155 to 4-hydroxy compound 215. Reagents 
and Conditions; i) See conditions in Table 28. 
Table 28: Attempted conditions for the formation of 4-hydroxy analogue 215. 
Attempt Reagents and conditions Observation 
1 BBr3, DCM, 0 
o
C-RT, 16 h 
No conversion to product; 
by-products detected 
2 
PhSSiMe3, ZnI2, nBu4NI, 
DCE, 60 
o
C, 16 h 
120
 
No conversion 
 
 
216     217 
Demethylation was subsequently attempted using an organosilane reagent in the presence of a 
Lewis acid (ZnI2) following a literature precedent.
120
 Cleavage of the ether may be brought 
about by treating with a strong oxygenophile (silane), enhanced in the presence of a Lewis 
acid, with tetrabutylammonium iodide (TBAI) as an additive. Unfortunately, heating at 60 
o
C 
overnight showed no conversion to the demethylated product. Following the challenges 
encountered in this series, investigation into the synthesis of 3-methoxy and 4-hydroxy 
analogues was suspended. The use of alternative pyrrole protecting groups was considered 
for the synthesis of the 3-methoxy analogue, and alternative Lewis acids (e.g AlCl3) for the 
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demethylation of 155 but further work was postponed pending biological results on this 
series. 
6.7.1.4 Introduction of Cyclic Tertiary Amides 
In order to synthesise tertiary amide based analogues, an alternative strategy was devised 
(Scheme 30). The use of 2,2,2-trichloro-1-arylethanones with a range of nitrogen containing 
nucleophiles is reported as a high yielding strategy towards the synthesis of amides and 
hydrazides.
121
 It was envisaged that the trichloroacetyl group may be introduced to the 
pyrrole via established Friedel-Crafts chemistry, to give a stable intermediate 218 which 
could be isolated and reacted further with a range of secondary amines. 
 
Scheme 30: Reagents and Conditions; i) trichloroacetyl chloride, AlCl3, DCM, 0 
o
C-RT, 16 
h; ii) R
1
H, DMF, 50 
o
C, 4 h; iii) LiOH monohydrate, THF, H2O, 40 
o
C, 4 h; iv) CDI, THF, 70 
o
C, 3 h, then 4-picolylamine, 50 
o
C, 3 h. 
Friedel-Crafts acylation introduced the trichloroacetyl group at the 4-position of the methyl 
1H-pyrrole-2-carboxylate scaffold. The trichloromethyl moiety acts as an excellent leaving 
group, yet is stable enough to isolate. SN2 substitutions on the relevant amine were performed 
in variable yields (61-99%). Hydrolysis of the ester using the conditions previously used (20 
eq. LiOH monohydrate, 65 
o
C, 16 h), were found to also hydrolyse the newly formed amide 
bond to the corresponding carboxylic acid. Use of lithium chloride in a Krapcho-like 
demethylation was investigated for ester cleavage with the morpholine analogue 219, 
(Scheme 31). The lithium ion co-ordinates one lone pair of each oxygen, stabilising the 
resulting negative charge following attack of the methyl group by the chloride ion.
119
 A 
number of impurities were observed, and only 65% conversion to the product achieved. 
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Scheme 31: Reagents and Conditions; i) LiCl, DMF, 160 
o
C, MW, 3 h. 
Optimisation of the hydrolysis conditions (1.5 eq. LiOH monohydrate, 40 
o
C, 4 h) achieved 
selectivity for the ester, leaving the amide intact. CDI couplings were then performed on the 
resulting carboxylic acids in good to excellent yield (50-95%). 
 
Table 29: Synthesis summary for incorporation of cyclic tertiary amides 
R
1
 
SN2 Substitution 
Yield (%) 
Hydrolysis 
Yield (%) 
CDI Coupling 
Yield (%) 
 
221; 61 222; 90 223; 95 
 
224; 63 225; 89 159; 43 
 
226; 75 227; 80 160; 82 
119 
 
 
228; 99 229; 75 161; 82 
 
219; 88 220; 77 162; 70 
 
230; 90 231; 98 163; 50 
 
Boc deprotection of 223 using TFA afforded piperazine 158 (Scheme 32) in a relatively low 
yield of 46%. 
 
Scheme 32: Reagents and Conditions; i) TFA, DCM, RT, 1 h. 
6.7.1.5 SARs for Biological Effect of Aromatic Ring Replacement with Non-Aromatic Groups 
The cyclopentane, 150 and cycloheptane, 151 analogues were inactive against ERK5. 
Whereas the cyclohexane analogue 149 was found to be have a similar potency to the 
corresponding analogue 232, bearing an unsubstituted aromatic ring (Table 30). This result 
indicated that a 6-membered saturated ring is the optimum size and shape for accommodation 
in the binding pocket. 5-membered and 7-membered rings were deemed too small and too big 
respectively for satisfactory occupation of the pocket. 
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Table 30: ERK5 inhibitory activity of analogues containing alkyl rings 
Compound R
1
 IC50 (µM)
a
 
149 
 
59.3 ± 1.5 
150 
 
>120 
151 
 
>120 
232 
 
40.4 ± 2.6 
a 
Determinations ± standard deviation  
Interestingly, in all cases substitution of the cyclohexane ring was not tolerated (Table 30). In 
the cases of the 2- and 3- substituted analogues, only one diastereoisomer pair was sent for 
biological evaluation due to the outcome of the syntheses. It is possible that only one of the 
four possible isomers is biologically active, and potentially the less stable kinetic product 
which is favourable. Due to the ability of the compounds to equilibrate to the thermodynamic 
products via the enolisable proton, synthesis of the isomers was not embarked upon. In 
addition, the 4-substituted diastereoisomeric mixtures did not confer any potency (Table 31). 
The 5-substituted regioisomers were also inactive (Table 32). The homology model indicates 
that the cyclohexane ring is the optimum size and shape to fit into the binding pocket. The 
inactivity of these compounds indicates that the electronic nature of the phenyl ring is crucial 
for activity. The π-system of the aromatic ring present in active compounds may participate 
in π-stacking interaction within the ERK5 binding site, which is not possible with the non-
aromatic analogues. Studies show that electron-withdrawing phenyl substituents confer the 
greatest potency, which is not examined in this non-aromatic series. However, comparison of 
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the 2-methylcyclohexane analogues, 189/190 with their aromatic counterpart, 233 reveals that 
activity is significantly diminished when the phenyl ring is not present. 
 
Table 31: ERK5 inhibitory activity of analogues containing substituted alkyl rings 
Compound R
1
 IC50 (µM)
a
 
189/190 
 
>120 
193/194 
 
>120 
154 
 
Mixture of cis/trans 
>120 
155 
 
Mixture of cis/trans 
>120 
210 
 
>120 
233 
 
26.5 ± 2.1 
a 
Determinations ± standard deviation  
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Table 32: ERK5 inhibitory activity of 5-substitued regioisomers 
Compound R
1
 IC50 (µM)
a
 
198/199 
 
>120 
202/203 
 
>120 
a 
Determinations ± standard deviation  
Activity was also abolished when amide linked heterocycles were incorporated. It was 
initially believed that conversion of the ketone to an amide would increase the hydrogen 
bonding potential of the carbonyl via a mesomeric effect.
116
 However, it is possible that the 
restricted rotation about the amide bond is resulting in an unfavourable conformation. Ketone 
analogues have the ability to rotate freely, enabling them to adopt a conformation favourable 
for binding.  
 
Figure 38: Conformational differences between cyclohexane analogue 149 (left) and 
piperidine analogue 160 (right) related to restricted rotation of amide bond. Structures are 
energy minimised using Chem3D, predicted at 31.57 kcal/mol and 31.87 kcal/mol 
respectively. 
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Table 33: ERK5 inhibitory activity of tertiary amide analogues 
Compound R
1
 
IC50 
(µM)
a
 
Compound R
1
 
IC50 
(µM)
a
 
223 
 
>120 161 
 
>120 
158 
 
>120 162 
 
>120 
159 
 
>120 163 
 
>120 
160 
 
>120    
a 
Determinations ± standard deviation 
6.7.2 Phenols as Molecular Probes 
The SARs for the non-aromatic libraries showed a loss of potency (Section 6.7.1), 
demonstrating that an aromatic group in the 4-position of the pyrrole carboxamide scaffold 
was essential for potency. For this reason, the remainder of the work conducted in this series 
focussed on modifications to the aromatic substituent, with the aim of gaining further 
understanding of the binding interaction and gaining improved potency. Although the SARs 
relating to the substitution pattern of the aromatic ring were understood in part, it was 
desirable to explore the chemical space further. 
6.7.2.1 Rationale 
Studies carried out by Dr Ruth Bawn highlighted that substituents much larger than the 
fluorine atom were tolerated, when in the o- and m-positions of the ring (Table 34). In 
124 
 
particular, the 2-nitro analogue, 237 was equipotent with compound 144. Electron 
withdrawing, ortho-substituents conferred the greatest potency (i.e. o-NO2; ERK5 IC50 = 2.9 
µM) compared with those in the meta position. Electron donating substituents (i.e. OMe) 
were not as active, but still tolerated. Phenols are undesirable features in drug molecules due 
to the possibility of giving rise to toxic quinone-based metabolites,
122
 and they are susceptible 
to phase 2 metabolism processes (e.g. glucuronidation) which results in poor pharmacokinetic 
properties.
123
 However, phenol analogues of 234, 235 and 236 were deemed desirable targets 
to understand the importance of substituent size and electronic nature. The phenol group also 
acts as both a hydrogen-bond donor and acceptor, to probe for hydrogen-bonding with the 
protein. These compounds were synthetically tractable from the parent methoxy analogues. 
 
Table 34: ERK5 inhibitory activity of substituted aromatic analogues 
Compound R
1
 IC50 (µM)
a
 
144 
 
2.3 ± 0.1 
234 
 
>120 
235 
 
19.1 ± 3.3 
236 
 
27.0 ± 1.2 
237 
 
2.9 ± 0.2 
238 
 
9.9 ± 0.6 
a 
Determinations ± standard deviation  
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6.7.2.2 Synthesis of Phenol Analogues 
The previously established route was utilised to synthesise the range of methoxy analogues 
outlined in Section 6.7.1.2. Phenol containing target compounds were synthesised in one step 
from the methoxy precursors 234, 235, and 236 by demethylation with boron tribromide 
(Scheme 33). Upon treatment of the dimethoxy compound 234 with BBr3, two compounds 
were isolated which were identified as the mono- and di-hydroxy products (239 and 240). All 
demethylation reactions proceeded in good yield (66-85% overall) (Table 35). 
 
Scheme 33: Reagents and Conditions; i) BBr3, DCM, 0 
o
C-RT, 16 h. 
Table 35: Synthesis summary for deprotection of methyl ethers 
Compound 
(R
1
) 
R
1
 
Compound 
(R
2
) 
R
2
 
Demethylation 
Yield (%) 
234 
 
239 
 
30 (85) 
234 
 
240 
 
55 (85) 
235 
 
241 
 
85 
236 
 
242 
 
66 
 
6.7.2.3 ERK5 Inhibitory Activity of Phenols 
The phenol analogues synthesised were no more active than the corresponding methoxy 
analogues (Table 36). Typically, o-substituted compounds are more potent than their m-
substituted counterparts.  
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Table 36: ERK5 inhibitory activity of phenol analogues and their methoxy counterparts 
Compound R
1
 
IC50 
(µM)
a
 
Compound R
1
 
IC50 
(µM)
a
 
239 
 
>120 234 
 
>120 
240 
 
40.7 ± 4.2 235 
 
19.1 ± 3.3 
241 
 
27.7 ± 1.5 236 
 
27.0 ± 1.2 
242 
 
17.1 ± 1.5    
a 
Determinations ± standard deviation (mean of n = 2 unless otherwise stated) 
Interestingly, the 3-hydroxy compound, 242 in this series was somewhat more potent than the 
corresponding 2-substituted analogue. 
1
H NMR provides an explanation for the slightly 
improved activity of the 3-substituted compound. When the hydroxyl group resides in the 2-
position of the aromatic ring, it may form an intramolecular H-bond with one lone pair of the 
carbonyl, forming a pseudocycle (Figure 39). The formation of an intramolecular hydrogen 
bond would affect the ability of the carbonyl to form the key hydrogen bond with the Lys83 
residue of the salt bridge, as shown in binding mode 2 (Figure 33). Also, H-bonding may lock 
the aroyl ring in plane of the carbonyl group, where normally the two are not in plane. The 
chemical shift of the OH peak is at δ 11.05 ppm in the ortho-hydroxy compound, 241. The 
meta-hydroxy proton is observed further upfield (δ 9.74 ppm), supporting this hypothesis. 
The positions of the aromatic protons, amide NH and pyrrole NH are largely unchanged 
between the two isomers. Figure 40 shows the differences between the 
1
H NMR spectra 
obtained for phenols 241 and 242. 
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Figure 39: 3D structure of 241; pseudocycle formation between carbonyl lone pair and 
phenolic proton. Structure is energy minimised using Chem3D, predicted at 864.92 kcal/mol. 
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Figure 40: Comparison of 
1
H NMR for ortho- (blue) and meta-hydroxy (red) derivatives; a 
significant change in chemical shift of the hydroxyl proton is observed between the two 
isomers. 
6.7.3 Incorporation of 2-, 3- and 4-Pyridyl Groups 
6.7.3.1 Rationale 
Binding mode 2, identified by homology modelling, suggested that the aroyl portion of the 
pyrrole-carboxamides was occupying a largely lipophilic pocket consisting mainly of leucine 
and isoleucine residues. However, it was desirable to test this hypothesis by incorporating 
aromatic heterocycles, (i.e. pyridine), which have increased polarity over their phenyl 
counterparts. The stereoelectronic nature of the 2-pyridyl group is similar to that of the 2, 6-
difluorophenyl moiety (Figure 41). Due to this observation, it was thought that the 2-pyridyl 
compound may be a suitable isosteric replacement for the difluorophenyl motif. The 
meta-hydroxy 
δ 9.74 ppm 
ortho-hydroxy 
δ 11.05 ppm 
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synthesis of the 2-pyridyl compound 242 would also probe the importance of steric effect, in 
addition to electronics. By comparison the unsubstituted phenyl analogue, 232 was found to 
inhibit ERK5 with an IC50 of 40.4 µM. 
 
 
Figure 41: Negative-field surfaces for the 2,6-difluorophenyl analogue 144 (above), and 2-
pyridyl analogue 243 (below). Images generated using FieldView software. 
6.7.3.2 Synthesis 
Friedel-Crafts acylation of methyl 1H-pyrrole-2-carboxylate with picolinoyl chloride 
hydrochloride was not successful (Scheme 34). No conversion to the desired product was 
observed. It was believed that the nitrogen lone pair of the pyridine ring was consuming one 
equivalent of AlCl3 by co-ordination. However, an increase in the number of equivalents did 
not result in any conversion to the product. 
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Scheme 34: Reagents and Conditions; i) picolinoyl chloride hydrochloride, AlCl3, DCM, 0 
o
C-RT, 16 h. 
A review of the literature revealed that regioselective acylation of N-(triisopropylsilyl)pyrrole 
has been achieved using N-acylbenzotriazoles in the presence of titanium tetrachloride.
124
 
Use of the bulky, electron donating TIPS protecting group directs acylation to the 3-position 
of the pyrrole. Studies by Katritzky et al describe the use of a number of N-acylbenzotriazole 
analogues for the synthesis of a variety of 3-acyl pyrroles, including the desired 2-pyridyl 
compound 244 (Scheme 34).
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 Several attempts were made to replicate this work, by 
reacting the relevant N-acylbenzotriazole with TiCl4 under anhydrous conditions, followed by 
the addition of N-(triisopropylsilyl)pyrrole 245, without any success (Scheme 35, Table 37). 
It is known that TiCl4 readily decomposes on contact with air to give hydrochloric acid, 
which, if present in the reaction mixture would remove the TIPS protecting group. As pyrrole 
was isolated as the major product from the reaction mixture, it is likely that this is the case.  
Based on the ability of the TIPS group to direct electrophilic aromatic substitution (EAS) 
reactions to the 3-position of the pyrrole, classical Friedel-Crafts conditions were attempted 
(Table 37). Reaction of picolinoyl chloride with AlCl3 to give the required reactive oxonium 
ion followed by EAS with N-(triisopropylsilyl)pyrrole, resulted in directed acylation in the 3-
position of the pyrrole. However, analysis of the reaction mixture by LCMS indicated that 
slow TIPS deprotection was occurring following acylation giving rise to a mixture of 
products. Based on this observation, it was decided that the crude mixture would be treated 
with TBAF to afford pyridin-2-yl(1H-pyrrol-3-yl)methanone, 247. A second Friedel-Crafts 
acylation on intermediate 247 with trichloroacetyl chloride afforded 250. The trichloroacetyl 
group was then substituted with the desired amine to afford amide 243. The method was 
applied to the synthesis of 3- and 4-pyridyl derivatives (Scheme 36). Surprisingly, it was not 
possible to isolate a pure sample of the 3-pyridyl analogue 253 for biological assay despite 
purification by HPLC. 
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Scheme 35: Reagents and Conditions; See conditions in Table 37. 
Table 37: Acylation attempts of TIPS pyrrole 
Attempt Acylating agent Reagents and conditions 
Observation 
(by LCMS) 
1 
 
(1H-benzo[d][1,2,3]triazol-1-
yl)(pyridin-2-yl)methanone, 
TiCl4, DCM, reflux, 24 h. 
Isolation of pyrrole; No 
conversion to product 
2 
 
picolinoyl chloride 
hydrochloride, AlCl3, DCM, 
0 
o
C-RT, 16 h. 
Acylation successful, 
some loss of TIPS 
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Scheme 36: Reagents and Conditions; i) R
1
COCl.HCl, AlCl3, DCM, 0 
o
C-RT, 16 h; ii) 
TBAF, THF, RT, 4 h; iii) trichloroacetyl chloride, AlCl3, DCM, 0 
o
C-RT, 16 h; iv) 4-
picolylamine, DMF, 50 
o
C, 4 h. 
6.7.3.3 ERK5 Inhibitory Activity of Pyridyl Analogues 
The unsubstituted phenyl analogue 232, was considered as the benchmark compound for this 
series. Incorporation of a nitrogen atom into the 2-position gave no improvement in activity. 
The 4-pyridyl analogue 255, displayed a 2-fold improvement in potency over the parent 232. 
Further investigation into the role of the 4-pyridyl substituent was required. The activity of 
the pyridyl analogues 243 and 255 was significantly diminished compared to the 2,6-
difluorophenyl analogue 144. This result indicates that substitution of the phenyl ring in the 
ortho-position is essential for potency, by maximising steric contacts in the protein. The 
stereoelectronic similarity of the pyridyl motif to the difluorophenyl group alone does not 
satisfy this requirement. 
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Table 38: ERK5 inhibitory activity of pyridyl analogues 
Compound R
1
 IC50 (µM)
a
 Compound R
1
 IC50 (µM)
a
 
232 
 
40.4 ± 2.6 255 
 
16.1 ± 2.8
b
 
243 
 
59.0 ± 19.8
b
 144 
 
2.3 ± 0.1 
a 
Determinations ± standard deviation (mean of n = 2 unless otherwise stated); 
b
 n = 4 
6.7.3.4 A Scaffold-Hopping Approach for a 3, 5-Difluoropyridine Analogue 
While investigation of the aroyl motif was continuing, it was discovered that truncation of the 
carboxamide side-chain resulted in a significant increase in potency. 2,6-Difluoro analogue 
256 had an IC50 of 0.9 µM, and was the first in the series to display sub-micromolar activity. 
Furthermore, counter-screening against p38α revealed that the truncated analogues were 
greater than 100-fold selective for ERK5. It was envisaged that a structural overlay between 
2,6-difluoro analogue 256 and 4-pyridyl analogue 255 could improve potency further. 
Homology modelling (Binding mode 2, Figure 33) suggested that the 2,6-difluoroaryl motif 
maximises steric contacts within the protein. A potential further interaction with the 4-pyridyl 
substituent was probed (Figure 42). 
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Table 39: Biological effect of side-chain truncation 
Compound Structure 
ERK5 IC50 
(µM)
a
 
p38α IC50 
(µM)
a
 
144 
 
2.3 ± 0.1 0.58 ± 0.27
c
 
256 
 
0.9 ± 0.2
b
 >120 
a 
Determinations ± standard deviation (mean of n = 2 unless otherwise stated); 
b 
n = 8; 
c
 n = 4. 
Figure 42: A scaffold-hopping approach towards the 3,5-difluoropyridine analogue 257 
6.7.3.5 Synthesis of 4-(3,5-Difluoroisonicotinoyl)-N-(pyridin-4-yl)-1H-pyrrole-2-
carboxamide 257 
Friedel-Crafts acylation of methyl 1H-pyrrole-2-carboxylate with 3,5-difluoroisonicotinoyl 
chloride proceeded in 31% yield (Scheme 37). The two electronegative fluorine atoms 
attenuate the pKa of the pyridine nitrogen, resulting in less co-ordination of the Lewis acid, 
and enabling the acylation reaction to proceed. Although relatively low, the yield of the 
reaction was deemed satisfactory. Hydrolysis of the ester 258 proceeded quantitatively. 
However, CDI coupling of 4-aminopyridine with carboxylic acid 259 was unsuccessful. 
Detection of the imidazole intermediate was possible, highlighting that the reactivity of 4-
aminopyridine was the problem. In 2009, Colombo et al reported the use of phosphorus 
trichloride mediated amide couplings.
125
 The method is particularly useful when using 
unreactive anilines with strongly electron withdrawing substituents. Microwave-assisted 
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coupling of carboxylic acid 259 with 4-aminopyridine in the presence of PCl3 allowed the 
synthesis of 257 in 30%. 
 
Scheme 37: Reagents and Conditions; i) 3,5-difluoroisonicotinoyl chloride, AlCl3, DCM, 0 
o
C-RT, 16 h; ii) LiOH monohydrate, H2O, THF, 65 
o
C, 16 h; iii) PCl3, 4-aminopyridine, 
MeCN, 150 
o
C, MW, 5 min. 
6.7.3.6 ERK5 Inhibitory Activity of 4-(3,5-Difluoroisonicotinoyl)-N-(pyridin-4-yl)-1H-
pyrrole-2-carboxamide 257 
 
257; ERK5 IC50 = 3.9 ± 4.2 µM (n = 2); p38α IC50 >120 µM (n = 2). 
Compound 257 was found to have an IC50 value of 3.9 ± 4.2 µM. Combining the 4-pyridyl 
and 6-difluorophenyl motifs did not give an additive effect to potency. The additional 
nitrogen atom in the 4-position is beneficial when the 2,6-difluoro substitution pattern is not 
present (i.e. comparing with phenyl analogue 232). However, the difluoroisonicotinoyl 
compound 257 is equipotent with the 2,6-difluorophenyl analogue 256. As the two 
electronegative fluorine atoms present on the pyridyl ring lower the pKa of the nitrogen lone 
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pair, it is significantly less available for hydrogen-bonding. This would weaken any possible 
interactions which were occurring in the unsubstituted analogue, 255. 
6.7.4 Achieving Selectivity Over p38α: Tuning the Aroyl Substituents 
Synthesis of two ERK5 selective tool compounds with reasonable potency had been achieved 
by tuning the carboxamide substituent (Table 40; Compounds 256 and 260). Compounds 
synthesised with large substituents in the ortho-position of the aroyl ring (i.e. CF3) also 
conferred selectivity over p38α (compounds 261 and 262), despite the CH2-linker of the side-
chain still being present. It was apparent from these results that there were two possible 
strategies for achieving selectivity. 
 
Table 40: Factors affecting selectivity for ERK5 over p38α  
Compound R
1
 R
2
 
ERK5 IC50 
(µM)
a
 
p38α IC50 
(µM)
a
 
256 
  
0.9 ± 0.2
b
 >120 
260 
  
1.1 ± 0.3
c
 33.2 ± 0.9 
261 
 
 
4.9 ± 1.2 66.3 ± 35.0 
262 
  
3.5 ± 1.0
d
 28.4 ± 19.9 
a 
Determinations ± standard deviation (mean of n = 2 unless otherwise stated); 
b 
n = 8; 
c
 n = 6; 
d
 n = 4. 
A library of compounds with substituents of varying sizes at the ortho-position was devised. 
A methyl group was chosen as an isostere for the trifluoromethyl group which confers 
selectivity over p38α. The size of the ortho-halogen was also probed, by incorporating a 
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chlorine or bromine atom. Homology modelling of a 2-bromo, 6-fluoro analogue 263, 
revealed that the larger bromine atom appeared to be tolerated in the binding site of ERK5 
(Figure 43). However, molecular modelling did not predict whether the compounds would be 
selective over p38α.  
 
Figure 43: Homology modelling of 2-bromo, 6-fluoro analogue 263. 
6.7.4.1 Synthesis of ortho-Substituted Analogues 
Synthesis via the efficient route outlined in Scheme 24 was employed. For couplings with 3- 
and 4-picolylamine, CDI was used, and for amide couplings with electron-poor 3- and 4-
aminopyridine, the method using PCl3 described in Section 6.7.3.5 was necessary (Table 41). 
All reactions proceeded in good yield (≥50%). 
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Table 41: Synthesis summary 
R
1
 R
2
 
Acylation 
Yield (%) 
Hydrolysis 
Yield (%) 
Amide Coupling 
Yield (%) 
2-F, 6-Me 4-Pyridyl 
264; 83 265; 98 
266; 70
b
 
2-F, 6-Me 3-Pyridyl 267; 76
b
 
2-F, 6-Me 4-Methylpyridine 268; 52
a
 
2-F, 6-Me 3-Methylpyridine 269; 58
a
 
2-Cl, 6-F 4-Pyridyl 
270; 89 271; 99 
272; 61
b
 
2-Cl, 6-F 3-Pyridyl 273; 64
b
 
2-Cl, 6-F 4-Methylpyridine 274; 50
a
 
2-Cl, 6-F 3-Methylpyridine 275; 68
a
 
2-Br, 6-F 4-Pyridyl 
276; 80 277; 90 
263; 84
b
 
2-Br, 6-F 3-Pyridyl 278; 76
b
 
2-Br, 6-F 4-Methylpyridine 279; 55
a
 
2-Br, 6-F 3-Methylpyridine 280; 68
a
 
a
 CDI mediated amide coupling; 
b
 PCl3 mediated amide coupling. 
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6.7.4.2 SARs for Substitution at the ortho-Position 
Table 42 shows that compounds with the CH2-linker present in the carboxamide side-chain 
were not selective for ERK5. Interestingly, the size of the substituent in the ortho position did 
have some effect on the degree of selectivity. Compounds 279 and 280 (with a bromine atom 
in the ortho-position) were 3-5 fold selective for ERK5 over p38α. However, the observed 
selectivity is small compared with that resulting from side-chain truncation which abolishes 
p38α activity. The 3- and 4-pyridyl 2-chloro-6-fluoro analogues 272 and 273 were equipotent 
with an ERK5 IC50 of 600 nM, giving a modest improvement on the initial 2,6-difluoro 
analogue 256 (ERK5 IC50 = 900 nM). 
 
Table 42: ERK5 inhibitory activity of disubstituted pyrrole analogues 
Compound R
1
 R
2
 
ERK5 IC50 
(µM)
a
 
p38α IC50 
(µM)
a
 
266 2-Me, 6-F 4-Pyridyl 1.9 ± 0.4
b
 25.7 ± 5.5 
267 2-Me, 6-F 3-Pyridyl 2.6 ± 0.7
b
 54.0 ± 7.1 
268 2-Me, 6-F 4-Methylpyridine 5.1 ± 0.7 1.0 ± 0.1 
269 2-Me, 6-F 3-Methylpyridine 7.2 ± 1.5 1.2 ± 0.2 
272 2-Cl, 6-F 4-Pyridyl 0.60 ± 0.3
b
 >120 
273 2-Cl, 6-F 3-Pyridyl 0.60 ± 0.2
b
 93.2 ± 12.5
c
 
274 2-Cl, 6-F 4-Methylpyridine 1.5 ± 0.3
b
 2.0 ± 0.1 
275 2-Cl, 6-F 3-Methylpyridine 1.6 ± 0.2
b
 1.7 ± 0.0 
263 2-Br, 6-F 4-Pyridyl 0.7 ± 0.2
b
 >120 
278 2-Br, 6-F 3-Pyridyl 0.82 ± 0.1
b
 >120 
279 2-Br, 6-F 4-Methylpyridine 1.9 ± 0.8 9.8 ± 0.2
b
 
280 2-Br, 6-F 3-Methylpyridine 1.7 ± 0.6
b
 5.8 ± 0.5
b
 
a 
Determinations ± standard deviation (mean of n = 2 unless otherwise stated); 
b
 n = 4; 
c 
n = 3 
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6.7.4.3 Investigation of Non-Aromatic Carboxamide Side-Chains 
Discovery of compound 281 revealed that an aromatic group on the terminus of the 
carboxamide side-chain was not essential for ERK5 activity. Homology modelling suggested 
that the pyridyl moiety of the molecule points out toward solvent in the binding site of ERK5 
(Figure 33). Whereas the sensitivity of the substitution pattern of the aroyl motif had been 
shown previously, a wider range of substituents may be tolerated in this position, in particular 
substituents containing basic residues or those with a strong dipole (e.g. 4-fluorobenzyl 
compound 138). 
 
         138      281 
138; ERK5 IC50 = 3.7 µM ± 0.8 (n = 2); 281; ERK5 IC50 = 1.3 µM ± 0.4 (n = 6); p38α IC50 = 
9.8 µM ± 0.5 (n = 2) 
Although selectivity for ERK5 over p38α was significantly diminished when substituting the 
aromatic pyridine moiety for piperidine, further investigation into the SARs around this motif 
was warranted. Previous studies had confirmed that the selectivity over p38α may be tuned, 
exploiting the differences in the ERK5 and p38α binding pockets. Scheme 24 was employed; 
CDI or PCl3 mediated couplings with the relevant carboxylic acids gave a range of 
compounds with non-aromatic variation in the R
2
 position (Table 43). All CDI couplings 
proceeded in good yields (65-89%). The microwave-assisted method was utilised for 
coupling of tert-butyl 4-aminopiperidine-1-carboxylate with carboxylic acids 265 and 271. 
However, relatively low yields (37 and 46% respectively) were observed. It was apparent that 
the harsh reaction conditions of the PCl3 method were cleaving the Boc protecting group in 
situ. For ease of workup and purification, the cleaner CDI mediated methodology was used 
wherever possible. 
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Table 43: Synthesis summary for amide couplings 
Compound R
1
 R
2
 
Amide Coupling 
Yield (%)
a
 
282 2-Me, 6-F 
 
37
b
 
283 2-Cl, 6-F 
 
78 
284 2-Cl, 6-F 
 
46
b
 
285 2-Cl, 6-F 
 
65 
286 2-Cl, 6-F 
 
65 
287 2-Br, 6-F 
 
82 
288 2-Br, 6-F 
 
89 
289 2-Br, 6-F 
 
67 
290 2-Br, 6-F 
 
71 
a
 Amide couplings performed via CDI mediated route (unless otherwise stated); 
b
 PCl3 
mediated amide coupling 
The tert-butyloxycarbonyl analogues 282, 284 and 288 were deprotected to give the 
corresponding piperidines 291, 292 and 293 using TFA. In the case of 2-chloro, 6-fluoro 
analogue 292, purification proved challenging despite the high purity of the starting material 
(≥95%). It is reported that the generation of a reactive tert-butyl carbocation during Boc 
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deprotection may be responsible for the occurrence of side-reactions, resulting in several 
impurities of small quantity.
126
 It is not understood why the 2-methyl, 6-fluoro analogue 291 
is unaffected. The deprotection was repeated, with the addition of triethylsilane as an additive 
during the reaction. The use of this additive improved the yield of the reaction significantly, 
from 51 to 99% yield for compound 289. All subsequent Boc deprotections were conducted 
using this optimised method. 
 
Table 44: Synthesis summary for Boc deprotections 
Compound R
1
 Reagents and conditions Yield (%) 
291 
 
TFA, DCM, RT, 1 h 100 
292 
 
TFA, DCM, RT, 1 h 51 
292 
 
TFA, Et3SiH (2.5 eq.), 
DCM, RT, 1 h 
99 
293 
 
TFA, Et3SiH (2.5 eq.), 
DCM, RT, 1 h 
100 
 
 
 
 
 
 
 
143 
 
6.7.4.4 SARs for Pyridyl Group Replacement 
 
Table 45: Biological effect of side-chain replacement 
Compound R
1
 R
2
 
ERK5 IC50 
(µM)
a
 
p38α IC50 
(µM)
b
 
Selectivity 
Ratio 
291 
  
1.4 ± 0.3 5.1 ± 0.6 3-4-fold 
283 
  
0.20 ± 0.06 8.5 ± 0.2 42-fold 
284 
  
1.1 ± 0.4 99.0
c
 90-fold 
292 
  
0.49 ± 0.04 11.1 ± 1.0
a
 22-fold 
285 
  
2.5 ± 1.0 >120 >48-fold 
286 
  
0.80 ± 0.3 12.5 ± 0.9 15-fold 
287 
  
0.29 ± 0.12
d
 11.2 ± 0.2 38-fold 
288 
  
2.7 ± 0.7 >120 >30-fold 
293 
  
0.39 ± 0.12 18.5 ± 0.3 47-fold 
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289 
  
5.5 ± 0.6
b
 >120 >21-fold 
290 
  
1.2 ± 0.2 18.1 ± 0.4 15-fold 
a 
Determinations ± standard deviation (mean of n = 4 unless otherwise stated); 
b
 n = 2; 
c 
n = 1; 
d
 n = 8.
 
NB: Green – ERK5 IC50 ≤1.0 µM; Amber – ERK5 IC50 = 1.0-2.0 µM; Red – ERK5 
IC50 >2.0 µM. 
Piperidine analogues 292 and 293, and N-methyl piperidine analogues 283 and 287 showed 
excellent potency (ERK5 IC50 range = 200-490 nM). Compound 283 is approximately 42-
fold for ERK5 over p38α, which exceeds the criteria set for a lead compound (Table 21; >10 
fold selectivity required for a lead). 
6.7.5 Pyrrole-Carboxamide Based Inhibitors of p38α 
In 2010, a series of pyrrole-carboxamide based inhibitors of p38α were described in the 
literature.
127
 Although not a validated target in the area of cancer therapeutics, investigation 
into the discovery of inhibitors of p38α has been undertaken for the potential treatment of 
inflammatory disease.
127
 A virtual screen based on a 3D pharmacophore query, was 
conducted at GSK using databases of commercially available compounds. Selected hits from 
the virtual screen were purchased, and assayed against p38α. Several pyrrole-carboxamide 
based hits were identified which showed sufficient activity for accurate IC50 measurement. 
Compound 294 has a pIC50 of 6.6 (n = 9) (IC50 = 0.25 µM).  
 
294; p38α IC50 = 0.25 µM 
Pyrrole 294 was co-crystallised with p38α and an X-ray structure was obtained (Figure 44). 
Structure-guided drug design enabled optimisation of the potency (Table 46). The best 
activity in the series (IC50 = 13 nM) was reported for the 2-fluoro compound 297, which 
incorporates a water-solubilising piperazine motif. Interestingly, the data suggests that para-
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substitution on the aroyl ring is not detrimental to activity (compound 297), in contrast to the 
SARs for ERK5. It was also reported that a number of aniline based compounds were 
prepared (although no structures were disclosed). These analogues all displayed inferior 
potency, which is attributed to the inflexibility of the aniline. A methionine residue (Met109) 
is believed to envoke a steric clash in the backbone of the protein with the truncated 
analogues. This information provides an explanation for the selectivity observed with the 
truncated aniline ERK5 inhibitors. 
 
Table 46: Pyrrole-carboxamides as inhibitors of p38α 
Compound R
1
 R
2
 p38α pIC50
a
 
p38α IC50 
(µM)
a
 
294 
 
 
6.6 0.25 
295 
  
7.0 0.10 
296 
  
7.3 0.05 
297 
 
 
7.5 0.03 
298 
  
7.6 0.025 
299 
  
7.9 0.013 
a 
Mean of at least three experiments. From ref 
127
. 
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The crystal structure of 294 bound to p38α shows a different binding mode of the pyrrole-
carboxamide scaffold to that suggested by the ERK2/p38α based homology model for ERK5. 
The compounds described bear a striking resemblance to those synthesised at Newcastle, and 
taking into account the conserved nature of the ATP binding site amongst the MAPK family, 
this alternative binding mode was considered in future studies. The aroyl ring is shown to 
occupy a small lipophilic pocket, adjacent to the gatekeeper residue (Thr106), although the 
orientation is different to that shown in the homology model for ERK5 (binding mode 2). In 
the ERK5 homology model the aroyl carbonyl interacts with a salt bridge lysine, whereas 
interaction with two water molecules is evident in the p38α crystal structure. A NH-
carboxamide-water interaction is also observed. This may explain why the N-methyl 
compound 146, is tolerated but not optimum for ERK5 inhibition (ERK5 IC50 = 9.0 µM). The 
pyrrole-NH and carboxamide carbonyl motif act as hydrogen bond donor and acceptor 
respectively in the hinge region of the protein to Met109 and His107.  
 
Figure 44: Crystal structure of 294 in complex with p38α. From ref 127. Magenta dotted lines 
indicate hydrogen bonds to the inhibitor. Red crosses are water molecules.  
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6.7.6 Towards the Allosteric Pocket: Tuning the Aroyl Substituents 
Molecular docking of pyrrole-carboxamide based ERK5 inhibitors in the updated homology 
model revealed that it may be possible to access an allosteric binding pocket via the 2- or 3-
position of the aroyl ring (Figure 45). The activation loop in protein kinases begins with a 
conserved DFG (Asp-Phe-Gly) sequence. The structural conformation of this sequence 
determines whether the kinase is active (DFG-in) or inactive (DFG-out). In the DFG-out 
conformation an additional binding site adjacent to the ATP binding site is accessible, 
potentially allowing additional interactions with a small-molecule inhibitor. Probing the 
allosteric site was therefore an attractive strategy for gaining potency against ERK5. The 
exceptionally high structural similarity of the pyrrole-carboxamide based p38α inhibitors to 
our compounds allowed us to make the assumption that these inhibitors bind to both p38α 
and ERK5 in the same manner. The crystal structure of 294 bound to p38α indicates that the 
binding mode is different to that of binding modes 1 and 2, which were predicted from the 
ERK2 based model. The p38α crystal structure was obtained from the protein data bank 
(PDB) and computationally mutated using MODELLER software to express the amino acid 
residues present in ERK5, retrieved from the Universal Protein Resource (Uniprot). The 
pyrrole-carboxamide based inhibitors were docked into the active site of the ERK5 model, 
according to the binding mode identified from the p38α crystal structure, and used as a 
template for docking the novel targets. Using COOT software, the novel ligands were 
inserted into the area of electron density occupied by compound 294. Finally, energy 
minimisation of the protein-ligand complex identified the most energetically favourable 
conformation. The processes involved in creating this homology model (excluding energy 
minimisation) are summarised in Figure 46. Crucially, a key difference in the portion of the 
binding site surrounding the aroyl motif of the ligand was identified. In ERK5, residue 165 is 
glycine; the smallest amino acid. This gives rise to a deep pocket which differs in shape to 
that of p38α, offering a third avenue towards achieving selectivity for ERK5 over p38α. 
Homology modelling using this new strategy suggested that a range of alkyl substituents, 
namely 2-ethyl, cyclopropyl and ethynyl would be tolerated (Figure 47) in ERK5. 
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Figure 45: Top; Compound 294 bound in the active site of p38α, using PDB file. Bottom; 
Compound 292 bound in the active site of ERK5 mutated p38α model. 
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Figure 46: Sequence of processes involved in designing and utilising the current ERK5 
homology model 
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Figure 47: Homology modelling of 2-ethyl 300 (top), 2-cyclopropyl 306 (middle) and 2-
ethynyl 310 (bottom) substituted analogues in the ERK5 active site.  
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Synthesis of 2-methyl, 6-fluoro analogues 266 and 291 indicated that a methyl group was 
tolerated in the ortho-position, but not as active as the di-halogenated analogues. 
Incorporation of larger alkyl substituents was investigated, which aimed to access the 
allosteric site via the 2-position (Table 47). The three carboxamide side-chains; 3-pyridyl, 
piperidine and N-methyl piperidine, were selected to achieve the greatest potency, while 
maintaining desirable physicochemical properties. 
 
Table 47: Proposed series for investigation of 2-position substituents 
Compound R
1
 R
2
 
300/301/302 
  
303/304/305 
  
306/307/308 
  
309/310/311 
  
 
6.7.6.1 Synthesis of ortho-Alkyl Analogues 
As a number of compounds had been synthesised with a bromine atom in the 2-position 
(Section 6.7.4), it was evident that palladium-mediated couplings could be exploited for the 
insertion of a range of alkyl or alkynyl substituents. The initial strategy (Scheme 38) utilised 
the previously optimised Suzuki coupling conditions to introduce the ethyl group into the 
ortho-position of methyl 2-bromo-6-fluorobenzoate, 313. Methylation of carboxylic acid 312 
using o-methyl-N,N'-diisopropylisourea under microwave irradiation was achieved in 87%. 
The subsequent Suzuki coupling with ethylboronic acid proceeded in 66%. Ester 314 was 
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then converted to the corresponding carboxylic acid, 318. Base-catalysed hydrolysis of ester 
314 was attempted using the conditions outlined previously in Scheme 24. Unfortunately, no 
conversion to the acid 318 was observed. Demethylation of 314 was achieved via a 
microwave-assisted reaction with lithium chloride in DMF in 75% yield.
119
 Conversion to the 
acid chloride followed by Friedel-Crafts acylation on methyl 1H-pyrrole-2-carboxylate 166 
gave ester 320 in 83% yield. Hydrolysis of pyrrole-ester 320 proceeded quantitatively, and 
couplings mediated by CDI or PCl3 gave amides 300, 302 and 322 in excellent yields (65-
72%). Finally, Boc deprotection to give piperidine analogue 301 proceeded in 93% (Scheme 
39). Following the successful synthesis of the ortho-ethyl analogues, the method was applied 
for synthesis of ortho-cyclopropyl and isopropyl analogues. Suzuki coupling with 
cyclopropylboronic acid and demethylation reactions proceeded in 76% and 64% 
respectively. However, coupling with isopropylboronic was less successful, achieving a low 
yield of 16%, attributed to steric hindrance of the boronic acid by the isopropyl group. 
Isopropenylboronic acid was utilised in the reaction, as it was thought that the boronic acid 
would be less sterically encumbered than in the isopropyl analogue. Successful conversion to 
the product was observed by LCMS in approximately 66%. Reduction of the alkene bond 
was to be performed in the final step of the synthesis, to give both isopropenyl and isopropyl 
target compounds, to compare the slightly different geometries of the two groups.  
 
 
 
153 
 
 
Scheme 38: Reagents and Conditions; i) O-methyl-N,N’-diisopropylisourea, MeCN, 120 oC, 
MW, 5 min; ii) RB(OH)2, Cs2CO3, Pd(dtbf)Cl2, dioxane, 110 
o
C, 16 h; iii) LiCl, DMF, 150 
o
C, MW, 1 h; iv) SOCl2, cat DMF, THF, RT, 3 h, then AlCl3, methyl 1H-pyrrole-2-
carboxylate, DCM, 0 
o
C-RT, 16 h; v) LiOH monohydrate, H2O/THF, 65 
o
C, 16 h; vi) For R
2
 
= 3-pyridyl; PCl3, 3-aminopyridine, MeCN, 150 
o
C, MW, 5 min; For R
2
 = Boc-piperidine, N-
methyl piperidine; CDI, THF, 70 
o
C, 3 h then R
2
NH2, 50 
o
C, 3 h. 
 
Scheme 39: Reagents and Conditions; i) TFA, triethylsilane, DCM, RT, 1 h. 
Unfortunately, use of 2-cyclopropyl-6-fluorobenzoyl chloride with AlCl3 in the Friedel-Crafts 
acylation step did not give any of the desired product, and recovery of starting material was 
not possible. It is likely that nucleophilic attack of a chloride ion generated during the 
reaction results in ring-opening of the cyclopropane moiety (E.g. Scheme 40). Similar 
problems were predicted during Friedel-Crafts acylation with an isopropenyl analogue and so 
the synthesis of ortho-isopropyl and isopropenyl analogues was suspended, pending 
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biological results in this series. It was evident that an alternative synthetic strategy would be 
required for the synthesis of the cyclopropyl analogues 306, 307 and 308. 
Scheme 40: Proposed cyclopropane ring-opening via attack of nucleophilic chloride ion 
It was desirable to introduce the cyclopropyl motif after Friedel-Crafts acylation of the 
relevant pyrrole-species had been performed. Protection of aroyl substituted pyrrole 325 with 
a tosyl group enabled a Suzuki coupling to be performed under microwave-assisted 
conditions. Using conventional heating (110 
o
C, 16 h), extensive reductive dehalogention 
occurred. Under the microwave-assisted conditions employed, the tosyl group was found to 
be partially cleaved, following Suzuki coupling with the relevant boronic acid. Due to this 
observation, hydrolysis of the ester and remaining tosyl groups was performed, without 
further purification. Carboxylic acid 326 was obtained in a good yield, 76% over the two 
steps. CDI couplings with tert-butyl 4-aminopiperidine-1-carboxylate and 4-amino-1-methyl 
piperidine proceeded in excellent yields (74% and 58% respectively). The PCl3 mediated 
coupling was much lower yielding than expected (30%). During the course of this reaction 
HCl is generated, which may have resulted in a similar ring-opening side reaction to that 
described previously, under the harsh coupling conditions. Deprotection of the Boc-protected 
piperidine analogue 328 gave the secondary amine 307 in 65% (Scheme 42). Following 
successful synthesis of cyclopropyl analogues 306, 307 and 308 the method was applied for 
the synthesis of alkynyl analogues, using 2-((tert-butyldimethylsilanyl)ethynyl) boronic acid 
pinacol ester. Monitoring of the Suzuki coupling by LCMS indicated high conversion 
(>50%). Hydrolysis of the tosyl and ester groups proceeded quantitatively by LCMS, and the 
silyl protecting group was also cleaved under the reaction conditions. However, purification 
of the carboxylic acid 327 was challenging, as the compound appeared to be unstable in 
solution, highlighted by a distinct colour change. Purification by semi-preparative HPLC 
under neutral conditions gave acid 327 in a low yield of 26%, attributed to the instability of 
the product. Due to the low yield obtained and the concerns over instability of 327, only one 
amide coupling reaction was attempted. A CDI-mediated coupling of acid 327 with 4-amino-
1-methyl piperidine was performed at RT, to give amide 311 in 50% yield. The PCl3 coupling 
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conditions which would be employed for synthesis of the 3-pyridyl analogue 309, were 
deemed too harsh for use with this intermediate.  
 
Scheme 41: Reagents and Conditions; i) TsCl, KO
t
Bu, 0 
o
C-RT, 16 h; ii) cyclopropylboronic 
acid or 2-((tert-butyldimethylsilanyl)ethynyl) boronic acid pinacol ester, Cs2CO3, 
Pd(dtbf)Cl2, dioxane, 150 
o
C, MW, 1 h; iii) LiOH monohydrate, H2O/THF, 65 
o
C, 16 h; iv) 
For R
2
 = 3-pyridyl; PCl3, 3-aminopyridine, MeCN, 150 
o
C, MW, 5 min; For R
2
 = Boc-
piperidine, N-methyl piperidine; CDI, THF, 70 
o
C, 3 h then R
2
NH2, 50 
o
C, 3 h. 
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Table 48: Synthesis summary for amide couplings 
Compound R R
2
 
Coupling 
Reagent 
Coupling 
Yield (%) 
306 
  
PCl3 30 
328 
  
CDI 74 
308 
  
CDI 58 
311 
  
CDI 50 
 
 
Scheme 42: Reagents and Conditions; i) TFA, triethylsilane, DCM, RT, 1 h. 
6.7.6.2 Additional SARs Around the ortho-Position 
Previous SAR data had revealed that the substitution pattern around the aroyl ring was 
essential for activity. The most potent compounds in the series to date (i.e. 2-chloro-6-fluoro 
compound 272 and 2-bromo-6-fluoro compound 278; IC50 values = 0.6 and 0.8 µM; 
respectively) contain a larger group in one ortho-position in the ring, maximising steric 
contacts with the protein. Introduction of a methyl group is tolerated, but compounds bearing 
the 2-fluoro, 6-methyl motif are not as potent as their di-halogenated counterparts (e.g. 267; 
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IC50 = 2.6 µM). Incorporation of larger alkyl substituents aimed to access the allosteric 
pocket, which seemed possible following homology modelling. Unfortunately, the larger 
substituents were not tolerated. The addition of ethyl or cyclopropyl groups in the ortho-
position appears to be particularly detrimental when combined with the rigid 3-pyridyl 
carboxamide substituent. Analogues containing the more flexible piperidine side-chains are 
more potent (e.g 302; IC50 = 5.0 µM). However, selectivity over p38α is lost with the 
piperidine analogues. It is likely that the three-dimensional shape of the side-chain influences 
the tolerance of the ortho-substituent, by subtle changes in overall 3D structure of the 
inhibitor. 
 
Table 49: ERK5 inhibitory activity of 2-substituted alkyl analogues 
Compound R
1
 R
2
 
ERK5 IC50 
(µM)
a
 
p38α IC50 
(µM)
a
 
267 
  
2.6 ± 0.7
b
 54.0 ± 7.1 
300 
  
12.7 ± 4.4 >120 
301 
  
5.0 ± 0.6 43.1 ± 7.9 
302 
 
 
5.0 ± 2.0 45.7 ± 1.9 
306 
 
 
23.0 ± 3.9 >120 
307 
 
 
5.8 ± 0.5 45.0 ± 6.2 
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308 
  
8.2 ± 0.1 57.1 ± 1.2 
311 
  
2.6 ± 0.05 52.9 ± 0.01 
a 
Determinations ± standard deviation (mean of n = 2 unless otherwise stated); 
b
 n = 4. 
6.7.6.3 Accessing a Possible Allosteric Pocket: Substitution at the meta-Position 
Overlay of another p38α inhibitor, 329, based around a quinazoline scaffold (p38α IC50 = 2.4 
nM ± 1.3) illustrates the space available for compounds probing the allosteric site, which 
appears to be accessible via the 3-position of the aroyl moiety. Quinazoline 329 makes a 
hydrogen bond with the backbone NH of an aspartate residue (Asp168), which is present on 
the activation loop. A second hydrogen bond interaction is between Glu71 and the amide NH 
of compound 329.
128
 
 
329 
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Figure 48: Docking of pyrrole-carboxamide scaffold (magenta) superimposed with 
quinazoline based p38α inhibitor 329 (green).  
A range of analogues were synthesised to investigate whether meta-substitution of the aroyl 
ring was tolerated. Fluoro-, chloro- and methyl groups were incorporated to establish whether 
further decoration of the aroyl motif would enhance potency. It was envisaged that a halogen 
in the 3-position (particularly chlorine or bromine) would enable palladium-mediated 
couplings to install additional functional groups at a later date if desired. At this stage in hit-
to-lead drug discovery, it was decided that replacement of the 3-pyridyl motif would be 
desirable. Inhibition of the CYP family of enzymes via interactions of strongly basic and/or 
acidic groups is a common challenge to overcome in drug discovery. One replacement for 
pyridine which may reduce the degree of CYP inhibition is the pyrimidine moiety.
129
 The 
pyrimidine group is the same shape and size as the pyridyl, but the pKa of the nitrogen lone 
pair is significantly attenuated by the presence of a second electron withdrawing atom in the 
ring (i.e. pKa of pyridine = 5.2; pKa of pyrimidine = 1.1). Other strategies considered for 
reducing CYP inhibition included incorporation of one or two methyl groups adjacent to the 
pyridine nitrogen, to sterically encumber the nitrogen lone-pair. However, this would increase 
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the lipophilicity of the molecule, and so the pyrimidine was considered a more suitable 
replacement. Pyrimidine analogues were synthesised containing selected aroyl motifs. 
 
Table 50: Proposed series of compounds with meta-substitution 
R
1
 R
2
 
 
 
 
 
6.7.6.4 Synthesis of Analogues with Substitution at the meta-Position 
The optimised Scheme 24 was applied for the parallel synthesis of meta-substituted 
analogues. Friedel-Crafts acylation proceeded successfully in all cases (59-95%) and 
subsequent hydrolyses were quantitative. PCl3-mediated amide couplings on the relevant 
carboxylic acids with 3-aminopyridine were all successful after 5 min at 150 
o
C. However, 
couplings were significantly slower with 3,5-aminopyrimidine. The reactions with the 
unreactive pyrimidine were heated in cycles at 150 
o
C for up to 30 min in order to reach 
completion. Yields were variable, ranging from 41-95%. The CDI mediated amide couplings 
for piperidine analogues proceeded in variable but good yields (54-100%). Deprotection of 
the Boc group gave piperidine analogues in greater than 90% in all cases, except with 2-
fluoro, 6-methyl compound 383 (Table 52). In this instance, the product obtained was a 
hygroscopic solid. Conversion of the free base to the corresponding TFA or HCl salts was 
attempted, but both forms were also found to be hygroscopic.  
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Table 51: Synthesis summary for compounds with meta-substitution 
R
1
 R
2
 
Friedel-Crafts 
Yield (%) 
Hydrolysis 
Yield (%) 
Amide 
Coupling Yield 
(%) 
2,3,6-TriF 3-Pyridine 
330; 95 331; 100 
332; 41
a
 
2,3,6-TriF 3,5-Pyrimidine 333; 52
a
 
2,3,6-TriF Boc-Piperidine 334; 93
b
 
2,3,6-TriF N-Me piperidine 335; 71
b
 
3-Cl, 2,6-DiF 3-Pyridine 
336; 90 337; 100 
335; 95
a
 
3-Cl, 2,6-DiF 3,5-Pyrimidine 339; 46
a
 
3-Cl, 2,6-DiF Boc-Piperidine 340; 87
b
 
3-Cl, 2,6-DiF N-Me piperidine 341; 88
b
 
2-Cl, 3,6-DiF 3-Pyridine 
342; 94 343; 98 
344; 58
a
 
2-Cl, 3,6-DiF Boc-Piperidine 345; 85
b
 
2-Cl, 3,6-DiF N-Me piperidine 346; 98
b
 
2,6-DiF, 3-Me 3-Pyridine 
347; 94 348; 98 
349; 92
a
 
2,6-DiF, 3-Me 3,5-Pyrimidine 350; 51
a
 
2,6-DiF, 3-Me Boc-Piperidine 351; 68
b
 
2,6-DiF, 3-Me N-Me piperidine 352; 88
b
 
6-Cl, 2,3-DiF 3-Pyridine 
353; 59 354; 100 
355; 57
a
 
6-Cl, 2,3-DiF 3,5-Pyrimidine 356; 55
a
 
6-Cl, 2,3-DiF Boc-Piperidine 357; 91
b
 
6-Cl, 2,3-DiF N-Me piperidine 358; 68
b
 
2,5-DiF 3-Pyridine 
359; 93 360; 100 
361; 41
a
 
2,5-DiF Boc-Piperidine 362; 87
b
 
2,5-DiF N-Me piperidine 363; 100
b
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5-Cl, 2-F 3-Pyridine 
364; 87 365; 98 
366; 91
a
 
5-Cl, 2-F 3,5-Pyrimidine 367; 42
a
 
5-Cl, 2-F Boc-Piperidine 368; 74
b
 
5-Cl, 2-F N-Me piperidine 369; 100
b
 
2-F, 5-Me 3-Pyridine 
370; 86 371; 99 
372; 89
a
 
2-F, 5-Me 3,5-Pyrimidine 373; 49
a
 
2-F, 5-Me Boc-Piperidine 374; 54
b
 
2-F, 5-Me N-Me piperidine 375; 88
b
 
a 
PCl3 mediated amide coupling; 
b
 CDI mediated amide coupling. 
 
Table 52: Synthesis summary for deprotection of Boc-piperidines 
Compound R
1
 Yield (%) 
376 2,3,6-TriF 95 
377 3-Cl, 2,6-DiF 97 
378 2-Cl, 3,6-DiF 94 
379 2,6-DiF, 3-Me 93 
380 6-Cl, 2,3-DiF 95 
381 2,5-DiF 95 
382 5-Cl, 2-F 100 
383 2-F, 5-Me NR – Hygroscopic solid 
 
6.7.6.5 SARs for Substitution at the meta-Position 
The data show that substitution in both ortho-positions is crucial for sub-micromolar ERK5 
activity. All compounds with trisubstitution are well tolerated, with IC50 values ≤ 1.0 µM. 
The 3-chloro-2, 6-difluoro substitution pattern confers the best overall potency, with all four 
carboxamide side-chains well tolerated in the binding site (IC50 = 140-240 nM). The 6-chloro, 
2, 3-difluoroaroyl motif when combined with the N-methylpiperidine side-chain, to give 
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compound 358 also confers high potency (110 nM). However, pyridyl and pyrimidyl side-
chains combined with the 6-chloro-2,3-difluoroaroyl scaffold (compounds 355 and 356) 
confer significantly less potency (IC50 = 0.96 and 0.71 µM, respectively). All compounds 
containing aromatic side-chains were completely inactive against p38α. Although selectivity 
for ERK5 over p38α is somewhat reduced when incorporating non-aromatic side-chains, all 
compounds retain at least 25-fold selectivity, with the exception of the less potent 2-, 5-
substituted analogues. No further in vitro pharmacology or DMPK studies have been carried 
out for this set of compounds as of yet, but may be evaluated in future studies. 
 
Table 53: ERK5 inhibitory activity of tri- and di-substituted analogues 
Compound R
1
 R
2
 
ERK5 IC50 
(µM)
a
 
p38α IC50 
(µM)
a
 
332 2,3,6-TriF 3-Pyridine 0.40 ± 0.10 >120 
333 2,3,6-TriF 3,5-Pyrimidine 0.94 ± 0.14 >120 
376 2,3,6-TriF Piperidine 0.73 ± 0.02 35.9 ± 6.0 
335 2,3,6-TriF N-Me piperidine 0.57 ± 0.10 29.3 ± 0.5 
338 3-Cl, 2,6-DiF 3-Pyridine 0.20 ± 0.05 >120 
339 3-Cl, 2,6-DiF 3,5-Pyrimidine 0.24 ± 0.02 >120 
377 3-Cl, 2,6-DiF Piperidine 0.24 ± 0.01 39.1 ± 7.8 
340 3-Cl, 2,6-DiF N-Me piperidine 0.14 ± 0.02 28.9 ± 5.2 
344 2-Cl, 3,6-DiF 3-Pyridine 1.00 ± 0.28 >120 
378 2-Cl, 3,6-DiF Piperidine 0.76 ± 0.01 31.9 ± 6.5 
346 2-Cl, 3,6-DiF N-Me piperidine 0.80 ± 0.00 20.4 ± 0.7 
348 2,6-DiF, 3-Me 3-Pyridine 0.42 ± 0.10 >120 
350 2,6-DiF, 3-Me 3,5-Pyrimidine 0.76 ± 0.09 >120 
379 2,6-DiF, 3-Me Piperidine 0.44 ± 0.02 65.9 ± 5.1 
352 2,6-DiF, 3-Me N-Me piperidine 0.39 ± 0.02 40.2 ± 3.3 
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354 6-Cl, 2,3-DiF 3-Pyridine 0.96 ± 0.15 >120 
356 6-Cl, 2,3-DiF 3,5-Pyrimidine 0.71 ± 0.02 >120 
380 6-Cl, 2,3-DiF Piperidine 0.21 ± 0.07 38.0 ± 0.09 
358 6-Cl, 2,3-DiF N-Me piperidine 0.11 ± 0.00 49.8 ± 6.4 
361 2,5-DiF 3-Pyridine 6.0 ± 0.6 >120 
381 2,5-DiF Piperidine 8.6 ± 0.4 52.7
b
 
357 2,5-DiF N-Me piperidine 6.2 ± 0.1 52.6 ± 4.9 
366 5-Cl, 2-F 3-Pyridine 1.2
b
 >120 
367 5-Cl, 2-F 3,5-Pyrimidine 1.6 ± 0.3 >120 
382 5-Cl, 2-F Piperidine 1.7 ± 0.1 44.1 ± 4.8 
369 5-Cl, 2-F N-Me piperidine 1.9 ± 0.2 30.9 ± 7.3 
372 2-F, 5-Me 3-Pyridine 4.0 ± 0.6 >120 
373 2-F, 5-Me 3,5-Pyrimidine 5.2 ± 0.3 >120 
375 2-F, 5-Me N-Me piperidine 4.4 ± 0.5 15.9 ± 2.3 
a 
Determinations ± standard deviation (mean of n = 2 unless otherwise stated); 
b 
n = 1. NB: 
Green – ERK5 IC50 ≤ 0.5 µM; Amber – ERK5 IC50 = 0.5-1.0 µM; Red – ERK5 IC50 = >1.0 
µM. 
6.7.7 Evaluation of Di-Substituted Aroyl Analogues as Lead Compounds 
Compounds synthesised in this series with potencies ≤1 µM were evaluated according to the 
criteria outlined in Section 6.4 for their suitability as potential lead compounds.  
6.7.7.1 Physicochemical Properties 
Analysis of the physicochemical properties of the most potent 2-chloro-6-fluoro analogues 
indicates that the basic criteria are met. N-Methyl piperidine analogue 283 has a slightly 
lower TPSA than desired, but this was not a cause for concern at this stage. The data for the 
analogous 2-bromo-6-fluoro compounds were largely the same as those shown in Table 54 
and for this reason, are not tabulated here. The Lipinski ‘Rule of 5’ states that compounds 
with a molecular weight below 500 amu, ≤ 5 H-bond donors and ≤ 10 H-bond acceptors, and 
a LogP below 5 have the greatest chance of giving rise to an orally active drug.
130
 
Topological polar surface area (TPSA) gives an indication of the compound’s ability to cross 
cell membranes, and a value between 75 and 100 Å
2
 increases the chance of good oral 
bioavailability, independent of molecular weight.
131
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Table 54: Physicochemical properties of potent 2-chloro, 6-fluoro analogues 
Compound Lead 272/273 292 283 
R
2
 - 3- or 4-Pyridyl Piperidine N-Me Piperidine 
MW <500 344 349 363 
sLogP <5 3.1 2.0 2.6 
TPSA 75-100 75 74 65 
H-Bond 
Donor/Acceptor 
<6/<10 2/5 3/5 2/5 
pKa Salt forming Y Y Y 
NB: Green – compound meets critera; Amber – borderline result; Red – compound fails 
criteria. 
6.7.7.2 In Vitro Pharmacology 
The in vitro pharmacology of the eight selected compounds was investigated. Selected 
compounds were screened against a panel of 131 diverse protein kinases, which was 
performed at the International Centre for Kinase Profiling (Dundee). hERG inhibition was 
measured by Cyprotex, specialists in ADME and toxicology profiling. Cellular activity in 
HEK293 cells was generated at the Babraham Institute by myself, in collaboration with Dr 
Simon Cook, assisted by Dr Pamela Lochhead. Further details of the assay procedure are 
described in Section 7.8. 
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Table 55: In vitro pharmacology for potent compounds with pyridyl-carboxamide groups 
Compound Lead 272 273 263 278 
R
1
 - 
2-Chloro, 6-
fluoro 
2-Chloro, 6-
fluoro 
2-Bromo, 6-
fluoro 
2-Bromo, 
6-fluoro 
R
2
 - 4-Pyridyl 3-Pyridyl 4-Pyridyl 3-Pyridyl 
ERK5 IC50 
(µM) 
<1 0.60 ± 0.3 0.60 ± 0.2 0.68 ± 0.2 0.82 ± 0.01 
LE >0.3 0.36 0.36 0.36 0.35 
Selectivity vs 
other kinases 
>10 
fold 
>120 fold 
p38α 
>120 fold 
p38α 
>120 fold 
p38α 
>120 fold p38α; 
No inhibition (131 
kinases 
Cellular 
Activity (µM) 
<10 2.3 ± 1.5 4.0 ± 1.4 4.0 ± 2.8 4.5 ± 2.1 
hERG Activity 
(µM) 
>25 ND ND ND >25 
NB: Green – compound meets critera; Amber – borderline result; Red – compound fails 
critera; ND – no data. 
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Table 56: In vitro pharmacology for potent compounds with piperidine based-carboxamide 
groups 
Compound Lead 292 283 293 287 
R
1
 - 
2-Chloro, 6-
fluoro 
2-Chloro, 6-
fluoro 
2-Bromo, 
6-fluoro 
2-Bromo, 
6-fluoro 
R
2
 - Piperidine 
N-Me 
Piperidine 
Piperidine 
N-Me 
Piperidine 
ERK5 IC50 
(µM) 
<1 0.49 ± 0.04 0.20 ± 0.06 0.39 ± 0.12 0.29 ± 0.12 
LE >0.3 0.37 0.38 0.38 0.37 
Selectivity vs 
other kinases 
>10 fold 
>20 fold over 
p38α; 
No inhibition 
(131 kinases) 
>40 fold over 
p38α; 
No inhibition 
(131 kinases) 
>45 fold 
over p38α. 
>35 fold over 
p38α. 
Cellular 
Activity (µM) 
<10 3.5 ± 3.5 1.9 ± 1.0 22.0 ND 
hERG Activity 
(µM) 
>25 >25 >25 >25 ND 
NB: Green – compound meets critera; Amber – borderline result; Red – compound fails 
critera; ND – no data. 
Compounds selected for selectivity screening were inactive against a wide range of protein 
kinases (131 in total). In addition, all compounds show at least 20-fold activity over p38α, 
and no hERG inhibitory activity is detected for compounds containing each of the three 
selected side-chains (i.e. 292, 283 and 278; hERG IC50 >25 µM). LE is above 0.35 for all 
analogues. Cellular activity is below 10 µM in all cases, except piperidine analogue 293 
which surprisingly, has a cellular IC50 of 22.0 µM (n = 1). Ligand efficiency (LE) was 
calculated using the formula LE = ∆G/HAC; where ∆G = -1.4 logIC50. 
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6.7.7.3 In Vitro DMPK Data 
Preliminary assessment of drug metabolism and pharmacokinetic properties was assessed in 
vitro. Solubility was assessed in a turbidimetric assay, by Cyprotex. Plasma protein binding 
(PPB), mouse/human microsomal stability, Caco-2 permeability and CYP inhibition assays 
were also performed by Cyprotex. Inhibition of the following CYP isoforms was measured; 
1A, 2C19, 2C9, 2D6, and 3A4.  
Table 57: In vitro DMPK data for selected pyridyl analogues 
Compound Lead 
 
272 
 
278 
Solubility (µM) >50 37.5 >100 
PPB (%) <99 ND 94 
MLM Clearance 
(µL/min/mg) 
<48 56 20 
HLM Clearance 
(µL/min/mg) 
<48 10 0 
Caco-2 A2B Papp 
(x10
-6
 cm/s) 
>10 ND 34 
Efflux Ratio <2 ND 0.82 
CYP Inhibition 
IC50 (µM) 
All >10 
0.07 (2C19), 0.35 (2C9), 
1.11 (2D6), 1.24 (3A4) 
All >5 
NB: Green – compound meets critera; Amber – borderline result; Red – compound fails 
critera; ND – no data. 
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Table 58: In vitro DMPK data for selected piperidine based analogues 
Compound Lead 
 
283 
 
292 
Solubility (µM) >50 >100 >100 
PPB (%) <99 68 50 
MLM Clearance 
(µL/min/mg) 
<48 8 1 
HLM Clearance 
(µL/min/mg) 
<48 0 2 
Caco-2 A2B Papp 
(x10
-6
 cm/s) 
>10 3.8 0.38 
Efflux Ratio <2 9.0 8.3 
CYP Inhibition 
IC50 (µM) 
All >10 All >15 All >10 
NB: Green – compound meets critera; Amber – borderline result; Red – compound fails 
critera; ND – no data. 
As anticipated, compounds containing the 4-pyridyl motif (i.e. 272) were found to be potent 
inhibitors of the CYP enzymes (0.07-1.24 µM). Interestingly, when the pyridine nitrogen 
atom is shifted to the 3-position, CYP inhibition is significantly decreased, and microsomal 
stability increased. It is evident that when in the 4-position, the pyridyl nitrogen lone pair 
increases the compound’s affinity for the CYP enzyme, both as an inhibitor and substrate. 
Aqueous solubility is also superior for 3-pyridyl analogue 278. Piperidine analogues 283 and 
292 also displayed excellent aqueous solubility (> 100 µM), with seemingly low affinity for 
CYP, demonstrated by high microsomal stability and lack of CYP inhibition characteristics. 
Unfortunately, the piperidine analogues both display low permeability properties, as 
demonstrated by the Caco-2 assay. Furthermore, the efflux ratio suggests that the compounds 
may be a substrate for P-glycoprotein 1 (P-gp). P-gp efflux is strongly associated with the 
presence of hydrogen-bond donors, particularly bases.
132
 The less basic 3-pyridyl analogue 
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278 shows no propensity for poor permeability as a result of P-gp efflux, supporting this 
hypothesis. Based on these observations, it is predicted that pyrimidine analogues will have 
less affinity for the CYP enzymes, and for P-gp. Considering the data generated investigating 
in vitro DMPK characteristics of pyrrole-carboxamide compounds, 3-pyridyl analogue 278 
was progressed for in vivo DMPK and efficacy evaluation.  
6.7.7.4 In Vivo DMPK and Efficacy Studies 
A single 10 or 100 mg/kg oral dose was administered to CD1 mice. Sample collection 
(plasma and tumour tissue) at five time points following oral dosing, enabled measurement of 
the pharmacokinetic properties of 278 (Figure 49). Tumour pharmacokinetic studies were 
performed using mice bearing a HCT116 human colorectal tumour xenograft. Intravenous 
and intraperitoneal dosing at 10 and 100 mg/kg was also performed; data is summarised in 
Table 59. Oral bioavailability is excellent at 68%, greatly exceeding the lead criteria (30%). 
In addition, the half-life of compound 278 is measured at 65 minutes. Clearance following 
oral dosing is higher than desired at 39 mL/min/kg. However, clearance following IV and IP 
dosing is within the desired range.  
 
Figure 49: Pharmacokinetic study of compound 278 in CD1 mice, following 10 mg/kg oral 
dosing for plasma PK and 100 mg/kg for tumour tissue PK (HCT116 human colorectal 
tumour xenograft). 
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Table 59: Summary of pharmacokinetic properties of 278 following 10 mg/kg PO, IP or IV 
dosing. 
Parameter Lead  PO Dosing  IP Dosing  IV Dosing 
Dose (mg/kg) - 10 10 10 
AUC inf 
(µg/mL.min) 
- 254 398 372 
Cmax (µM) - 6 12 25 
Vdss (L/kg) >1 - - 1.2 
Tmax (min) - 15 15 5 
Half-life (min) >60 65 43 38 
Clearance (mL/min/kg) <30 39 25 27 
Bioavailability, F (%) >30 68 108 - 
NB: Green – compound meets critera; Amber – borderline result; Red – compound fails 
critera. 
Compound 278 was assessed for in vivo efficacy using two techniques; a human tumour 
xenograft model and a Matrigel plug angiogenesis assay. Comparison with competitor 
compound XMD8-92, 33 (structure on page 43) was performed in each case.  
6.7.7.4.1 Matrigel Plug Assay 
Matrigel may be administered, and solidifies giving a plug; administration of the drug is 
performed via the desired route, i.e. PO, IP, or IV. This allows permeation of the plug by host 
cells, which form new blood vessels. Administration of an anti-angiogenic agent reduces the 
degree of blood vessel formation, to the tumour mimic. Histological examination of the plug 
7-21 days after dosing allows determination of the extent to which blood vessels have entered 
the plug.
133
 Matrigel containing basic fibroblast growth factor (bFGF) was injected sub-
cutanously into 15 CD1 mice which induces angiogenesis. 24 hours post dosing, mice were 
randomised to receive either vehicle, 50 mg/kg XMD8-92 IP twice daily for 7 days or 278 
PO twice daily for 7 days. On day 7, mice were sacrificed; Matrigel plugs were removed and 
snap frozen in liquid nitrogen. Haemoglobin was measured using the Drabkin’s method. 
Drabkin’s reagent (containing sodium bicarbonate, potassium ferricyanide and potassium 
cyanide) allowed quantitative colorimetric determination of haemoglobin concentrations in 
blood. Analysis of the Matrigel plugs indicated that inhibition of ERK5 in vivo resulted in an 
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angiogenic effect. A significant reduction in haemoglobin levels detected when CD1 mice 
received Matrigel with an ERK5 inhibitor (XMD8-92 or 278) was observed (Figure 50). This 
result confirms the anti-angiogenic potential of a clinical ERK5 inhibitor.  
 
Figure 50: Haemoglobin levels from Matrigel plugs; Animals received vehicle, 50 mg/kg 
XMD8-92 IP twice daily for 7 days or 278 PO twice daily for 7 days. 
6.7.7.4.2 Human Tumour Xenograft Models 
CD1 mice were inoculated with A2780 cells (human ovarian carcinoma) cells 
subcutaneously, and tumour volume was allowed to develop for 7 days to an average volume 
of 72 mm
3
. Mice were randomised to receive either vehicle, 50 mg/kg XMD8-92 IP or 100 
mg/kg 278 PO twice daily for 11 days. Tumour volumes were then measured. Nadir weight 
was monitored as an assessment of drug toxicity. No toxicity was observed in animals dosed 
with pyrrole-carboxamide 278. However, one mouse in the XMD8-92 group showed body 
weight loss (78% of original body weight) at day 10 of the study. Dosing with either XMD8-
92 or 278 resulted in a significant decrease in tumour growth compared with the vehicle 
group. Pyrrole-carboxamide 278 is equipotent with XMD8-92 in terms of slowing tumour 
progression, but shows an improved toxicity profile (Nadir weight 98% in all cases). 
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Figure 51: Treatment of CD1 mice bearing A2780 xenograft with XMD8-92 at 50 mg/kg IP 
or 278 at 100 mg/kg PO twice daily. 
6.7.8 Replacement of the Aroyl Substituent 
In parallel to the work conducted around the substitution pattern of the aroyl substituent 
(Sections 6.7.1-6.7.7), investigation into isosteric replacement of the aroyl group was also 
performed.  
6.7.8.1 Rationale 
Previous studies had confirmed the importance of the carbonyl group, as removal of the motif 
or reduction to the corresponding secondary alcohol abolished activity (IC50 values >120 
µM). The most likely explanation for this observation is the ability of the ketone to act as a 
hydrogen bond acceptor in the ERK5 binding site. Replacement of the carbonyl group with 
an isoquinoline group was probed, comparable to aroyl pyrrole 232. Incorporation of these 
groups introduced rigidity to the scaffold, while maintaining a lone pair capable of hydrogen 
bonding. At the time of investigation, it had not yet been discovered that truncation of the 
carboxamide side-chain resulted in a significant increase in potency. Therefore, the CH2-
linked 4-pyridyl side-chain was incorporated into the target molecule (Figure 52). 
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             230; ERK5 IC50 = 40.4 µM        384 
Figure 52: Comparison of aroyl pyrrole 232 with proposed isoquinoline 384. 
6.7.8.2 Synthetic Strategy 
It was initially envisaged that synthesis of isoquinoline pyrrole 384 may be achieved via 
Suzuki coupling of the relevant bromo-pyrrole, 386 with 1-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)isoquinoline. Protection of the pyrrole nitrogen was required, to prevent 
deprotonation by the base and cross-coupling at this position. Suzuki coupling was performed 
on the pyrrole ester 387 to minimise the risk of side-reactions (Figure 53). Initially, 
optimisation of the reaction with 2-pyridyl boronic acid as a model provided an intermediate 
towards a second target compound, 390 (Scheme 43). However, a review of the literature 
revealed that 2-pyridyl boronic acids and esters are notoriously unstable and present a 
challenge during cross-couplings, and unsurprisingly the reaction was unsuccessful. Although 
complex N-methyliminodiacetic acid based (MIDA) boronates have been developed which 
reduce the instability of the boronate species,
134
 it was decided in this case to reverse the 
coupling partners so that 2-bromopyridine was reacted with the pyrrole-3-pinacol boronic 
ester (Scheme 44). Previously optimised Suzuki coupling conditions were found to give 
excellent, reproducible yields over 2 steps.
135
 Isolation of boronic ester 389 was not 
performed. 
 
Figure 53: Retrosynthetic analysis of isoquinoline analogue 384. 
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Scheme 43: Reagents and Conditions; i) 2-pyridylboronic acid, KOAc, Pd(dbpf)Cl2, 
dioxane, 110 
o
C, 16 h. 
 
Scheme 44: Reagents and Conditions; i) bis(pinacolato) diboron, KOAc, Pd(dbpf)Cl2, 
dioxane, 110 
o
C, 16 h; ii) 2-bromopyridine, Na2CO3, Pd(PPh3)4, dioxane, H2O, 110 
o
C, 16 h. 
6.7.8.3 Synthesis of 4-(isoquinolin-1-yl)-N-(pyridin-4-ylmethyl)-1H-pyrrole-2-carboxamide, 
384 and 4-(pyridin-2-yl)-N-(pyridin-4-ylmethyl)-1H-pyrrole-2-carboxamide, 393 
Tosyl protection of 4-bromopyrrole proceeded in 55% using sodium hydride as the base. The 
protection strategy was implemented to prevent deprotonation and potential cross-couplings 
at the pyrrole nitrogen. Suzuki couplings gave the biaryl species 390 and 385 in 73% and 
62% respectively. Hydrolysis of the relevant esters proceeded quantitatively by LCMS. 
However, isolation of the carboxylic acids, 391 and 392 was challenging due to their 
zwitterionic nature and relatively low yields of 48-52% were achieved, respectively. CDI-
mediated couplings of the carboxylic acids 391 and 392 with 4-picolylamine also proved to 
be problematic. Poor solubility of the 2-pyridyl carboxylic acid in organic solvents resulted in 
isolation of only 22% of the amide product 393. The isoquinolyl acid 392 was found to be 
more soluble under the reaction conditions with 51% of the amide product isolated (Scheme 
45). 
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Scheme 45: Reagents and Conditions; i) i) NaH, TsCl, THF, 0 
o
C-RT, 16 h; ii) 
bis(pinacolato) diboron, KOAc, Pd(dbpf)Cl2, dioxane, 110 
o
C, 16 h; iii) 2-bromopyridine, 
Na2CO3, Pd(PPh3)4, dioxane, H2O, 110 
o
C, 16 h; iv) LiOH monohydrate, H2O/THF, 65 
o
C, 
16 h; v) CDI, THF, 70 
o
C, 3 h, then 4-picolylamine, 50 
o
C, 3 h. 
6.7.8.4 SARs for Isosteric Replacement of the Aroyl Motif 
Both biaryl compounds 393 and 384 were found to be inactive against ERK5 (IC50 values 
>120 µM) (Table 60). This may be due to the planar nature of the biaryl species, whereas the 
aroyl moiety has the ability to rotate into the correct conformation for binding. Recent data 
regarding the homology model and the crystal structure of p38α supports this idea. Also, the 
oxygen atom of the carbonyl group has two lone pairs available for hydrogen bonding. It is 
currently not known which of these pairs is involved in this interaction. It could be that the 
lone pair of the pyridine/isoquinoline is in the wrong position to participate in crucial bonding 
with the salt bridge. As neither compound showed any activity against ERK5, it was not 
deemed a priority to synthesise analogues without the methylene linker, known to improve 
potency. Furthermore, the compounds were not counter-screened against p38α due to their 
lack of ERK5 activity. 
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Table 60: ERK5 inhibitory activity of pyridyl and isoquinoline analogues 
Compound R
1
 
ERK5 IC50 
(µM)
a
 
393 
 
>120 
384 
 
>120 
232 
 
40.4 ± 2.6 
a 
Determinations ± standard deviation (mean of n = 2) 
6.8 Development of the Pyrrolopyridone Scaffold 
Another area of interest which was investigated in parallel with the modification to aroyl 
substituents was the development of a pyrrolopyridone scaffold.  
6.8.1 Rationale  
Homology modelling (using the initial ERK2-based model) suggested that incorporation of 
the pyrrolopyridone heterocycle may lock the carbonyl of the carboxamide motif into a 
favourable conformation for binding (Figure 54). Previous SAR studies have shown that 
although N-methylation of the amide nitrogen is detrimental to activity it is not completely 
lost (146; ERK5 IC50 = 9.0 µM).  
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It was hoped that an increase in potency would be obtained as a result of the conformational 
restraint imposed by the pyrrolopyridone scaffold. When investigation into this series began, 
the 2.6-difluoroaroyl moeity was present in the most potent compounds, i.e. 144 (ERK5 IC50 
= 2.3 µM) and the effect of side-chain truncation had not been discovered. Therefore, the 
CH2-linked 4-pyridyl carboxamide side-chain was incorporated (Figure 55). 
 
Figure 54: Homology modelling of pyrrolopyridone 394. 
 
Figure 55: Comparison of pyrrole-carboxamide 144 with pyrrolopyridone target 394. 
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6.8.2 Synthetic Strategy 
It was envisaged that synthesis of pyrrolopyridone 396 would allow decoration of the 
scaffold by N-methylation of the pyridone, followed by Friedel-Crafts acylation of the 
pyrrole (Figure 56).  
 
Figure 56: Retrosynthetic analysis of functionalised pyrrolopyridone 394. 
Only one synthetic route towards pyrrolopyridone 396 was present in the literature, when 
devising the methodology towards substituted pyrrolopyridones.
136
 The chlorosulfonium 
chloride intermediate used in the first step of the reported route was prepared by chlorination 
of 2-(phenylthio)acetaldehyde dimethyl acetal with liquid chlorine. This was reacted with 2-
methoxypyridin-3-amine, in an SN2 substitution, to give sulfonium chloride intermediate 399. 
Treatment with sodium methoxide induced a rearrangement to aniline 400. Cyclisation under 
acidic conditions resulted in formation of pyrrolopyridone 402, via the methoxypyridine 
analogue and reduction of the thioether with Raney nickel gave 1H-pyrrolo[2,3-c]pyridin-
7(6H)-one, 396. Replication of this method using the literature conditions was attempted, 
however, the synthesis was found to be lengthy and unreliable (Scheme 46). It was therefore 
necessary to implement a new strategy towards the synthesis of functionalised 
pyrrolopyridone compounds.  
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Scheme 46: Reported synthesis of pyrrolopyridone 396.
136
 Reagents and Conditions; i) Et3N, 
DCM, -70 
o
C, 4 h; ii) NaOMe, MeOH, RT, 18 h; iii) HCl, CHCl3, reflux, 72 h; iv) RaNi, H2, 
EtOH, reflux, 72 h. 
6.8.3 Synthesis of Substituted Pyrrolopyridones 
It was envisaged that cyclisation of the pyridone could be achieved following an 
intramolecular electrophilic aromatic substitution reaction with an aldehyde, giving a 5-
hydroxy-5,6-dihydropyridin-2(1H)-one intermediate, 404 (Scheme 47). Condensation of the 
5-hydroxy intermediate was deemed favourable due to the generation of an aromatic species. 
The aldehyde intermediate was formed via acid-catalysed hydrolysis of the corresponding 
diethyl acetal. 
 
Scheme 47: Pyridone synthesis via EAS followed by condensation 
402 
397 398 
399 
400 
401 
396 
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Pyrrolopyridone 396 was synthesised from methyl 1H-pyrrole-2-carboxylate via hydrolysis 
to the carboxylic acid followed by a CDI-mediated coupling with aminoacetaldehyde diethyl 
acetal. Under acidic conditions, cleavage of the acetal and subsequent cyclization was 
achieved at moderate temperature. The desired compound was obtained in good yield at 60% 
on a small scale (Scheme 48). However, scale up of the synthesis of 396 resulted in formation 
of an insoluble solid. It was not possible to analyse the material by 
1
H NMR due to the 
insolubility of the polymorph in organic solvents, including DMSO and TFA. The planar 
nature of the molecule combined with the potential to form intermolecular hydrogen bonds is 
thought to be responsible for strong crystal packing and poor solubility. Introduction of the 
pyridyl side-chain prior to acid-catalysed cyclisation was believed to be a reasonable strategy 
to improve the solubility of the product formed, by increasing the number of rotatable bonds 
and decreasing its planarity. 
 
Scheme 48: Reagents and Conditions: i) LiOH monohydrate, THF/H2O, 65 
o
C, 16 h; ii) CDI, 
THF, 70 
o
C, 3 h, then aminoacetaldehyde diethyl acetal, 50 
o
C, 3 h; iii) TFA:H2O (1:1), 50 
o
C, 16 h. 
Synthesis of the required pyridine side-chain, 409 was achieved via imine formation of 
isonicotinaldehyde with aminoacetaldehyde diethyl acetal, followed by reduction, mediated 
by sodium borohydride (Scheme 49). Amide coupling of amine 409 with pyrrole-carboxylic 
acid 405 was unsuccessful using CDI. Conversion of the carboxylic acid 405 to the 
corresponding acid chloride, followed by substitution with amine 409 gave amide 410 in a 
low yield of 18%. Acid-catalysed cyclisation of 410 proceeded cleanly using acetic acid, in 
83% yield. Unfortunately, Friedel-Crafts acylation of pyrrolopyridone 395 was unsuccessful 
and a complex reaction mixture was detected by LCMS. Interpretation of the 
1
H NMR 
spectrum of amide 410 conducted at RT was not possible. Restricted rotation about the amide 
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bond resulted in broadening of NMR signals, and some signals were not visible. To resolve 
the spectrum, a 
1
H NMR variable temperature experiment was conducted (Figure 57). The 
1
H 
NMR spectrum for amide 410 was conducted at a range of temperatures; 50, 80 and 110 
o
C. 
80 
o
C was found to be the optimum temperature, as the greatest peak intensity was achieved 
with the best resolution of peaks. Future substituted amides exhibiting restricted rotation in 
NMR spectra were therefore analysed at this optimum temperature. It was not possible to 
obtain suitable 
13
C NMR spectra, as this would involve heating up the NMR probe for 
prolonged periods of time. 
 
Scheme 49: Reagents and Conditions; i) aminoacetaldehyde diethyl acetal, MgSO4, toluene, 
110 
o
C, 16 h; ii) NaBH4, MeOH, 0 
o
C, 4 h. 
 
Scheme 50: Reagents and Conditions; i) LiOH monohydrate, THF/H2O, 65 
o
C, 16 h; ii) 
SOCl2, DMF, THF, 0 
o
C-RT, 2 h; iii) 409, DCM, RT, 16 h; iv) acetic acid:H2O (1:1), 70 
o
C, 
16 h; v) 2,6-difluorobenzoyl chloride, AlCl3, DCM, 0 
o
C-RT, 16 h. 
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Figure 57:  
1
H NMR variable temperature experiment of amide 410, aromatic region. Blue = 
RT; Red = 50 
o
C; Green = 80 
o
C; Purple = 110 
o
C.  A: 4.78 (1H, t, J = 4.9 Hz, CH); B: 4.88 
(2H, s, CH2-pyridine); C: 6.10 (1H, dd, J = 2.4 and 3.5 Hz, H-4); D: 6.45 (1H, s, H-3); E: 
6.91 (1H, dd, J = 1.6 and 2.4 Hz, H-5); F: 7.25 (2H, d, J = 6.0 Hz, CH-pyridine); G: 8.53 
(2H, d, J = 6.0 Hz, N-CH-pyridine). 
Following the failure of the Friedel-Crafts acylation, an alternative strategy was 
implemented. Acylation of the pyrrole was completed in the first step of the synthesis in 62% 
yield, which was followed by hydrolysis of ester 411 and coupling of the amine via the acid 
chloride (Scheme 51). The cyclisation step proved to be much more difficult when the 4-
aroyl group was present. The electron withdrawing nature of the aroyl substituent results in a 
reduction in the pyrrole’s electron density making it less reactive for cyclisation. Reaction 
monitoring by LCMS was used extensively during the optimisation of the reaction.  The use 
G F 
E D C B A 
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of acetic acid:H2O was first investigated as this was found to give a cleaner reaction mixture, 
as opposed to TFA:H2O. No evidence of cyclisation was observed at 100 
o
C or 120 
o
C under 
microwave heating, although cleavage of the acetal was observed. The use of TFA was 
reinstated, using water or TFE as the solvent but reaction was not observed until temperatures 
were increased to 160 
o
C with microwave heating. Where TFE was used as the solvent, a 
large impurity peak was observed with m/z 466 which corresponds to the addition of 
trifluoroethanol to the molecule. 1:1 TFA:H2O showed 90% conversion by LCMS to a 
product bearing the correct m/z ratio (Table 61). 
Table 61: Reaction optimisation – acid-catalysed cyclisation of acetal 413. 
Attempt Acid Solvent Temp (
o
C) Time Observation 
1 Acetic H2O 100 conv 16 h NR 
2 Acetic H2O 120 mw 30 min NR 
3 TFA H2O 100 conv 16 h NR 
4 TFA H2O 120 mw 30 min NR 
5 TFA TFE 120 mw 30 min NR 
6 TFA TFE 160 mw 30 min 
30% conversion; 
impurity forming  
m/z = product + 
TFE added 
7 TFA H2O 160 mw 
2 h 
(in 30 min 
cycles) 
90% conversion to 
product – no 
impurities 
 
As the nitrogen atom of pyrrole is not nucleophilic without prior deprotonation, it was 
assumed that cyclisation about the pyrrole nitrogen would not occur. However, analysis by 
1
H NMR, followed by 
1
H-
15
N HSQC and HMBC techniques did not confirm the desired 
structure, and cyclisation had occurred to give the undesired product 414 instead. 
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Scheme 51: Reagents and Conditions; i) 2,6-difluorobenzoyl chloride, AlCl3, DCM, 0 
o
C-
RT, 16 h; ii) LiOH monohydrate, THF/H2O, 65 
o
C, 16 h; iii) SOCl2, DMF, THF, 0 
o
C-RT, 2 
h; iv) 409, DCM, RT, 16 h; v) TFA:H2O (1:1), 160 
o
C, MW, 2 h. 
In order to prevent cyclisation onto the pyrrole nitrogen, a protection strategy was 
implemented (Scheme 52). As the electron withdrawing aroyl moiety makes the cyclisation 
reaction more difficult, due to the pyrrole being more electron-poor, it was proposed that an 
electron donating protecting group would be beneficial. The SEM protecting group was 
chosen due to its apparent robustness to acidic and basic conditions, its electron donating 
properties, and its ease of removal using a fluoride source. The cyclisation conditions were 
re-optimised in order to achieve the desired product in the mildest conditions possible (Table 
62).  At 60 and 100 
o
C in acetic acid with conventional heating no cyclisation was observed. 
A small amount of product was observed using microwave heating at 120 
o
C or above. It was 
noted that during the cyclisation under various conditions (Table 62, entries 3, 4, 5 and 6), 
cleavage of the SEM protecting group was observed. This resulted in the formation of the 
undesired cyclisation product observed previously (Scheme 51). Following attempts using 
water as the solvent, it was postulated that use of an aprotic solvent (DME) would improve 
the ratio of product to impurities. Hydrolysis of the amide bond under the reaction conditions 
was also observed, giving rise to carboxylic acid and amine by-products. Fortunately, an 
acceptable proportion of the SEM protected pyrrole withstood the conditions to give the 
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desired SEM protected cyclised product 418 in 35% yield following column chromatography. 
Subsequent deprotection of the SEM group was achieved using TBAF in 83% yield.  
Table 62: Reaction optimisation – acid-catalysed cyclisation of acetal 417. 
Attempt Acid Solvent Temp (
o
C) Time Observation 
 
1 
Acetic H2O 60 conv 16 h NR 
 
2 
Acetic H2O 100 conv 16 h NR 
3 Acetic H2O 120 MW 20 min 
V. small product peak, small peak 
m/z 383 ( aldehyde, SEM off) 
4 Acetic H2O 160 MW 20 min 
32% product in complex mixture. 
SEM group off (38%) 
5 TFA DME 120 MW 20 min 
V. small product peak, small peak 
m/z 383 ( aldehyde, SEM off) 
6 TFA DME 120 MW 1.5 h 
Major peak is product. Several 
other peaks corresponding to 
various impurities 
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Scheme 52: Reagents and Conditions; i) 2,6-difluorobenzoyl chloride, AlCl3, DCM, 0 
o
C-
RT, 16 h; ii) SEMCl, Et3N, DMAP, THF, 0 
o
C-RT, 2 h; iii) LiOH monohydrate, THF/H2O, 
65 
o
C, 16 h; iv) SOCl2, DMF, THF, 0 
o
C-RT, 2 h; v) 409, DCM, RT, 16 h; vi) 20% TFA in 
DME, 120 
o
C, 1.5 h; vii) TBAF, THF, 0 
o
C-RT, 16 h. 
6.8.4 Discovery of Pyrrolopyridones as Inhibitors of p38α 
Subsequent to the optimisation of methodology for the synthesis of substituted 
pyrrolopyridone 394 we found that discovery of pyrrolopyridone based inhibitors of p38α 
had been described in a patent by Merck, Sharpe and Dohme.
137
 Compounds displaying low 
nanomolar potency were reported, as summarised in Table 63. Interestingly, the most potent 
compounds all feature a 2, 4, 6-trifluoro substitution pattern about the aroyl ring. It is known 
that para-substitution is not tolerated in ERK5, even with a small fluorine atom. All side-
chains contained the CH2-linker, with a 5-, 6-fused heterocycle attached. The most potent 
compounds contained amide or carboxylic acid based substituents on the 6-membered ring. 
Based on these results, it was expected that pyrrolopyridone compound 394 would be a p38α 
inhibitor and so not selective for ERK5. 
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Table 63: Example p38α inhibitors.  From ref 137. 
Compound R
2
 
p38α IC50 
(nM) 
419 
 
1.0 
420 
 
1.3 
421 
 
2.0 
422 
 
3.0 
 
6.8.5 Biological Evaluation of 3-(2,6-Difluorobenzoyl)-6-(pyridin-4-ylmethyl)-1H-
pyrrolo[2,3-c]pyridin-7(6H)-one 394 
Pyrrolopyridone 394 was found to be a modest inhibitor of ERK5 with an IC50 of 7.7 µM. 
This result is comparable to the effect of amide N-methylation (ERK5 IC50 = 9.0 µM). 
However, counter-screening revealed that 394 was a very potent inhibitor of p38α at 100 nM. 
As the homology model available for structure-guided drug design is based in part on p38α, it 
is currently not possible to identify the exact differences in the two binding sites (ERK5 vs 
p38α) which are giving rise to the dramatic differences in potency. Previously reported 
pyrrole-carboxamide based inhibitors of p38α are known to form a hydrogen bond between 
their amide NH and a water molecule present in the binding site (i.e. 294; Section 6.7.5). It 
may be that displacement of this water molecule by incorporation of a lipophilic group on the 
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amide nitrogen is more entropically favoured in p38α than in ERK5. The excellent potency of 
pyrrolopyridone 394 against p38α and tolerance in ERK5 led us to the investigation of 
pyrrolopyridone compounds containing truncated side-chains. Evolution of the project had 
resulted in discovery of truncated 4- and 3-pyridyl side-chains and the 2-bromo-6-fluoro and 
2-chloro-6-fluoro aroyl substituents conferring the greatest potency in target molecules 
during the course of the research into the pyrrolopyridone scaffold.  
Table 64: ERK5 inhibitory activity of 394 
Compound Structure 
ERK5 IC50 
(µM)
a
 
p38α IC50 
(µM)
a
 
394 
 
7.7 ± 0.9 0.10 ± 0.01 
a 
Determinations ± standard deviation (mean of n = 2) 
6.8.6 Synthesis of N-Pyridyl Pyrrolopyridones  
The initial synthetic strategy implemented for synthesis of pyrrolopyridones incorporating N-
pyridyl substituents was (as for the synthesis of pyrrolopyridone 394), to react the relevant 
aniline in a substitution reaction with the corresponding acid chloride of carboxylic acid 416. 
N-(2,2-Diethoxyethyl)pyridin-4-amine, 424 was synthesised via SNAr substitution of 4-
chloropyridine hydrochloride 423 with aminoacetaldehyde diethyl acetal (Scheme 53). 
Unfortunately, due to the electron poor nature of the amine, the coupling reaction between 
amine 424 and the acid chloride failed to give the desired product (Scheme 54). The 
alternative PCl3-mediated amide coupling of amine 424 and carboxylic acid 416 was not 
attempted as previous experience taught that cleavage of the acetal group would undoubtedly 
occur under the harsh reaction conditions. 
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Scheme 53: Reagents and Conditions; i) aminoacetaldehyde diethyl acetal, NMP, 130 
o
C, 
MW, 30 min. 
 
Scheme 54: Reagents and Conditions; i) 2,6-difluorobenzoyl chloride, AlCl3, DCM, 0 
o
C-
RT, 16 h; ii) SEMCl, KO
t
Bu, THF, 0 
o
C-RT, 2 h; iii) LiOH monohydrate, THF/H2O, 65 
o
C, 
16 h; iv) SOCl2, DMF, THF, 0 
o
C-RT, 2 h; v) 424, DCM, RT, 16 h. 
It was envisaged that, as an alternative, key intermediate 425 could be synthesised by 
alkylation of the secondary amide, 426. The electron poor 4-aminopyridine was successfully 
coupled to carboxylic acid using the PCl3-mediated approach, and the SEM protecting group 
remained intact during the course of the reaction, giving amide 426 in 77%. Unfortunately, it 
was not possible to alkylate amide 426 with bromoacetaldehyde diethyl acetal using 
potassium tert-butoxide as a base (Scheme 55). A model reaction was conducted, attempting 
methylation of amide 426 using highly reactive methyl iodide with KO
t
Bu. N-Methyl amide 
427 was isolated in 21% yield, confirming that potassium tert-butoxide is a strong enough 
base to deprotonate the amide (Scheme 56). However, no starting material was recovered, 
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and no by-products were isolated following an aqueous work-up. It is thought that N-
methylation of the pyridine, leading to the formation of an aqueous soluble pyridine salt, is 
occurring more rapidly than N-methylation of the amide. 
 
Scheme 55: Reagents and Conditions; i) 2,6-difluorobenzoyl chloride, AlCl3, DCM, 0 
o
C-
RT, 16 h; ii) SEMCl, KO
t
Bu, THF, 0 
o
C-RT, 2 h; iii) LiOH monohydrate, THF/H2O, 65 
o
C, 
16 h; iv) PCl3, 4-aminopyridine, MeCN, 150 
o
C, MW, 5 min; vi) bromoacetaldehyde diethyl 
acetal, KOtBu, THF, 0 
o
C-RT, 2 h. 
 
Scheme 56: Reagents and Conditions; i) KO
t
Bu, MeI, THF, 0 
o
C-RT, 2 h. 
The final strategy relied on cyclisation of the pyrrolopyridone prior to the addition of the 
pyridyl group. Amide coupling mediated by CDI of aminoacetaldehyde diethyl acetal with 
carboxylic acid 412 proceeded in 87% yield. Regioselective acid-catalysed cyclisation was 
achieved with neat methanesulfonic acid, using the method described in the Merck patent, to 
give pyrrolopyridone 429 in 46% yield.
137
 SEM protection proceeded in 58% yield. There is 
literature precedent for Ullmann couplings of 2-pyridones with aryl halides.
138
 Classical 
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Ullmann coupling conditions were employed without use of the N, N’-dimethylcyclohexane-
1, 2-diamine (DMCDA) additive described by Wang et al, and N-arylation was achieved in 
21% yield via coupling of 430 with 4-bromopyridine hydrochloride. The reaction was 
unsuccessful when using diamine-based additives. Application of the method for use with 3-
bromopyridine was not successful. However, conversion of the pyridine species to the 
hydrochloride salt prior to coupling resulted in successful and reproducible coupling results. 
A series of compounds based on this scaffold incorporating features of the most potent 
pyrrole-carboxamide compounds to date was prepared, summarised in Tables 65 and 66. It 
was noted that purification of protected compounds was difficult, which may be responsible 
for the low yields reported for intermediates bearing the silyl group. Furthermore, during the 
course of the Ullmann coupling, the SEM group was cleaved in a number of cases. The crude 
mixtures were deprotected to give the final products. In the case of 2-bromo, 6-fluoro 
analogue 449, only 9% of the desired product was isolated following the tandem Ullmann 
coupling with 4-bromopyridine hydrochloride and silyl deprotection steps. The low yield 
recorded is attributed to the presence of a second aryl bromide species, which offers an 
alternative reaction site.  Purification via semi-preparative HPLC was required due to the 
presence of closely running impurities. The 3-pyridyl analogue was not able to be 
synthesised. 
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Scheme 57: Reagents and Conditions; i) CDI, THF, 70 
o
C, 3 h, then aminoacetaldehyde 
diethyl acetal, 50 
o
C, 3 h; ii) MeSO3H, 95 
o
C,  1 h; iii) SEMCl, Et3N, DMAP, THF, RT, 16 h; 
iv) 4-bromopyridine HCl, K2CO3, CuI, DMF, 135 
o
C, 48-72 h; v) TBAF, THF, 65 
o
C, 16 h. 
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Table 65: Synthesis summary for N-pyridyl pyrrolopyridone series, part 1 
R
1
 
Acylation 
Yield (%) 
Hydrolysis 
Yield (%) 
Amide 
Coupling 
Yield (%) 
Cyclisation 
Yield (%) 
SEM 
Protection 
Yield (%) 
 
411; 62 412; 97 428; 87 429; 46 430; 58 
 
434; 79 435; 97 436; 84 437; 55 438;72 
 
270; 89 271; 99 441; 64 442; 53 443; 48 
 
276; 80 277; 90 446; 57 447; 59 448; 64 
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Table 66: Synthesis summary for N-pyridyl pyrrolopyridone series, part 2 
R
1
 R
2
 
Ullmann Coupling 
Yield (%) 
SEM Deprotection 
Yield (%) 
  
431; 21 432; 60 
  
- 433; 37 
 
 
- 439; 69 
 
 
- 440; 40 
  
- 444; 51 
  
- 445; 19 
  
- 449; 9 
 
6.8.7 Biological Evaluation of N-Pyridyl Pyrrolopyridones 
Unfortunately, all compounds in the N-pyridyl pyrrolopyridone series were found to be 
insoluble at higher concentrations under the IMAP
™ 
assay conditions rendering the 
interpretation of IC50 values unreliable. Despite their insolubility, some ERK5 inhibitory 
activity was recorded (i.e. 444 ERK5 IC50 = 3.0 µM, insoluble in 40% DMSO). We can 
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compare the pyrrolopyridone-based compounds to their uncyclised counterparts but must 
consider the caveat of the reduced solubility. It appears that cyclisation does not improve 
ERK5 activity, but selectivity against p38α is certainly diminished; i.e. Compound 444 is 
only 3-fold selective for ERK5 over p38α. Conversion of compounds 444 and 449 to their 
corresponding HCl salts was subsequently performed, and the salts were re-tested. However, 
no significant improvement in solubility was observed (in order to obtain a reliable IC50 
measurement). As a result of the poor solubility and selectivity profiles of this series, research 
into the pyrrolopyridone series was discontinued. 
 
Table 67: ERK5 inhibitory activity of pyrrolopyridone analogues 
Compound R
1
 R
2
 
ERK5 IC50 
(µM)
a
 
p38α IC50 
(µM)
a
 
432 
  
>120 >120 
433 
  
17.9 ± 2.0 15.8
d
 
439 
 
 
>120 >120 
440 
 
 
78.6 ± 11.7 >120 
444 
  
3.0 ± 0.5
b
 8.8 ± 1.0
b
 
445 
  
4.4 ± 0.3
c
 15.8 ± 0.5
b
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449 
  
2.8 ± 0.1 13.2 ± 1.1 
a 
Determinations ± standard deviation (mean of n = 2, unless otherwise stated); 
b
 n = 4; 
c
 n = 
3; 
d
 n = 1 
6.9 Future Work and Conclusions 
6.9.1 Future Work 
The potency of leading compounds in the pyrrole-carboxamide series has been improved by 
approximately 10 to 20-fold over the course of hit-to-lead optimisation. Future studies aim to 
improve potency further by probing previously uninvestigated sites in the ERK5 ATP-
binding site, ideally below 100 nM in the enzymatic assay. Synthetic efforts to improve 
ERK5 activity will focus on further investigation around accessing an allosteric pocket via 
the 3-position of the aroyl motif as described in Section 6.7.6. The presence of a 3-chloro 
group in the most potent compound to date provides an opportunity to exploit palladium 
mediated chemistry (i.e. Suzuki, Sonogashira, Buchwald couplings etc), in order to build up 
SAR around this position. In addition, homology modelling has revealed that access to the 
ribose pocket may be possible, via incorporation of substituents on the 3-position of the 
pyrrole (Figure 58). 
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Figure 58: Identification of a ribose pocket in the ERK5 active site, possibly accessible via 
the pyrrole 3-position. 
Substitution of the carboxamide side-chain appears to be less constrained than that of the 
aroyl group, and wider range of substituents may be incorporated. Therefore, it is envisaged 
that tuning of the ADME properties, primarily CYP inhibition and compound efflux, may be 
eliminated via optimisation of this motif. Figure 59 summarises the ongoing research on the 
project. 
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Figure 59: Summary of the future areas for investigation around the pyrrole-carboxamide 
scaffold. 
6.9.2 Conclusions 
Structure activity relationships (SARs) around the pyrrole-carboxamide scaffold have been 
thoroughly investigated, owing to their synthetic tractability. Homology modelling (based on 
the structures of ERK2, and later, p38α) was the driving force for structure based drug design 
throughout the project.  
Early homology modelling studies suggested that replacement of the aroyl motif with non-
aromatic groups may be tolerated in the ERK5 binding site. However, activity was abolished 
in the majority of cases, with only the unsubstituted cyclohexane analogue, 149 conferring 
any potency within the limits of the IMAP assay (IC50 = 59.3 µM).  
Parallel investigation of the substitution pattern of the aroyl ring and carboxamide side-chain 
motifs led to the discovery of compound 278, a selective ERK5 inhibitor with sub-
micromolar potency (278; ERK5 IC50 = 0.82 µM; p38α >120 µM; no significant inhibitory 
activity against a panel of 131 protein kinases). It was discovered that non-aromatic 
carboxamide substituents, particularly N-methyl piperidine, were tolerated i.e. compound 
283; IC50 = 0.20 µM. 
Owing to the excellent physicochemical properties exhibited (according to Lipinski’s rule of 
5), compounds 278 and 283 performed well in in vitro DMPK studies, and no inhibition of 
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hERG (IC50 >25 µM) was recorded. However, inhibition of the CYP enzymes, attributed to 
the presence of an unflanked pyridine ring, was observed with compound 272, and poor cell 
permeability and high efflux ratio was observed with compound 292. Pyrrole 278 was 
progressed into preliminary in vivo studies due to the higher probability of cell permeation, 
and demonstrated efficacy comparable to the competitor compound XMD8-92 in both an 
angiogenesis model and in tumour xenograft models. 
 
It was hypothesised that access to an allosteric site may be achieved via further substitution 
of the 2- or 3-positions of the aroyl ring. However, incorporation of small alkyl substituents 
in the 2-position was not well tolerated, with diminished activity observed compared to that 
of the di-halogenated analogues e.g. 278. Overlay of pyrrole-carboxamide based compounds 
with the quinazoline-based p38α inhibitor 341 suggested that substitution of the 3-position 
was a superior strategy towards accessing the prospective allosteric site. Incorporation of 
substituents at this position was tolerated, giving the most potent compound to date, 341, with 
an IC50 of 110 nM.  
 
341 
Strategies to introduce rigidity to the pyrrole-carboxamide scaffold were also investigated. 
Replacement of the aroyl motif with a biaryl scaffold, while maintaining the presence of a 
hydrogen bond acceptor was not tolerated. Furthermore, cyclisation of the pyrrole-
carboxamide scaffold to give pyrrolopyridone was extensively investigated. The synthesis of 
the novel pyrrolopyridones were not trivial, and unfortunately, these compounds suffered 
from poor aqueous solubility, micromolar potency and reduced selectivity against p38α. 
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The pyrrole-carboxamide series has now entered the lead optimisation phase of drug 
discovery following successful hit-to-lead studies. The programme is well positioned to 
exploit structure-based drug design for rapid lead optimisation with the aim of providing 
compounds for preclinical development. 
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Chapter 7: Experimental and Analysis 
7.1 Solvents and Reagents  
Chemicals were purchased from Sigma-Aldrich Chemical Company and Alfa Aesar unless 
otherwise stated. Anhydrous DCM, DMF, DMSO, EtOH, MeOH, pyridine and THF were 
purchased in SureSeal™ bottles from Sigma-Aldrich or Acroseal™ bottles from Acros. 
Deuterated solvents used for NMR were purchased from Sigma-Aldrich. Unless stated, 
reactions were carried out under an inert atmosphere of nitrogen.  
7.2 Analytical Techniques  
The structures of reported compounds were elucidated through use of proton (
1
H) and carbon 
(
13
C) nuclear magnetic resonance techniques and run in the following deuterated solvents; 
CDCl3, DMSO-d6 or MeOD. Samples were run on either a Bruker Spectrospin AC 300E 
(300MHz) NMR spectrometer or a Bruker Avance III (500 MHz) NMR spectrometer. 
Chemical shifts are reported in parts per million (ppm) and coupling constants in Hertz (Hz). 
The abbreviations for spin multiplicity are as follows: s = singlet; d = doublet; t = triplet; q = 
quartet, quin = quintet and m = multiplet. Combinations of these abbreviations are employed 
to describe more complicated splitting patterns e.g. dd = doublet of doublets; dt = doublet of 
triplets etc. Where broadening of the peak is observed, spin multiplicity is accompanied by 
the prefix br = broad. 
LC-MS (Liquid Chromatography - Mass Spectrometry) was carried out on a Micromass 
Platform LC or a Waters Acquity UPLC system with PDA and ELSD employing positive or 
negative electrospray modes as appropriate to the individual compound. High-resolution 
mass spectrometry results were obtained from the EPSRC National Mass Spectrometry 
Service, University of Wales, Singleton Park, Swansea, SAZ 8PP. Analytical purity of 
compounds were determined using Waters XTerra RP18, 5 μm (4.6 × 150 mm) column at 1 
mL/min using either 0.1% aqueous ammonia and acetonitrile or 0.1% aqueous formic acid 
and acetonitrile with a gradient of 5-100% over 15 minutes.  
FTIR spectra were recorded using a Bio-Rad FTS 3000MX diamond ATR as a neat sample. 
Melting Points were measured on either the Stuart Scientific SMP3 or SMP40 and are 
uncorrected. Ultraviolet spectra were measured using a Hitachi UV-U2800A 
spectrophotometer and were performed in EtOH. 
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7.3 Chromatography  
MPLC performed on a Biotage SP4 system used prepacked columns from Biotage or Varian 
(KP-Sil, KP-NH, KP-C18 or Agilent Si 50 or 35). Thin layer chromatography was performed 
on Merck TLC silica gel 60 F254 plates unless otherwise stated, or NH2F254s plates on 
aluminium sheets, which were dried and visualised using short wave (245 nm) ultraviolet 
light.  
Compounds requiring semi-preparative HPLC were purified on one of the following 
machines: (i) Varian Prostar Modular HPLC system equipped with a binary pumping system, 
UV detector and fraction collector and controlled by Varian Star software. (ii) Agilent 1200 
HPLC system equipped with a binary pump, autosampler, fraction collector and diode array 
detector and controlled by Agilent ChemStation software. 
7.4 Microwave Reactions  
All reactions carried out in a microwave were performed in a Biotage Initiator with Sixty 
robot. 
7.5 Crystallography  
X-ray crystal structures were obtained by Dr. Ross W. Harrington and Prof. William Clegg at 
X-ray Crystallography, School of Chemistry, Bedson Building, Newcastle University, 
Newcastle upon Tyne, NE1 7RU. 
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7.6 ERK5 IMAP™ Assay Protocol  
Preparation of Assay Buffer (1x)  
The 0.01% Tween
®
-20 5x stock was supplied as part of IMAP
TM
 FP Progressive Binding 
System Kit (Molecular Devices R7436), which was diluted to 1x using miliQ H2O. 1 µL of a 
1M DTT stock was added for every 1 mL of 1x assay buffer to give a final concentration of 1 
mM DTT.  
Preparation of ERK5 Working Solution  
The final dilution was dependent on activity of the enzyme batches. The initial batch 
(08/08/08) was used at a 1 in 1 in 350 final dilution in assay buffer. A 1:175 dilution of ERK5 
stock was performed in 1x assay buffer. For 1 plate, 13 µL of ERK5 stock was added to 2262 
µL of 1x assay buffer. ERK5 was expressed and purified at CRT by Leon Pang and Sue 
Young. Aliquots were stored at –80 C. Batch PO080808 was used at a stock concentration 
of 73.4 ng/µl. 
Preparation of ATP/Substrate Working Solution 
For one plate, ATP disodium salt (90 µL, 20 mM) (Sigma A7699) and FAM-EGFR-derived 
peptide (15 µL, 100 µM) (LVEPLTPSGEAPNQ(K-5FAM)-COOH) (Molecular Devices 
RP7129; reconstituted in miliQ H2O to a stock concentration of 100 µL; Stored at -20C) was 
added to 2295 µL of 1x assay buffer. 
Preparation of IMAP
™
 binding solution 
For one plate 20.5 µL of IMAP
™
 binding reagent stock, 1476 µL of 1x binding buffer A 
(60%), and 984 µL of binding buffer B (40%) (IMAP™ FP Progressive screening express kit 
(Molecular Devices R8127) was added to 9819.5 µL of milliQ H2O. 
Assay Procedure 
1 µL of compound (in 60:40 H2O/DMSO) or 60:40 H2O/DMSO (for controls and blanks) 
were dry-spotted into the relevant wells of a 384-well assay plate using the MATRIX 
PlateMate

 Plus. 5 µL of ERK5 working solution was added to test and control wells, and 5 
µL of 1x assay buffer added to blanks; 4 µL of ATP/substrate working solution was added to 
all wells using a Matrix multichannel pipette. The plate was sealed using DMSO resistant 
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clear seal and incubated for 2 h at 37 C. 1 µL of the kinase reaction mixture from the first 
plate was dry spotted into a second 384-well assay plate using the MATRIX PlateMate

 Plus. 
9 µL of assay buffer was added, followed by 30 µL of IMAP
™
 binding solution using a 
multichannel pipette. The plate was incubated at RT in darkness for 2 h. The assay plate was 
then read on an Analyst HT plate reader (Molecular Devices) using the settings described 
below;  
Measurement mode = Fluorescence polarisation; Method ID = ERK5; Integration time = 100 
ms; Excitation filter = Fluorescein 485-20; Emission filter = 530-25; Dichroic mirror = 505 
nm; Plate definition file = Corning 384 black fb; Z-height = 5.715 mm (middle); G-factor = 
1; Attenuator = out; Detector counting = Smartread+; Sensitivity = 2. 
7.7 p38α LANCE Assay Protocol  
Preparation of Assay Buffer (1x)  
1x assay buffer was prepared freshly in house, consisting of the following reagents; 250 mM 
tris(hydroxymethyl)aminomethane (Tris) pH 7.5, 25 mM MgCl2, 2.5 mM ethylene glycol 
tetraacetic acid (EGTA), 10 mM dithiothreitol (DTT) and 0.05% Triton X100 in milliQ H2O 
(NB: 1x buffer final assay concentrations were 5x lower than stated above). 
Preparation of p38α/SAPK2 Working Solution 
The p38α/SAPK2, active N-terminal GST-tagged recombinant full length protein (Millipore 
14-251) was supplied as a 10 µg/4 µL stock. This was diluted to a 10 µg/40 µL (1 µM) 
concentration by addition of 156 µL of Tris/HCl (pH 7.5, 50 mM), NaCl (150 mM), EGTA 
(0.1 mM), Brij-35 surfactant (0.03%), glycerol (50%) and 0.1% 2-mercaptoethanol (0.1%). 
The final dilution was dependent on activity of the enzyme batches. The p38α concentration 
used in the assay was 1 nM. A 2x working stock solution (2 nM, 500 fold dilution of 1 µM 
stock) in 1x assay buffer was prepared. For one plate, 9.4 µL of p38α (1 µM) was added to 
1870.6 µL of milliQ H2O.  
Preparation of ATP/Substrate working solution 
For one plate, ATP disodium salt (17.5 µL, 200 mM stock), (Sigma A7699) and Ulight-MBP 
Peptide (50 µL, 5 µM stock) (Perkin Elmer TRF0109) was added to 400 µL of 5x assay 
buffer and 1532.5 µL of milliQ H2O. 
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Preparation of EDTA/Antibody Detection Reagent 
For one plate, 84 µL of ethylenediaminetetraacetic acid (EDTA) (0.5 M) (Sigma E4378-
100G) and 27 µL of Europium-anti-phospho-MBP antibody (0.625 µM) (Perkin Elmer) was 
added to 420 µL of LANCE detection buffer (1x) and 3669 of milliQ H2O. 
Assay Procedure 
1 µL of compound (in 80:20 H2O/DMSO) or 80:20 H2O/DMSO was dry-spotted into the 
relevant wells of a 384-well assay plate using the MATRIX PlateMate

 Plus. 5 µL of p38α 
working solution was added to test and control wells, and 5 µL of assay buffer added to 
blanks; 4 µL of ATP/substrate working solution was added to all wells using a Thermo 
Multidrop Combi or Matrix multichannel pipette. The plate was sealed using DMSO resistant 
clear seal and incubated for 1 h at 37 C. 10 µL of the EDTA/antibody working solution was 
added to all wells using a Thermo Multidrop Combi or Matrix multichannel pipette. The plate 
was incubated at RT in darkness for 2 h. The assay plate was then read on a PheraStar 
microplate reader using the settings described below; 
Pherastar: Measurement mode = TRF; Method ID = LANCE HTRF ERK5; Optic Module: 
337, 665, 620 nm. Focal Height = 6.0, Positioning delay, 0.1 sec, Number of flashes per well 
= 100, Integration start = 60 µs, Integration time = 200 µs, Simultaneous dual emission, Ratio 
multiplicator = 1000 
7.8 Dual-Luciferase Reporter Assay 
Preparation of Agar Plates for Bacterial Colony Growth 
250 mL of lysogeny broth (LB) agar was spiked with 250 µL of an antibacterial agent 
(kanomycin or ampicillin), and using a sterile pipette, 25 mL of spiked LB agar was 
transferred into 12 petri dishes. The E.Coli bacteria used to express DNA plasmids are 
antibiotic resistant; therefore the addition of an antibacterial agent maintains selective 
bacterial growth.  
Growth of Transformed Bacterial Colonies 
To a polypropylene tube was added 48 µL of E. coli in glycerol stock (prepared in-house at 
the Babraham Institute), and 2 µL of either the Gal4-Luciferase or MEK5D DNA plasmid. 
The resulting mixture was incubated at 0 
o
C for 15 min. Bacteria were subjected to stress by 
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heating at 42 
o
C for 30 sec, then returning to 0 
o
C. 200 µL of LB agar was added at 0 
o
C, and 
the resulting mixture was incubated with shaking for 30 min to 1 h at 37 
o
C.  
At 37 
o
C, 250 µL of the solution containing Gal4-Luciferase transformed bacteria was 
transferred onto one LB agar/kanomycin plate. 250 µL of the solution containing MEK5D 
transformed bacteria was transferred onto one LB agar/ampicillin plate. Agar plates were 
allowed 24 h at 37 
o
C for bacterial colony growth.  
To a conical flask was added 100 mL LB agar, 100 µL of the relevant antibiotic, and a 
sample of the bacterial colonies from the relevant petri dish. The flasks were incubated for a 
further 24 h at 37 
o
C, with stirring (150-170 rpm). 
DNA Purification 
2 x 50 mL portions of the incubated bacteria in agar obtained were transferred into 50 mL 
Falcon tubes and subjected to centrifugation at 6000 G for 15 min. DNA plasmids were 
isolated in aqueous media from the remaining bacterial pellet using a Qiagen Plasmid Plus 
Midi Kit, according to kit instructions. 
DNA Quantification 
The concentration of the purified aqueous DNA was determined using a NanoDrop 1000 
spectrophotometer. DNA stock solutions were at 2419.4 ng/µL and 1965.6 ng/µL for Gal-4-
Luciferase and MEK5D plasmid stocks respectively. All other DNA plasmid stocks used 
were prepared in house at the Babraham Institute by Dr Pamela Lochhead. 
Cell Maintenance 
HEK293 cells were grown as adherent colonies on tissue culture dishes in Dulbecco’s 
Modified Eagle Medium (DMEM) tissue culture medium (Gibco
®
 41966) containing L-
glutamine (2 mM, Gibco
®
 1499), penicillin/streptomycin (100 µg/mL, PAA P11-010), foetal 
bovine serum (FBS) (10%, PAA A15-151) as additives. 
Penicillin and streptomycin are antibacterial agents, which minimise the risk of bacterial 
infection occurring in cell culture. FBS is a serum supplement, which contains growth factors 
that promote eukaryotic cell growth. L-glutamine is a nutrient which supports the growth of 
cells which have high energy demands, such as cells which synthesise large amounts of 
proteins and/or nucleic acids or those which use glucose inefficiently. 
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Trypsinizing of Adherent Cell Colonies 
Cells were regularly passaged in order to maintain optimum colony sizes on plates. In order 
to do this, and to harvest cells for use in the dual-luciferase reporter assay, adherent cells 
were lifted from tissue culture dishes. Cell media was removed via aspiration, and the cell 
monolayer was washed with phosphate buffered saline (PBS) solution (10 mL), which was 
then aspirated. The cells were lifted from the plate through incubation at 37 
o
C for 5-10 min 
with 1 mL trypsin (0.5% trypsin-EDTA (1x), Gibco
®
 15400054). 
PBS (10x): NaCl (4% w/v), KCl (0.1% w/v), Na2HPO4.7H2O (0.6% w/v), KH2PO4 (0.1% 
w/v), NaN3 (0.01% w/v). 
Reverse Transfection of HEK293 cells 
Preparation of EGFP Control (C3) Working Solution (For 1 x 96 well plate) 
To a 50 mL Falcon tube was added 250 µL Opti-MEM
®
 growth media (reduced serum 
medium, Invitrogen 31985), and the following DNA plasmids; MEF2D-Gal4 (2.5 µL, 0.25 
mg/mL stock), Gal4-Luc (2.5 µL, 1.25 mg/mL stock), Renilla Luciferase (2.5 µL, 0.1 mg/mL 
stock), EGFP construct, containing no MEK5D (0.25 µL, 0.5 mg/mL stock), and HA-ERK5 
wt (2.5 µL, 0.5 mg/mL stock). To this mixture was then added 5 µL of Lipofectamine™ 2000 
transfection reagent (Invitrogen 11668) and complexation allowed for 15-20 min. 
Preparation of EGFP-MEK5D (5D) Working Solution (For 1 x 96 well plate) 
To a 50 mL Falcon tube was added 1500 µL Opti-MEM
®
 growth media (reduced serum 
medium, Invitrogen 31985), and the following DNA plasmids; MEF2D-Gal4 (15 µL, .25 
mg/mL stock), Gal4-Luc (15 µL, 1.25 mg/mL stock), Renilla Luciferase (15 µL, 0.1 mg/mL 
stock), EGFP-MEK5D construct (1.5 µL, 0.5 mg/mL stock), HA-ERK5 wt (15 µL, 0.5 
mg/mL stock). To this mixture was then added 30 µL of Lipofectamine™ 2000 transfection 
reagent (Invitrogen 11668) and complexation allowed for 15-20 min. 
Preparation of HEK293 Cells for Reverse Transfection 
Trypsinized HEK293 cells were re-suspended in 19 mL of fresh cell media and counted using 
haemocytometry. Cells were then diluted with fresh cell media to achieve a final cell 
concentration of 2 x 10
5 
cells/mL. 1237.5 µL and 7425 µL of this cell media was added to the 
C3 and 5D working solutions respectively. 100 µL of the transfected cells were then 
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aliquoted into the appropriate wells in a 96-well opaque sided tissue culture plate, and 
incubated at 37 
o
C for 6 h. 
Addition of Compounds to HEK293 Cells 
Each compound supplied was prepared as a 10 mM working solution in DMSO, from which 
the following stocks were prepared in DMSO; 3.33 mM, 1 mM, 0.11 mM and 10 µM. 4 
compounds was assayed per 96-well plate. For each compound, 1 mL of growth media was 
added to eight 1.5 mL Eppendorf
®
 tubes. 6 µL of DMSO was added to two tubes for C3 and 
blank 5D wells, and 6 µL of the relevant compound stock solution was added to the 6 
remaining tubes. BIX02189 was added to each plate in varying concentrations as an indicator 
of assay reliability. Solutions of drug in media were thoroughly mixed, and 100 µL of the 
relevant compound was transferred (in triplicate) to the 96-well plate containing transfected 
HEK293 cells using an electronic multichannel pipette with variable tip spacing. Sealed 
plates were incubated at 37 
o
C for 24 h. Final compound concentrations were as follows; 30 
µM, 10 µM, 3 µM, 1 µM and 0.3 µM. 
Assay Plate Lysis 
15 mL of 1x passive lysis buffer (PLB) was prepared using 5x PLB (Dual-Luciferase 
Reporter Assay System, Promega
®
 E1960), diluting with H2O. Assay plates prepared were 
removed from the incubator and the growth media removed by aspiration. 20 µL of 1x PLB 
was dispensed into each well and the plates shaken for 10 min. Assay plates were sealed and  
stored at -80 
o
C overnight.  
Quantification of Cellular Inhibition of ERK5 
Cellular inhibition of ERK5 was quantified using the Dual-Luciferase® Reporter Assay 
System (Promega
®
 E1960). Luciferase assay buffer/Luciferase assay substrate and Stop and 
Glo
®
 assay buffer/Stop and Glo
®
 substrate were prepared according to kit instructions. 100 
µL of the Luciferase system was added to each well using a multichannel pipette, before 
analysis using an EG&G Berthold Microlumat Plus luminometer. 100 µL of the Stop and 
Glo
®
 system was subsequently added, and the plate was analysed once again by luminometer. 
Raw data was processed using Microsoft Excel, enabling generation of IC50 values for each 
compound. IC50 values obtained are based on the means of 3 experiments. Each data point is 
the mean of 3 values ± standard deviation to produce one curve using Microsoft Excel. IC50 
values were calculated by eye. 
210 
 
7.9 General Procedures  
A number of compounds have been synthesised using similar procedures. These general 
protocols are described below. Quantities used and variations are indicated with the analytical 
data for a specific compound.  
General Procedure A: Aldol Condensation 
To a solution of the relevant methyl ketone (1 eq.) in EtOH (1 mL/mmol) was added the 
relevant aldehyde (1.2 eq.) and KOH (2.4 eq.) at 0 
o
C. After 10 min, the mixture was warmed 
to RT and stirred for 16 h. The resulting solid was filtered and recrystallised from a minimum 
amount of hot EtOH to give the desired product.  
General Procedure B: 3-Cyanopyridine Synthesis  
A 1.6M solution of NaOMe was prepared by slowly dissolving sodium metal in MeOH at 
RT. To the relevant chalcone (1 eq.) and 2-cyanothioacetamide (1 eq.) was added 8.5% w/v 
NaOMe (2.4 eq.). The resulting solution was heated at 80 
o
C for 1.5 h, then allowed to cool to 
RT and concentrated in vacuo. The crude material was redissolved in DMF (1 mL/mmol) and 
the relevant bromoacetate (1.5 eq.) was added. The solution was heated at 100 
o
C for 3-4 h, 
and monitored by LCMS. The mixture was then cooled and diluted with H2O (20 mL). The 
product was extracted with EtOAc (3 x 100 mL), washed with H2O (3 x 100 mL) and brine 
(50 mL). Combined organic layers were dried over Na2SO4 and concentrated in vacuo. 
Purification via column chromatography (silica; 0-50% EtOAc/petrol) gave the desired 
product. 
General Procedure C: Deprotection of a tert-Butyl Ester using TFA 
To the relevant tert-butyl ester (1 eq.) in DCM (1 mL/mmol) was added TFA (2 eq.) The 
resulting solution was stirred at RT for 30 min. The mixture was concentrated in vacuo and 
triturated with petrol to give the desired product as the TFA salt. The salt was dissolved in 
H2O (10 mL) and neutralised with a 1M aqueous solution of NaOH. Extraction with EtOAc 
(3 x 30 mL) gave the desired product.  
General Procedure D: CDI Mediated Amide Coupling 
A solution of carbonyldiimidazole (2.0 eq.) and the relevant carboxylic acid (1.0 eq.) in THF 
(5 mL/mmol) was heated to 70 ºC for 3 h. The appropriate amine (2.5 eq.) was added and the 
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mixture heated at 50 °C for 3 h then at RT for 16 h. The product was extracted with EtOAc (2 
x 100 mL), washed with brine (100 mL) and dried over Na2SO4. Purification via column 
chromatography gave the desired product 
General Procedure E: Acid chloride Synthesis 
To a solution or suspension of the relevant carboxylic acid (1 eq.) in THF (1 mL/mmol) was 
added SOCl2 (1.5 eq.) at 0 
o
C, followed by DMF (cat). The resulting mixture was stirred at 
RT for 3 h, and then concentrated in vacuo. The crude material was used in the next step 
without further purification. 
General Procedure F: Friedel-Crafts Acylation 
To a suspension of AlCl3 (2.5 eq.) in DCM (1 mL/mmol AlCl3) at 0 
o
C was added the 
relevant acid chloride (2 eq.) followed by methyl 1H-pyrrole-2-carboxylate (1 eq.). The 
resulting mixture was allowed to reach RT and stirred for 16 h. The reaction was quenched at 
0 
o
C with a 1M aqueous solution of HCl (20 mL). The product was extracted with DCM (3 x 
100 mL), washed with an aqueous saturated solution of NaHCO3 (2 x 100 mL) and brine 
(100 mL). Combined organic layers were dried over Na2SO4 and concentrated in vacuo. 
Purification via column chromatography (silica; 0-50% EtOAc/Petrol) gave the desired 
product. 
General Procedure G: Ester Hydrolysis and/or Tosyl Group Hydrolysis 
To a solution of the relevant ester (1 eq.) in THF (8 mL/mmol) was added a solution of LiOH 
monohydrate (20 eq.) in H2O (13 mL/mmol). The resulting mixture was heated at 65 
o
C for 
16 h, cooled to RT and acidified to pH 3-4 with a 1M aqueous solution of HCl. The product 
was extracted with EtOAc (3 x 100 mL). Combined organic layers were washed with brine 
(200 mL), dried over Na2SO4 and concentrated in vacuo to give the desired product. 
General Procedure H: Deprotection of Silyl Protecting Groups 
To a solution of the relevant pyrrolopyridone (1 eq.) was added a 1M solution of TBAF in 
THF (2 mL/mmol). When deprotecting SEM groups, the resulting solution was stirred at 65 
o
C for 16 h.  When deprotecting TIPS/TMS groups, the resulting solution was stirred at RT 
for 4 h. After the allocated time, the mixture was concentrated in vacuo. Purification via 
column chromatography gave the desired products.  
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General Procedure I: Nucleophilic Substitution of Amines 
To a solution of methyl 4-(2,2,2-trichloroacetyl)-1H-pyrrole-2-carboxylate (1 eq.) in DMF (3 
mL/mmol) was added the relevant amine (3 eq.). The resulting mixture was heated at 50 
o
C 
for 4 h. The solution was cooled, diluted with water and extracted with EtOAc (3 x 30 mL). 
Combined organic layers were washed with brine, dried over Na2SO4 and concentrated in 
vacuo. Purification via column chromatography or recrystallisation gave the desired product.  
General Procedure J: Selective Ester Hydrolysis  
To a solution of the relevant methyl ester (1 eq.) in THF (5 mL/mmol) was added a solution 
of LiOH monohydrate (1.5 eq.) in water (5 mL/mmol). The resulting solution was heated to 
40 
o
C for 4 h. The mixture was cooled, acidified to pH 5-6 with a 1M aqueous solution of 
HCl and extracted with EtOAc (3 x 30 mL). Combined organic layers were washed with 
brine, dried over Na2SO4 and concentrated in vacuo to give the desired products. 
General Procedure K: Deprotection of a Boc Protecting Group with TFA 
To a solution of the relevant Boc protected amine (1 eq.) in DCM (5 mL/mmol) was added 
triethylsilane (2.5 eq.) where indicated, followed by TFA (2 mL/mmol). The resulting 
solution was stirred at RT for 1 h. The mixture was concentrated in vacuo, and triturated with 
diethyl ether (10 mL) to give the TFA salt. To obtain the free base, the TFA salt was 
triturated with an aqueous saturated solution of NaHCO3 (10 mL) and the product extracted 
with EtOAc (2 x 30 mL). Combined organic layers were washed with brine (30 mL), dried 
over Na2SO4 and concentrated in vacuo to give the desired product. 
General Procedure L: Demethylation of Methyl Ethers with BBr3 
To a 1M solution of BBr3 in DCM (5 mL/mmol) was added the relevant methyl ether (1 eq.) 
at 0 
o
C. The resulting mixture was warmed to room temperature and stirred for 16 h. The 
reaction was quenched with water, and adjusted to pH 10 with a 1M aqueous solution of 
NaOH. The mixture was extracted with EtOAc (3 x 20 mL). Combined organic layers were 
washed with brine, dried over Na2SO4 and concentrated in vacuo. Column chromatography 
gave the desired products. 
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General Procedure M: PCl3 Mediated Amide Coupling 
A microwave vial was charged with the relevant carboxylic acid (1 eq.), the desired amine 
(2.5 eq), MeCN (2 mL/mmol) and PCl3 (1 eq.). The resulting mixture was heated at 150 
o
C 
with microwave irradiation for 5 min unless otherwise stated. The mixture was quenched 
with an aqueous saturated solution of NaHCO3 (10 mL) and diluted with H2O (30 mL). The 
crude product was extracted with EtOAc (3 x 30 mL). Combined organic layers were washed 
with brine (50 mL), dried over Na2SO4, and concentrated in vacuo. Purification via column 
chromatography gave the desired product. 
General Procedure N: Suzuki Coupling 1  
A microwave vial was charged with the relevant bromoaryl species (1 eq.), Cs2CO3 (1.5 eq.) 
the desired boronic acid (3 eq.), dichloro [1,1'-bis(di-tert-butylphosphino)]ferrocene 
palladium (II) (10 mol%), and dioxane (10 mL/mmol). The resulting mixture was degassed 
for 20 min, and then heated at 150 
o
C under microwave irradiation for 1 h. The mixture was 
diluted with MeOH (20 mL) and passed through a Celite cartridge to remove metallic 
impurities. The resulting solution was concentrated in vacuo and the crude material was 
either engaged directly in the next step or purified by column chromatography to give the 
desired product. 
General Procedure O: Suzuki Coupling 2  
A microwave vial was charged with the relevant bromoaryl species (1 eq.), KOAc (3 eq.), 
bis(pinacolato)diboron (1.5 eq.), dichloro [1,1' bis(di-tert-butylphosphino)]ferrocene 
palladium (II) (10 mol%) and dioxane (10 mL/mmol). The resulting mixture was degassed 
for 20 min, and then heated at 150 
o
C under microwave irradiation for 15 min. To this 
mixture was then added 2-bromopyridine (1.5 eq.), Na2CO3 (1.2 eq), H2O (0.2 mL), and 
tetrakis(triphenylphosphine)palladium (0) (10 mol%). The resulting mixture was degassed for 
20 min, and then heated conventionally at 110 
o
C for 16 h. The mixture was diluted with 
MeOH (20 mL), passed through a Celite cartridge, and the resulting solution concentrated in 
vacuo. Purification via column chromatography (silica; 10-50% EtOAc/petrol) gave the 
desired product.  
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General Procedure P: Acid-catalysed Cyclisation 
To neat methanesulfonic acid (3 mL/mmol) was added the relevant diethyl acetal (1 eq.). The 
resulting solution was heated at 95 
o
C for 1 h. The mixture was then allowed to cool to RT, 
diluted with H2O and the product was extracted with EtOAc (3 x 100 mL). Combined organic 
layers were washed with brine, dried over Na2SO4 and concentrated in vacuo. Purification via 
column chromatography (silica; 0-10% MeOH/DCM) gave the desired product. 
General Procedure Q: SEM Protection 
To a solution of the relevant pyrrolopyridone (1 eq.) in THF (3 mL/mmol) was added SEMCl 
(1.2 eq), Et3N (1.2 eq.) and DMAP (10 mol%). The resulting mixture was stirred for 16 h at 
RT. An additional 1.2 eq. of Et3N and SEMCl were added if the reaction had not reached 
completion and the mixture allowed to stir for a further 24 h. The reaction was quenched with 
H2O and the product extracted with EtOAc (3 x 50 mL). Combined organic layers were dried 
over Na2SO4 and concentrated in vacuo. Purification via column chromatography (silica; 
 10-70% EtOAc/petrol) gave the desired product. 
General Procedure R: Ullmann Coupling 
To a microwave vial was added the relevant pyrrolopyridone (1 eq.), the relevant 
bromopyridine hydrochloride (1.3 eq), K2CO3 (3.3 eq.) and CuI (10 mol%). The vial was 
sealed under an inert atmosphere and DMF (1 mL/mmol) was subsequently added. The 
mixture was degassed for 20 min, heated conventionally at 135 
o
C for 48-72 h and monitored 
by LCMS. The mixture was allowed to cool, filtered through Celite, and washed with 
EtOAc/MeOH (7:3). The resulting solution was concentrated in vacuo. Purification via 
column chromatography (silica; 0-5% MeOH/DCM) gave the product. In cases where some 
deprotection of the SEM group occurred during the course of the Ullmann reaction, the crude 
material was engaged directly in the next step without purification. 
  
215 
 
7.10 Experimental Data 
Methyl 4-chloro-3-nitrobenzoate, 50 
 
To a solution of 4-chloro-3-nitrobenzoic acid (600 mg, 2.98 mmol) in MeOH (1.5 mL/mmol 
acid) was added thionyl chloride (0.11 mL, 1.49 mmol) at 0 
o
C. The resulting solution was 
heated at 60 
o
C overnight. The mixture was then cooled in an ice bath, resulting in the 
formation of a precipitate. The solid was filtered and collected in vacuo. Recrystallisation 
(MeOH) gave 50 as beige crystals (550 mg, 85%). Rf 0.83 (1:1 EtOAc/petrol); m.p. 80-81 ˚C 
(lit.
139 
78-79 ˚C); λmax (EtOH/nm) 230.5; IR υmax/cm
-1 
3102, 2961, 1714, 1604, 1536;  
1
H 
NMR (500 MHz, CDCl3) δ ppm 4.00 (3H, s, O-CH3), 7.67 (1H, d, J = 8.5 Hz, H-5), 8.19 
(1H, dd, J = 2.0 and 8.5 Hz, H-6), 8.54 (1H, d,  J = 2.0 Hz, H-2);  
13
C NMR (125 MHz, 
CDCl3) δ ppm 53.0 (O-CH3), 126.7 (C-Ar), 130.1 (C-Ar), 131.7 (C-Ar), 132.2 (C-Ar), 133.6 
(C-Ar), 148.7 (C-Ar), 164.2 (CO); MS (ES+) m/z 216.5 [M+H]
+
 . 
Dimethyl 2-(4-(methoxycarbonyl)-2-nitrophenyl)malonate, 51 
 
To a solution of potassium tert-butoxide (560 mg, 4.98 mmol) in NMP (1 mL/mmol base) 
was added dimethyl malonate (0.57 mL, 4.98 mmol) and the resulting solution heated at 75 
o
C. A solution of methyl 4-chloro-3-nitrobenzoate (540 mg, 2.49 mmol) in NMP (1 mL/mmol 
ester) was added dropwise and the resulting mixture heated at 75 
o
C for 2 h. The solution was 
allowed to cool, and acidified to pH 2 with a 1M aqueous solution of HCl, and stirred at 0 
o
C 
for a further 2 h. The mixture was diluted with DCM (50 mL), washed with water (50 mL), 
and brine (30 mL). Combined organic layers were dried over MgSO4 and concentrated in 
vacuo. Purification via column chromatography (silica; 0-50% EtOAc/petrol) gave 51 as a 
yellow oil (500 mg, 66%). Rf 0.66 (1:1 EtOAc/petrol); λmax (EtOH/nm) 228.0; IR υmax/cm
-1
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2957, 1729, 1620, 1537; 
1
H NMR (500 MHz, CDCl3) δ ppm 3.74 (6H, s, O-CH3), 3.91 (3H, 
s, O-CH3), 5.30 (1H, s, CH), 7.55 (1H, d, J = 8.1 Hz, H-6), 8.21 (1H, dd, J = 1.8 and 8.1 Hz, 
H-5), 8.63 (1H, d, J = 1.8 Hz, H-3); 
13
C NMR (125 MHz, CDCl3) δ ppm 52.9 (O-CH3), 53.4 
(O-CH3), 54.1 (CH), 126.3 (C-Ar), 131.6 (C-Ar), 131.9 (C-Ar), 132.1 (C-Ar), 134.0 (C-Ar), 
148.8 (C-Ar), 164.1 (CO), 167.1 (CO); MS (ES+) m/z 311.2 [M+H]
+
. 
Methyl 2-oxoindoline-6-carboxylate, 52 
 
To a solution of dimethyl 2-(4-(methoxycarbonyl)-2-nitrophenyl)malonate (420 mg, 1.35 
mmol) in acetic acid (5 mL/mmol malonate) was added ammonium formate (430 mg, 6.75 
mmol) and palladium on carbon (10% 
w
/w). The resulting mixture was heated at 100 
o
C for 10 
minutes under microwave irradiation. The mixture was then filtered through Celite and 
concentrated in vacuo. Purification via column chromatography (silica; 0-50% EtOAc/petrol) 
gave 52 as a white solid (310 mg, 98%). Rf 0.23 (6:4 EtOAc/petrol); m.p. 212-215 
o
C (lit.
105
 
208-211
 oC); λmax (EtOH/nm) 306.0, 222.0; IR υmax/cm
-1
 3047, 2955, 2923, 2850, 1696, 1628; 
1
H NMR (500 MHz, CDCl3) δ ppm 3.52 (2H, s, CH2), 3.85 (3H, s, O-CH3), 7.23 (1H, d, J = 
7.8 Hz, H-4), 7.46 (1H, br s, H-7), 7.68 (1H, dd,  J = 1.3 and 7.8 Hz, H-5), 7.72 (1H, s, NH); 
MS (ES+) m/z  192.2 [M+H]
+
. 
Methyl 1-acetyl-3-(ethoxy(phenyl)methylene)-2-oxoindoline-6-carboxylate (Inseparable 
mixture of E and Z), 53 
 
A solution of methyl 2-oxoindoline-6-carboxylate (160 mg, 0.83 mmol) in acetic anhydride 
(4 mL/mmol) was heated at 130 
o
C for 3 h. The mixture was cooled to 100 
o
C, triethyl 
orthobenzoate (0.21 mL, 0.91 mmol) was added and the mixture heated for a further 3 h. The 
solution was allowed to cool, and diluted with DCM (30 mL). The mixture was washed with 
water (30 mL) and brine (20 mL). Combined organic layers were dried over MgSO4 and 
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concentrated in vacuo. Purification via column chromatography (silica; 0-30% EtOAc/petrol) 
gave 53 as a yellow solid (240 mg, 79%). Rf 0.80 (1:1 EtOAc/petrol); m.p. 167-169 
oC; λmax 
(EtOH/nm) 342.0, 313.5, 266.0, 223.0; IR υmax/cm
-1
 2994, 2953, 1699, 1621, 1595; 
1
H NMR 
(500 MHz, CDCl3, major isomer) δ ppm 1.44 (3H, t, J = 7.1 Hz, CH2-CH3), 2.58 (3H, s, N-
CO-CH3), 3.94 (3H, s, O-CH3), 4.00 (2H, q, J = 7.1 Hz, CH2-CH3), 7.40-7.42 (2H, m, H-Ar), 
7.56-7.59 (3H, m, H-Ar), 7.97 (1H, dd, J = 1.6 and 8.1 Hz, H-5), 8.05 (1H, d, J = 8.1 Hz, H-
4), 8.84 (1H, d, J = 1.6 Hz, H-7); 
13
C NMR (125 MHz, CDCl3, major isomer) δ ppm 15.1 
(CH3), 26.5 (CH3), 52.2 (O-CH3), 67.3 (CH2), 104.6 (Cq), 115.4 (C-Ar), 122.3 (C-Ar), 125.9 
(C-Ar), 127.3 (C-Ar), 128.3 (C-Ar), 128.6 (C-Ar), 128.6 (C-Ar), 130.4 (C-Ar), 130.8 (C-Ar), 
136.1 (C-Ar), 166.1 (Cq), 166.1 (CO), 170.8 (CO), 172.3 (CO); MS (ES+) m/z = 366.1 
[M+H]
+
.  
(Z)-Methyl 1-acetyl-3-(((3-((dimethylamino)methyl)phenyl)amino)(phenyl)methylene)-
2-oxoindoline-6-carboxylate, 54 
 
To a solution of methyl 1-acetyl-3-(ethoxy(phenyl)methylene)-2-oxoindoline-6-carboxylate 
(230 mg, 0.63 mmol) in DMF (5 mL/mmol) was added 3-dimethylamino methylaniline (100 
mg, 0.67 mmol) and the resulting mixture heated at 80 
o
C for 3 h. The mixture was allowed 
to cool, diluted with DCM, and washed with water (30 mL) and brine (20 mL). Combined 
organic layers were dried over Na2SO4 and concentrated in vacuo. Purification via column 
chromatography (silica; 0-8% MeOH/DCM) gave 54 as a yellow solid (150 mg, 52%). Rf 
0.39 (7:3 EtOAc/petrol); m.p. 157-159 
oC; λmax (EtOH/nm) 385, 303; IR υmax/cm
-1
 2927, 
2812, 2764, 1699, 1666, 1569; 
1H NMR (500 MHz, MeOD) δ ppm 2.12 (6H, s, N-CH3), 2.84 
(3H, s, N-CO-CH3), 3.31 (2H, s, CH2), 3.88 (3H, s, O-CH3), 5.90 (1H, d, J = 8.4 Hz, H-4), 
6.93-6.94 (1H, m, H-Ar), 6.96-6.98 (1H, m, H-Ar), 7.11-7.13 (1H, m, H-Ar), 7.23 (1H, dd, J 
= 7.7 and 7.8 Hz, H-Ar), 7.43 (1H, dd, J = 1.6 and 8.4 Hz, H-5), 7.46-7.49 (2H, m, H-Ar), 
7.56-7.64 (3H, m, H-Ar), 8.88 (1H, d, J = 1.6 Hz, H-7); 
13
C NMR (125 MHz, MeOD) δ ppm 
Insufficient quantity of material to perform analysis; MS (ES+) m/z = 470.4 [M+H]
+
.  
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(Z)-3-(((3-((Dimethylamino)methyl)phenyl)amino)(phenyl)methylene)-2-oxoindoline-6-
carboxylic acid, 55 
 
To a solution of (Z)-methyl 1-acetyl-3-(((3-
((dimethylamino)methyl)phenyl)amino)(phenyl)methylene)-2-oxoindoline-6-carboxylate 
(100 mg, 0.21 mmol) in THF (5 mL/mmol ester) was added LiOH (180 mg, 4.20 mmol) in 
water (5 mL/mmol ester) and the resulting mixture heated at 60 
o
C overnight. The solution 
was allowed to cool, and concentrated in vacuo. Trituration of the residue with EtOH 
afforded the crude material. Purification via semi-preparative HPLC (55:45 0.1% formic acid 
(aq)/MeOH) gave 55 as a yellow solid (33 mg, 38%). Rf 0.45 (MeOH); m.p. 278-280 
oC; λmax 
(EtOH/nm) 387.0; IR υmax/cm
-1
 3146, 2923, 2853, 1705, 1647, 1582; 
1
H NMR (500 MHz, 
DMSO-d6) δ ppm 2.01 (6H, s, N-CH3), 3.24 (2H, s, CH2), 5.83 (1H, d, J = 8.2 Hz, H-4), 
6.78-6.79 (2H, m, H-Ar), 6.98 (1H, d, J = 7.6 Hz, H-Ar), 7.15 (1H, dd, J = 7.6 and 7.7 Hz, H-
Ar), 7.18 (1H, dd, J = 1.5 and 8.2 Hz, H-5), 7.42 (1H, d, J = 1.5 Hz, H-7), 7.49-7.51 (2H, m, 
H-Ar), 7.56-7.62 (3H, m, H-Ar), 10.95 (1H, s, NH), 12.25 (1H, s, NH), COOH not 
visualised; 
13
C NMR (125 MHz, DMSO-d6) δ ppm Insufficient quantity of material to 
perform analysis; MS (ES+) m/z = 414.5 [M+H]
+
; HRMS calcd for C25H23N3O3 [M+H]
+ 
414.1812, found 414.1812. 
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(Z)-3-(((3-((Dimethylamino)methyl)phenyl)amino)(phenyl)methylene)-2-oxoindoline-6-
carboxamide, 47 
 
To a suspension of (Z)-3-(((3-((dimethylamino)methyl)phenyl)amino)(phenyl)methylene)-2-
oxoindoline-6-carboxylic acid (100 mg, 0.22 mmol) in DMF (10 mL/mmol) was added 
PyBOP (170 mg, 0.33 mmol), HOBt (45 mg, 0.33 mmol), ammonium chloride (24 mg, 0.44 
mmol) and DIPEA (0.15 mL, 0.88 mmol). The resulting solution was stirred at RT for 18 h. 
The solvent was removed in vacuo, and the residue triturated with EtOH to give the crude 
material. Purification by semi-preparative HPLC (3:7 0.1% formic acid (aq)/MeCN) gave 47 
as a yellow, hygroscopic solid (16 mg, 16%). Rf 0.45 (95:5 DCM/MeOH); m.p. 120-122 
o
C 
decomp.; λmax (EtOH/nm) 284.5, 386.5; IR υmax/cm
-1
 3250, 3195, 3118, 3052, 2933, 2837, 
1615, 1545; 
1H NMR (500 MHz, MeOD) δ ppm 2.56 (6H, s, N-CH3), 3.99 (2H, s, CH2), 5.94 
(1H, d, J = 8.2 Hz, H-4), 6.96-7.02 (2H, m, H-Ar), 7.10 (1H, dd, J = 1.6 and 8.2 Hz, H-4), 
7.14 (1H, d, J = 7.6 Hz, H-Ar), 7.25-7.28 (1H, dd, J = 7.6 and 7.7 Hz, H-Ar), 7.43 (1H, d, J = 
1.6 Hz, H-7), 7.45-7.50 (2H, m, H-Ar), 7.53-7.49-7.54 (3H, m, H-Ar), 8.40 (2H, s, NH2), NH 
not visualised; MS (ES+) m/z = 413.3 [M+H]
+
. 
(Z)-3-(((3-((Dimethylamino)methyl)phenyl)amino)(phenyl)methylene)-N,N-dimethyl-2-
oxoindoline-6-carboxamide, 48 
 
To a suspension of (Z)-3-(((3-((dimethylamino)methyl)phenyl)amino)(phenyl)methylene)-2-
oxoindoline-6-carboxylic acid (30 mg, 0.07 mmol) in DMF (10 mL/mmol) was added 
PyBOP (50 mg, 0.10 mmol), HOBt (14 mg, 0.10 mmol), dimethylamine hydrochloride (11 
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mg, 0.13 mmol) and DIPEA (45 µL, 0.27 mmol). The resulting solution was stirred at room 
temperature for 18 h. The solvent was removed in vacuo, and the residue obtained triturated 
with EtOH afforded the crude material. Purification by semi-preparative HPLC (95:5 0.1% 
formic acid (aq)/MeOH) gave 48 as a yellow solid (22 mg, 71 %). Rf 0.59 (95:5 
DCM/MeOH); m.p. 108-110 
o
C decomp.; λmax (EtOH/nm) 282.0, 379.0; IR υmax/cm
-1
 2934, 
2817, 2770, 1611, 1573; 
1H NMR (500 MHz, MeOD) δ ppm 1.95 (6H, s, CH2-N(CH3)2), 
2.89 (6H, br s, CO-N(CH3)2), 3.15 (2H, s, CH2), 5.82 (1H, d, J = 8.2 Hz, H-4), 6.52 (1H, dd, 
J = 1.5 and 8.2 Hz, H-5), 6.66-6.70 (2H, m, H-Ar), 6.85-6.89 (2H, m, H-Ar), 7.00-7.03 (1H, 
m, H-Ar), 7.33-7.76 (2H, m, H-Ar), 7.38-7.46 (3H, m, H-Ar), NH not visualised; 
13
C NMR 
(125 MHz, MeOD) δ ppm Insufficient quantity of material to perform analysis; MS (ES+) 
m/z = 441.3 [M+H]
+
. 
(E)-3-(4-Fluorophenyl)-1-phenylprop-2-en-1-one, 85 
 
General procedure A: acetophenone (1.03 g, 8.60 mmol), 4-fluorobenzaldehyde (1.07 mL, 
10.20 mmol), and NaOH (0.82 g, 20.60 mmol) gave 85 as yellow crystals (1.46 g, 75%). Rf  
0.47 (1:9 EtOAc/petrol); m.p. 85-86 ˚C (lit.140 88-90 oC); λmax (EtOH/nm) 297.0, 379.0; IR 
υmax/cm
-1
 1661; 
1
H-NMR (500 MHz, CDCl3) δ ppm 7.14 (2H, dd, J = 6.6 and 8.5 Hz, H-3 
and H-5), 7.48-7.55 (3H, m, CH, H-3’ and H-5’), 7.62 (1H, ddd, J = 1.2, 1.5 and 7.4 Hz, H-
4’), 7.66 (2H, dd, J = 5.4 and 8.5 Hz, H-2 and H-6), 7.80 (1H, d, J = 15.8 Hz, CO-CH), 8.03-
8.05 (2H, m, H-2 and H-6’); 13C NMR (125 MHz, CDCl3) δ ppm 116.2 (d, JCF = 22.0 Hz, C-
3 and C-5), 121.8 (d, JCF = 2.2 Hz, CH), 128.5 (C-Ar), 128.7 (C-Ar), 130.4 (d, JCF = 8.6 Hz, 
C-2 and C-6), 131.2 (d, JCF = 3.1 Hz, Cq), 132.9 (C-4’), 138.2 (Cq), 143.5 (CO-CH), 164.1 
(d, JCF = 251.3, C-F), 190.3 (CO); MS (ES+) m/z = 227.0 [M+H]
+
. 
tert-Butyl 2-(2-bromoacetamido)acetate, 88 
 
To a solution of bromoacetyl chloride (0.67 mL, 8.1 mmol) in DCM (1 mL/mmol) was added 
a solution of glycine tert-butyl ester (1.0 mL, 7.3 mmol), Et3N (1.22 mL, 8.8 mmol) and 
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DMAP (10 mol%) in DCM (1 mL/mmol) at 0 
o
C dropwise. The resulting mixture was 
warmed to RT and stirred for 3 h. Addition of EtOAc (80 mL) resulted in formation of a 
precipitate, which was filtered and discarded. The filtrate was concentrated in vacuo to give 
88 as a beige solid (1.66 g, 96%). Rf 0.46 (3:7 EtOAc/petrol); m.p. 67-68 ˚C ; 
1
H-NMR (300 
MHz, CDCl3) δ ppm 1.48 (9H, s, CH3), 3.92 (2H, s, CH2), 3.97 (2H, d, J = 5.0 Hz, N-CH2), 
7.04 (1H, br s, NH); 
13
C-NMR (75 MHz, CDCl3) δ ppm 28.0 (CH3), 28.6 (CH2), 46.6 (CH2), 
82.9 (CH), 166.0 (CO), 168.6 (CO); HRMS calcd for C8H14
79
BrNO3 [M+NH4]
+
 269.0495, 
found 269.0495. 
tert-Butyl 2-(2-(3-cyano-4-(4-fluorophenyl)-6-phenylpyridin-2-ylthio)acetamido)acetate, 
89 
 
General procedure B: 4-fluorochalcone (88 mg, 0.39 mmol), 8.5% w/v sodium methoxide 
in MeOH (0.60 mL, 0.94 mmol), 2-cyanothioacetamide (39 mg, 0.39 mmol) followed by tert-
butyl 2-(2-bromoacetamido)acetate (149 mg, 0.59 mmol) gave 89 as a white solid (71 mg, 
38%). Rf 0.75 (1:1 EtOAc/petrol); m.p. 172-174 ˚C; λmax (EtOH/nm) 270.0 and 342.0; IR 
υmax/cm
-1 
3279, 2977, 2214, 1740, 1657; 
1
H NMR (500 MHz, DMSO-d6) δ ppm 1.39 (9H, s, 
CH3), 3.77 (2H, d,  J = 5.9 Hz, CH2-NH), 4.21 (2H, s, S-CH2),  7.47 (1H, dd, J = 8.3 and 9.1 
Hz, H-3’ and H-5’), 7.54-7.55 (3H, m, H-2’, H-6’ and H-4’), 7.84 (2H, dd, J = 5.5 and 8.8 
Hz, H-3 and H-5), 7.95 (1H, s, CH-pyridine), 8.29-8.31 (2H, m, H-2 and H-5), 8.65 (1H, t, J 
= 5.9 Hz, NH); MS (ES+) m/z = 478.2 [M+H]
+
; HRMS calcd for C26H24FN3O3S [M+H]
+
 
478.1595, found 478.1602. 
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2-(2-(3-Cyano-4-(4-fluorophenyl)-6-phenylpyridin-2-ylthio)acetamido)acetic acid, 68 
 
General procedure C: tert-butyl 2-(2-(3-cyano-4-(4-fluorophenyl)-6-phenylpyridin-2-
ylthio)acetamido)acetate (91 mg, 0.19 mmol), TFA (29 µL, 0.38 mmol) gave 68 as a white 
solid (80 mg, 99%). Rf 0.37 (EtOH); m.p. 169-172 ˚C; λmax (EtOH/nm) 270.0, 342.0; IR 
υmax/cm
-1
 3260, 2215, 1730, 1622; 
1
H NMR (300 MHz, DMSO-d6) δ ppm 3.80 (2H, d, J = 
5.4 Hz, NH-CH2), 4.21 (2H, s, S-CH2),7.43-7.54 (4H, m, H-Ar), 7.82-7.87 (2H, m, H-Ar), 
7.94 (1H, s, CH-pyridine), 8.28-8.30 (2H, m, H-Ar), 8.64 (1H, t, J = 5.4 Hz, NH), 12.62 (1H, 
s, COOH); MS (ES+) m/z = 422.2 [M+H]
+
; HRMS calcd for C22H16FN3O3S [M+H]
+
 
422.0976, found 422.0969. 
2-(3-Cyano-4-(4-fluorophenyl)-6-phenylpyridin-2-ylthio)-N-(2-(4 methoxybenzylamino)-
2-oxoethyl)acetamide, 90 
 
To a solution of 2-(2-(3-cyano-4-(4-fluorophenyl)-6-phenylpyridin-2-ylthio)acetamido)acetic 
acid (180 mg, 0.43 mmol) in DMF (20 mL) was added HBTU (200 mg, 0.52 mmol), DIPEA 
(50 µL, 0.52 mmol) and p-methoxybenzylamine (0.56 mL, 4.3 mmol). The resulting mixture 
was heated at 60 
o
C for 4.5 h. The mixture was cooled and water (10 mL) added, which 
resulted in precipitation of the product. Filtration gave 90 as a white solid (110 mg, 47%). 
 Rf  0.52 (EtOH); m.p. 216-220 ˚C; λmax (EtOH/nm) 269.5, 339.0; IR υmax/cm
-1
 3281, 3069, 
2212, 1632, 1547, 1508; 
1
H NMR (300 MHz, DMSO-d6) δ ppm 3.71 (3H, s, O-CH3), 3.77 
(2H, d,  J = 3.9 Hz, NH-CH2-CO), 4.17 (2H, d, J = 3.9 Hz, NH-CH2-Ar), 4.21 (2H, s, S-
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CH2), 6.84 (2H, d, J = 8.9 Hz, H-Ar),  7.14 (2H, d, J = 8.9 Hz, H-Ar), 7.43-7.53 (5H, m, H-
Ar), 7.80-7.83 (2H, m, H-Ar), 7.93 (1H, s, CH-pyridine), 8.21-8.30 (3H, m, NH and H-Ar), 
8.63 (1H, t, J = 5.9 Hz, NH); MS (ES+) m/z = 541.6 [M+H]
+
; HRMS calcd for 
C30H25FN4O3S [M+H]
+
 541.1704, found 541.1700. 
N-(2-Amino-2-oxoethyl)-2-((3-cyano-4-(4-fluorophenyl)-6-phenylpyridin-2-
yl)thio)acetamide, 69 
 
To 2-((3-cyano-4-(4-fluorophenyl)-6-phenylpyridin-2-yl)thio)-N-(2-((4- 
methoxybenzyl)amino)-2-oxoethyl)acetamide (50 mg, 0.093 mmol) was added TFA (5 
mL/mmol) and the resulting solution was heated at 70 
o
C for 48 h. The solution was allowed 
to cool, and concentrated in vacuo. The residue was triturated with EtOAc, filtered and 
washed with petrol to give 69 as a white solid (11 mg, 52%).  
Rf 0.36 (MeOH); m.p. 231-232 ˚C; λmax (EtOH/nm) 338.0, 269.5; IR υmax/cm
-1 
3285, 3073, 
2926, 2215, 1653, 1508; 
1
H NMR (500 MHz, DMSO-d6) δ ppm 3.57 (2H, d, J = 5.5 Hz, NH-
CH2), 4.09 (2H, s, S-CH2),  7.24 (1H, s, NH2), 7.35 (2H, dd, J = 8.6 and 8.7 Hz, H-Ar), 7.42-
7.43 (3H, m, H-Ar and H-4’), 7.72 (2H, dd, J = 5.4 and 8.6 Hz, H-Ar), 7.83 (1H, s, CH-
pyridine), 8.17-8.19 (2H, m, H-Ar), 8.40 (1H, t, J = 5.5 Hz, NH); MS (ES+) m/z = 421.3 
[M+H]
+
; HRMS calcd for C22H17FN4O2S [M+H]
+
 421.1129, found 421.1130. 
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tert-Butyl 5-(3-cyano-4-(4-fluorophenyl)-6-phenylpyridin-2-ylthio)pentanoate, 95 
 
General procedure B: 4-fluorochalcone (118 mg, 0.52 mmol), 8.5% w/v sodium methoxide 
in MeOH (0.80 mL, 1.25 mmol), 2-cyanothioacetamide (52 mg, 0.52 mmol) followed by tert-
butyl bromovalerate (185 mg, 0.78 mmol) gave 95 as a white solid (140 mg, 58%). Rf 0.81 
(3:7 EtOAc/petrol); m.p. 120-121˚C; λmax (EtOH/nm) 272.0, 347.5; IR υmax/cm
-1
 2984, 2936, 
2214, 1707, 1595, 1566; 
1
H NMR (300 MHz, CDCl3) δ ppm 1.44 (9H, s, CH3), 1.80-1.92 
(4H, m, CH2-CH2-CH2-CH2), 2.30 (2H, t, J = 7.3 Hz, S-CH2), 3.43 (2H, t,  J = 6.9 Hz, CH2-
CO), 7.25 (2H, dd, J = 8.4 and 8.6 Hz, H-3 and H-5), 7.50 (1H, s, CH-pyridine), 7.51-7.56 
(3H, m, H-3’, H-4’ and H-5’), 7.61-7.65 (2H, m, H-2 and H-6), 8.09-8.11 (2H, m, H-2’ and 
H-6’); 13C NMR (125 MHz, CDCl3) δ ppm 24.4 (CH2), 28.1 (CH3), 28.7 (CH2), 30.3 (CH2), 
35.1 (CH2), 80.3 (Cq), 103.7 (Cq), 115.4 (CH-pyridine), 115.8 (Cq), 116.2 (d, JCF = 23.0 Hz, 
C-3 and C-5), 127.3 (C-Ar), 129.0 (C-Ar), 130.4 (d, JCF = 8.7 Hz, C-2 and C6), 130.7 (C-4’), 
132.3 (d, JCF = 3.4 Hz, Cq), 137.4 (Cq), 153.4 (Cq), 158.6 (Cq), 164.0 (d, JCF = 254.6 Hz, C-
F), 164.3 (Cq), 172.7 (CO); MS (ES+) m/z = 463.1 [M+H]
+
; HRMS calcd for C27H27FN2O2S 
[M+H]
+
 463.1850, found 463.1848. 
tert-Butyl 4-(3-cyano-4-(4-fluorophenyl)-6-phenylpyridin-2-ylthio)butanoate, 96 
 
General procedure B: 4-fluorochalcone (75 mg, 0.33 mmol), 8.5% w/v sodium methoxide 
in MeOH (0.50 mL, 0.80 mmol), 2-cyanothioacetamide (33 mg, 0.33 mmol) followed by tert-
butyl bromobutyrate (112 mg, 0.50 mmol) gave 96 as a white solid (50 mg, 34%). Rf 0.23 
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(1:9 EtOAc/petrol); m.p. 104-105 ˚C; λmax (EtOH/nm) 271.0; IR υmax/cm
-1
 2978, 2930, 2212, 
1721, 1603, 1570; 
1
H NMR (500 MHz, CDCl3) δ ppm 1.46 (9H, s, CH3), 2.15 (2H, quint, J = 
7.3 Hz, CH2-CH2-CH2), 2.48 (2H, t, J = 7.3 Hz, S-CH2), 3.48 (2H, t, J = 7.3 Hz, CH2-CO), 
7.24 (2H, dd, J = 8.4 and 8.6 Hz, H-3 and H-5), 7.51-7.55 (4H, m, CH-pyridine, H-3’, H-4’ 
and H-5’), 7.61-7.66 (2H, m, H-2 and H-6), 8.09-8.11 (2H, m, H-2’ and H-6’); MS (ES+) m/z 
= 449.1 [M+H]
+
. 
5-(3-Cyano-4-(4-fluorophenyl)-6-phenylpyridin-2-ylthio)pentanoic acid, 70 
 
General procedure C: tert-butyl 5-(3-cyano-4-(4-fluorophenyl)-6-phenylpyridin-2-
ylthio)pentanoate (120 mg, 0.26 mmol), TFA (40 µL, 0.52 mmol) gave 70 as a white solid 
(58 mg, 54%). Rf  0.65 (EtOH); m.p. 205-206 ˚C; λmax (EtOH/nm) 270.0, 345.5; IR υmax/cm
-1
 
2898, 2210, 1695; 
1
H NMR (500 MHz, DMSO-d6) δ ppm 1.69-1.83 (4H, m, CH2-CH2-CH2-
CH2), 2.30 (2H, t, J = 7.4 Hz, S-CH2), 3.42 (2H, t,  J = 7.0 Hz, CH2-CO), 7.44 (2H, dd, J = 
8.7 and 8.8 Hz, H-Ar), 7.55-7.57 (3H, m, H-Ar), 7.84 (2H, dd, J = 5.5 and 8.8 Hz, H-Ar and 
H-4’), 7.91 (1H, s, CH-pyridine), 8.27-8.30 (2H, m, H-Ar), 12.05 (1H, s, COOH); 13C NMR 
(125 MHz, DMSO-d6) δ ppm 23.8 (CH2), 28.3 (CH2), 29.6 (CH2), 33.2 (CH2), 103.1 (Cq), 
115.7 (CH-pyridine), 115.8 (d, JCF = 21.8 Hz, C-3 and C-5), 116.0 (Cq), 127.5 (C-Ar) ,129.0 
(C-Ar), 130.8 (C-4’), 131.2 (d, JCF = 8.9 Hz, C-2 and C-6), 132.1 (d, JCF = 2.7 Hz, Cq), 136.7 
(Cq), 153.2 (Cq), 157.9 (Cq), 162.7 (Cq), 163.2 (d, JCF = 248.3 Hz, C-F), 174.3 (CO); MS 
(ES+) m/z = 405.2 [M-H]
-
; HRMS calcd for C23H19FN2O2S [M-H]
-
 405.41362, found 
405.40444. 
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4-(3-Cyano-4-(4-fluorophenyl)-6-phenylpyridin-2-ylthio)butanoic acid, 71 
 
General procedure C: tert-butyl 4-(3-cyano-4-(4-fluorophenyl)-6-phenylpyridin-2-
ylthio)butanoate (100 mg, 0.22 mmol), TFA (34 µL, 0.44 mmol) gave 71 as a white solid (64 
mg, 72%). Rf  0.61 (EtOH); m.p. 160-164 ˚C; λmax (EtOH/nm) 272.0, 346.0; IR υmax/cm
-1
 
2924, 2217, 1711, 1596, 1568, 1525, 1509; 
1
H NMR (500 MHz, DMSO-d6) δ ppm 1.95 (2H, 
quint, J = 7.1 Hz, CH2-CH2-CH2), 2.38 (2H, t,  J = 7.1 Hz, S-CH2), 3.41 (2H, t, J = 7.1 Hz, 
CH2-CO), 7.40 (2H, dd, J = 8.8 and 8.9 Hz, H-3 and H-5), 7.49-7.50 (3H, m, H-Ar), 7.78 
(2H, dd, J = 5.4 and 8.8 Hz, H-2 and H-6), 7.89 (1H, s, CH-pyridine), 8.24-8.26 (2H, m, H-
Ar), 12.12 (1H, s, COOH); MS (ES+) m/z = 393.2 [M+H]
+
; HRMS calcd for C22H17FN2O2S 
[M+H]
+
 393.1068, found 393.1069.  
tert-Butyl 2-(2-hydroxyethylamino)acetate, 92 
 
To a solution of ethanolamine (3.0 mL, 49.7 mmol) in THF (0.5 mL/mmol) was added tert- 
butyl bromoacetate (2 mL, 13.5 mmol) dropwise. The resulting solution was stirred at RT for 
72 h. The mixture was concentrated in vacuo and the residue redissolved in DCM (50 mL). 
The organic phase was washed with an aqueous solution of saturated NaHCO3 (50 mL) and 
brine (50 mL), then dried over Na2SO4 and concentrated in vacuo to give 92 as a yellow oil 
(1.96 g, 82%). Rf 0.35 (8:2 petol/EtOAc); IR υmax/cm
-1 
3399, 2970, 1730, 1638; 
1
H NMR 
(300 MHz, CDCl3) δ ppm 1.49 (9H, s, CH3), 2.82 (2H, t, J = 5.0 Hz, CH2-NH), 3.36 (2H, s, 
CH2-CO), 3.65 (2H, t, J = 5.0 Hz, CH2-OH), NH and OH not visualised; MS (ES+) m/z = 
176.2 [M+H]
+
. 
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tert-Butyl 2-((tert-butoxycarbonyl)(2-((3-cyano-4-(4-fluorophenyl)-6-phenylpyridin-2-
yl)thio)ethyl)amino)acetate, 97 
 
To a solution of tert-butyl 2-(2-hydroxyethylamino)acetate (0.53 g, 3.03 mmol) in DCM (3 
mL/mmol) was added Boc anhydride (0.80 g, 3.64 mmol), Et3N (0.51 mL, 3.64 mmol) and 
DMAP (10 mol%). The resulting solution was stirred at RT for 3 h. The mixture was diluted 
with water (15 mL) and the product extracted with DCM (2 x 15 mL). Combined organic 
layers were dried over Na2SO4 and concentrated in vacuo. The resulting solid was redissolved 
in DCM (3 mL/mmol). Mesyl chloride (0.28 mL, 3.64 mmol) and triethylamine (0.63 mL, 
4.55 mmol) were added at 0 
o
C. The resulting solution was warmed to RT and stirred for 16 
h. The reaction mixture was quenched with an aqueous solution of NaHCO3 and extracted 
with EtOAc (3 x 50 mL). Combined organic layers were washed with brine, dried over 
Na2SO4 and concentrated in vacuo. The resulting oil was redissolved in DMF (4 mL) and 4-
(4-fluorophenyl)-6-phenyl-2-thioxo-1,2-dihydropyridine-3-carbonitrile (90 mg, 0.29 mmol) 
and KOH (17 mg, 0.32 mmol) were added. The resulting solution was heated to 100 
o
C for 3 
h, cooled, diluted with water and extracted with DCM (3 x 20 mL). Combined organic layers 
were washed with brine, dried over Na2SO4 and concentrated in vacuo. Purification via 
column chromatography (silica; 0-50% EtOAc/petrol) gave 97 as a white solid (20 mg, 12%). 
Rf 0.56 (3:7 EtOAc/petrol); m.p. 152-154 ˚C; λmax (EtOH/nm) 338.0, 270.0; IR υmax/cm
-1 
3282, 2926, 2215, 1653, 1526, 1508; 
1
H NMR (500 MHz, CDCl3) δ ppm 1.25 (9H, s, CH3), 
1.34 (9H, s, CH3), 3.38 (2H, t, J = 7.0 Hz, S-CH2),  3.57 (2H, t, J = 7.0 Hz, S-CH2-CH2), 4.59 
(2H, s, NH-CH2), 7.17-7.20 (2H, m, dd, J = 8.6 and 8.7 Hz, H-Ar), 7.39-7.42 (3H, m, H-Ar), 
7.57-7.80 (3H, m, H-Ar and CH-pyridine), 8.02-8.09 (2H, m, H-Ar); MS (ES+) m/z = 564.7 
[M+H]
+
. 
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2-((2-((3-Cyano-4-(4-fluorophenyl)-6-phenylpyridin-2-yl)thio)ethyl)amino)acetic acid, 
72 
 
General procedure C: tert-butyl 2-((tert-butoxycarbonyl)(2-((3-cyano-4-(4-fluorophenyl)-6-
phenylpyridin-2-yl)thio)ethyl)amino)acetate (15 mg, 0.027 mmol), TFA (5 µL, 0.054 mmol) 
gave 72 as a white solid (10 mg, 91%). Rf 0.30 (MeOH); m.p. 193-194 ˚C; λmax (EtOH/nm) 
339.0, 269.0; IR υmax/cm
-1 
3285, 3073, 2926, 2215, 1653, 1508; 
1
H NMR (500 MHz, MeOD) 
δ ppm 3.17 (2H, t, J = 7.1 Hz, CH2), 3.31 (2H, s, CH2), 3.63 (2H, t,  J = 7.1 Hz, CH2),  7.45-
7.51 (2H, m, H-Ar), 7.54-7.62 (3H, m,  H-Ar), 7.83-7.88 (2H, m, H-Ar), 7.97 (1H, s, CH-
pyridine), 8.30-8.39 (2H, m, H-Ar); MS (ES+) m/z = 408.3 [M+H]
+
; HRMS calcd for 
C22H18FN3O2S [M-H]
-
 406.1031, found 406.1026. 
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(E)-3-(3-Fluorophenyl)-1-phenylprop-2-en-1-one, 98 
 
General procedure A: acetophenone (1.03 g, 8.60 mmol), 3-fluorobenzaldehyde (1.07 mL, 
10.20 mmol), and NaOH (0.82 g, 20.60 mmol) gave 98 as yellow crystals (1.24 g, 64%). Rf  
0.48 (1:9 EtOAc/petrol); m.p. 86-88 ˚C; λmax (EtOH/nm) 297.0, 379.0; IR υmax/cm
-1
 1661, 
1594, 1578, 1481, 1444, 1338, 1313, 1267; 
1
H NMR (500 MHz, CDCl3) δ ppm 7.06 (1H, 
dddd, J = 1.0, 8.4, 9.3 and 10.8 Hz, H-2), 7.13 (1H, ddd, J = 1.0, 7.6 and 8.4 Hz, H-5), 7.29-
7.34 (1H, m, H-4), 7.42-7.45 (2H, m, H-3’ and H-5’), 7.52 (1H, ddd, J = 1.3, 2.0 and 7.3 Hz, 
H-4’), 7.56-7.59 (2H, m, CH and H-6), 7.83 (1H, d, J = 16.0 Hz, CO-CH), 7.95-7.97 (2H, m, 
H-2’ and H-6’); 13C NMR (125 MHz, CDCl3) δ ppm 116.3 (d, JCF = 22.2 Hz, C-2), 123.0 (d, 
JCF = 11.3 Hz, Cq), 124.5 (d, JCF = 3.4 Hz, CH), 124.6 (d, JCF = 7.3 Hz, C-5), 128.6 (C-Ar), 
128.7 (C-Ar), 129.8 (d, JCF = 2.9 Hz, C-6), 131.8 (d, JCF = 8.8 Hz, C-4), 132.9 (C-4’), 137.5 
(CO-CH), 138.0 (Cq), 161.0 (d, JCF = 253.1 Hz, C-F), 190.5 (CO); MS (ES+) m/z = 227.0 
[M+H]
+
. 
(E)-3-(2-Fluorophenyl)-1-phenylprop-2-en-1-one, 100 
 
General procedure A: acetophenone (1.03 g, 8.60 mmol), 2-fluorobenzaldehyde (1.07 mL, 
10.20 mmol), and NaOH (0.82 g, 20.60 mmol) gave 100 as yellow crystals (1.08 g, 56%). Rf  
0.48 (1:9 EtOAc/petrol); m.p. 49-51 ˚C; λmax (EtOH/nm) 302.0, 345.5; IR υmax/cm
-1
 1659, 
1603, 1572; 
1
H NMR (500 MHz, CDCl3) δ ppm 7.11-7.14 (1H, m, H-Ar), 7.35-7.42 (3H, m, 
H-Ar), 7.51-7.55 (3H, m, CH and H-Ar), 7.61 (1H, dd, J = 7.5 and 7.8 Hz, H-Ar), 7.77 (1H, 
d, J = 15.8 Hz, CH), 8.02-8.04 (2H, m, H-Ar); MS (ES+) m/z = 227.0 [M+H]
+
. 
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(E)-3-(2,4-Difluorophenyl)-1-phenylprop-2-en-1-one, 102 
 
General procedure A: acetophenone (0.82 mL, 7.0 mmol), 2,4-difluorobenzaldehyde (1.3 
mL, 7.0 mmol) and NaOH (350 mg, 8.80 mmol) gave 102 as yellow crystals (1.40 g, 80%). 
Rf 0.58 (3:7 EtOAc/petrol); m.p. 59-61 ˚C; λmax (EtOH/nm) 311.0; IR υmax/cm
-1 
1659, 1604, 
1589, 1497; 
1
H NMR (500 MHz, CDCl3) δ ppm 7.25 (1H, ddd, J = 2.5, 8.5 and 10.9 Hz, H-
3), 7.41 (1H, ddd, J = 2.5, 9.3 and 11.5 Hz, H-5), 7.58-7.61 (2H, m, H-3’ and H-5’), 7.70 
(1H, ddd, J = 1.2, 1.3 and 7.4 Hz, H-4’), 7.78 (1H, d, J = 15.8 Hz, CH), 7.98 (1H, d, J = 15.8 
Hz, CO-CH), 8.15-8.17 (2H, m, H-2’ and H-6’), 8.24 (1H, ddd, J = 6.8, 9.3 and 15.5 Hz, H-
6); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 104.6 (dd, JCF = 26.2 and 26.3 Hz, C-3), 112.6 
(dd, JCF = 3.5 and 21.7 Hz, C-5), 119.2 (dd, JCF = 3.8 and 11.6 Hz, Cq), 123.8 (dd, JCF = 2.3 
and 3.7 Hz, CH), 128.6 (C-Ar), 128.8 (C-Ar), 130.7 (dd, JCF = 3.7 and 10.0 Hz, C-6), 133.4 
(H-4’), 134.2 (dd, JCF = 1.4 and 3.7 Hz, Cq), 137.2 (CO-CH), 161.1 (dd, JCF = 12.5 and 254.5 
Hz, C-F), 163.1 (dd, JCF = 13.1 and 252.1 Hz, C-F), 188.9 (CO); MS (ES+) m/z = 245.2 
[M+H]
+
; HRMS calcd for C15H10F2O [M+H]
+
 245.0772, found 245.0771. 
 (E)-1-Phenyl-3-(4-(trifluoromethyl)phenyl)prop-2-en-1-one, 104 
 
General procedure A: acetophenone (0.87 mL, 7.50 mmol), 4-
(trifluoromethyl)benzaldehyde (1.0 mL, 7.50 mmol) and NaOH (380 mg, 9.38 mmol) gave 
104 as yellow crystals (1.51 g, 73%). Rf 0.67 (3:7 EtOAc/petrol); m.p. 125-127 ˚C (lit.
140
 
129-131 
o
C); λmax (EtOH/nm) 220.0, 291.0; IR υmax/cm
-1 
1663, 1608, 1575; 
1
H NMR (500 
MHz, DMSO-d6) δ ppm 7.67 (2H, dd, J = 7.9 and 8.1 Hz, H-3’ and H-5’), 7.77 (1H, ddd, J 
=1.8, 7.9 and 8.1 Hz, H-4’), 7.86-7.90 (3H, m, CH, H-2 and H-6), 8.15-8.21 (3H, m,  CH, H-
3 and H-5), 8.25-8.27 (2H, m, H-2 and H-6); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 123.9 
(q, JCF = 272.3 Hz, C-F3), 124.3 (CH), 125.9 (q, JCF = 3.7 Hz, C-3 and C-5), 128.5 (C-Ar), 
128.6 (C-2 and C-6), 128.8 (C-Ar), 131.9 (q, JCF = 32.9 Hz, Cq), 133.2 (C-4’), 137.8 (Cq), 
231 
 
138.3 (Cq), 142.7 (CO-CH), 190.0 (CO); MS (ES+) m/z = 276.0 [M+H]
+
; HRMS calcd for 
C16H11F3O [M+H]
+
 277.0835, found 277.0835. 
 (E)-1-Phenyl-3-(pyridin-4-yl)prop-2-en-1-one, 106 
 
To a solution of 4-pyridine carboxaldehyde (0.56 g, 5.20 mmol),  in toluene (1 mL/mmol) 
was added (benzoylmethylene)triphenylphosphorane (1.97 g, 5.20 mmol) and the resulting 
mixture was heated at 110 
o
C for 3 h. The mixture was allowed to cool to RT and 
concentrated in vacuo. The resulting residue was triturated with petrol, and the resulting 
precipitate filtered, washed with a 1M aqueous solution of HCl and discarded. The filtrate 
was neutralised with a 2.5 M aqueous solution of NaOH, resulting in precipitation. Filtration 
gave 106 as a yellow solid (0.85 g, 78%). Rf  0.38 (3:7 EtOAc/petrol); m.p. 75-77 ˚C (lit.
141
 
77-78 
oC);  λmax (EtOH/nm) 282.5; IR υmax/cm
-1
 3058, 3034, 1659, 1593, 1578; 
1
H NMR (300 
MHz, CDCl3) δ ppm 7.41-7.7.56 (5H, m, H-Ar, CH and CO-CH), 7.63 (2H, d, J = 1.8 Hz, H-
Ar), 7.95-7.98 (2H, m, H-Ar), 8.64 (2H, d, J = 4.5 Hz, N-CH-pyridine); MS (ES+) m/z = 
210.0 [M+H]
+
 . 
tert-Butyl 2-(2-(3-cyano-4-(3-fluorophenyl)-6-phenylpyridin-2-ylthio)acetamido)acetate, 
99 
 
General procedure B: 3-fluorochalcone (88 mg, 0.39 mmol), 8.5% w/v sodium methoxide 
in MeOH (0.60 mL, 0.94 mmol), 2-cyanothioacetamide (39 mg, 0.39 mmol) followed by tert-
butyl 2-(2-bromoacetamido)acetate (149 mg, 0.59 mmol) gave 99 as a white solid (86 mg, 
46%). Rf 0.54 (1:1 EtOAc/petrol); m.p. 173-174 ˚C; λmax (EtOH/nm) 270.0, 339.5; IR 
υmax/cm
-1 
2980, 2932, 2218, 1724, 1649, 1570, 1526, 1483, 1437, 1366; 
1
H NMR (500 MHz, 
CDCl3) δ ppm 1.31 (9H, s, CH3), 3.84 (2H, d, J = 5.1 Hz, NH-CH2), 4.03 (2H, s,  S-CH2), 
7.07 (1H, br s, NH), 7.17-7.20 (1H, m, H-Ar), 7.26 (1H, ddd, J = 2.2, 2.3 and 9.1 Hz, H-Ar), 
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7.36-7.38 (1H, ddd, J = 1.0, 2.2 and 7.7 Hz, H-Ar), 7.43-7.49 (4H, m, H-Ar), 7.53 (1H, s, 
CH-pyridine), 7.99-8.01 (2H, m, H-Ar); MS (ES+) m/z = 478.1 [M+H]
+
. 
tert-Butyl 2-(2-(3-cyano-4-(2-fluorophenyl)-6-phenylpyridin-2-ylthio)acetamido)acetate, 
101 
 
General procedure B: 2-fluorochalcone (54 mg, 0.23 mmol), 8.5% w/v sodium methoxide 
in MeOH (0.35 mL, 0.55 mmol), 2-cyanothioacetamide (35 mg, 0.23 mmol) followed by tert-
butyl 2-(2-bromoacetamido)acetate (88 mg, 0.35 mmol) gave 101 as a white solid (22 mg, 
20%). Rf 0.50 (1:1 EtOAc/petrol); m.p. 164-168 ˚C; λmax (EtOH/nm) 270.0, 341.5; IR 
υmax/cm
-1 
2972, 2216, 1730, 1653, 1616, 1573, 1525, 1485; 
1
H NMR (500 MHz, CDCl3) δ 
ppm 1.31 (9H, s, CH3), 3.84 (2H, d, J = 5.1 Hz, NH-CH2), 4.03 (2H, s, S-CH2), 7.09 (1H, br 
s, NH), 7.20-7.27 (2H, m, H-Ar), 7.40-7.49 (5H, m, H-Ar), 7.56 (1H, s, CH-pyridine), 7.98-
8.00 (2H, m, H-Ar); MS (ES+) m/z = 478.1 [M+H]
+
; HRMS calcd for C26H24FN3O3S 
[M+H]
+
 478.1595, found 478.1590. 
tert-Butyl 2-(2-((3-cyano-4-(2,4-difluorophenyl)-6-phenylpyridin-2-
yl)thio)acetamido)acetate, 103 
 
General procedure B: (E)-3-(2,4-difluorophenyl)-1-phenylprop-2-en-1-one (590 mg, 2.43 
mmol), 8.5% w/v sodium methoxide in MeOH (3.70 mL, 5.83 mmol), 2-cyanothioacetamide 
(370 mg, 3.65 mmol) and tert-butyl 2-(2-bromoacetamido)acetate (1.83 g, 7.29 mmol) gave 
103 as a white solid (490 mg, 41%). Rf 0.69 (1:1 EtOAc/petrol); m.p. 156-158 ˚C; λmax 
(EtOH/nm) 274.0, 328.0, 380.5; IR υmax/cm
-1 
3326, 2973, 2924, 2218, 1729, 1655, 1618; 
1
H 
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NMR (500 MHz, CDCl3) δ ppm 1.30 (9H, s, CH3), 3.83 (2H, d, J = 5.5 Hz, NH-CH2), 4.02 
(2H, s, S-CH2), 6.94-7.02 (2H, m, H-Ar), 7.05 (1H, t, J = 5.5 Hz, NH), 7.40-7.46 (4H, m, H-5 
and H-Ar), 7.51 (1H, d, J = 1.5 Hz, H-Ar,), 7.97-7.98 (2H, m, H-Ar); 
13
C NMR (125 MHz, 
CDCl3) δ ppm 27.9 (CH3), 33.9 (NH-CH2), 42.3 (S-CH2), 82.3 (Cq), 105.2 (dd, JCF = 25.4 
and 25.5 Hz, C-3), 105.3 (Cq), 112.4 (dd, JCF = 3.9 and 21.8 Hz, C-5), 114.7 (CH-pyridine), 
117.6 (d, JCF = 1.9 Hz, Cq), 120.0 (dd, JCF = 3.9 and 14.6 Hz, Cq), 127.5 (C-Ar), 129.2 (C-
Ar), 131.0 (C-4’), 131.7 (dd, JCF = 3.8 and 10.0 Hz, C-6), 136.5 (Cq), 148.5 (Cq), 159.3 (Cq), 
159.7 (dd, JCF = 12.3 and 253.5 Hz, C-F), 161.5 (Cq), 164.2 (dd, JCF = 11.9 and 253.6 Hz, C-
F), 167.9 (CO), 168.4 (CO); MS (ES+) m/z = 496.3 [M+H]
+
; HRMS calcd for 
C26H23F2N3O3S [M+H]
+
 496.1501, found 496.1498. 
tert-Butyl 2-(2-((3-cyano-6-phenyl-4-(4-(trifluoromethyl)phenyl)pyridin-2-
yl)thio)acetamido)acetate, 105 
 
General procedure B: (E)-1-phenyl-3-(4-(trifluoromethyl)phenyl)prop-2-en-1-one (320 mg, 
1.14 mmol), 8.5% w/v sodium methoxide in MeOH (1.75 mL, 2.74 mmol), 2-
cyanothioacetamide (170 mg, 1.71 mmol)  and tert-butyl 2-(2-bromoacetamido)acetate (860 
mg, 3.42 mmol) gave 105 as a white solid (170 mg, 28%). Rf 0.75 (1:1 EtOAc/petrol); m.p. 
203-205 ˚C; λmax (EtOH/nm) 269.0, 340.5; IR υmax/cm
-1 
3294, 2982, 2212, 1743, 1660, 1572, 
1525; 
1
H NMR (500 MHz, CDCl3) δ ppm 1.30 (9H, s, CH3), 3.83 (2H, d, J = 5.1 Hz, NH-
CH2), 4.03 (2H, s, S-CH2), 7.03 (1H, t, J = 5.1 Hz, NH), 7.43-7.45 (3H, m, H-Ar), 7.53 (1H, 
s,  CH-pyridine), 7.67 (2H, d, J = 8.2 Hz, H-Ar), 7.75 (2H, d, J = 8.2 Hz, H-Ar), 7.98-8.00 
(2H, m, H-Ar); 
13
C NMR (125 MHz, CDCl3) δ ppm 28.0 (CH3), 34.0 (NH-CH2), 42.3 (S-
CH2), 82.3 (Cq), 103.9 (Cq), 114.9 (Cq), 116.5 (CH-pyridine), 126.2 (q, JCF = 3.9 Hz, C-3 
and C-5), 127.5 (C-Ar), 128.9 (C-2 and C-6), 129.2 (C-Ar), 131.1 (C-4’), 136.5 (Cq),139.4 
(Cq), 153.3 (Cq), 159.5 (Cq), 162.0 (Cq), 167.8 (CO), 168.4 (CO), C-F3, C-CF3 and 
quaternary carbons are not visualised; MS (ES+) m/z = 528.3 [M+H]
+
; HRMS calcd for 
C27H24F3N3O3S [M+H]
+
 528.1563, found 528.1560. 
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tert-Butyl 2-(2-(3-cyano-6-phenyl-4-4’-bipyridin-2-ylthio)acetamido)acetate, 108 
 
General procedure B: 4-pyrdiylchalcone (140 mg, 0.67 mmol), 8.5% w/v sodium methoxide 
in MeOH (1.0 mL, 1.68 mmol), 2-cyanothioacetamide (67 mg, 0.67 mmol) followed by tert-
butyl 2-(2-bromoacetamido)acetate (0.25 g, 1.01 mmol) gave 108 as a white solid (114 mg, 
39%). Rf 0.26 (1:1 EtOAc/petrol); m.p. 166-168 ˚C; λmax (EtOH/nm) 221.0, 249.0, 276.5, 
347.5; IR υmax/cm
-1 
2938, 2863, 2212, 1665; 
1
H NMR (500 MHz, CDCl3) δ ppm 1.40 (9H, s, 
CH3), 3.94 (2H, d, J = 5.2 Hz, NH-CH2), 4.15 (2H, s, S-CH2), 7.03 (1H, br s, NH), 7.56-7.57 
(3H, m, H-Ar), 7.65 (1H, s, CH-pyridine), 7.90 (2H, d, J = 4.6 Hz, H-2 and H-6), 8.10 (2H, 
dd, J = 2.5 and 6.1 Hz, H-Ar), 8.95 (2H, d, J = 4.6 Hz, H-3 and H-5); 
13
C NMR (125 MHz, 
CDCl3) δ ppm 28.0 (CH3), 34.0 (NH-CH2), 42.3 (S-CH2), 82.5 (Cq), 103.2 (Cq), 114.3 (Cq), 
115.8 (CH-pyridine), 121.2 (Cq), 124.5 (C-2 and C-6), 127.7 (C-Ar), 129.4 (C-Ar), 131.6 (C-
4’), 136.1 (Cq), 146.7 (Cq), 150.1 (Cq), 160.2 (C-3 and C-5), 162.7 (Cq), 167.4 (CO), 168.5 
(CO); MS (ES+) m/z = 461.3 [M+H]
+
; HRMS calcd for C25H24N4O3S [M+H]
+
 461.1642, 
found 461.1636. 
tert-Butyl 2-(2-((3-cyano-4,6-dimethylpyridin-2-yl)thio)acetamido)acetate, 116 
 
To a solution of 2-mercapto-4,6-dimethylnicotinonitrile (110 mg, 0.69 mmol) in DMF (2 
mL/mmol) was added  tert-butyl 2-(2-bromoacetamido)acetate (210 mg, 0.83 mmol) and 
KOH (39 mg, 0.69 mmol) and the resulting solution heated at 100 
o
C for 3 h. The mixture 
was allowed to cool, diluted with water and extracted with DCM (3 x 20 mL). Combined 
organic layers were washed with brine, dried over Na2SO4 and concentrated in vacuo. 
Purification via column chromatography (silica; 0-60% EtOAc/petrol) gave 116 as a white 
solid (120 mg, 52%). Rf 0.48 (1:1 EtOAc/petrol); m.p. 132-134 ˚C; λmax (EtOH/nm) 266.0, 
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302.0; IR υmax/cm
-1 
2218, 1737, 1652; 
1
H NMR (500 MHz, CDCl3) δ ppm 1.44 (9H, s, CH3), 
2.47 (3H, s, CH3), 2.59 (3H, s, CH3), 3.92-3.93 (4H, m, NH-CH2 and S-CH2), 6.89 (1H, s, 
CH-pyridine), 7.56 (1H, br s, NH); 
13
C NMR (125 MHz, CDCl3) δ ppm 20.4 (CH3), 24.8 
(CH3), 28.4 (CH3), 33.8 (NH-CH2), 42.9 (S-CH2), 82.0 (Cq) 105.8 (Cq), 114.7 (Cq), 121.1 
(CH-pyridine), 152.8 (Cq), 162.2 (Cq), 168.9 (CO), 168.9 (CO); MS (ES+) m/z = 336.1 
[M+H]
+
; HRMS calcd for C16H21N3O3S [M+H]
+
 336.1376, found 336.1377. 
2-(2-(3-Cyano-4-(3-fluorophenyl)-6-phenylpyridin-2-ylthio)acetamido)acetic acid, 73 
 
General procedure C: tert-butyl 2-(2-(3-cyano-4-(3-fluorophenyl)-6-phenylpyridin-2-
ylthio)acetamido)acetate (35 mg, 0.067 mmol), TFA (11 µL, 0.14 mmol) gave 73 as a white 
solid (28 mg, 100%). Rf  0.50 (EtOH); m.p. 221-224 ˚C; λmax (EtOH/nm) 279.0, 348.5; IR 
υmax/cm
-1
 3241, 2217, 2174, 1735, 1624, 1574, 1525; 
1
H NMR (500 MHz, DMSO-d6) δ ppm 
3.82 (2H, d,  J = 5.7 Hz, NH-CH2), 4.22 (2H, s, S-CH2), 7.44-7.48 (1H, m, H-Ar), 7.54-7.58 
(3H, m, H-Ar), 7.61-7.71 (3H, m,  H-Ar), 7.99 (1H, s, CH-pyridine), 8.31-8.33 (2H, m, H-
Ar), 8.68 (1H, t, J = 5.7 Hz, NH), 12.67 (1H, s, COOH); MS (ES+) m/z = 422.2 [M+H]
+
, 
420.1 [M-H]
-
; HRMS calcd for C22H16FN3O3S [M+H]
+
 422.0967, found 422.0967. 
2-(2-((3-Cyano-4-(2-fluorophenyl)-6-phenylpyridin-2-yl)thio)acetamido)acetic acid, 74 
 
General procedure C: tert-butyl 2-(2-(3-cyano-4-(2-fluorophenyl)-6-phenylpyridin-2-
ylthio)acetamido)acetate (18 mg,  0.038 mmol), TFA (6 µL,  0.076 mmol) gave 74 as a white 
solid (16 mg, 99%). Rf  0.51 (EtOH); m.p. 200-202 ˚C; λmax (EtOH/nm) 340.0, 270.5; IR 
υmax/cm
-1
 2220,1719, 1653, 1573, 1526; 
1
H NMR (500 MHz, DMSO-d6) δ ppm 3.82 (2H, d, J 
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= 5.7 Hz, NH-CH2), 4.23 (2H, s, S-CH2), 7.44-7.51 (2H, m, H-Ar), 7.52-7.55 (3H, m, H-Ar 
and H-4’), 7.64-7.71 (2H, m, H-Ar), 8.00 (1H, s, CH-pyridine), 8.28-8.30 (2H, m, H-Ar), 
8.67 (1H, t, J = 5.7 Hz, NH), 12.67 (1H, s, COOH); MS (ES+) m/z = 422.2 [M+H]
+
, 420.1 
[M-H]
-
; HRMS calcd for C22H16FN3O3S [M+H]
+
 422.0967, found 422.0968. 
2-(2-((3-Cyano-4-(2,4-difluorophenyl)-6-phenylpyridin-2-yl)thio)acetamido)acetic acid, 
75 
 
General procedure C: tert-butyl 2-(2-((3-cyano-4-(2,4-difluorophenyl)-6-phenylpyridin-2-
yl)thio)acetamido)acetate (450 mg, 0.91 mmol), TFA (139 µL, 1.82 mmol) gave 75 as a 
white solid (400 mg, 100%). Rf 0.23 (MeOH); m.p. 226-227 ˚C; λmax (EtOH/nm) 339.5, 
270.5; IR υmax/cm
-1 
3259, 3079, 2221, 1728, 1619;  
1
H NMR (500 MHz, DMSO-d6) δ ppm 
3.75 (2H, d, J = 5.8 Hz, NH-CH2), 4.23 (2H, s, S-CH2), 7.30 (1H, ddd, J = 2.1, 8.4 and 10.6 
Hz, H-5), 7.53-7.60 (4H, m, H-Ar, H-4’ and H-3) 7.77 (1H, ddd, J = 6.6, 8.7 and 15.1 Hz, H-
6), 7.99 (1H, s, CH-pyridine), 8.27-8.29 (2H, m, H-Ar), 8.60 (1H, t, J = 5.8 Hz, NH), 12.62 
(1H, s, COOH); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 33.7 (NH-CH2), 41.1 (S-CH2), 104.1 
(Cq), 104.8 (dd, JCF = 26.8 and 26.9 Hz, C-3), 112.4 (dd, JCF = 3.4 and 21.7 Hz C-5), 115.0 
(CH-pyridine), 117.2 (Cq), 120.1 (dd, JCF = 4.0 and 15.0 Hz, Cq)  127.8 (C-Ar), 128.9 (C-
Ar), 131.0 (C-4’), 132.8 (dd, JCF = 3.8 and 10.3 Hz, C-6), 136.3 (Cq), 148.1 (Cq), 158.3 (Cq), 
159.1 (dd, JCF = 12.7 and 250.3 Hz, C-F), 161.6 (Cq), 163.4 (dd, JCF = 12.3 and 250.7 Hz, C-
F), 167.2 (CO), 171.0 (CO); MS (ES+) m/z = 440.2 [M+H]
+
; HRMS calcd for 
C22H15F2N3O3S [M+H]
+
 440.0875, found 440.0874. 
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2-(2-((3-Cyano-6-phenyl-4-(4-(trifluoromethyl)phenyl)pyridin-2-
yl)thio)acetamido)acetic acid, 76 
 
General procedure C: tert-butyl 2-(2-((3-cyano-6-phenyl-4-(4-
(trifluoromethyl)phenyl)pyridin-2-yl)thio)acetamido)acetate (100 mg, 0.19 mmol), TFA (29 
µL, 0.38 mmol) gave 76 as a white solid (80 mg, 90%). Rf 0.25 (MeOH); m.p. 243-244 ˚C; 
λmax (EtOH/nm) 345.0, 268.0; IR υmax/cm
-1 
3285, 3069, 2214, 1738, 1667; 
1
H NMR (500 
MHz, DMSO-d6) δ ppm 3.82 (2H, d, J = 5.7 Hz, NH-CH2), 4.23 (2H, s, S-CH2), 7.54-7.56 
(3H, m, H-Ar and H-4’), 7.99-8.01 (5H, m, H-Ar and CH-pyridine) 8.30-8.32 (2H, m, H-Ar), 
8.67 (1H, t, J = 5.7 Hz, NH), COOH not visualised; 
13
C NMR (125 MHz, DMSO-d6) δ ppm 
33.8 (S-CH2), 41.3 (NH-CH2), 102.7 (Cq), 115.4 (Cq), 116.0 (CH-pyridine), 124.0 (q, JCF = 
273.4 Hz, C-F3), 125.7 (q, JCF = 3.6 Hz, C-3 and C-5), 127.8 (C-Ar), 128.9 (C-2 and C-6), 
129.8 (C-Ar), 130.2 (q, JCF = 32.2 Hz, Cq), 130.9 (C-4’), 136.4 (Cq), 139.7 (Cq), 152.7 (Cq), 
158.3 (Cq), 162.1 (Cq), 167.1 (CO), 171.0 (CO); MS (ES+) m/z = 472.2 [M+H]
+
; HRMS 
calcd for C23H16F3N3O3S [M+H]
+
 472.0937, found 472.0932.  
2-(2-((3-Cyano-6-phenyl-[4,4'-bipyridin]-2-yl)thio)acetamido)acetic acid, 77 
 
General procedure C: tert-butyl 2-(2-(3-cyano-6-phenyl-4-4’-bipyridin-2-
ylthio)acetamido)acetate (80 mg, 0.17 mmol), TFA (26 µL, 0.34 mmol) gave 77 as a white 
solid (67 mg, 98%). Rf  0.35 (EtOH); m.p. 268-271 
oC; λmax (EtOH/nm) 348.5, 276.5, 249.0; 
IR υmax/cm
-1
 3267, 2212, 1726, 1665, 1570, 1520; 
1
H NMR (500 MHz, DMSO-d6) δ ppm 
3.82 (2H, d, J = 5.7 Hz, NH-CH2), 4.23 (2H, s, S-CH2), 7.54-7.57 (3H, m, H-Ar and H-4’),  
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7.78 (2H, d, J = 6.1 Hz, CH-pyridine), 8.02 (1H, s, CH-pyridine), 8.30-8.32 (2H, m, H-Ar), 
8.66 (1H, t, J = 5.7 Hz, NH), 8.83 (2H, d J = 6.1 Hz, N-CH-pyridine), 12.64 (1H, s, COOH); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 33.7 (NH-CH2), 41.1 (S-CH2), 102.5 (Cq), 115.2 
(Cq), 116.0 (CH-pyridine), 123.1 (C-2 and C-5), 127.8 (C-Ar), 128.9 (C-Ar), 131.0 (C-4’), 
136.3 (Cq), 143.1 (Cq), 150.2 (C-3 and C-5), 151.6 (Cq), 158.4 (Cq), 162.2 (Cq), 167.2 (CO), 
171.0 (CO); MS (ES+) m/z = 405.2 [M+H]
+
; HRMS calcd for C21H16N4O3S [M+H]
+
 
405.1016, found 405.1015. 
2-(2-((3-Cyano-4,6-dimethylpyridin-2-yl)thio)acetamido)acetic acid, 80 
 
General procedure C: tert-butyl 2-(2-((3-cyano-4,6-dimethylpyridin-2-
yl)thio)acetamido)acetate (100 mg, 0.29 mmol), TFA (44 µL, 0.58 mmol) gave 80 as a white 
solid (83 mg, 100%). Rf 0.25 (MeOH); m.p. 225-226 ˚C; λmax (EtOH/nm) 265.0, 304.0; IR 
υmax/cm
-1 
3321, 3014, 2216, 1714, 1638; 
1
H NMR (500 MHz, DMSO-d6) δ ppm 2.42 (3H, s, 
CH3), 2.48 (3H, s, CH3), 3.78 (2H, d, J = 5.9 Hz, NH-CH2), 4.03 (2H, s, S-CH2), 7.13 (1H, s, 
CH-pyridine), 8.47 (1H, t, J = 5.9 Hz, NH,), 12.61 (1H, s, OH); 
13
C NMR (125 MHz, CDCl3) 
δ ppm 19.6 (CH3), 24.2 (CH3), 33.1 (NH-CH2), 41.0 (S-CH2), 103.6 (Cq), 115.0 (CH-
pyridine), 120.5 (Cq), 152.4 (Cq), 160.0 (Cq), 161.5 (Cq), 167.4 (CO), 171.0 (CO); MS 
(ES+) m/z = 280.1 [M+H]
+
; HRMS calcd for C12H13N3O3S [M+H]
+
 280.0750, found 
280.0753. 
tert-Butyl (2-(methoxy(methyl)amino)-2-oxoethyl)carbamate, 110 
 
General procedure D: 2-((tert-butoxycarbonyl)amino)acetic acid (660 mg, 3.74 mmol), CDI 
(1.21 g, 7.48 mmol), N,O-dimethylhydroxylamine hydrochloride (910 mg, 9.35 mmol) and 
triethylamine (1.30 mL, 9.35 mmol). Recrystallisation from EtOAc/petrol (7:3) gave 110 as a 
white solid (400 mg, 49%). Rf 0.59 (1:1 EtOAc/petrol); m.p. 95-97 ˚C (lit.
142
 95-98 
o
C); IR 
υmax/cm
-1 
3312, 2915, 1618, 1569, 1530; 
1
H NMR (500 MHz, CDCl3) δ ppm 1.39 (9H, s, 
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CH3)3, 3.14 (3H, s, N-CH3), 3.65 (3H, s, O-CH3), 4.02 (2H, d, J = 3.2 Hz, CH2), 5.20 (1H, br 
s, NH).  
tert-Butyl (2-oxopropyl)carbamate, 111 
 
To a solution of tert-butyl (2-(methoxy(methyl)amino)-2-oxoethyl)carbamate (260 mg, 1.22 
mmol) in THF (5 mL/mmol) was added methyl magnesium chloride (0.84 mL, 2.56 mmol) 
dropwise at 0 
o
C. The reaction mixture was warmed to RT and allowed to stir for 16 h. The 
reaction was quenched with a 1M aqueous solution of HCl and the product extracted with 
EtOAc (3 x 50 mL).  Combined organic layers were washed with brine, dried over Na2SO4 
and concentrated in vacuo. Purification via column chromatography (silica; 0-30% 
EtOAc/petrol) gave 111 as a yellow oil (190 mg, 89%). Rf 0.63 (1:1 EtOAc/petrol); IR 
υmax/cm
-1
 3356, 2978, 2925, 1692, 1514; 
1
H NMR (500 MHz, CDCl3) δ ppm 1.38 (9H, s, C-
CH3), 2.11 (3H, s, CO-CH3), 4.05 (2H, s, N-CH2), 5.16 (1H, s, NH).  
2-Bromo-N-(2-oxopropyl)acetamide, 113 
 
tert-Butyl (2-oxopropyl)carbamate (170 mg, 0.98 mmol) was dissolved in a 4M solution of 
HCl in dioxane (1 mL/mmol), and the mixture was stirred for 12 h at RT. The solution was 
concentrated in vacuo, the resulting oil redissolved in DCM (3 mL/mmol) and the solution 
cooled to 0 
o
C. An ice cold solution of Et3N (0.16 mL, 1.18 mmol), DMAP (5 mol%) and 
bromoacetyl chloride (0.1 mL, 1.08 mmol)  in DCM (3 mL/mmol) was added dropwise. The 
resulting mixture was warmed to RT and stirred for 12 h. The solution was diluted with DCM 
(30 mL), washed with water (3 x 30 mL) and brine. Combined organic layers were dried over 
Na2SO4 and concentrated in vacuo. Recrystallisation from EtOAc/petrol (7:3) gave 113 as a 
beige solid (160 mg, 86%). Rf 0.57 (1:1 EtOAc/petrol); m.p. 77-79 ˚C; IR υmax/cm
-1 
3074, 
1724, 1643;  
1
H NMR (500 MHz, CDCl3) δ ppm 2.17 (3H, s, CH3), 3.84 (2H, s, Br-CH2), 
4.11 (2H, d, J = 4.6 Hz, NH-CH2), 7.10 (1H, s, NH); 
13
C NMR (125 MHz, CDCl3) δ ppm 
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27.4 (CH3), 28.5 (CH2), 50.2 (CH2), 165.5 (CO), 201.7 (CO); HRMS calcd for C5H8BrNO2 
[M-H]
- 
191.9666, found 191.9671. 
2-((3-Cyano-4-(4-fluorophenyl)-6-phenylpyridin-2-yl)thio)-N-(2-oxopropyl)acetamide, 
67 
 
General procedure B: 4-fluorochalcone (15 mg, 0.067 mmol), 8.5% w/v sodium methoxide 
in MeOH (0.10 mL, 0.16 mmol), 2-cyanothioacetamide (7 mg, 0.067 mmol) and 2-bromo-N-
(2-oxopropyl)acetamide (20 mg, 0.10 mmol) gave 67 as a white solid (10 mg, 36%). Rf 0.20 
(1:1 EtOAc/petrol); m.p. 231-233 ˚C; λmax (EtOH/nm) 270.0, 338.0; IR υmax/cm
-1 
3281, 2920, 
2216, 1732, 1659; 
1
H NMR (500 MHz, CDCl3) δ ppm 2.02 (3H, s, CH3), 4.03 (2H, s, S-
CH2), 4.04 (2H, d, J = 5.9 Hz, NH-CH2), 7.16-7.20 (2H, m, H-Ar), 7.26 (1H, br s, NH), 7.44-
7.45 (3H, m, H-Ar), 7.52 (1H, s, CH-pyridine), 7.56-7.59 (2H, m, H-Ar), 7.99-8.00 (2H, m, 
H-Ar); MS (ES+) m/z = 420.3 [M+H]
+
; HRMS calcd for C23H18FN3O2S [M+H]
+
 420.1177, 
found 420.1180. 
2-((3-Cyano-6-phenyl-[4,4'-bipyridin]-2-yl)thio)-N-(2-oxopropyl)acetamide, 114 
 
General procedure B: 4-pyridylchalcone (48 mg, 0.23 mmol), 8.5% w/v sodium methoxide 
in MeOH (0.35 mL, 0.56 mmol), 2-cyanothioacetamide (46 mg, 0.23 mmol) and 2-bromo-N-
(2-oxopropyl)acetamide (67 mg, 0.35 mmol). Purification via column chromatography 
(silica; 0-15% MeOH/DCM) gave 114 as a white solid (72 mg, 78%). Rf 0.30 (MeOH); m.p. 
238-240 ˚C; λmax (EtOH/nm) 345.0, 277.0, 249.0; IR υmax/cm
-1
 2913, 2213, 1730, 1657, 1570, 
241 
 
1517; 
1
H NMR (500 MHz, DMSO-d6) δ ppm 2.03 (3H, s, CH3), 3.98 (2H, d, J = 5.5 Hz, NH-
CH2), 4.25 (2H, s, S-CH2), 7.55-7.56 (3H, m, H-Ar and H-4’), 7.78 (2H, d, J = 6.9 Hz, CH-
pyridine), 8.03 (1H, s, CH-pyridine), 8.30-8.32 (2H, m, H-Ar), 8.61 (1H, t, J = 5.5 Hz, NH), 
8.83 (2H, d, J = 6.9 Hz, N-CH-pyridine); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 26.9 (CH3), 
33.7 (CH2), 49.5 (CH2), 102.5 (Cq), 115.2 (Cq), 116.0 (CH-pyridine), 123.1 (CH-pyridine), 
127.8 (C-Ar), 128.9 (C-Ar), 131.0 (C-4’), 136.3 (Cq), 143.1 (Cq), 150.2 (N-CH-pyridine), 
151.6 (Cq), 158.4 (Cq), 162.2 (Cq), 167.2 (CO), 204.3 (CO); MS (ES+) m/z = 403.3 [M+H]
+
; 
HRMS calcd for C22H18N4O2S [M+H]
+
 403.1223, found 403.1218. 
2-((3-Cyano-4,6-dimethylpyridin-2-yl)thio)-N-(2-oxopropyl)acetamide, 117 
 
To a solution of 2-mercapto-4,6-dimethylnicotinonitrile (100 mg, 0.61 mmol) in DMF (5 
mL/mmol) was added 2-bromo-N-(2-oxopropyl)acetamide (153 mg, 0.79 mmol) and KOH 
(34 mg, 0.61 mmol). The resulting mixture was heated at 100 
o
C for 3 h. The solution was 
cooled, diluted with water, and the product extracted with DCM (3 x 10 mL). Combined 
organic layers were washed with brine, dried over Na2SO4 and concentrated in vacuo. 
Purification via column chromatography (silica; 0-50% EtOAc/petrol) gave 117 as a white 
solid (134 mg, 79%). Rf 0.40 (8:2 petrol/EtOAc); m.p. 147-148 ˚C; λmax (EtOH/nm) 222.0, 
266.5, 305.5; IR υmax/cm
-1 
3325, 2998, 2216, 1709, 1660; 
1
H NMR (500 MHz, CDCl3) δ ppm 
2.09 (3H, s, CH3), 2.40 (3H, s, CH3), 2.57 (3H, s, CH3), 3.84 (2H, s, S-CH2), 4.08 (2H, d, J = 
5.9 Hz, NH-CH2), 6.83 (1H, s, CH-pyridine), 7.75 (1H, br s, NH); 
13
C NMR (125 MHz, 
CDCl3) δ ppm 20.3 (CH3), 24.7 (CH3), 27.4 (CH3), 33.0 (NH-CH2), 50.4 (S-CH2), 105.1 
(Cq), 114.6 (CH-pyridine), 120.9 (Cq), 152.7 (Cq), 160.6 (Cq), 162.1 (Cq), 169.1 (CO), 
202.4 (CO); MS (ES+) m/z = 278.1 [M+H]
+
; HRMS calcd for C13H15N3O2S [M+H]
+
 
278.0958, found 278.0956. 
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4-(4-Fluorophenyl)-6-phenylpyridin-2(1H)-one, 118 
 
To a solution of 4-fluorochalcone (1.50 g, 6.6 mmol) in DMF (15 mL) was added 
acetamidoacetamide (0.96 g, 8.3 mmol) and Cs2CO3 (2.70 g, 8.3 mmol). The resulting 
mixture was stirred at 100 
o
C for 2.5 h. The reaction mixture was cooled to RT and poured 
into a 10% w/v aqueous solution of HCl (40 mL). An orange-brown precipitate formed which 
was filtered, dried and collected to yield the crude product. Purification via column 
chromatography (silica; 10-70% EtOAc/petrol) and recrystallisation from minimum hot 
EtOH gave 118 as beige crystals (0.60 g, 34%). Rf  0.60 (1:1 EtOAc/petrol); m.p. 215-217 ˚C; 
λmax (EtOH/nm) 252.0, 334.5; IR υmax/cm
-1
 2882, 1634, 1596, 1574, 1528, 1506; 
1
H NMR 
(500 MHz, DMSO-d6) δ ppm 6.70 (1H, s, H-5 pyridine), 7.01 (1H, s, H-3 pyridine), 7.34 
(2H, dd, J = 8.6 and 8.7 Hz, H-Ar), 7.49-7.53 (3H, m, H-Ar and H-4’), 7.89-7.92 (4H, m, H-
Ar), 11.72 (1H, s, NH); 
13
C NMR (125 MHz, CDCl3) δ ppm 115.8 (d, JCF = 21.3 Hz C-3 and 
C-5), 127.0 (C-Ar), 128.7 (C-Ar), 129.2 (d, JCF = 8.8 Hz, C-2 and C-6), 129.6 (C-4’), 133.8 
(d, JCF = 2.8 Hz, Cq), 150.6 (Cq), 163.0 (d, JCF = 245.8 Hz, C-F), 163.6 (CO), CH-pyridines 
and some quarternary carbons not visualised; MS (ES+) m/z = 266.0 [M+H]
+
. 
3-Bromo-4-(4-fluorophenyl)-6-phenylpyridin-2(1H)-one, 119 
 
To a solution of 4-(4-fluorophenyl)-6-phenylpyridin-2(1H)-one (100 mg, 0.38 mmol) in 
glacial acetic acid (2.5 mL) was added N-bromosuccinamide (0.68 g, 0.38 mmol). The 
mixure was stirred at RT for 1 h, then at 60 
o
C for a further 5 h. The reaction mixture was 
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cooled and neutralised with a 2.5 M aqueous solution of NaOH, and precipitation was 
observed. The resulting solid was filtered, washed with water, dried and collected to give 119 
as an off white solid (130 mg, 100%). Rf  0.78 (3:7 EtOAc/petrol); m.p. 257-260 ˚C; λmax 
(EtOH/nm) 252.0, 339.0; IR υmax/cm
-1
 2994, 1632, 1601; 
1
H NMR (500 MHz, DMSO-d6) δ 
ppm 6.60 (1H, s, H-5 pyridine), 7.34 (2H, dd, J = 8.6 and 8.7 Hz, H-Ar), 7.48-7.52 (3H, m,  
H-Ar and H-4’), 7.60 (2H, dd, J = 5.5 and 8.7 Hz, H-Ar), 7.83-7.84 (2H, m, H-Ar) 12.43 (1H, 
s, NH); MS (ES+) m/z = 344.2 [(
79
BrM)+H]
+
, 346.0 2 [(
81
BrM)+H]
+
; HRMS calcd for 
C17H11
79
BrFNO [M+H]
+
 344.0081, found 344.0086. 
tert-Butyl 2-(2-(3-bromo-4-(4-fluorophenyl)-6-phenylpyridin-2-ylthio)acetamido)acetate, 
121 
 
To a solution of 3-bromo-4-(4-fluorophenyl)-6-phenylpyridin-2(1H)-one (84 mg, 0.77 mmol) 
in toluene (6 mL) was added Lawesson’s reagent (158 mg, 0.39 mmol). The resulting 
solution was stirred at 110 
o
C for 20 h. The mixture was allowed to cool, and evaporated to 
dryness to yield the crude product which was used directly in the next step. To a solution of 
3-bromo-4-(4-fluorophenyl)-6-phenylpyridine-2(1H)-thione and 3-bromo-4-(4-fluorophenyl)-
6-phenylpyridine-2-thiol (280 mg, 0.77 mmol) in DMF (5 mL) was added  KOH (43 mg, 
0.77 mmol) and tert-butyl 2-(2-bromoacetamido)acetate (390 mg, 1.5 mmol). The resulting 
mixture was heated at 100 
o
C for 4 h. The mixture was cooled and diluted with H2O. The 
product was extracted with EtOAc (3 x 20 mL), washed with H2O (5 x 50 mL) and brine (50 
mL). Combined organic layers were dried over Na2SO4 and concentrated in vacuo. 
Purification via column chromatography (silica; 0-50% EtOAc/petrol) gave 121 as an off 
white solid (160 mg, 39%). Rf  0.31 (2:8 EtOAc/petrol); m.p. 178-181 ˚C; λmax (EtOH/nm) 
250.0, 322.5; IR υmax/cm
-1
 3071, 2974, 2911, 1718, 1649, 1605, 1555, 1507; 
1
H NMR (500 
MHz, CDCl3) δ ppm 1.30 (9H, s, CH3), 3.82 (2H, d, J = 5.3 Hz, NH-CH2), 3.96 (2H, s, S-
CH2), 7.12 (2H, dd, J = 8.6 and 8.7 Hz, H-Ar), 7.20 (1H, br s,  NH), 7.35-7.42 (6H, m, H-Ar 
and CH-pyridine), 7.93-7.95 (2H, m,  H-Ar); 
13
C NMR (75 MHz, CDCl3) δ ppm 28.0 (CH3), 
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35.3 (NH-CH2), 42.3 (S-CH2), 82.1 (Cq), 115.6 (d, JCF = 22.0 Hz, C-3 and C-5), 117.3 (Cq), 
118.7 (CH-pyridine), 126.7 (C-Ar), 129.0 (C-Ar), 129.7 (C-4’), 130.7 (d, JCF = 8.3 Hz, C-2 
and C-6), 137.3 (Cq), 150.4 (Cq), 155.3 (Cq), 157.7 (Cq), 168.5 (CO), 168.8 (CO), C-F, and 
F split quarternary carbon not visualised; MS (ES+) m/z = 531.2 [(
79
BrM)+H]
+
, 533.2 
[(
81
BrM)+H]
+
. 
2-(2-(3-Bromo-4-(4-fluorophenyl)-6-phenylpyridin-2-ylthio)acetamido)acetic acid, 82 
 
General procedure C: 2-(2-(3-bromo-4-(4-fluorophenyl)-6-phenylpyridin-2-
ylthio)acetamido)acetate (80 mg, 0.15 mmol), TFA (23 µL, 0.30 mmol) gave 82 as a white 
solid (68 mg, 93%). Rf  0.52 (EtOH); m.p. 197-200 ˚C; λmax (EtOH/nm) 248.5, 349.0; IR 
υmax/cm
-1
 2955, 2876, 1575, 1500; 
1
H NMR (500 MHz, CDCl3) δ ppm 3.80 (2H, d, J = 5.8 
Hz, NH-CH2), 4.08 (2H, s, S-CH2), 7.39 (2H, dd, J = 8.6 and 8.7 Hz, H-Ar), 7.47-7.51 (3H, 
m, H-Ar and H-4’), 7.59 (2H, dd, J = 5.6 and 8.7 Hz, H-Ar), 7.71 (1H, s, CH-pyridine), 8.19-
8.21 (2H, m, H-Ar), 8.60 (1H, t, J = 5.8 Hz, NH), 12.65 (1H, s, COOH); MS (ES+) m/z = 
473.1 [(
79
BrM)+H]
+
, 475.0 [(
81
BrM)+H]
+
; HRMS calcd for C21H16BrFN2O3S [M+H]
+
 
472.9976 [(
79
BrM)+H]
+
, 474.9955 [(
81
BrM)+H]
+
, found 472.9974 [(
79
BrM)+H]
+
, 474.9945 
[(
81
BrM)+H]
+
. 
Methyl 4-(cyclohexanecarbonyl)-1H-pyrrole-2-carboxylate, 170 
 
General procedure F: methyl 1H-pyrrole-2-carboxylate (300 mg, 2.40 mmol), 
cyclohexanecarbonyl chloride (0.64 mL, 4.80 mmol) and AlCl3 (800 mg, 6.0 mmol). 
Purification via column chromatography (silica; 0-50% EtOAc/petrol) gave 170 as a white 
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solid (458 mg, 81%). Rf 0.43 (3:7 EtOAc/petrol); m.p. 164-166 ˚C; λmax (EtOH/nm) 223.0, 
273.0; IR υmax/cm
-1 
3215, 2949, 2859, 1705, 1635, 1554; 
1
H NMR (500 MHz, CDCl3) δ ppm 
1.17-1.29 (4H, m, CH-cyclohexane), 1.39-1.46 (2H, m, CH-cyclohexane), 1.74-1.81 (4H, m, 
CH-cyclohexane), 2.84 (1H, tt, J = 3.2 and 11.6 Hz, CO-CH), 3.81 (3H, s, O-CH3), 7.21 (1H, 
dd, J = 1.6 and 2.4 Hz, H-3), 7.47 (1H, dd, J = 1.6 and 3.3 Hz, H-5), 9.32 (1H, s, NH-
pyrrole); 
13
C NMR (125 MHz, CDCl3) δ ppm 25.8 (C-cyclohexane) 25.9 (C-cyclohexane), 
47.6 (C-cyclohexane), 50.9 (CO-C-cyclohexane) 51.9 (O-CH3), 115.0 (C-Ar), 123.8 (C-Ar), 
126.1 (C-Ar), 126.4 (C-Ar), 161.2 (CO), 199.4 (CO); MS (ES+) m/z = 236.0 [M+H]
+
. 
Methyl 4-(cyclopentanecarbonyl)-1H-pyrrole-2-carboxylate, 172 
 
General procedure F: methyl 1H-pyrrole-2-carboxylate (300 mg, 2.40 mmol), 
cyclopentanecarbonyl chloride (0.58 mL, 4.80 mmol) and AlCl3 (800 mg, 6.0 mmol). 
Purification via column chromatography (silica; 0-50% EtOAc/petrol) gave 172 as a white 
solid (426 mg, 80%). Rf 0.42 (3:7 EtOAc/petrol); m.p. 125-127 ˚C; λmax (EtOH/nm) 223.5, 
273.0; IR υmax/cm
-1 
3213, 2951, 2868, 1702, 1638, 1555; 
1
H NMR (500 MHz, CDCl3) δ ppm 
1.51-1.55 (2H, m, CH-cyclopentane), 1.61-1.68 (2H, m,  CH-cyclopentane), 1.80-1.84 (4H, 
m, CH-cyclopentane), 3.34 (1H, quin, J = 7.9 Hz, CO-CH), 3.81 (3H, s, O-CH3), 7.23 (1H, 
dd, J = 1.6 and 2.4 Hz, H-3), 7.48 (1H, dd, J = 1.6 and 3.3 Hz, H-5), 9.51 (1H, s, NH-
pyrrole); 
13
C NMR (125 MHz, CDCl3) δ ppm 26.3 (C-cyclopentane), 29.9 (C-cyclopentane), 
48.0 (CO-C-cyclopentane), 51.9 (O-CH3), 115.1 (C-Ar), 123.7 (C-Ar), 126.3 (C-Ar), 127.1 
(C-Ar), 161.4 (CO), 198.5 (CO); MS (ES+) m/z = 222.0 [M+H]
+
; HRMS calcd for 
C12H15NO3 [M+H]
+
 222.1125, found 222.1125. 
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Methyl 4-(cycloheptanecarbonyl)-1H-pyrrole-2-carboxylate, 174 
 
General procedure E: cycloheptane carboxylic acid (1.0 mL, 7.28 mmol) and SOCl2 (0.79 
mL, 10.92 mmol) gave cycloheptanecarbonyl chloride which was used directly in the next 
step. General procedure F:  methyl 1H-pyrrole-2-carboxylate (460 mg, 3.64 mmol), and 
AlCl3 (1.22 g, 9.10 mmol). Purification via column chromatography (silica; 0-50% 
EtOAc/petrol) gave 174 as a white solid (890 mg, 98%). Rf 0.40 (3:7 EtOAc/petrol); m.p. 
110-111 ˚C; λmax (EtOH/nm) 224.0, 273.0; IR υmax/cm
-1 
3256, 2926, 2855, 1708, 1641, 1553; 
1
H NMR (500 MHz, DMSO-d6) δ ppm 1.50-1.56 (6H, m, CH-cycloheptane), 1.57-1.70 (4H, 
m, CH-cycloheptane), 1.76-1.81 (2H, m, CH-cycloheptane), 3.22 (1H, m, CO-CH), 3.80 (3H, 
s, O-CH3), 7.14 (1H, br s, H-3), 7.72 (1H, dd, J = 1.6 and 3.2 Hz, H-5), 12.54 (1H, s, NH-
pyrrole); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 26.1 (C-cycloheptane), 27.9 (C-
cycloheptane), 30.6 (C-cycloheptane), 47.2 (CO-C-cycloheptane), 51.5 (O-CH3), 114.5 (C-
Ar), 123.4 (C-Ar), 125.0 (C-Ar), 127.9 (C-Ar), 160.6 (CO), 198.8 (CO); MS (ES+) m/z = 
250.0 [M+H]
+
; HRMS calcd for C14H19NO3 [M+H]
+ 
250.1438, found 250.1437. 
4-(Cyclohexanecarbonyl)-1H-pyrrole-2-carboxylic acid, 171 
 
General procedure G:  methyl 4-(cyclohexanecarbonyl)-1H-pyrrole-2-carboxylate (370 mg, 
1.56 mmol) and LiOH monohydrate (1.30 g, 31.23 mmol) gave 171 as a white solid (344 mg, 
100%). Rf 0.21 (8:2 DCM/MeOH); m.p. 218-220 ˚C; λmax (EtOH/nm) 224.5, 272.5; IR 
υmax/cm
-1 
3270, 2931, 2826, 2609, 1645, 1551, 1435; 
1
H NMR (500 MHz, DMSO-d6) δ ppm 
1.16-1.40 (6H, m, CH-cyclohexane), 1.65-1.74 (4H, m, CH-cyclohexane), 3.03-3.09 (1H, m, 
CO-CH), 7.08 (1H, br s, H-3), 7.70 (1H, dd, J = 1.6 and 3.3 Hz, H-5), 12.37 (1H, s, NH-
pyrrole), 12.71 (1H, s, COOH); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 25.1 (C-
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cyclohexane), 25.6 (C-cyclohexane), 29.2 (C-cyclohexane), 45.9 (CO-C-cyclohexane), 114.0 
(C-Ar), 124.7 (C-Ar), 124.9 (C-Ar), 127.5 (C-Ar), 161.6 (CO), 198.3 (CO); MS (ES+) m/z = 
222.1 [M+H]
+
; HRMS calcd for C12H15NO3 [M+H]
+
 222.1125, found 222.1125. 
4-(Cyclopentanecarbonyl)-1H-pyrrole-2-carboxylic acid, 173 
 
General procedure G:  methyl 4-(cyclopentanecarbonyl)-1H-pyrrole-2-carboxylate (290 
mg, 1.32 mmol) and LiOH monohydrate (1.10 g, 26.40 mmol) gave 173 as a white solid (264 
mg, 97%). Rf 0.19 (8:2 DCM/MeOH); m.p. 209-210 ˚C; λmax (EtOH/nm) 223.5, 277.0; IR 
υmax/cm
-1 
3246, 2917, 2853, 1704, 1638, 1554;  
1
H NMR (500 MHz, DMSO-d6) δ ppm 1.56-
1.62 (4H, m, CH-cyclopentane), 1.67-1.73 (2H, m, CH-cyclopentane), 1.79-1.86 (2H, m, CH-
cyclopentane), 3.49-3.55 (1H, m, CO-CH), 7.08 (1H, dd, J = 1.7 and 2.4 Hz, H-3), 7.68 (1H, 
dd, J = 1.7 and 3.3 Hz, H-5), 12.36 (1H, s, NH-pyrrole), 12.72 (1H, s, COOH); 
13
C NMR 
(125 MHz, DMSO-d6) δ ppm 25.9 (C-cyclopentane), 29.5 (C-cyclopentane), 46.7 (CO-C-
cyclopentane), 114.1 (C-Ar), 124.6 (C-Ar), 125.6 (C-Ar), 127.6 (C-Ar), 161.6 (CO), 197.3 
(CO); MS (ES+) m/z = 208.1 [M+H]
+
; HRMS calcd for C11H13NO3 [M+H]
+
 208.0968, found 
208.0968. 
4-(Cycloheptanecarbonyl)-1H-pyrrole-2-carboxylic acid, 175 
 
General procedure G:  methyl 4-(cycloheptanecarbonyl)-1H-pyrrole-2-carboxylate (220 
mg, 0.90 mmol) and LiOH monohydrate (0.76 g, 18.00 mmol) gave 175 as a white solid (190 
mg, 100%). Rf 0.19 (8:2 DCM/MeOH); m.p. 219-220 ˚C; λmax (EtOH/nm) 229.0, 270.5; IR 
υmax/cm
-1 
3290, 2922, 2854, 1655, 1552; 
1
H NMR (500 MHz, DMSO-d6) δ ppm 1.42-1.64 
(10H, m, CH-cycloheptane), 1.70-1.75 (2H, m, CH-cycloheptane), 3.10-3.15 (1H, m, CO-
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CH), 7.00 (1H, br s, H-3), 7.56 (1H, dd, J = 1.6 and 3.2 Hz, H-5), 12.19 (1H, s, NH-pyrrole), 
12.48 (1H, s, COOH); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 26.1 (C-cycloheptane), 28.0 
(C-cycloheptane), 30.6 (C-cycloheptane), 47.1 (CO-C-cycloheptane), 114.1 (C-Ar), 124.7 (C-
Ar), 124.8 (C-Ar), 127.4 (C-Ar), 161.6 (CO), 198.8 (CO); MS (ES+) m/z = 236.7 [M+H]
+
; 
HRMS calcd for C13H17NO3 [M-H]
- 
234.1136, found 234.1129. 
4-(Cyclohexanecarbonyl)-N-(pyridin-4-ylmethyl)-1H-pyrrole-2-carboxamide, 149 
 
General procedure D:  4-(cyclohexanecarbonyl)-1H-pyrrole-2-carboxylic acid (220 mg, 
1.01 mmol), CDI (330 mg, 2.03 mmol), and 4-picolylamine (0.26 mL, 2.53 mmol). 
Purification via column chromatography (silica; 0-8% MeOH/DCM) gave 149 as a white 
solid (188 mg, 60%). Rf 0.66 (95:5 EtOAc/MeOH); m.p. 235-236 ˚C; λmax (EtOH/nm) 397.5, 
276.0, 230.0; IR υmax/cm
-1 
3340, 3188, 3116, 2930, 2852, 1626, 1569; 
1
H NMR (500 MHz, 
DMSO-d6) δ ppm 1.18-1.24 (2H, m, CH-cyclohexane), 1.30-1.42 (4H, m, CH-cyclohexane), 
1.66-1.76 (4H, m, CH-cyclohexane), 3.01-3.05 (1H, m, CO-CH), 4.46 (2H, d,  J = 6.1 Hz, 
NH-CH2), 7.28-7.30 (3H, m,  H-3 and CH-pyridine), 7.66 (1H, br s, H-5), 8.50 (2H, d, J = 
6.0 Hz, N-CH-pyridine), 8.90 (1H, t, J = 6.1 Hz, CO-NH), 12.19 (1H, s, NH-pyrrole); 
13
C 
NMR (125 MHz, DMSO-d6) δ ppm 25.2 (C-cyclohexane), 25.6 (C-cyclohexane), 29.3 (C-
cyclohexane), 41.0 (NH-CH2), 46.1 (CO-C-cyclohexane), 109.9 (C-Ar), 122.1 (C-Ar), 124.6 
(C-Ar), 126.4 (C-Ar), 127.4 (C-Ar), 148.6 (C-Ar), 149.5 (C-Ar), 160.4 (CO), 198.3 (CO); 
MS (ES+) m/z = 312.2 [M+H]
+
; HRMS calcd for C18H21N3O2 [M+H]
+
 312.1707, found 
312.1702.  
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4-(Cyclopentanecarbonyl)-N-(pyridin-4-ylmethyl)-1H-pyrrole-2-carboxamide, 150 
 
General procedure D:  4-(cyclopentanecarbonyl)-1H-pyrrole-2-carboxylic acid (160 mg, 
0.75 mmol), CDI (240 mg, 1.50 mmol), and 4-picolylamine (0.19 mL, 1.88 mmol). 
Purification via column chromatography (silica; 0-8% MeOH/DCM) gave 150 as a white 
solid (140 mg, 63%). Rf 0.65 (95:5 EtOAc/MeOH); m.p. 245-246 ˚C; λmax (EtOH/nm) 275.0, 
229.5; IR υmax/cm
-1 
3346, 3182, 2948, 2867, 1625, 1572; 
1
H NMR (500 MHz, DMSO-d6) δ 
ppm 1.56-1.63 (4H, m, CH-cyclopentane), 1.68-1.74 (2H, m,  CH-cyclopentane), 1.80-1.87 
(2H, m, CH-cyclopentane), 3.49 (1H, quin, J = 7.9 Hz, CO-CH), 4.46 (2H, d, J = 5.9 Hz, 
NH-CH2), 7.29 (2H, d, J = 6.0 Hz, CH-pyridine), 7.31 (1H, d, J = 1.4 Hz, H-3), 7.65 (1H, d, J 
= 1.4 Hz, H-5), 8.51 (2H, d, J = 6.0 Hz, N-CH-pyridine), 8.90 (1H, t, J = 5.9 Hz, CO-NH), 
12.18 (1H, s, NH-pyrrole); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 25.9 (C-cyclopentane), 
29.7 (C-cyclopentane), 41.0 (NH-CH2), 46.8 (CO-C-cyclopentane), 109.9 (C-Ar), 122.1 (C-
Ar), 125.3 (C-Ar), 126.5 (C-Ar), 127.3 (C-Ar), 148.6 (C-Ar), 149.5 (C-Ar), 160.4 (CO), 
197.4 (CO); MS (ES+) m/z = 298.2 [M+H]
+
; HRMS calcd for C17H19N3O2 [M+H]
+
 298.1550, 
found 298.1553. 
4-(Cycloheptanecarbonyl)-N-(pyridin-4-ylmethyl)-1H-pyrrole-2-carboxamide, 151 
 
General procedure D:  4-(cycloheptanecarbonyl)-1H-pyrrole-2-carboxylic acid (130 mg, 
0.54 mmol), CDI (200 mg, 1.22 mmol) and 4-picolylamine (0.15 mL, 1.53 mmol). 
Purification via column chromatography (silica; 0-8% MeOH/DCM) gave 151 as a white 
solid (190 mg, 98%). Rf 0.65 (95:5 EtOAc/MeOH); m.p. 224-226 ˚C; λmax (EtOH/nm) 274.5, 
229.0; IR υmax/cm
-1 
3344, 3109, 2922, 2856, 1739, 1641; 
1
H NMR (500 MHz, DMSO-d6) δ 
ppm 1.51-1.63 (8H, m,  CH-cycloheptane), 1.68-1.72 (2H, m, CH-cycloheptane), 1.77-1.82 
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(2H, m,  CH-cycloheptane), 3.15-3.20 (1H, m, CO-CH), 4.46 (2H, d, J = 6.1 Hz, NH-CH2), 
7.28-7.30 (3H, m,  H-3 and CH-pyridine), 7.63 (1H, dd, J = 1.5 and 3.1 Hz, H-5), 8.51 (2H, 
d, J = 6.0 Hz, N-CH-pyridine), 8.89 (1H, t, J = 6.1 Hz, CO-NH), 12.17 (1H, s, NH-pyrrole); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 26.6 (C-cycloheptane), 28.0 (C-cycloheptane), 30.8 
(C-cycloheptane), 41.2 (NH-CH2), 47.5 (CO-C-cycloheptane), 110.4 (C-Ar), 122.2 (C-Ar), 
125.0 (C-Ar), 126.6 (C-Ar), 127.6 (C-Ar), 148.9 (C-Ar), 149.8 (C-Ar), 160.7 (CO), 199.1 
(CO); MS (ES+) m/z = 326.2 [M+H]
+
; HRMS calcd for C19H23N3O2 [M-H]
-
 324.1718, found 
324.1715. 
Methyl 4-((1S,2S)-2-methylcyclohexanecarbonyl)-1H-pyrrole-2-carboxylate and Methyl 
4-((1R,2R)-2-methylcyclohexanecarbonyl)-1H-pyrrole-2-carboxylate, 178/179 
 
General procedure E: 2-methylcyclohexane carboxylic acid (1.0 mL, 7.10 mmol), and 
SOCl2 (0.77 mL, 10.64 mmol) gave 2-methylcyclohexanecarbonyl chloride as a colourless oil 
which was used directly in the next step. General procedure F:  methyl 1H-pyrrole-2-
carboxylate (440 mg, 3.55 mmol), and AlCl3 (1.19 g, 8.88 mmol). Purification via column 
chromatography (silica; 0-50% EtOAc/petrol) gave a mixture of 178 and 179 as a white solid 
(517 mg, 59%). Rf 0.76 (EtOAc); m.p. 123-126 ˚C; λmax (EtOH/nm) 228.5; IR υmax/cm
-1 
3250, 
2921, 2861, 1707, 1639, 1554;  
1
H NMR (500 MHz, DMSO-d6) δ ppm 0.73 (3H, d, J = 7.1 
Hz, CH3), 1.26-1.72 (8H, m, CH-cyclohexane), 2.10-2.17 (1H, m, CH-cyclohexane), 3.27 
(1H, dt, J = 3.9 and 10.0 Hz, CO-CH), 3.80 (3H, s, O-CH3), 7.14 (1H, br s, H-3), 7.72 (1H, br 
s, H-5), 12.52 (1H, s, NH-pyrrole); 
13
C NMR (125 MHz, CDCl3) δ ppm 22.8 (CH3), 24.8, 
26.0, 32.3, 32.7, 34.7 (C-cyclohexane), 50.0 (CO-CH), 51.9 (O-CH3), 115.0 (C-Ar), 123.6 
(C-Ar), 126.2 (C-Ar), 126.8 (C-Ar), 161.4 (CO), 198.9 (CO); MS (ES+) m/z = 249.99 
[M+H]
+
; HRMS calcd for C14H19NO3 [M+H]
+
 250.1438, found 250.1437.   
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Methyl 5-((1R,2R)-2-methylcyclohexanecarbonyl)-1H-pyrrole-2-carboxylate and Methyl 
5-((1S,2S)-2-methylcyclohexanecarbonyl)-1H-pyrrole-2-carboxylate, 180/181 
 
General procedure E: 2-methylcyclohexane carboxylic acid (1.0 mL, 7.10 mmol), and 
SOCl2 (0.77 mL, 10.64 mmol gave 2-methylcyclohexane carbonyl chloride as a colourless oil 
which was used directly in the next step. General procedure F:  methyl 1H-pyrrole-2-
carboxylate (440 mg, 3.55 mmol), 2-methylcyclohexanecarbonyl chloride (1.14 g, 7.10 
mmol) and AlCl3 (1.19 g, 8.88 mmol). Purification via column chromatography (silica; 0-
50% EtOAc/petrol) gave a mixture of 180 and 181 as a white solid (182 mg, 21%). Rf 0.84 
(EtOAc); m.p. 127-130 
o
C; λmax (EtOH/nm) 220.5, 288.5; IR υmax/cm
-1
 3285, 2926, 2853, 
1708, 1655, 1545; 
1
H NMR (500 MHz, DMSO-d6) δ ppm 0.69 (3H, d, J = 7.1 Hz, CH3,), 
1.01-1.49 (8H, m, CH-cyclohexane), 1.89-1.91 (1H, m, CH-cyclohexane), 3.25 (1H, dt, J = 
3.9 and 10.0 Hz, CO-CH), 3.62 (3H, s, O-CH3),  6.65 (1H, dd, J = 1.5 and 3.9 Hz, H-3), 6.81 
(1H, d, J = 1.5 and 3.9 Hz, H-4), 11.76 (1H, s, NH-pyrrole); 13C NMR (125 MHz, DMSO- 
d6) δ ppm Innsufficient quantity of material retained to perform analysis; MS (ES+) m/z = 
250.0 [M+H]
+
.  
Methyl 4-((1R,3S)-3-methylcyclohexanecarbonyl)-1H-pyrrole-2-carboxylate and methyl 
4-((1S,3R)-3-Methylcyclohexanecarbonyl)-1H-pyrrole-2-carboxylate, 182/183 
 
General procedure E:  3-methylcyclohexane carboxylic acid (1.0 mL, 9.96 mmol), and 
SOCl2 (0.76 mL, 10.44 mmol) gave 3-methylcyclohexane carbonyl chloride as a colourless 
oil which was used directly in the next step. General procedure F:   methyl 1H-pyrrole-2-
carboxylate (440 mg, 3.48 mmol), and AlCl3 (1.17 g, 8.70 mmol). Purification via column 
chromatography (silica; 0-50% EtOAc/petrol) gave a mixture of 182 and 183 as a white solid 
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(456 mg, 53%). Rf 0.86 (1:1 EtOAc); m.p. 131-134 ˚C; λmax (EtOH/nm) 224.0, 273.5; IR 
υmax/cm
-1 
3208, 2926, 2851, 1712, 1642, 1556; 
1
H NMR (500 MHz, DMSO-d6) δ ppm 0.88 
(3H, d, J = 7.1 Hz, CH3), 1.16-1.89 (9H, m, CH-cyclohexane), 3.08-3.14 (1H, m, CO-CH), 
3.80 (3H, s, O-CH3), 7.15 (1H, br s, H-3), 7.76 (1H, br s, H-5), 12.55 (1H, s, NH-pyrrole); 
13
C NMR (125 MHz, CDCl3) δ ppm 22.7 (CH3), 25.8, 28.9, 32.4, 34.6, 37.7 (C-cyclohexane), 
47.7 (CO-CH), 51.9 (O-CH3), 115.1 (C-Ar), 123.7 (C-Ar), 126.4 (C-Ar), 126.5 (C-Ar), 161.4 
(CO), one CO not visualised; MS (ES+) m/z = 250.0 [M+H]
+
; HRMS calcd for C14H19NO3 
[M+H]
+
 250.1438, found 250.1437. 
Methyl 5-((1R,3S)-3-methylcyclohexanecarbonyl)-1H-pyrrole-2-carboxylate and  methyl 
5-((1S,3R)-3-Methylcyclohexanecarbonyl)-1H-pyrrole-2-carboxylate, 184/185 
 
General procedure E: 3-methylcyclohexanecarboxylic acid (1.0 mL, 9.96 mmol), and 
SOCl2 (0.76 mL, 10.44 mmol) gave 3-methylcyclohexane carbonyl chloride as a colourless 
oil which was used directly in the next step. General procedure F: methyl 1H-pyrrole-2-
carboxylate (440 mg, 3.48 mmol), and AlCl3 (1.17 g, 8.70 mmol). ). Purification via column 
chromatography (silica; 0-50% EtOAc/petrol) gave a mixture of 184 and 185 as a white solid 
(44 mg, 6%). Rf 0.74 (EtOAc); m.p. 135-137 
oC; λmax (EtOH/nm) 220.5, 287.5; IR υmax/cm
-1 
3290, 2924, 2855, 1707, 1656, 1546;  
1
H NMR (500 MHz, DMSO-d6) δ ppm 0.75 (3H, d, J = 
7.1 Hz, CH3), 1.17-1.91 (9H, m, CH-cyclohexane),  3.12 (1H, m, CO-CH), 3.67 (3H, s, O-
CH3), 6.71 (1H, d, J = 4.0 Hz, H-3), 6.89 (1H, d, J = 4.0 Hz, H-4), 11.86 (1H, s, NH-pyrrole); 
13
C NMR (125 MHz, DMSO-d6) δ ppm Insufficient quantity of material obtained to perform 
analysis; MS (ES+) m/z = 250.0 [M+H]
+
.  
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Methyl 4-(4-methylcyclohexanecarbonyl)-1H-pyrrole-2-carboxylate (cis/trans 1:4), 186 
 
General procedure E: 4-methylcyclohexanecarboxylic acid (0.69 g, 4.80 mmol), SOCl2 
(0.52 mL, 7.20 mmol) gave 4-methylcyclohexanecarbonyl chloride as a colourless oil which 
was used directly in the next step. General procedure F:  methyl 1H-pyrrole-2-carboxylate 
(300 mg, 2.40 mmol) and AlCl3 (0.80 g, 6.00 mmol). Purification via column 
chromatography (silica; 0-50% EtOAc/petrol) gave 186 as a white solid (350 mg, 59%). Rf 
0.32 (9:1 Petrol/EtOAc); m.p. 159-160 ˚C; λmax (EtOH/nm) 273.0, 224.0; IR υmax/cm
-1 
3330, 
3241, 2924, 2855, 1692, 1645, 1558, 1488; 
1
H NMR (500 MHz, DMSO-d6) δ ppm 0.72 (3H, 
d, J = 6.9 Hz, CH3), 1.15-1.56 (9H, m, CH-cyclohexane), 2.81 (0.2H, dddd, J = 3.2, 3.4 and 
11.8 and 12.0 Hz, CO-CH trans), 2.94-2.99 (0.8H, m, CO-CH cis), 3.61 (3H, s, O-CH3), 6.96 
(1H, br s, H-3), 7.55 (1H, br s, H-5), 12.34 (1H, s, NH-pyrrole); 
13
C NMR (125 MHz, 
DMSO-d6) δ ppm 22.6 (CH3), 25.2, 28.7, 29.2, 30.6, 31.8, 33.9 (C-cyclohexane cis and 
trans), 45.8 (CO-CH), 58.8 (O-CH3), 114.7 (C-Ar), 123.3 (C-Ar), 125.4 (C-Ar), 128.0 (C-
Ar), 160.6 (CO), 198.5 (CO); MS (ES+) m/z = 250.1 [M+H]
+
; HRMS calcd for C14H19NO3 
[M+H]
+
 250.1438, found 250.1436. 
4-((1R,2R)-2-Methylcyclohexanecarbonyl)-1H-pyrrole-2-carboxylic acid and 4-((1S,2S)-
2-Methylcyclohexanecarbonyl)-1H-pyrrole-2-carboxylic acid, 187/188 
 
General procedure G: methyl 4-((1S,2S)-2-methylcyclohexanecarbonyl)-1H-pyrrole-2-
carboxylate and methyl 4-((1R,2R)-2-methylcyclohexanecarbonyl)-1H-pyrrole-2-carboxylate 
(500 mg, 2.00 mmol) and LiOH monohydrate (1.68 g, 40.0 mmol) gave a mixture of 187 and 
188 as an off-white solid (380 mg, 81%). Rf 0.24 (8:2 DCM/MeOH); m.p. 188-189 ˚C; λmax 
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(EtOH/nm) 227.0, 273.5; IR υmax/cm
-1 
3201, 2924, 1642, 1557; 
1
H NMR (500 MHz, DMSO-
d6) δ ppm 0.73 (3H, d, J = 7.1 Hz, CH3), 1.06-1.71 (9H, m,  CH-cyclohexane), 2.76-2.81 (1H, 
m, CO-CH), 7.09 (1H, br s, H-3), 7.73 (1H, dd, J = 1.6 and 3.3 Hz, H-5), 12.38 (1H, s, NH-
pyrrole), 12.72 (1H, s, COOH); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 20.5 (CH3), 25.2, 
25.7, 30.4, 33.5, 33.9 (C-cyclohexane), 52.6 (CO-CH), 113.9 (C-Ar), 124.8 (C-Ar), 126.4 (C-
Ar), 127.6 (C-Ar), 161.6 (CO), 198.6 (CO); MS (ES+) m/z = 236.0 [M+H]
+
; HRMS calcd for 
C13H17NO3 [M-H]
-
 234.1136, found 234.1131.  
5-((1R,2R)-2-Methylcyclohexanecarbonyl)-1H-pyrrole-2-carboxylic acid and 5-((1S,2S)-
2-Methylcyclohexanecarbonyl)-1H-pyrrole-2-carboxylic acid, 196/197 
 
General procedure G: methyl 5-((1R,2R)-2-methylcyclohexanecarbonyl)-1H-pyrrole-2-
carboxylate and methyl 5-((1S,2S)-2-methylcyclohexanecarbonyl)-1H-pyrrole-2-carboxylate 
(170 mg, 0.68 mmol) and LiOH monohydrate (570 mg, 13.65 mmol) gave a mixture of 196 
and 197 as an off-white solid (120 mg, 75%). Rf 0.20 (8:2 DCM/MeOH); m.p. 177-179 ˚C; 
λmax (EtOH/nm) 219.0, 295.5; IR υmax/cm
-1 
3264, 2923, 2857, 1685, 1648, 1543; 
1
H NMR 
(500 MHz, DMSO-d6) δ ppm 0.74 (3H, d, J = 7.1 Hz, CH3), 1.05-1.75 (9H, m, CH-
cyclohexane), 2.92-2.97 (1H, m, CO-CH), 6.78 (1H, d, J = 1.9 and 3.8 Hz, H-3), 7.03 (1H, d, 
J = 1.9 and 3.8 Hz H-4), 12.15 (1H, s, NH-pyrrole), 12.91 (1H, s, COOH); 13C NMR (125 
MHz, DMSO-d6) δ ppm Insufficient quantity of material retained to perform analysis; MS 
(ES+) m/z = 236.0 [M+H]
+
; HRMS calcd for C13H17NO3 [M-H]
- 
234.1136, found 234.1129. 
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4-((1R,3S)-3-Methylcyclohexanecarbonyl)-1H-pyrrole-2-carboxylic acid and 4-((1S,3R)-
3-Methylcyclohexanecarbonyl)-1H-pyrrole-2-carboxylic acid, 191/192 
 
General procedure G: methyl 4-((1R,3S)-3-methylcyclohexanecarbonyl)-1H-pyrrole-2-
carboxylate and methyl 4-((1S,3R)-3-methylcyclohexanecarbonyl)-1H-pyrrole-2-carboxylate 
(430 mg, 1.71 mmol) and LiOH monohydrate (1.44 g, 34.20 mmol) gave a mixture of 191 
and 192 as an off-white solid (340 mg, 85%). Rf 0.24 (8:2 DCM/MeOH); m.p. 189-191 ˚C; 
λmax (EtOH/nm) 226.0, 273.0; IR υmax/cm
-1 
3200, 2924, 2850, 1671, 1642, 1558; 
1
H NMR 
(500 MHz, DMSO-d6) δ ppm 0.88 (3H, d, J = 7.1 Hz, CH3), 1.17-1.76 (9H, m, CH-
cyclohexane), 3.09 (1H, tt, J = 3.1 and 12.0 Hz, CO-CH), 7.08 (1H, br s, H-3), 7.70 (1H, dd, 
J = 1.6 and 3.2 Hz, H-5), 12.36 (1H, s, NH-pyrrole), 12.72 (1H, s, COOH); 
13
C NMR (125 
MHz, DMSO-d6) δ ppm 22.7 (CH3), 25.0, 28.8, 31.4, 34.3, 37.7 (C-cyclohexane), 46.0 (CO-
CH), 113.9 (C-Ar), 124.9 (C-Ar), 127.2 (C-Ar), 127.4 (C-Ar), 161.7 (CO), 198.1 (CO); MS 
(ES+) m/z = 236.0 [M+H]
+
; HRMS calcd for C13H17NO3 [M-H]
- 
234.1136, found 234.1129. 
5-((1R,3S)-3-Methylcyclohexanecarbonyl)-1H-pyrrole-2-carboxylic acid and  5-((1S,3R)-
3-Methylcyclohexanecarbonyl)-1H-pyrrole-2-carboxylic acid 200/201 
 
General procedure G: methyl 5-((1R,3S)-3-methylcyclohexanecarbonyl)-1H-pyrrole-2-
carboxylate and methyl 5-((1S,3R)-3-methylcyclohexanecarbonyl)-1H-pyrrole-2-carboxylate 
(40 mg, 0.14 mmol) and LiOH monohydrate (120 mg, 2.89 mmol) gave a mixture of 200 and 
201 as an off-white solid (30 mg, 86%). Rf 0.20 (8:2 DCM/MeOH); m.p. 178-180 ˚C; λmax 
(EtOH/nm) 219.5, 289.5; IR υmax/cm
-1 
3263, 2922, 2852, 1683, 1547;  
1
H NMR (500 MHz, 
DMSO-d6) δ ppm 0.89 (3H, d, J = 7.1 Hz, CH3), 1.18-1.76 (9H, m, CH-cyclohexane), 3.25 
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(1H, tt, J = 3.2 and 11.9 Hz, CO-CH), 6.78 (1H, dd, J = 2.3 and 3.9 Hz, H-3), 7.00 (1H, dd, J 
= 2.3 and 3.9 Hz, H-4), 12.18 (1H, s, NH-pyrrole), 12.88 (1H, s, COOH); MS (ES+) m/z = 
236.0 [M+H]
+
; HRMS calcd for C13H17NO3 [M-H]
-
 234.1136, found 234.1131.    
4-(4-Methylcyclohexanecarbonyl)-1H-pyrrole-2-carboxylic acid (cis/trans 2:3), 195 
 
General procedure G:  methyl 4-(4-methylcyclohexanecarbonyl)-1H-pyrrole-2-carboxylate 
(319 mg, 1.28 mmol) and LiOH monohydrate (1.08 g, 25.62 mmol) gave 195 as an off-white 
solid (294 mg, 98%). Rf 0.22 (9:1 Petrol/EtOAc); m.p. 201-202 ˚C; λmax (EtOH/nm) 224.0; 
IR υmax/cm
-1 
3331, 2918, 2857, 1646, 1558, 1501, 1451; 
1
H NMR (500 MHz, DMSO-d6) δ 
ppm 0.94-0.97 (3H, m, CH3), 1.08-1.16 (1H, m, CH-cyclohexane), 1.33-1.45 (2H, m, CH-
cyclohexane), 1.56-1.65 (2H, m, CH-cyclohexane), 1.75-1.80 (4H, m, CH-cyclohexane), 3.05 
(0.6H, ddd, J = 3.2, 3.4 and 11.8 and 12.0 Hz, CO-CH trans), 3.16-3.22 (0.4H, m, CO-CH 
cis), 7.12-7.13 (1H, m, H-3), 7.70-7.75 (1H, m, H-5), 12.40 (1H, s, NH-pyrrole), 12.74 (1H, 
s, COOH); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 22.6 (CH3), 25.2, 28.6, 29.3, 30.6, 31.7, 
33.9 (C-cyclohexane cis and trans), 45.7 (CO-CH), 114.1 (C-Ar), 124.7 (C-Ar), 125.2 (C-
Ar), 127.6 (C-Ar), 161.8 (CO), 200.0 (CO); MS (ES+) m/z = 236.0 [M+H]
+
; HRMS calcd for 
C13H17NO3 [M+H]
+
 236.1281, found 236.1283. 
4-((1R,2R)-2-Methylcyclohexanecarbonyl)-N-(pyridin-4-ylmethyl)-1H-pyrrole-2-
carboxamide and 4-((1S,2S)-2-Methylcyclohexanecarbonyl)-N-(pyridin-4-ylmethyl)-1H-
pyrrole-2-carboxamide, 189/190 
 
General procedure D: 4-((1R,2R)-2-methylcyclohexanecarbonyl)-1H-pyrrole-2-carboxylic 
acid and 4-((1S,2S)-2-methylcyclohexanecarbonyl)-1H-pyrrole-2-carboxylic acid (110 mg, 
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0.45 mmol), CDI (150 mg, 0.90 mmol), and 4-picolylamine (0.11 mL, 1.13 mmol). 
Purification via column chromatography (silica; 0-5% MeOH/DCM) gave 189 and 190 as a 
white solid (110 mg, 76%). Rf 0.62 (95:5 EtOAc/MeOH); m.p. 218-220 ˚C; λmax (EtOH/nm) 
275.0, 230.0; IR υmax/cm
-1 
3334, 3175, 2924, 2856, 1626, 1571; 
1
H NMR (500 MHz, DMSO-
d6) δ ppm 0.74 (3H, d, J = 6.9 Hz, CH3), 1.03-1.10 (1H, m, CH-cyclohexane), 1.28-1.74 (8H, 
m, CH-cyclohexane), 2.72-2.77 (1H, m, CO-CH), 4.46 (2H, d, J = 6.1 Hz, NH-CH2), 7.29-
7.31 (3H, m, H-3 and CH-pyridine), 7.70 (1H, br s, H-5), 8.51 (2H, d, J = 6.0 Hz, N-CH-
pyridine), 8.88 (1H, t, J = 6.1 Hz, CO-NH), 12.19 (1H, s, NH-pyrrole); 
13
C NMR (125 MHz, 
DMSO-d6) δ ppm 20.6 (CH3), 25.3 (C-cyclohexane), 25.8 (C-cyclohexane), 30.5 (C-
cyclohexane), 33.5 (C-cyclohexane), 34.0 (C-cyclohexane), 41.0 (NH-CH2), 52.8 (CO-C-
cyclohexane),109.9 (C-Ar), 122.3 (C-Ar), 126.2 (C-Ar), 126.6 (C-Ar), 127.6 (C-Ar), 149.0 
(C-Ar), 149.7 (C-Ar), 160.6 (CO), 198.7 (CO); MS (ES+) m/z = 326.1 [M+H]
+
; HRMS calcd 
for C19H23N3O2 [M+H]
+
 326.1863, found 326.1859. 
5-((1R,2R)-2-Methylcyclohexanecarbonyl)-N-(pyridin-4-ylmethyl)-1H-pyrrole-2-
carboxamide and 5-((1S,2S)-2-Methylcyclohexanecarbonyl)-N-(pyridin-4-ylmethyl)-1H-
pyrrole-2-carboxamide, 198/199 
 
General procedure D: 5-((1R,2R)-2-methylcyclohexanecarbonyl)-1H-pyrrole-2-carboxylic 
acid and 5-((1S,2S)-2-methylcyclohexanecarbonyl)-1H-pyrrole-2-carboxylic acid (40 mg, 
0.18 mmol), CDI (60 mg, 0.36 mmol), and 4-picolylamine (0.09 mL, 0.90 mmol). 
Purification via column chromatography (silica; 0-5% MeOH/DCM) gave 198 and 199 as a 
white solid (50 mg, 83%). Rf 0.65 (95:5 EtOAc/MeOH); m.p. 197-200 ˚C; λmax (EtOH/nm) 
293.5, 220.0; IR υmax/cm
-1 
3285, 2923, 2850, 1652, 1647; 
1
H NMR (500 MHz, DMSO-d6) δ 
ppm 0.75 (3H, d, J = 6.4 Hz, CH3), 1.04-1.11 (1H, m, CH-cyclohexane), 1.26-1.72 (8H, m, 
CH-cyclohexane), 2.86-2.92 (1H, m, CO-CH), 4.49 (2H, d, J = 5.9 Hz, NH-CH2), 6.85 (1H, 
d, J = 3.9 Hz, H-3), 7.08 (1H, d, J = 3.9 Hz, H-4), 7.10 (2H, d, J = 6.0 Hz CH-pyridine), 8.30 
(2H, d, J = 6.0 Hz, N-CH-pyridine), 8.77 (1H, t, J = 5.9 Hz, CO-NH), 11.73 (1H, s, NH-
pyrrole); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 20.5 (CH3), 25.2 (C-cyclohexane), 25.6 (C-
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cyclohexane), 30.5 (C-cyclohexane), 33.6 (C-cyclohexane), 34.0 (C-cyclohexane), 41.3 (NH-
CH2), 51.7 (CO-CH), 112.9 (C-Ar), 116.0 (C-Ar), 122.2 (C-Ar), 131.5 (C-Ar), 133.8 (C-Ar), 
148.2 (C-Ar), 149.6 (C-Ar), 159.6 (CO), 194.5 (CO); MS (ES+) m/z = 326.13 [M+H]
+
; 
HRMS calcd for C19H23N3O2 [M+H]
+
 326.1863, found 326.1861. 
4-((1R,3S)-3-Methylcyclohexanecarbonyl)-N-(pyridin-4-ylmethyl)-1H-pyrrole-2-
carboxamide and  4-((1S,3R)-3-Methylcyclohexanecarbonyl)-N-(pyridin-4-ylmethyl)-
1H-pyrrole-2-carboxamide, 193/194 
 
General procedure D: 4-((1R,3S)-3-methylcyclohexanecarbonyl)-1H-pyrrole-2-carboxylic 
acid and 4-((1S,3R)-3-methylcyclohexanecarbonyl)-1H-pyrrole-2-carboxylic acid (80 mg, 
0.35 mmol), CDI (110 mg, 0.70 mmol), and 4-picolylamine (0.085 mL, 0.88 mmol). 
Purification via column chromatography (silica; 0-5% MeOH/DCM) gave 193 and 194 as a 
white solid (100 mg, 89%). Rf 0.62 (95:5 EtOAc/MeOH); m.p. 222-224 ˚C; λmax (EtOH/nm) 
276.5, 229.5; IR υmax/cm
-1 
3341, 3200, 2926, 2856, 1627, 1573;  
1
H NMR (500 MHz, 
DMSO-d6) δ ppm 0.69 (3H, d, J = 6.5 Hz, CH3), 0.76-0.83 (1H, m, CH-cyclohexane), 1.03-
1.56 (8H, m, CH-cyclohexane), 2.86 (1H, tt, J = 2.9 and 11.9 Hz, CO-CH), 4.25 (2H, d, J = 
5.9 Hz, NH-CH2), 7.08-7.10 (3H, m, CH-pyridine and H-3), 7.46 (1H, br s, H-5), 8.30 (2H, d, 
J = 6.0 Hz, N-CH-pyridine), 8.68 (1H, t, J = 5.9 Hz, CO-NH), 11.98 (1H, s, NH-pyrrole); 
13
C 
NMR (125 MHz, DMSO-d6) δ ppm 22.7 (CH3), 25.2 (C-cyclohexane), 28.9 (C-cyclohexane), 
31.5 (C-cyclohexane), 34.3 (C-cyclohexane), 37.8 (C-cyclohexane), 41.0 (CO-CH), 46.1 
(NH-CH2), 109.9 (C-Ar), 122.1 (C-Ar), 124.6 (C-Ar), 126.4 (C-Ar), 127.4 (C-Ar), 148.6 (C-
Ar), 149.5 (C-Ar), 160.4 (CO), 195.6 (CO); MS (ES+) m/z = 326.14 [M+H]
+
; HRMS calcd 
for C19H23N3O2 [M+H]
+
 326.1863, found 326.1861. 
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5-((1R,3S)-3-Methylcyclohexanecarbonyl)-N-(pyridin-4-ylmethyl)-1H-pyrrole-2-
carboxamide and 5-((1S,3R)-3-Methylcyclohexanecarbonyl)-N-(pyridin-4-ylmethyl)-1H-
pyrrole-2-carboxamide, 202/203 
 
General procedure D: 5-((1R,3S)-3-methylcyclohexanecarbonyl)-1H-pyrrole-2-carboxylic 
acid and 5-((1S,3R)-3-methylcyclohexanecarbonyl)-1H-pyrrole-2-carboxylic acid (10 mg, 
0.04 mmol), CDI (14 mg, 0.09 mmol), and 4-picolylamine (0.01 mL, 0.11 mmol). 
Purification via column chromatography (silica; 0-5% MeOH/DCM) gave 202 and 203 as a 
white solid (11 mg, 79%). Rf 0.64 (95:5 EtOAc/MeOH); m.p. 198-200 ˚C; λmax (EtOH/nm) 
291.0, 221.5; IR υmax/cm
-1 
3275, 2922, 2848, 1653, 1649; 
1H NMR (500 MHz, MeOD) δ ppm 
0.80 (3H, d, J = 6.5 Hz, CH3), 0.95-1.73 (9H, m, CH-cyclohexane), 3.03 (1H, tt, J = 3.1 and 
11.9 Hz, CO-CH), 4.47 (2H, s, NH-CH2), 6.76 (1H, d, J = 4.0 Hz, H-3), 6.90 (1H, d, J = 4.0 
Hz, H-4), 7.26 (2H, d, J = 6.0 Hz, CH-pyridine), 8.34 (2H, d, J = 6.0 Hz, N-CH-pyridine); 
13C NMR (125 MHz, MeOD) δ ppm Insufficient quantity of material obtained to perform 
analysis; MS (ES+) m/z = 326.1 [M+H]
+
; HRMS calcd for C19H23N3O2 [M+H]
+
 326.1863, 
found 326.1857. 
4-(4-Methylcyclohexanecarbonyl)-N-(pyridin-4-ylmethyl)-1H-pyrrole-2-carboxamide 
(cis/trans 2:3), 154 
 
General procedure D:  4-(4-methylcyclohexanecarbonyl)-1H-pyrrole-2-carboxylic acid (80 
mg, 0.34 mmol), CDI (110 mg, 0.68 mmol) and 4-picolylamine (90 μL, 0.85 mmol). 
Recrystallisation (9:1 EtOAc/petrol) gave 154 as a white solid (75 mg, 68%). Rf 0.31 (9:1 
DCM/MeOH); m.p. 217-219 ˚C; λmax (EtOH/nm) 228.5, 275.0; IR υmax/cm
-1 
3336, 3113, 
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3047, 2915, 2850, 1738, 1640, 1606, 1569; 
1
H NMR (500 MHz, DMSO-d6) δ ppm 0.95-0.98 
(3H, m, CH3), 0.79-087 (2H, m, CH-cyclohexane), 1.10-1.19 (3H, m, CH-cyclohexane), 
1.30-1.53 (4H, m, CH-cyclohexane), 2.73 (0.6H, ddd, J = 3.2, 3.4 and 11.8 and 12.0 Hz  CO-
CH trans), 2.86-2.91 (0.4H, m, CO-CH cis), 4.23 (2H, d, J = 6.0 Hz, NH-CH2), 7.06-7.08 
(3H, m, H-3 and CH-pyridine), 7.41 (1H, br s, H-5), 8.28 (2H, d, J = 6.0 Hz, N-CH-pyridine), 
8.66 (1H, t, J = 6 Hz, CO-NH), 11.95 (1H, s, NH-pyrrole); 
13
C NMR (125 MHz, DMSO-d6) δ 
ppm 22.6 (CH3), 25.2, 28.5, 29.3, 30.8, 31.8, 34.0 (C-cyclohexane cis and trans), 41.1 (NH-
CH2), 45.9 (CO-CH), 109.9 (C-Ar), 122.1 (C-Ar), 126.4 (C-Ar), 148.6 (C-Ar), 149.5 (C-Ar), 
160.4 (CO), 200.0 (CO); MS (ES+) m/z = 326.1 [M+H]
+ 
; HRMS calcd for C19H23N3O2 
[M+H]
+ 
326.1863, found 326.1866. 
Methyl 4-(4-methoxycyclohexanecarbonyl)-1H-pyrrole-2-carboxylate (cis/trans ratio 
unknown), 204 
 
General procedure E: 4-methoxycyclohexanecarboxylic acid (1.01 g, 6.40 mmol), SOCl2 
(0.70 mL, 9.60 mmol) gave 4-methoxycyclohexanecarbonyl chloride which was used directly 
in the next step General procedure F: methyl 1H-pyrrole-2-carboxylate (400 mg, 3.20 
mmol), and AlCl3 (1.07 g, 8.00 mmol). Purification via column chromatography (silica; 0-
50% EtOAc/petrol) gave 204 as a white solid (240 mg, 28%). Rf 0.37 (9:1 petrol/EtOAc); 
m.p. 133-134 ˚C; λmax (EtOH/nm) 272.5, 225.5; IR υmax/cm
-1
 3281, 3112, 2932, 1686, 1652, 
1560; 
1
H NMR (500 MHz, DMSO-d6) δ ppm 1.09-1.29 (4H, m, CH-cyclohexane), 1.65-1.68 
(2H, m, CH-cyclohexane), 1.89-1.92 (2H, m, CH-cyclohexane), 2.90-2.99 (2H, m, CO-CH 
and CH-O-CH3), 3.12 (3H, s, O-CH3), 3.67 (3H, s, COO-CH3), 7.03 (1H, br s, H-3), 7.66 
(1H, br s, H-5), 12.44 (1H, s, NH-pyrrole). 
13
C NMR (125 MHz, DMSO-d6) δ ppm 27.4 (C-
cyclohexane), 30.7 (C-cyclohexane), 45.2 (CO-CH), 51.5 (O-CH3), 57.1 (COO-CH3), 78.1 
(C-O-CH3), 114.4 (C-Ar), 123.5 (C-Ar), 125.1 (C-Ar), 128.2 (C-Ar), 160.5 (CO), 200.0 
(CO); MS (ES+) m/z = 266.3 [M+H]
+
; HRMS calcd for C14H19NO4 [M+H]
+
 266.1387, found 
266.1390. 
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4-(4-Methoxycyclohexanecarbonyl)-1H-pyrrole-2-carboxylic acid (cis/trans 7:3), 205 
 
General procedure G: methyl 4-(4-methoxycyclohexanecarbonyl)-1H-pyrrole-2-
carboxylate (219 mg, 0.83 mmol) and LiOH monohydrate (0.70 g, 16.60 mmol) gave 205 as 
an off-white solid (203 mg, 97%). Rf 0.20 (9:1 petrol/EtOAc); m.p. 175-176 ˚C; λmax 
(EtOH/nm) 273.0, 226.5; IR υmax/cm
-1
 3265, 2938, 2865, 1681, 1645, 1557, 1498, 1437; 
1
H 
NMR (500 MHz, DMSO-d6) δ ppm 1.22-1.67 (5H, m, CH-cyclohexane), 1.76-1.89 (2H, m, 
CH-cyclohexane), 2.02-2.06 (1H, m, CH-cyclohexane), 3.01-3.14 (2H, m, CO-CH and CH-
O-CH3), 3.21-3.25 (3H, m, O-CH3 cis and trans), 7.08 (1H, br s, H-3), 7.71 (1H, br s, H-5), 
12.37 (1H, s, NH-pyrrole), 12.70 (1H, s, COOH); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 
27.6 (C-cyclohexane), 30.9 (C-cyclohexane), 45.3 (CO-CH), 55.0 (C-O-CH3), 78.4 (O-CH3), 
114.3 (C-Ar), 123.1 (C-Ar), 125.0 (C-Ar), 127.8 (C-Ar), 161.8 (CO), 200.0 (CO); MS (ES+) 
m/z = 252.1 [M+H]
+
;
 
HRMS calcd for C13H17NO4 [M-H]
- 
250.1085, found 250.1078. 
4-(4-Methoxycyclohexanecarbonyl)-N-(pyridin-4-ylmethyl)-1H-pyrrole-2-carboxamide 
(cis/trans 75:25), 155 
 
General procedure D: 4-(4-methoxycyclohexanecarbonyl)-1H-pyrrole-2-carboxylic acid 
(136 mg, 0.54 mmol), CDI (174 mg, 1.08 mmol), and 4-picolylamine (130 μL, 1.35 mmol). 
Purification via column chromatography (silica; 0-8% MeOH/DCM) gave 155 as a white 
solid (112 mg, 61%). Rf 0.35 (9:1 DCM/MeOH); m.p. 198-199 ˚C; λmax (EtOH/nm) 229.0, 
275.5; IR υmax/cm
-1 
3341, 3114, 2930, 2857, 1635, 1606, 1569, 1528; 
1
H NMR (500 MHz, 
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DMSO-d6) δ ppm 1.23-1.54 (4H, m CH-cyclohexane), 1.61-1.92 (3H, m CH-cyclohexane), 
2.04-2.07 (1H, m, CH-cyclohexane), 3.00 (0.75H, dddd, J = 3.2, 3.4, 11.8 and 12.0 Hz, CO-
CH trans), 3.05-3.13 (1.25H, m, CO-CH cis and CH-O-CH3), 3.21 (0.75H, s, O-CH3 cis), 
3.25 (2.25H, s, O-CH3 trans), 4.46 (2H, d, J = 6.0 Hz, NH-CH2), 7.28-7.31 (3H, m, H-3 and 
CH-pyridine), 7.68 (0.25H, dd, J = 1.6 and 3.2 Hz, H-5 cis), 7.71 (0.75H, dd, J =  1.6 and 3.2 
Hz, H-5 trans,), 8.50 (2H, d, J = 6.0 Hz, N-CH-pyridine), 8.90 (1H, t, J = 6.0 Hz, CO-NH), 
12.21 (1H, s, NH-pyrrole); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 26.9 (C-cyclohexane), 
30.8 (C-cyclohexane), 41.1 (NH-CH2), 45.3 (CO-CH), 54.9 (O-CH3), 78.1 (C-OCH3), 109.8 
(C-Ar), 122.1 (C-Ar), 126.6 (C-Ar), 127.5 (C-Ar), 148.6 (C-Ar), 149.5 (C-Ar), 160.4 (CO), 
200.0 (CO); MS (ES+) m/z = 342.3 [M+H]
+
; HRMS calcd for C19H23N3O3 [M+H]
+ 
342.1812, 
found 342.1815. 
cis Methyl 4-(3-hydroxycyclohexanecarbonyl)-1H-pyrrole-2-carboxylate, 206 
 
General procedure E: 3-methoxycyclohexanecarboxylic acid (1.01 g, 6.40 mmol), SOCl2 
(0.70 mL, 9.60 mmol) gave 3-methoxycyclohexanecarbonyl chloride which was used directly 
in the next step. General procedure F: methyl 1H-pyrrole-2-carboxylate (400 mg, 3.20 
mmol), and AlCl3 (1.07 g, 8.00 mmol). Purification via column chromatography (silica; 30-
100% EtOAc/petrol) gave 206 as a white solid (305 mg, 48%). Rf 0.31 (2:8 petrol/EtOAc); 
m.p. 168-169 ˚C; λmax (EtOH/nm) 274.0, 220.5; IR υmax/cm
-1 
3421, 3123, 2923, 2859, 1707, 
1644, 1559; 
1
H NMR (500 MHz, DMSO-d6) δ ppm 0.87-1.08 (3H, m, CH-cyclohexane), 
1.21-1.30 (1H, m, CH-cyclohexane), 1.50-1.76 (4H, m, CH-cyclohexane), 2.96-3.05 (1H, m, 
CO-CH), 3.37-3.43 (1H, m, CH-OH), 3.66 (3H, s, O-CH3), 4.44 (1H, d, J = 4.6 Hz, OH), 
7.01 (1H, d, J = 1.6 Hz, H-3), 7.62 (1H, d, J = 1.6 Hz, H-5), 12.42 (1H, s, NH-pyrrole); 
13
C 
NMR (125 MHz, DMSO-d6) δ ppm 23.3 (C-cyclohexane), 28.4 (C-cyclohexane), 35.2 (C-
cyclohexane), 38.6 (C-cyclohexane), 45.1 (C-cyclohexane), 51.7 (CO-CH), 68.5 (C-OH), 
114.5 (C-Ar), 123.4 (C-Ar), 124.9 (C-Ar), 128.1 (C-Ar),160.5 (CO), 197.2 (CO); MS (ES+) 
m/z = 252.3 [M+H]
+
; HRMS calcd for C13H17NO4 [M+H]
+ 
252.1230, found 252.1228. 
 
263 
 
cis Methyl 4-(3-((triisopropylsilyl)oxy)cyclohexanecarbonyl)-1H-pyrrole-2-carboxylate, 
207 
 
To a suspension of methyl 4-(3-hydroxycyclohexanecarbonyl)-1H-pyrrole-2-carboxylate 
(480 mg, 1.91 mmol) in DCM (8 mL) was added TIPS chloride (0.82 mL, 3.82 mmol) and 
imidazole (390 mg, 5.73 mmol). The resulting solution was stirred for 16 h at RT. The 
reaction was quenched with water, and the mixture extracted with EtOAc (3 x 30 mL). 
Combined organic layers were washed with brine, dried over Na2SO4 and concentrated in 
vacuo. Purification via column chromatography (silica; 0-30% EtOAc/petrol) gave 207 as a 
yellow oil (0.72 g, 93%). Rf 0.32 (8:2 petrol/EtOAc); λmax (EtOH/nm) 275.0, 247.0, 223.5; IR 
υmax/cm
-1 
3304, 3125, 2939, 2864, 1700, 1650, 1561, 1445; 
1
H NMR (500 MHz, CDCl3) δ 
ppm 0.97-0.98 (21H, s, TIPS-CH and TIPS-CH3), 1.22-1.37 (3H, m, CH-cyclohexane), 1.45-
1.52 (1H, m, CH-cyclohexane), 1.73-1.94 (3H, m, CH-cyclohexane), 2.00-2.04 (1H, m, CH-
cyclohexane), 2.85-2.91 (1H, m, CO-CH), 3.67-3.73 (1H, m, CH-OSi), 3.82 (3H, s, O-CH3), 
7.20 (1H, dd, J = 1.6 and 2.4 Hz, H-3), 7.47 (1H, dd, J = 1.6 and 3.2 Hz, H-5), 9.43 (1H, s, 
NH-pyrrole); 
13
C NMR (125 MHz, CDCl3) δ ppm 12.4 (TIPS-CH), 18.1 (TIPS-CH3), 24.2 
(C-cyclohexane), 28.6 (C-cyclohexane), 36.0 (C-cyclohexane), 38.7 (C-cyclohexane), 46.4 
(CO-CH), 51.9 (O-CH3), 71.8 (CH-OSi), 114.9 (C-Ar), 123.9 (C-Ar), 126.2 (C-Ar), 161.2 
(CO), 197.6 (CO); MS (ES+) m/z = 408.3 [M+H]
+
;
 
HRMS calcd for C22H37NO4Si [M+H]
+
 
408.2565, found 408.2566.    
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cis 4-(3-((Triisopropylsilyl)oxy)cyclohexanecarbonyl)-1H-pyrrole-2-carboxylic acid, 208 
 
General procedure G: methyl 4-(3-((triisopropylsilyl)oxy)cyclohexanecarbonyl)-1H-
pyrrole-2-carboxylate (0.71 g, 1.74 mmol) and LiOH monohydrate (110 mg, 2.61 mmol) 
gave 208 as an off-white solid (0.55 g, 80%). Rf 0.22 (8:2 petrol/EtOAc); m.p. 157-159 ˚C; 
λmax (EtOH/nm) 280.0, 218.5; IR υmax/cm
-1 
3268, 2940, 2864, 1649, 1556; 
1
H NMR (500 
MHz, DMSO-d6) δ ppm 0.79-0.80 (21H, m, TIPS-CH and TIPS-CH3), 0.91-0.99 (2H, m, 
CH-cyclohexane), 1.03-1.10 (1H, m, CH-cyclohexane), 1.16-1.25 (1H, m, CH-cyclohexane), 
1.42-1.54 (2H, m, CH-cyclohexane), 1.66-1.71 (2H, m, CH-cyclohexane), 2.96 (1H, dddd, J 
= 3.2, 3.4 and 11.8 and 12 Hz, CO-CH), 3.58-3.64 (1H, m, CH-OSi), 6.86 (1H, dd, J = 1.6 
and 2.4 Hz, H-3), 7.48 (1H, dd, J = 1.6 and 3.3 Hz, H-5), 12.14 (1H, s, NH-pyrrole), 12.47 
(1H, s, COOH); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 11.8 (TIPS-CH), 17.9 (TIPS-CH3), 
23.4 (C-cyclohexane), 28.4 (C-cyclohexane), 35.8 (C-cyclohexane), 38.9 (C-cyclohexane), 
44.6 (CO-CH), 70.4 (C-OSi), 114.1 (C-Ar), 124.7 (C-Ar), 124.8 (C-Ar), 127.6 (C-Ar), 161.6 
(CO), 193.9 (CO); MS (ES+) m/z = 394.3 [M+H]
+
; HRMS calcd for C21H35NO4Si [M+H]
+
 
394.2408, found 394.2410. 
cis N-(Pyridin-4-ylmethyl)-4-(3-((triisopropylsilyl)oxy)cyclohexanecarbonyl)-1H-
pyrrole-2-carboxamide, 209 
 
General procedure D: 4-(3-((triisopropylsilyl)oxy)cyclohexanecarbonyl)-1H-pyrrole-2-
carboxylic acid (390 mg, 0.99 mmol), CDI (321 mg, 1.98 mmol), and 4-picolylamine (240 
μL, 2.48 mmol). Purification via column chromatography (silica; 0-5% MeOH/DCM) gave 
209 as a white solid (256 mg, 54%). Rf 0.36 (9:1 DCM/MeOH); m.p. 190-191 ˚C; λmax 
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(EtOH/nm) 275.5, 229.0; IR  
υmax/cm
-1 
3334, 3202, 2939, 2864 1630, 1574, 1537; 
1
H NMR (500 MHz, DMSO-d6) δ ppm 
0.78-0.80 (21H, m, TIPS-CH and TIPS-CH3), 0.90-0.99 (2H, m, CH-cyclohexane), 1.05-1.22 
(2H, m, CH-cyclohexane), 1.43-1.55 (2H, m, CH-cyclohexane), 1.67-1.69 (2H, m, CH-
cyclohexane), 2.91 (1H, dddd, J = 3.2, 3.4, 11.8 and 12.0 Hz, CO-CH), 3.55-3.61 (1H, m, 
CH-OSi), 4.21 (2H, d, J = 6.2 Hz, NH-CH2), 7.04-7.05 (3H, m, CH-pyridine and H-3), 7.46 
(1H, br s, H-5), 8.26 (2H, d, J = 6.1 Hz, N-CH-pyridine), 8.64 (1H, t, J = 6.2 Hz, CO-NH), 
11.94 (1H, s, NH-pyrrole); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 11.8 (TIPS-CH), 17.9 
(TIPS-CH3), 23.4 (C-cyclohexane), 28.6 (C-cyclohexane), 35.8 (C-cyclohexane), 41.0 (C-
cyclohexane), 42.0 (NH-CH2), 44.6 (CO-CH), 70.4 (C-OSi), 109.9 (C-Ar), 122.05 (C-Ar), 
126.7 (C-Ar), 127.5 (C-Ar), 148.6 (C-Ar), 149.4 (C-Ar), 149.5 (C-Ar), 160.4 (CO), 197.0 
(CO); MS (ES+) m/z = 484.2 [M+H]
+
; HRMS calcd for C27H41N3O3Si [M+H]
+
 484.2990, 
found 484.2984. 
cis 4-(3-Hydroxycyclohexanecarbonyl)-N-(pyridin-4-ylmethyl)-1H-pyrrole-2-
carboxamide, 210 
 
General procedure H: N-(pyridin-4-ylmethyl)-4-(3-
((triisopropylsilyl)oxy)cyclohexanecarbonyl)-1H-pyrrole-2-carboxamide (100 mg, 0.21 
mmol) and TBAF (250 μL, 0.25 mmol). Purification via column chromatography (silica; 0-
8% MeOH/DCM) gave 210 as a white solid (55 mg, 80%). Rf 0.17 (9:1 DCM/MeOH); m.p. 
220-221 ˚C; λmax (EtOH/nm) 275.5, 229.5; IR υmax/cm
-1 
3370, 3208, 2932, 2857, 1632, 1573, 
1531; 
1
H NMR (500 MHz, DMSO-d6) δ ppm 1.04-1.39 (4H, m, CH-cyclohexane), 1.65-1.91 
(4H, m, CH-cyclohexane), 3.08 (1H, dddd, J = 3.2, 3.4, 11.8 and 12.0 Hz, CO-CH), 3.50-3.56 
(1H, m, CH-OH), 4.46 (2H, d, J = 6.0 Hz, NH-CH2), 4.58 (1H, d, J = 4.8 Hz, OH), 7.28-7.29 
(3H, m, CH-pyridine and H-3), 7.67 (1H, br s, H-5), 8.50 (2H, d, J = 6.0 Hz, N-CH-pyridine), 
8.89 (1H, t, J = 6.0 Hz, CO-NH), 12.19 (1H, s, NH-pyrrole);
13
C NMR (125 MHz, DMSO-d6) 
δ ppm 23.5 (C-cyclohexane), 28.5 (C-cyclohexane), 35.3 (C-cyclohexane), 38.7 (C-
cyclohexane), 41.1 (NH-CH2), 44.9 (CO-CH), 68.4 (C-OH), 109.9 (C-Ar), 122.1 (C-Ar), 
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124.5 (C-Ar), 126.5 (C-Ar), 127.5 (C-Ar), 148.6 (C-Ar), 149.5 (C-Ar), 160.4 (CO), 197.3 
(CO); MS (ES+) m/z = 328.3 [M+H]
+
; HRMS calcd for C18H21N3O3 [M+H]
+ 
328.1656, found 
328.1660. 
Methyl 4-(2,2,2-trichloroacetyl)-1H-pyrrole-2-carboxylate, 218 
 
General procedure F: methyl 1H-pyrrole-2-carboxylate (800 mg, 6.39 mmol), 
trichloroacetyl chloride (1.44 mL, 12.79 mmol), and AlCl3 (2.14 g, 15.98 mmol). Purification 
via column chromatography (silica; 0-50% EtOAc/petrol) gave 218 as a beige solid (1.55 g, 
90%). Rf 0.46 (3:7 EtOAc/petrol); m.p. 122-123 ˚C (lit.
143
 118-119 
o
C); λmax (EtOH/nm) 
237.0, 290.0; IR υmax/cm
-1 
3273, 1683, 1565; 
1
H NMR (500 MHz, CDCl3) δ ppm 3.84 (3H, s, 
O-CH3), 7.46 (1H, dd, J = 1.6 and 2.4 Hz, H-3), 7.80 (1H, dd, J = 1.6 and 3.4 Hz, H-5), 9.67 
(1H, s, NH-pyrrole); 
13
C NMR (125 MHz, CDCl3) δ ppm 52.2 (O-CH3), 117.0 (C-Ar), 117.6 
(C-Ar), 124.0 (C-Ar), 130.4 (C-Ar), 161.0 (CO), 176.8 (CO); MS (ES+) m/z = 269.8 
[(
35
ClM)+H]
+
, 271.8 [(
37
ClM)+H]
+
. 
tert-Butyl 4-(5-(methoxycarbonyl)-1H-pyrrole-3-carbonyl)piperazine-1-carboxylate, 221 
 
General procedure I:  methyl 4-(2,2,2-trichloroacetyl)-1H-pyrrole-2-carboxylate (340 mg, 
1.25 mmol), and tert-butyl piperazine-1-carboxylate (700 mg, 3.75 mmol). Purification via 
column chromatography (silica; 0-30% EtOAc/petrol) gave 221 as a white solid (260 mg, 
61%). Rf 0.56 (EtOAc); m.p. 169-171 ˚C; λmax (EtOH/nm) 263.5, 340.5; IR υmax/cm
-1 
3120, 
2923, 2857, 1706, 1589, 1497; 
1
H NMR (500 MHz, DMSO-d6) δ ppm 1.42 (9H, s, C-CH3), 
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3.37 (4H, br s, CH-piperazine), 3.57 (4H, br s, CH-piperazine), 3.79 (3H, s, O-CH3), 6.94 
(1H, br s, H-3), 7.33 (1H, br s, H-5), 12.37 (1H, s, NH-pyrrole); 
13
C NMR (125 MHz, 
DMSO-d6) δ ppm 28.0 (C-CH3), 51.3 (C-piperazine), 54.9 (O-CH3), 79.1 (C-CH3), 115.1 (C-
Ar), 119.3 (C-Ar), 121.9 (C-Ar), 125.9 (C-Ar), 153.8 (CO), 160.6 (CO), 164.3 (CO); MS 
(ES+) m/z = 338.2 [M+H]
+
; HRMS calcd for C16H23N3O5 [M+H]
+ 
338.1710, found 338.1708. 
Methyl 4-(4-methylpiperazine-1-carbonyl)-1H-pyrrole-2-carboxylate, 224 
 
General procedure I:  methyl 4-(2,2,2-trichloroacetyl)-1H-pyrrole-2-carboxylate (300 mg, 
1.11 mmol) and N-methyl piperazine (0.37 mL, 3.33 mmol). Recrystallisation from 
EtOAc/petrol (9:1) gave 224 as white crystals (180 mg, 63%). Rf 0.28 (9:1 DCM/MeOH); 
m.p. 188-189 ˚C; λmax (EtOH/nm) 210.5, 261.0; IR υmax/cm
-1 
2950, 2807, 1703, 1607, 1562; 
1
H NMR (500 MHz, DMSO-d6) δ ppm 2.09 (3H, s, N-CH3), 2.19-2.21 (4H, m, CH-
piperazine), 3.47-3.49 (4H, m, CH-piperazine), 3.69 (3H, s, O-CH3), 6.80 (1H, d, J = 1.7 Hz, 
H-3), 7.19 (1H, d, J = 1.7 Hz, H-5), 12.23 (1H, s, NH-pyrrole); 
13
C NMR (125 MHz, DMSO-
d6) δ ppm 45.6 (N-CH3), 48.6 (C-piperazine), 51.3 (C-piperazine), 54.6 (O-CH3), 114.9 (C-
Ar), 119.5 (C-Ar), 121.8 (C-Ar), 125.8 (C-Ar), 160.6 (CO), 164.1 (CO); MS (ES+) m/z = 
252.0 [M+H]
+
; HRMS calcd for C12H17N3O3 [M+H]
+
 252.1343, found 252.1346.   
Methyl 4-(piperidine-1-carbonyl)-1H-pyrrole-2-carboxylate, 226 
 
General procedure I: methyl 4-(2,2,2-trichloroacetyl)-1H-pyrrole-2-carboxylate (320 mg, 
1.16 mmol) and piperidine (0.34 mL, 3.48 mmol). Purification via column chromatography 
(silica; 0-5% MeOH/DCM) gave 226 as a white solid (210 mg, 75%). Rf 0.44 (EtOAc); m.p. 
143-144 ˚C; λmax (EtOH/nm) 209.0, 264.0; IR υmax/cm
-1 
3115, 2939, 2855, 1704, 1581, 1553; 
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1
H NMR (500 MHz, DMSO-d6) δ ppm 1.48-1.52 (4H, m, CH-piperidine), 1.59-1.64 (2H, m,  
CH-piperidine), 3.53-3.55 (4H, m, N-CH-piperidine), 3.78 (3H, s, O-CH3), 6.87 (1H, d, J = 
1.6 Hz, H-3), 7.26 (1H, d, J = 1.6 Hz, H-5), 12.32 (1H, s, NH-pyrrole); 
13
C NMR (125 MHz, 
DMSO-d6) δ ppm 24.2 (C-piperidine), 25.7 (C-piperidine), 48.6 (C-piperidine), 51.3 (O-
CH3), 114.7 (C-Ar), 119.9 (C-Ar), 121.7 (C-Ar), 125.5 (C-Ar), 160.6 (CO), 164.0 (CO); MS 
(ES+) m/z = 237.0 [M+H]
+
; HRMS calcd for C12H16N2O3 [M+H]
+
 237.1234, found 237.1231.    
Methyl 4-(pyrrolidine-1-carbonyl)-1H-pyrrole-2-carboxylate, 228 
 
General procedure I:  methyl 4-(2,2,2-trichloroacetyl)-1H-pyrrole-2-carboxylate (220 mg, 
0.81 mmol) and pyrrolidine (0.20 mL, 2.43 mmol). Purification via column chromatography 
(silica; 0-5% MeOH/DCM) gave 228 as a white solid (180 mg, 99%). Rf 0.34 (EtOAc); m.p. 
207-208 ˚C; λmax (EtOH/nm) 211.0, 263.0; IR υmax/cm
-1 
3167, 2953, 2890, 1703, 1590, 1553; 
1
H NMR (500 MHz, DMSO-d6) δ ppm 1.84-1.89 (2H, m, CH-pyrrolidine), 1.93-1.98 (2H, m, 
CH-pyrrolidine), 3.48 (2H, t, J = 6.8 Hz, N-CH-pyrrolidine), 3.71 (2H, t, J = 6.8 Hz, N-CH-
pyrrolidine) 7.13 (1H, d, J = 1.6 Hz, H-3), 7.47 (1H, d, J = 1.6 Hz, H-5), 12.43 (1H, s, NH-
pyrrole); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 23.6 (C-pyrrolidine), 26.1 (C-pyrrolidine), 
46.4 (C-pyrrolidine), 47.8 (C-pyrrolidine), 51.3 (O-CH3), 115.4 (C-Ar), 121.0 (C-Ar), 121.9 
(C-Ar), 126.2 (C-Ar), 160.7 (CO), 162.6 (CO); MS (ES+) m/z = 233.0 [M+H]
+
; HRMS calcd 
for C11H14N2O3 [M+H]
+ 
223.1077, found 223.1074. 
Methyl 4-(morpholine-4-carbonyl)-1H-pyrrole-2-carboxylate, 219 
 
General procedure I: methyl 4-(2,2,2-trichloroacetyl)-1H-pyrrole-2-carboxylate (330 mg, 
1.20 mmol) and morpholine (0.31 mL, 3.60 mmol). Purification via column chromatography 
(silica; 0-8% MeOH/DCM) gave 219 as a white solid (250 mg, 88%). Rf 0.18 (EtOAc); m.p. 
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130-131 ˚C; λmax (EtOH/nm) 236.5, 288.5;  IR υmax/cm
-1 
3273, 1683, 1565, 1446; 
1
H NMR 
(500 MHz, DMSO-d6) δ ppm 3.65 (8H, br s, CH2-N-morpholine and CH2-O-morpholine), 
3.84 (3H, s, O-CH3), 6.99 (1H, br s, H-3), 7.38 (1H, br s, H-5), 12.42 (1H, s, NH-pyrrole); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 51.3 (CH2-N-morpholine), 59.7 (O-CH3), 66.2 (CH2-
O-morpholine), 115.1 (C-Ar), 119.2 (C-Ar), 121.9 (C-Ar), 125.9 (C-Ar), 160.6 (CO), 170.3 
(CO); MS (ES+) m/z = 239.1 [M+H]
+
; HRMS calcd for C11H14N2O4 [M+H]
+ 
239.1026, found 
239.1025. 
Methyl 4-((2S,6R)-2,6-dimethylmorpholine-4-carbonyl)-1H-pyrrole-2-carboxylate, 230 
 
General procedure I: methyl 4-(2,2,2-trichloroacetyl)-1H-pyrrole-2-carboxylate (210 mg, 
2.34 mmol) and (2S,6R)-2,6-dimethylmorpholine (290 μL, 2.34 mmol). Recrystallisation (9:1 
EtOAc/petrol) gave 230 as white needles (187 mg, 90%). Rf 0.37 (9:1 DCM/MeOH); m.p. 
146-147 ˚C; λmax (EtOH/nm) 261.0, 209; IR υmax/cm
-1 
3076, 3045, 2971, 2856, 1712, 1601, 
1566; 
1
H NMR (500 MHz, DMSO-d6) δ ppm 1.50 (6H, d, J = 5.9 Hz, CH3), 3.39 (4H, s, N-
CH2-morpholine), 3.53-3.59 (2H, m, CH2-O-morpholine), 3.84 (3H, s, O-CH3), 6.98 (1H, br 
s, H-3), 7.38 (1H, br s, H-5), 12.40 (1H, s, NH-pyrrole); 
13
C NMR (125 MHz, CDCl3) δ ppm 
18.7 (CH3), 51.8 (CH2-N-morpholine and O-CH3), 72.0 (CH2-O-morpholine), 114.5 (C-Ar), 
120.5 (C-Ar), 122.8 (C-Ar), 125.3 (C-Ar), 161.1 (CO) 171.2 (CO); MS (ES+) m/z = 267.0 
[M+H]
+
; HRMS calcd for C13H18N2O4 [M+H]
+ 
267.1339, found 267.1344. 
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4-(4-(tert-Butoxycarbonyl)piperazine-1-carbonyl)-1H-pyrrole-2-carboxylic acid, 222 
 
General procedure J: tert-butyl 4-(5-(methoxycarbonyl)-1H-pyrrole-3-carbonyl)piperazine-
1-carboxylate (200 mg, 0.59 mmol) and LiOH monohydrate (500 mg, 11.87 mmol) gave 222 
as a white solid (170 mg, 90%). Rf 0.34 (8:2 DCM/MeOH); m.p. 229-230 ˚C; λmax 
(EtOH/nm) 210.0, 264.5; IR υmax/cm
-1 
3303, 2964, 2925, 1685, 1553, 1511; 
1
H NMR (500 
MHz, DMSO-d6) δ ppm 1.42 (9H, s, C-CH3), 3.37 (4H, br s, CH-piperazine), 3.58 (4H, br s, 
CH-piperazine), 6.88 (1H, dd, J = 1.6 and 2.4 Hz, H-3), 7.27 (1H, dd, J = 1.6 and 3.2 Hz, H-
5), 12.17 (1H, s, NH-pyrrole), 12.50 (1H, s, COOH); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 
28.0 (C-CH3), 65.6 (C-piperazine), 68.3 (C-piperazine), 79.1 (C-CH3), 114.7 (C-Ar), 119.0 
(C-Ar), 125.3 (C-Ar), 127.3 (C-Ar), 153.8 (CO), 161.6 (CO), 164.5 (CO); MS (ES+) m/z = 
324.2 [M+H]
+
; HRMS calcd for C15H21N3O5 [M-H]
-
 322.1408, found 322.1399.    
4-(4-Methylpiperazine-1-carbonyl)-1H-pyrrole-2-carboxylic acid, 225 
 
General procedure J with exceptions to the workup: methyl 4-(4-methylpiperazine-1-
carbonyl)-1H-pyrrole-2-carboxylate (120 mg,  0.48 mmol) and LiOH monohydrate (0.34 g, 
0.72 mmol). The mixture was cooled and concentrated in vacuo. Purification via column 
chromatography (C18 silica; 9:1 H2O/MeOH, 0.1% formic acid) gave 225 as a white solid 
(100 mg, 89%). Rf 0.45 (H2O, reverse phase silica); m.p. 248-250 ˚C; λmax (EtOH/nm) 208.0, 
253.0; IR υmax/cm
-1 
3178, 2946, 2813, 1561, 1504; 
1
H NMR (500 MHz, DMSO-d6) δ ppm 
2.19 (3H, s, N-CH3), 2.28-2.30 (4H, m, CH-piperazine), 3.60 (4H, br s, CH-piperazine),  6.43 
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(1H, d, J = 1.6 Hz, H-3), 6.93 (1H, d, J = 1.6 Hz, H-5), 11.31 (1H, s, NH-pyrrole), 12.02 (1H, 
s, COOH); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 45.7 (N-CH3), 47.6 (C-piperazine), 54.8 
(C-piperazine), 109.3 (C-Ar), 117.3 (C-Ar), 120.7 (C-Ar), 133.1 (C-Ar), 164.3 (CO), 165.7 
(CO); MS (ES+) m/z = 238.1 [M+H]
+
; HRMS calcd for C11H15N3O3 [M-H]
- 
236.1041, found 
236.1037. 
4-(Piperidine-1-carbonyl)-1H-pyrrole-2-carboxylic acid, 227 
 
General procedure J: methyl 4-(piperidine-1-carbonyl)-1H-pyrrole-2-carboxylate (150 mg, 
0.63 mmol) and LiOH monohydrate (41 mg, 0.95 mmol) gave 227 as a white solid (110 mg, 
80%). Rf 0.20 (8:2 DCM/MeOH); m.p. 230-233 ˚C; λmax (EtOH/nm) 209.5, 262.5; IR 
υmax/cm
-1 
3299, 2927, 2856, 1680, 1543, 1510; 
1
H NMR (500 MHz, DMSO-d6) δ ppm 1.52-
1.58 (4H, m, CH-piperidine), 1.65-1.69 (2H, m, CH-piperidine), 3.59-3.61 (4H, m, N-CH-
piperidine) 6.87 (1H, dd, J = 1.6 and 2.4 Hz, H-3), 7.25 (1H, dd, J = 1.6 and 3.2 Hz, H-5), 
12.16 (1H, s, NH-pyrrole), 12.61 (1H, s, COOH); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 
24.2 (C-piperidine), 25.7 (C-piperidine), 114.4 (C-piperidine), 119.7 (C-Ar), 122.9 (C-Ar), 
124.9 (C-Ar), 161.6 (CO), 164.2 (CO); MS (ES+) m/z = 223.0 [M+H]
+
; HRMS calcd for 
C11H14N2O3 [M-H]
-
 221.0932, found 221.0928. 
4-(Pyrrolidine-1-carbonyl)-1H-pyrrole-2-carboxylic acid, 229 
 
General procedure J: methyl 4-(pyrrolidine-1-carbonyl)-1H-pyrrole-2-carboxylate (130 mg, 
0.57 mmol) and LiOH monohydrate (40 mg, 0.86 mmol) gave 229 as a white solid (90 mg, 
75%). Rf 0.20 (8:2 DCM/MeOH); m.p. 250-252 ˚C; λmax (EtOH/nm) 211.0, 261.5; IR 
υmax/cm
-1 
2967, 2882, 1655, 1578, 1554, 1499; 
1
H NMR (500 MHz, DMSO-d6) δ ppm 1.84-
1.89 (2H, m, CH-pyrrolidine), 1.93-1.98 (2H, m, CH-pyrrolidine), 3.48 (2H, t, J = 6.7 Hz, N-
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CH-pyrrolidine), 3.70 (2H, t, J = 6.7 Hz, N-CH-pyrrolidine), 7.07 (1H, dd, J = 1.6 and 2.4 
Hz, H-3), 7.41 (1H, dd, J = 1.6 and 3.2 Hz, H-5), 12.21 (1H, s, NH-pyrrole), 12.62 (1H, s, 
COOH); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 23.6 (C-pyrrolidine), 26.2 (C-pyrrolidine), 
46.4 (C-pyrrolidine), 47.8 (C-pyrrolidine), 115.1 (C-Ar), 120.9 (C-Ar), 123.1 (C-Ar), 125.6 
(C-Ar), 161.7 (CO), 162.7 (CO); MS (ES+) m/z = 209.0 [M+H]
+
; HRMS calcd for 
C10H12N2O3 [M-H]
-
 207.0775, found 207.0772.  
4-(Morpholine-4-carbonyl)-1H-pyrrole-2-carboxylic acid, 220 
 
General procedure J: methyl 4-(morpholine-4-carbonyl)-1H-pyrrole-2-carboxylate (160 
mg, 0.68 mmol) and LiOH monohydrate (43 mg, 1.02 mmol) gave 220 as a white solid (117 
mg, 77%). Rf 0.12 (8:2 DCM/MeOH); m.p. 226-228 ˚C; λmax (EtOH/nm) 210.0, 261.5; IR 
υmax/cm
-1 
2914, 2680, 1663, 1589, 1561; 
1
H NMR (500 MHz, DMSO-d6) δ ppm 3.65 (8H, s, 
CH2-N-morpholine and CH2-O-morpholine), 6.92 (1H, br s, H-3), 7.31 (1H, dd, J = 1.6 and 
3.2 Hz, H-5), 12.20 (1H, s, NH-pyrrole), 12.64 (1H, s, COOH); 
13
C NMR (125 MHz, DMSO-
d6) δ ppm 66.2 (CH2-O-morpholine), 114.7 (C-Ar), 118.9 (C-Ar), 123.3 (C-Ar), 125.3 (C-
Ar), 161.6 (CO), 164.5 (CO), CH2-N-morpholine not visualised; MS (ES+) m/z = 224.97 
[M+H]
+
; HRMS calcd for C10H12N2O4 [M+H]
+
 225.0870, found 225.0871.    
4-((2S,6R)-2,6-Dimethylmorpholine-4-carbonyl)-1H-pyrrole-2-carboxylic acid, 231 
 
General procedure J: methyl 4-((2S,6R)-2,6-dimethylmorpholine-4-carbonyl)-1H-pyrrole-
2-carboxylate (175 mg, 0.66 mmol) and LiOH monohydrate (42 mg, 0.99 mmol) gave 231 as 
a white solid (163 mg, 98%). Rf 0.24 (9:1 DCM/MeOH); m.p. 205-206 ˚C; λmax (EtOH/nm) 
261.0, 209.5; IR υmax/cm
-1
3285, 2974, 1664, 1559, 1506, 1437; 
1
H NMR (500 MHz, DMSO-
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d6) δ ppm 1.15 (6H, d, J = 5.9 Hz, CH3), 2.67 (2H, br s, CH2-N-morpholine), 3.52-3.59 (2H, 
m, CH2-O-morpholine), 4.19 (2H, br s, CH2-N-morpholine), 6.91 (1H, dd, J = 1.6 and 2.4 Hz, 
H-3), 7.32 (1H, dd, J = 1.6 and 3.2 Hz, H-5), 12.21 (1H, s, NH-pyrrole), 12.62 (1H, s, 
COOH); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 18.6 (CH3), 59.7 (N-C-morpholine), 71.2 
(C-morpholine), 114.7 (C-Ar), 119.1 (C-Ar), 123.1 (C-Ar), 125.3 (C-Ar), 161.6 (CO), 164.2 
(CO); MS (ES+) m/z = 253.4 [M+H]
+
; HRMS calcd for C12H16N2O4 [M-H]
-
 251.1037, found 
251.1031.   
tert-Butyl 4-(5-((pyridin-4-ylmethyl)carbamoyl)-1H-pyrrole-3-carbonyl)piperazine-1-
carboxylate, 223 
 
General procedure D: 4-(4-(tert-butoxycarbonyl)piperazine-1-carbonyl)-1H-pyrrole-2-
carboxylic acid (110 mg, 0.34 mmol), CDI (110 mg, 0.67 mmol) and 4-picolylamine (0.08 
mL, 0.84 mmol). Purification via column chromatography (silica; 0-5% MeOH/DCM) gave 
223 as a white solid (130 mg, 95%). Rf  0.23 (95:5 EtOAc/MeOH); m.p. 238-239 ˚C; λmax 
(EtOH/nm) 263.5; IR υmax/cm
-1 
3255, 2973, 2906, 2868, 1703, 1645, 1597; 
1
H NMR (500 
MHz, DMSO-d6) δ ppm 1.42 (9H, s, C-CH3), 3.38 (4H, br s, CH-piperazine), 3.60 (4H, br s, 
CH-piperazine), 4.47 (2H, d, J = 5.9 Hz, NH-CH2), 7.11 (1H, br s, H-3), 7.21 (1H, dd,  J = 
1.6 and 3.2 Hz, H-5), 7.30 (2H, d, J = 6.0 Hz, CH-pyridine), 8.51 (2H, d, J = 6.0 Hz, N-CH-
pyridine), 8.81 (1H, t, J = 5.9 Hz, CO-NH), 11.99 (1H, s, NH-pyrrole); 
13
C NMR (125 MHz, 
DMSO-d6) δ ppm 28.0 (C-CH3), 41.0 (NH-CH2), 42.8 (C-piperazine), 43.9 (C-piperazine), 
79.1 (C-CH3), 111.0 (C-Ar), 118.4 (C-Ar), 122.1 (C-Ar), 123.9 (C-Ar), 125.9 (C-Ar), 148.7 
(C-Ar), 149.5 (C-Ar), 153.8 (CO), 160.5 (CO), 164.7 (CO); MS (ES+) m/z = 414.2 [M+H]
+
; 
HRMS calcd for C21H27N5O4 [M+H]
+
 414.2136, found 414.2136. 
 
274 
 
4-(4-Methylpiperazine-1-carbonyl)-N-(pyridin-4-ylmethyl)-1H-pyrrole-2-carboxamide, 
159 
 
General procedure D: 4-(4-methylpiperazine-1-carbonyl)-1H-pyrrole-2-carboxylic acid (50 
mg, 0.21 mmol), CDI (70 mg, 0.42 mmol), and 4-picolylamine (0.05 mL, 0.53 mmol). 
Purification via semi-preparative HPLC gave 159 as a white solid (30 mg, 43%) Rf 0.30 (9:1 
DCM/MeOH); 
1
H NMR (500 MHz, DMSO-d6) δ ppm 2.20 (3H, s, N-CH3), 2.31-2.33 (4H, 
m, CH-piperazine), 3.61 (4H, br s, CH-piperazine), 4.46 (2H, d, J = 5.9 Hz, NH-CH2), 7.08 
(1H, br s, H-3), 7.17 (1H, br s, H-5), 7.30 (2H, d, J = 6.0 Hz, CH-pyridine), 8.51 (2H, d, J = 
6.0 Hz, N-CH-pyridine), 8.80 (1H, t,  J = 5.9 Hz, CO-NH), 11.94 (1H, s, NH-pyrrole); MS 
(ES+) m/z = 328.2 [M+H]
+
; 
13
C NMR (125 MHz, DMSO-d6) δ ppm  Insufficient quantity of 
material to perform analysis; HRMS calcd for C17H21N5O2 [M+H]
+
 328.1768, found 
328.1772. 
4-(Piperidine-1-carbonyl)-N-(pyridin-4-ylmethyl)-1H-pyrrole-2-carboxamide, 160 
 
General procedure D: 4-(piperidine-1-carbonyl)-1H-pyrrole-2-carboxylic acid (60 mg, 0.27 
mmol), CDI (90 mg, 0.54 mmol), and 4-picolylamine (0.07 mL, 0.68 mmol). 
Recrystallisation from EtOAc/petrol (9:1) gave 160 as a white solid (70 mg, 82%). Rf 0.36 
(EtOAc); m.p. 231-233 ˚C; λmax (EtOH/nm) 261.5; IR υmax/cm
-1 
3248, 2923, 2855, 1643, 
1593, 1564, 1534; 
1
H NMR (500 MHz, DMSO-d6) δ ppm 1.26-1.31 (4H, m, CH-piperidine), 
1.37-1.43 (2H, m, CH-piperidine), 3.34 (4H, br s, N-CH-piperidine), 4.23 (2H, d, J = 5.9 Hz, 
NH-CH2), 6.83 (1H, dd, J = 1.6 and 2.4 Hz, H-3), 6.91 (1H, dd, J = 1.6 and 3.2 Hz, H-5), 
7.06 (2H, d, J =  6.0 Hz, CH-pyridine), 8.28 (2H, d, J = 6.0 Hz, N-CH-pyridine), 8.58 (1H, t, 
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J = 5.9 Hz, CO-NH), 11.68 (1H, s, NH-pyrrole); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 24.2 
(C-piperidine), 25.8 (C-piperidine), 41.0 (NH-CH2), 110.7 (C-Ar), 119.1 (C-Ar), 122.1 (C-
Ar), 123.4 (C-Ar), 125.7 (C-Ar), 148.8 (C-Ar), 149.5 (C-Ar), 160.5 (CO), 164.4 (CO); MS 
(ES+) m/z = 313.2 [M+H]
+
; HRMS calcd for C17H20N4O2 [M+H]
+
 313.1659, found 313.1662. 
N-(Pyridin-4-ylmethyl)-4-(pyrrolidine-1-carbonyl)-1H-pyrrole-2-carboxamide, 161 
 
General procedure D: 4-(pyrrolidine-1-carbonyl)-1H-pyrrole-2-carboxylic acid (60 mg, 
0.30 mmol), CDI (100 mg, 0.60 mmol), and 4-picolylamine (0.07 mL, 0.75 mmol). 
Recrystallisation (EtOAc/petrol 9:1) gave 161 as a white solid (70 mg, 82%). Rf 0.34 
(EtOAc); m.p. 228-230 ˚C; λmax (EtOH/nm) 263.0; IR υmax/cm
-1 
3232, 2972, 2865, 1627, 
1569, 1596; 
1
H NMR (500 MHz, DMSO-d6) δ ppm 1.80-1.83 (2H, m, CH-pyrrolidine), 1.90-
1.93 (2H, m, CH-pyrrolidine), 3.44 (2H, t, J = 6.7 Hz, N-CH-pyrrolidine), 3.67 (2H, t, J = 6.7 
Hz, N-CH-pyrrolidine), 4.46 (2H, d, J = 5.9 Hz, NH-CH2), 7.28-7.30 (4H, m,  H-3, H-5 and 
CH-pyridine), 8.51 (2H, d, J = 6.0 Hz, N-CH-pyridine), 8.85 (1H, t, J = 5.9 Hz, CO-NH), 
11.97 (1H, s, NH-pyrrole); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 23.6 (C-pyrrolidine), 26.2 
(C-pyrrolidine), 41.0 (NH-CH2), 46.4 (C-pyrrolidine), 47.8 (C-pyrrolidine), 111.4 (C-Ar), 
120.4 (C-Ar), 122.1 (C-Ar), 124.1 (C-Ar), 125.8 (C-Ar), 148.8 (C-Ar), 149.5 (C-Ar), 160.6 
(CO), 162.9 (CO); MS (ES+) m/z = 299.4 [M+H]
+
; HRMS calcd for C16H18N4O2 [M+H]
+
 
299.1503, found 299.1507. 
4-(Morpholine-4-carbonyl)-N-(pyridin-4-ylmethyl)-1H-pyrrole-2-carboxamide, 162 
 
General procedure D: 4-(morpholine-4-carbonyl)-1H-pyrrole-2-carboxylic acid (60 mg, 
0.25 mmol), CDI (80 mg, 0.50 mmol), and 4-picolylamine (0.06 mL, 0.63 mmol). 
Recrystallisation from EtOAc/petrol (9:1) gave 162 as a white solid (50 mg, 70%). Rf 0.24 
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(8:2 DCM/MeOH); m.p. 227-228 ˚C; λmax (EtOH/nm) 262.5; IR υmax/cm
-1 
3129, 2962, 2920, 
2859, 1644, 1597, 1567, 1535; 
1
H NMR (500 MHz, DMSO-d6) δ ppm 3.61 (8H, br s, CH2-N-
morpholine and CH2-O-morpholine), 4.47 (2H, d, J = 5.9 Hz, NH-CH2), 7.11 (1H, dd, J = 1.6 
and 2.4 Hz, H-3), 7.21 (1H, dd, J = 1.6 and 3.2 Hz, H-5), 7.29 (2H, d, J = 6.0 Hz, CH-
pyridine), 8.51 (2H, d, J = 6.0 Hz, N-CH-pyridine), 8.82 (1H, t,  J = 5.9 Hz, CO-NH), 11.98 
(1H, s, NH-pyrrole); 13C NMR (125 MHz, DMSO-d6) δ ppm 41.0 (CH2), 66.3 (CH2-N-
morpholine and CH2-O-morpholine), 110.9 (C-Ar), 118.3 (C-Ar), 122.1 (C-Ar), 123.9 (C-
Ar), 125.9 (C-Ar), 148.7 (C-Ar), 149.5 (C-Ar), 160.5 (CO), 164.7 (CO); MS (ES+) m/z = 
315.4 [M+H]
+
; HRMS calcd for C16H18N4O3 [M+H]
+
 315.1452, found 315.1450. 
4-((2S,6R)-2,6-Dimethylmorpholine-4-carbonyl)-N-(pyridin-4-ylmethyl)-1H-pyrrole-2-
carboxamide, 163 
 
General procedure D: 4-((2S,6R)-2,6-dimethylmorpholine-4-carbonyl)-1H-pyrrole-2-
carboxylic acid (115 mg, 0.46 mmol), CDI (149 mg, 0.92 mmol), and 4-picolylamine (110 
μL, 1.15 mmol). Purification via column chromatography (silica; 0-8% DCM/MeOH) gave 
163 as a white solid (55 mg, 50%). Rf 0.29 (9:1 DCM/MeOH); m.p. 262-264 ˚C; λmax 
(EtOH/nm) 262.5, 340.5; IR υmax/cm
-1 
3293, 3209, 2924, 2861, 1633, 1600, 1573, 1541;  
1
H 
NMR (500 MHz, DMSO-d6) δ ppm 1.10 (6H, d, J = 5.9 Hz, CH3), 2.61 (2H, br s, CH2-N-
morpholine), 3.48-3.55 (2H, m, CH2-O-morpholine), 4.19 (2H, br s, CH2-N-morpholine), 
4.46 (2H, d, J = 6.0 Hz, NH-CH2), 7.09 (1H, dd, J = 1.6 and 2.4 Hz, H-3), 7.21 (1H, dd, J = 
1.6 and 3.2 Hz, H-5), 7.29 (2H, d, J = 6.0 Hz, CH-pyridine), 8.51 (2H, d, J = 6.0 Hz, N-CH-
pyridine), 8.81 (1H, t, J = 6.0 Hz, CO-NH), 11.97 (1H, s, NH-pyrrole); 
13
C NMR (125 MHz, 
DMSO-d6) δ ppm 18.6 (CH3), 41.0 (NH-CH2), 59.9 (CH2-N-morpholine), 71.3 (CH2-O-
morpholine), 110.9 (C-Ar), 118.5 (C-Ar), 122.1 (C-Ar), 123.9 (C-Ar), 125.9 (C-Ar), 148.7 
(C-Ar), 149.5 (C-Ar), 160.5 (CO), 164.4 (CO); MS (ES+) m/z = 343.3 [M+H]
+
; HRMS calcd 
for C18H22N4O3 [M+H]
+ 
343.1765, found 343.1768. 
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4-(Piperazine-1-carbonyl)-N-(pyridin-4-ylmethyl)-1H-pyrrole-2-carboxamide, 158 
 
General procedure K: tert-butyl 4-(5-((pyridin-4-ylmethyl)carbamoyl)-1H-pyrrole-3-
carbonyl)piperazine-1-carboxylate (80 mg, 0.19 mmol). Purification via column 
chromatography (NH silica; 0-8% MeOH/DCM) gave 158 as a white solid (30 mg, 46%). Rf 
0.26 (9:1 DCM/MeOH); m.p. 43-46˚C; λmax (EtOH/nm) 264.0; IR υmax/cm
-1 
2918, 2858, 
1636, 1603, 1569; 
1
H NMR (500 MHz, DMSO-d6) δ ppm 2.60-2.62 (4H, m, CH-piperazine), 
3.45 (4H, br s, CH-piperazine), 4.38 (2H, d, J = 5.9 Hz, NH-CH2), 6.99 (1H, br s, H-3), 7.07 
(1H, br s, H-5), 7.21 (2H, d, J = 6.0 Hz CH-pyridine), 8.43 (2H, d, J = 6.0 Hz, N-CH-
pyridine), 8.73 (1H, t, J = 5.9 Hz, CO-NH), 11.85 (1H, s, NH-pyrrole); 
13
C NMR (125 MHz, 
DMSO-d6) δ ppm 41.0 (NH-CH2), 45.8 (C-piperazine), 67.0 (C-piperazine), 110.8 (C-Ar), 
118.8 (C-Ar), 122.1 (C-Ar), 123.7 (C-Ar), 125.8 (C-Ar), 148.7 (C-Ar), 149.5 (C-Ar), 160.5 
(CO), 164.5 (CO); MS (ES+) m/z = 314.1 [M+H]
+
; HRMS calcd for C16H19N5O2 [M+H]
+
 
314.1612, found 314.1612. 
4-(2-Hydroxy-6-methoxybenzoyl)-N-(pyridin-4-ylmethyl)-1H-pyrrole-2-carboxamide, 
239 
 
General procedure L: 4-(2,6-dimethoxybenzoyl)-N-(pyridin-4-ylmethyl)-1H-pyrrole-2-
carboxamide (70 mg, 0.19 mmol). Purification via column chromatography (silica; 0-8% 
MeOH/DCM) gave 239 as a white solid (20 mg, 30%). Rf 0.32 (9:1 DCM/MeOH); m.p. 247-
249 ˚C; λmax (EtOH/nm) 235.0; IR υmax/cm
-1 
3315, 3123, 2962, 2838, 1607, 1568, 1535;  
1
H 
NMR (500 MHz, DMSO-d6) δ ppm 3.65 (3H, s, CH3), 4.45 (2H, d, J = 5.9 Hz, NH-CH2), 
6.53 (2H, dd, J = 8.2 and 8.4 Hz, H-3’and H-5’), 7.07 (1H, br s, H-3), 7.15-7.19 (2H, m, H-5 
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and H-4’), 7.28 (2H, d, J = 6.0 Hz, CH-pyridine), 8.50 (2H, d, J = 6.0 Hz, N-CH-pyridine), 
8.90 (1H, t, J = 5.9 Hz, CO-NH), 9.53 (1H, s, OH), 12.09 (1H, s, NH-pyrrole); 
13
C NMR 
(125 MHz, DMSO-d6) δ ppm Insufficient quantity of material to perform analysis; MS (ES+) 
m/z = 352.3 [M+H]
+
; HRMS calcd for C19H17N3O4 [M+H]
+ 
352.1292, found 352.1291. 
4-(2,6-Dihydroxybenzoyl)-N-(pyridin-4-ylmethyl)-1H-pyrrole-2-carboxamide, 240 
 
General procedure L: 4-(2,6-dimethoxybenzoyl)-N-(pyridin-4-ylmethyl)-1H-pyrrole-2-
carboxamide (70 mg, 0.19 mmol). Purification via Semi-preparative HPLC (75:25 
H2O/MeCN) gave 240 as a white solid (35 mg, 55%). Rf 0.25 (9:1 DCM/MeOH); m.p. 240-
241˚C; λmax (EtOH/nm) 234.5; IR υmax/cm
-1 
3312, 3326, 3129, 2958, 2834, 1606, 1564, 1530; 
1
H NMR (500 MHz, DMSO-d6) δ ppm 4.45 (2H, d, J = 6.1 Hz, NH-CH2), 6.34 (2H, d, J = 
8.2 Hz, H-3’ and H-5’), 6.99 (1H, dd, J = 8.1 and 8.2 Hz, H-4’), 7.10 (1H, br s, H-3), 7.18 
(1H, br s, H-5), 7.29 (2H, d, J = 5.3 Hz, CH-pyridine), 8.50 (2H, d, J = 5.3 Hz, N-CH-
pyridine), 8.92 (1H, t, J = 6.1 Hz, CO-NH), 9.39 (2H, s, OH), 12.07 (1H, s, NH-pyrrole);
 13
C 
NMR (125 MHz, DMSO-d6) δ ppm Insufficient quantity of material to perform analysis; MS 
(ES+) m/z = 338.2 [M+H]
+
; HRMS calcd for C18H15N3O4 [M+H]
+ 
338.1135, found 338.1138. 
4-(2-Hydroxybenzoyl)-N-(pyridin-4-ylmethyl)-1H-pyrrole-2-carboxamide, 241 
 
General procedure L: 4-(2-methoxybenzoyl)-N-(pyridin-4-ylmethyl)-1H-pyrrole-2-
carboxamide (31 mg, 0.09 mmol). Purification via column chromatography (silica; 0-8% 
MeOH/DCM) gave 241 as a white solid (25 mg, 85%). Rf 0.26 (9:1 DCM/MeOH); m.p. 191-
192 ˚C; λmax (EtOH/nm) 244.5, 331.5; IR υmax/cm
-1 
3031, 2926, 2853, 1638, 1565, 1542; 
1
H 
NMR (500 MHz, DMSO-d6) δ ppm 4.46 (2H, d, J = 6.2 Hz, NH-CH2), 6.93-6.98 (2H, m, H-
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2’and H-5’), 7.29 (2H, d, J = 6.0 Hz, CH-pyridine), 7.37 (1H, d, J = 1.6 Hz, H-3), 7.42-7.45 
(2H, m, H-5 and H-4’), 7.65 (1H, dd, J = 1.6 and 7.8 Hz, H-6’), 8.50 (2H, d, J = 6.0 Hz, N-
CH-pyridine), 8.96 (1H, t, J = 6.2 Hz, CO-NH), 11.05 (1H, s, OH), 12.35 (1H, s, NH-
pyrrole); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 41.1 (CH2), 111.4 (C-Ar), 117.1 (C-Ar), 
118.9 (C-Ar), 122.1 (C-Ar), 123.7 (C-Ar), 124.3 (C-Ar), 127.4 (C-Ar), 128.0 (C-Ar), 130.4 
(C-Ar), 133.4 (C-Ar), 148.6 (C-Ar), 149.5 (C-Ar), 158.4 (C-OH), 160.3 (CO), 191.7 (CO); 
MS (ES+) m/z = 322.2 [M+H]
+
; HRMS calcd for C18H15N3O4 [M+H]
+ 
322.1186, found 
322.1188. 
4-(3-Hydroxybenzoyl)-N-(pyridin-4-ylmethyl)-1H-pyrrole-2-carboxamide, 242 
 
General procedure L: 4-(3-methoxybenzoyl)-N-(pyridin-4-ylmethyl)-1H-pyrrole-2-
carboxamide (112 mg, 0.33 mmol). Purification via column chromatography (silica; 0-8% 
MeOH/DCM) gave 242 as a white solid (70 mg, 66%). Rf 0.26 (9:1 DCM/MeOH); m.p. 261-
263 ˚C; λmax (EtOH/nm) 243.0, 289.5, 340.5; IR υmax/cm
-1 
3346, 3204, 3116, 2674, 1642, 
1608, 1575, 1534;  
1
H NMR (500 MHz, DMSO-d6) δ ppm 4.46 (2H, s, J = 6.0 Hz, NH-CH2), 
6.98 (1H, ddd, J = 1.0, 2.5 and 8.1 Hz, H-4’), 7.15 (1H, dd, J = 1.6 and 2.5 Hz, H-2’), 7.20 
(1H, ddd, J = 1.0, 1.2 and  7.6 Hz, H-6’), 7.29 (2H, d, J = 6.0 Hz, CH-pyridine), 7.32 (1H, dd, 
J = 7.6 and 8.1 Hz, H-5’), 7.37 (1H, br s, H-3), 7.41 (1H, br s, H-5), 8.50 (2H, d, J = 6.0 Hz, 
N-CH-pyridine), 8.96 (1H, t, J = 6.0 Hz, CO-NH), 9.74 (1H, s, OH), 12.32 (1H, s, NH-
pyrrole); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 41.1 (CH2), 111.5 (C-Ar), 115.0 (C-Ar), 
118.7 (C-Ar), 119.3 (C-Ar), 122.1 (C-Ar), 124.1 (C-Ar), 127.4 (C-Ar), 127.6 (C-Ar), 129.5 
(C-Ar), 140.5 (C-Ar), 148.6 (C-Ar), 149.5 (C-Ar), 157.3 (C-OH), 160.3 (CO), 189.2 (CO); 
MS (ES+) m/z = 322.2 [M+H]
+
; HRMS calcd for C18H15N3O3 [M+H]
+ 
322.1186, found 
322.1185. 
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Pyridin-2-yl(1H-pyrrol-3-yl)methanone, 247 
 
General procedure F: TIPS pyrrole (0.70 mL, 2.81 mmol), picolinoyl chloride (1.09 g, 5.62 
mmol) and AlCl3. After quenching with 1M HCl (aq) the mixture was adjusted to pH 9 with 
1M NaOH (aq) before extraction.  The crude material was used directly in the next step. 
General procedure H: pyridin-2-yl(1-(triisopropylsilyl)-1H-pyrrol-3-yl)methanone (0.92 g, 
2.81 mmol) and TBAF (562 μL, 5.62 mmol). Purification via column chromatography (silica; 
0-8% MeOH/DCM) gave 247 as a beige solid (231 mg, 48%). Rf 0.32 (9:1 DCM/MeOH);  
m.p. 116-117 ˚C; λmax (EtOH/nm) 270.0, 234.5; IR υmax/cm
-1 
3159, 2865, 1630, 1587, 1564, 
1511;  
1
H NMR (500 MHz, DMSO-d6) δ ppm 6.73 (1H, br s, H-4), 6.89 (1H, br s, H-5), 7.61 
(1H, ddd, J = 1.4, 4.7 and 7.4 Hz, CH-pyridine), 7.94-8.02 (3H, m, CH-pyridine and H-2), 
8.73 (1H, ddd, J  = 0.9, 1.7 and 4.7 Hz, N-CH-pyridine), 11.56 (1H, s, NH-pyrrole); 
13
C 
NMR (125 MHz, DMSO-d6) δ ppm 109.7 (C-Ar), 119.5 (C-Ar), 122.9 (C-Ar), 126.1 (C-Ar), 
128.3 (C-Ar), 137.3 (C-Ar), 148.5 (C-Ar); MS (ES+) m/z = 173.1 [M+H]
+
; HRMS calcd for 
C10H8N2O [M+H]
+
 173.0709, found 173.0708.    
Pyridin-4-yl(1H-pyrrol-3-yl)methanone, 249 
 
General procedure F: TIPS pyrrole (1.39 mL, 5.62 mmol), isonicotinoyl chloride (2.00 g, 
11.23 mmol) and AlCl3 (2.64 g, 19.67 mmol). After quenching with 1M HCl (aq) the mixture 
was adjusted to pH 9 with 1M NaOH (aq) before extraction.  The crude material was used 
directly in the next step. General procedure H: pyridin-4-yl(1-(triisopropylsilyl)-1H-pyrrol-
3-yl)methanone (1.84 g, 5.62 mmol) and TBAF (1.12 mL, 11.24 mmol). Purification via 
column chromatography (silica; 0-8% MeOH/DCM) gave 249 as a beige solid (380 mg, 
39%). Rf 0.32 (9:1 DCM/MeOH); m.p. 114-116 ˚C; λmax (EtOH/nm) 267.5; IR υmax/cm
-1
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2941, 2831, 1636, 1532, 1492; 
1
H NMR (500 MHz, DMSO-d6) δ ppm 6.58 (1H, br s, H-4), 
6.96 (1H, br s, H-5), 7.43-7.45 (1H, m, H-2), 7.63 (2H, d, J = 6.0 Hz, CH-pyridine), 8.75 
(2H, d, J = 6.0 Hz, N-CH-pyridine), 11.76 (1H, s, NH-pyrrole);
13
C NMR (125 MHz, DMSO-
d6) δ ppm 108.9 (C-Ar), 120.7 (C-Ar), 122.0 (C-Ar), 122.9 (C-Ar), 127.1 (C-Ar), 146.5 (C-
Ar), 150.1 (C-Ar), 188.1 (CO); MS (ES+) m/z = 173.1 [M+H]
+
; HRMS calcd for C10H8N2O 
[M+H]
+ 
173.0709, found 173.0707. 
2,2,2-Trichloro-1-(4-picolinoyl-1H-pyrrol-2-yl)ethanone, 250 
 
General procedure F: pyridin-2-yl(1H-pyrrol-3-yl)methanone (59 mg, 0.34 mmol), 
trichloroacetyl chloride (76 μL, 0.68 mmol) and AlCl3 (159 mg, 1.19 mmol). After quenching 
with 1M HCl (aq) the mixture was adjusted to pH 9 with 1M NaOH (aq) before extraction.  
Purification via column chromatography (silica; DCM) gave 250 as a beige solid (40 mg, 
37%). Rf 0.38 (95:5 DCM/MeOH); m.p. Degrades >250 
o
C; λmax (EtOH/nm) 327.0, 245.0; IR 
υmax/cm
-1 
3112, 1679, 1632, 1545, 1498, 1445;  
1
H NMR (500 MHz, DMSO-d6) δ ppm 7.67-
7.72 (1H, m, CH-pyridine), 7.99 (1H, d, J = 1.6 Hz, H-3), 8.06-8.07 (2H, m, CH-pyridine), 
8.47 (1H, d, J = 1.6 Hz, H-5), 8.80 (1H, ddd, J = 1.3, 1.5 and 4.7 Hz, N-CH-pyridine), 13.17 
(1H, s, NH-pyrrole); 
13
C NMR (125 MHz, DMSO-d6) δ ppm Insufficient quantity of material 
to perform analysis; MS (ES+) m/z = 315.1 [(
35
Cl)-H]
-
; HRMS calcd for C12H7Cl3N2O2 
[(
35
ClM)-H]
- 
314.9500, found 314.9504. 
2,2,2-Trichloro-1-(4-isonicotinoyl-1H-pyrrol-2-yl)ethanone, 252 
 
General procedure F: pyridin-3-yl(1H-pyrrol-3-yl)methanone (140 mg, 0.81 mmol), 
trichloroacetyl chloride (180 μL, 1.62 mmol) and AlCl3 (381 mg, 2.84 mmol). After 
282 
 
quenching with 1M HCl (aq) the mixture was adjusted to pH 9 with 1M NaOH (aq) before 
extraction. Purification via column chromatography (silica; DCM) gave 252 as a beige solid 
(70 mg, 27%). Rf 0.38 (95:5 DCM/MeOH); m.p. Degrades >250 
o
C; λmax (EtOH/nm) 314.0, 
257.0; IR υmax/cm
-1 
3115, 1681, 1635, 1545; 
1
H NMR (500 MHz, DMSO-d6) δ ppm 7.70 (1H, 
dd, 1.6 and 2.4 Hz, H-3), 7.71 (2H, d, J = 6.0 Hz, CH-pyridine), 7.94 (1H, dd, J = 1.5 and 3.2 
Hz, H-5), 8.81 (2H, d, J = 6.0 Hz, N-CH-pyridine); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 
Insufficient quantity of material to perform analysis; MS (ES+) m/z = 316.1, [M-H]
-
; HRMS 
calcd for C12H7Cl3N2O2 [
35
ClM-H]
- 
316.9646, found 316.9652.  
4-Picolinoyl-N-(pyridin-4-ylmethyl)-1H-pyrrole-2-carboxamide, 243 
 
General procedure I: 2,2,2-trichloro-1-(4-picolinoyl-1H-pyrrol-2-yl)ethanone (24 mg, 0.08 
mmol) and 4-picolylamine (24 μL, 0.24 mmol). Recrystallisation (9:1 EtOAc/petrol) gave 
243 as a white solid (10 mg, 40%). Rf 0.15 (9:1 DCM/MeOH); m.p. 194-196 ˚C; λmax 
(EtOH/nm) 243.0, 309.0; IR υmax/cm
-1 
3343, 3206, 1623, 1575, 1535, 1494;  
1
H NMR (500 
MHz, MeOD) δ ppm 4.62 (2H, s, NH-CH2), 7.43 (2H, d, J = 6.0 Hz, CH-pyridine), 7.60-7.63 
(2H, m, H-3 and CH-pyridine) 8.00-8.07 (2H, m, CH-pyridine and N-CH-pyridine), 8.18 
(1H, d, J = 1.6 Hz, H-5), 8.50 (2H, d, J = 6.0 Hz, N-CH-pyridine), 8.73-8.75 (1H, m, N-CH-
pyridine); 
13C NMR (125 MHz, MeOD) δ ppm 43.17 (CH2), 113.6 (C-Ar), 124.1 (C-Ar), 
124.6 (C-Ar), 125.0 (C-Ar), 128.0 (C-Ar), 132.4 (C-Ar), 138.6 (C-Ar), 149.5 (C-Ar), 149.7 
(C-Ar), 152.6 (C-Ar), 157.1 (C-Ar), 163.2 (CO), 189.0 (CO); MS (ES+) m/z = 307.1 [M+H]
+
; 
HRMS calcd for C17H14N4O2 [M+H]
+ 
307.1190, found 307.1193. 
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4-Isonicotinoyl-N-(pyridin-4-ylmethyl)-1H-pyrrole-2-carboxamide, 255 
 
General procedure I:  2,2,2-trichloro-1-(4-isonicotinoyl-1H-pyrrol-2-yl)ethanone (25 mg, 
0.08 mmol) and 4-picolylamine (24 μL, 0.24 mmol). Recrystallisation (9:1 EtOAc/petrol) 
gave 255 as an off-white solid (15 mg, 61%). Rf 0.15 (9:1 DCM/MeOH); m.p. 189-192 ˚C; 
λmax (EtOH/nm) 243.0; IR υmax/cm
-1 
3323, 3118, 1628, 1566, 1537;  
1
H NMR (500 MHz, 
MeOD) δ ppm 4.61 (2H, s, NH-CH2), 7.39 (1H, d, J = 1.6 Hz, H-3), 7.42 (2H, d, J = 6.1 Hz, 
CH-pyridine), 7.60 (1H, d, J = 1.6 Hz, H-5), 7.77 (2H, d, J = 6.0 Hz, CH-pyridine), 8.50 (2H, 
d, J = 6.1 Hz, N-CH-pyridine), 8.77 (2H, d, J = 6.0 Hz, N-CH-pyridine); 
13
C NMR (125 
MHz, MeOD) δ ppm 42.9 (CH2), 112.6 (C-Ar), 123.9 (C-Ar), 125.3 (C-Ar), 129.3 (C-Ar), 
130.4 (C-Ar), 148.4 (C-Ar), 145.0 (C-Ar), 150.9 (C-Ar), 151.4 (C-Ar), 162.8 (CO), 190.6 
(CO); MS (ES+) m/z = 307.1 [M+H]
+
; HRMS calcd for C17H14N4O2 [M+H]
+ 
307.1190, found 
307.1192. 
Methyl 4-(3,5-difluoroisonicotinoyl)-1H-pyrrole-2-carboxylate, 258 
 
General procedure E: 3,5-difluoroisonicotinic acid (379 mg, 2.38 mmol), SOCl2 (0.43 mL, 
5.95 mmol), and DMF (10 mol%) gave 3,5-difluoroisonicotinoyl chloride as a yellow oil 
which was used directly in the next step. General procedure F: methyl 1H-pyrrole-2-
carboxylate (150 mg, 1.19 mmol), and AlCl3 (0.64 g, 4.76 mmol). Purification via column 
chromatography (silica; 0-60% EtOAc/petrol) gave 258 as a pink solid (99 mg, 31%). Rf 0.10 
(80:20 petrol/EtOAc); m.p. 211-212 ˚C; λmax (EtOH/nm) 232.5; IR υmax/cm
-1 
3120, 3049, 
2954, 2926, 2851, 1702, 1654, 1617, 1559;  
1
H NMR (500 MHz, DMSO-d6) δ ppm 3.82 (3H, 
s, O-CH3), 7.17 (1H, d, J = 1.6 Hz, H-3), 7.79 (1H, d, J = 1.4 Hz, H-5), 8.70 (2H, s, N-CH-
pyridine), 13.00 (1H, s, NH-pyrrole); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 51.7 (O-CH3), 
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114.5 (C-Ar), 125.0 (C-Ar), 131.4 (C-Ar), 135.2 (dd, JCF = 3.7 and 23.1 Hz, C-Ar), 154.5 (d, 
JCF = 260.1 Hz, C-F), 160.2 (CO), 179.4 (CO), two C-Ar not visualised; HRMS calcd for 
C12H8F2N2O3 [M+H]
+ 
267.0576, found 267.0580. 
4-(3,5-Difluoroisonicotinoyl)-1H-pyrrole-2-carboxylic acid, 259 
 
General procedure G: methyl 4-(3,5-difluoroisonicotinoyl)-1H-pyrrole-2-carboxylate (90 
mg, 3.38 mmol), and LiOH monohydrate (213 mg, 5.07 mmol). Extraction at pH3 gave 259 
as a pink solid (85 mg, 100%). Rf 0.13 (9:1 DCM/MeOH); m.p. 242-244 ˚C; λmax (EtOH/nm) 
231.0; IR υmax/cm
-1 
3329, 2785, 2700, 2630, 1699, 1630, 1540;  
1
H NMR (500 MHz, DMSO-
d6) δ ppm 7.10 (1H, br s, H-3), 7.72 (1H, br s, H-5), 8.70 (2H, s, N-CH-pyridine), 12.83 (1H, 
s NH-pyrrole), 12.97 (1H, s, COOH); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 114.0 (C-Ar), 
124.0 (t, JCF = 20.1 Hz, C-Ar), 124.9 (C-Ar), 126.3 (C-Ar), 131.1 (C-Ar), 135.1 (dd, JCF = 3.9 
and 22.9 Hz, C-Ar), 154.4 (d, JCF = 260.4 Hz, C-F), 161.2 (CO), 179.4 (CO); Insufficient 
material retained for HRMS analysis. 
4-(3,5-Difluoroisonicotinoyl)-N-(pyridin-4-yl)-1H-pyrrole-2-carboxamide, 257 
 
General procedure M: 4-(3,5-Difluoroisonicotinoyl)-1H-pyrrole-2-carboxylic acid (43 mg, 
0.17 mmol), PCl3 (14 µL, 0.17 mmol), and 4-aminopyridine (40 mg, 0.43 mmol). Purification 
via column chromatography (silica; 0-8% MeOH/DCM) gave 257 as a pink solid (17 mg, 
30%). Rf 0.16 (95:5 DCM/MeOH); m.p. Degrades >250 ˚C; λmax (EtOH/nm) 270.5; IR 
υmax/cm
-1 
3112, 2924, 1689, 1649, 1590, 1558, 1509, 1416;  
1
H NMR (500 MHz, DMSO-d6) 
δ ppm 7.65 (1H, br s, H-3), 7.74 (2H, d, J = 6.4 Hz, CH-pyridine), 7.78 (1H, br s, H-5), 8.47 
(2H, d, J = 6.4 Hz, N-CH-pyridine), 8.73 (2H, s, H-3’ and H-5’), 10.38 (1H, s, CO-NH), 
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12.91 (1H, s, NH-pyrrole); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 111.8 (C-Ar), 113.7 (C-
Ar), 124.1 (t, JCF = 20.8 Hz, C-Ar), 124.9 (C-Ar), 128.4 (C-Ar), 131.2 (C-Ar), 135.2 (dd, JCF 
= 4.4 and 23.0 Hz, C-Ar), 145.6 (C-Ar), 150.3 (C-Ar), 154.5 (dd, JCF = 2.1 and 261.6 Hz, C-
F), 158.9 (CO), 179.6 (CO); HRMS calcd for C16H10F2N4O2 [M+H]
+ 
329.0845, found 
329.0847. 
Methyl 4-(2-fluoro-6-methylbenzoyl)-1H-pyrrole-2-carboxylate, 264 
 
General procedure E: 2-fluoro, 6-methylbenzoic acid (0.73 g, 4.73 mmol), SOCl2 (0.52 mL, 
7.10 mmol) and DMF (10 mol%) gave 2-fluoro, 6-methylbenzoyl chloride as a yellow oil 
which was used directly in the next step. General procedure F: methyl 1H-pyrrole-2-
carboxylate (297 mg, 2.37 mmol), and AlCl3 (0.80 g, 5.93 mmol). Purification via column 
chromatography (silica; 0-50% EtOAc/petrol) gave 264 as a white solid (0.51 g, 83%). Rf 
0.22 (8:2 Petrol/EtOAc); m.p. 105-108 
o
C; λmax (EtOH/nm) 282.0, 229.5; IR υmax/cm
-1
 3125, 
3090, 2975, 1709, 1638, 1612, 1550; 
1
H NMR (500 MHz, DMSO-d6) δ ppm 2.17 (3H, s, 
CH3), 3.80 (3H, s, O-CH3), 6.96 (1H, br s, H-3), 7.13-7.18 (2H, m, H-3’ and H-5’), 7.40-7.44 
(2H, m, H-5 and H-4’), 12.80 (1H, s, NH); 13C NMR (125 MHz, DMSO-d6) δ ppm 18.4 
(CH3), 51.6 (O-CH3), 112.9 (d, JCF = 21.8 Hz, C-Ar), 114.6 (C-Ar), 124.2 (C-Ar), 126.2 (C-
Ar), 126.3 (d, JCF = 2.4 Hz, C-Ar), 128.3 (C-Ar), 129.4 (C-Ar), 130.6 (d, JCF = 8.9 Hz, C-Ar), 
136.9 (d, JCF = 3.5 Hz, C-Ar), 158.3 (d, JCF = 243.3 Hz, C-F), 160.3 (CO), 187.5 (CO); 
HRMS calcd for C14H12FNO3 [M+H]
+ 
262.0874, found 262.0879. 
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4-(2-Fluoro-6-methylbenzoyl)-1H-pyrrole-2-carboxylic acid, 265 
 
General procedure G: methyl 4-(2-fluoro-6-methylbenzoyl)-1H-pyrrole-2-carboxylate (0.50 
g, 1.92 mmol) and LiOH monohydrate (0.92 g, 38.30 mmol) gave 265 as a white solid (465 
mg, 98%). Rf 0.36 (9:1 DCM/MeOH); m.p. 193-195 
o
C; λmax (EtOH/nm) 280.0, 230.5; IR 
υmax/cm
-1 
3337, 2798, 2705, 2626, 1689, 1642, 1561; 
1
H NMR (500 MHz, DMSO-d6) δ ppm 
2.17 (3H, s, CH3), 6.92 (1H, br s, H-3), 7.13-7.18 (2H, m, H-3’ and H-5’), 7.34 (1H, br s, H-
5), 7.42 (1H, ddd, J = 6.2, 8.3 and 8.4 Hz, H-4’), 12.59 (1H, s, NH), 12.87 (1H, s, COOH); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 18.4 (CH3), 112.9 (d, JCF = 21.5 Hz, C-Ar), 114.1 (C-
Ar), 125.6 (C-Ar), 126.1 (C-Ar), 126.2 (d, JCF = 2.5 Hz, C-Ar), 128.3 (d, JCF = 18.3 Hz, C-
Ar), 128.9 (C-Ar), 130.5 (d, JCF = 8.5 Hz, C-Ar), 136.9 (d, JCF = 3.3 Hz, C-Ar), 158.3 (d, JCF 
= 243.2 Hz, C-F), 161.3 (CO), 187.6 (CO); HRMS calcd for C13H10FNO3 [M-H]
- 
246.0572, 
found 246.0562. 
4-(2-Fluoro-6-methylbenzoyl)-N-(pyridin-4-yl)-1H-pyrrole-2-carboxamide, 266 
 
General procedure M:  4-(2-fluoro-6-methylbenzoyl)-1H-pyrrole-2-carboxylic acid (50 mg, 
0.20 mmol), PCl3 (17 µL, 0.20 mmol) and 4-aminopyridine (47 mg, 0.50 mmol). Purification 
via column chromatography (silica; 0-8% MeOH/DCM) gave 266 as a white solid (45 mg, 
70%). Rf 0.24 (95:5 DCM/MeOH); m.p. 288-290 
o
C; λmax (EtOH/nm) 292.0, 271.0, 210.0; IR 
υmax/cm
-1
 3280, 2943, 2845, 1630, 1568, 1535; 
1
H NMR (500 MHz, DMSO-d6) δ ppm 2.19 
(3H, s, CH3), 7.15-7.20 (2H, m, H-3’ and H-5’), 7.39 (1H, br s, H-3), 7.43 (1H, ddd, J = 6.2, 
8.3 and 8.4 Hz, H-4’), 7.51 (1H, br s, H-5), 7.73 (2H, d, J = 6.4 Hz, CH-pyridine), 8.46 (2H, 
d, J = 6.4 Hz, N-CH-pyridine), 10.34 (1H, s, CO-NH), 12.66 (NH-pyrrole); 
13
C NMR (125 
MHz, DMSO-d6) δ ppm 18.4 (CH3), 112.1 (C-Ar), 113.0 (d, JCF = 21.5 Hz, C-Ar), 113.7 (C-
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Ar), 126.2 (C-Ar), 126.3 (d, JCF = 2.3 Hz, C-Ar), 127.7 (C-Ar), 128.4 (d, JCF = 18.7 Hz, C-
Ar), 129.1 (C-Ar), 130.5 (d, JCF = 8.7 Hz, C-Ar), 136.9 (d, JCF = 3.5 Hz, C-Ar), 145.7 (C-Ar), 
150.3 (C-Ar), 158.4 (d, JCF = 243.6 Hz, C-F), 159.1 (CO), 187.8 (CO); HRMS calcd for 
C18H14FN3O2 [M+H]
+
 324.1143, found 324.1146. 
4-(2-Fluoro-6-methylbenzoyl)-N-(pyridin-3-yl)-1H-pyrrole-2-carboxamide, 267 
 
General procedure M: 4-(2-fluoro-6-methylbenzoyl)-1H-pyrrole-2-carboxylic acid (50 mg, 
0.20 mmol), PCl3 (17 µL, 0.20 mmol) and 3-aminopyridine (47 mg, 0.50 mmol). Purification 
via column chromatography (silica; 0-8% MeOH/DCM) gave 267 as a white solid (49 mg, 
76%). Rf 0.25 (95:5 DCM/MeOH); m.p. 191-193 
o
C; λmax (EtOH/nm) 248.0; IR υmax/cm
-1
 
3280, 2955, 2842, 1629, 1566, 1535; 
1
H NMR (500 MHz, DMSO-d6) δ ppm 2.20 (3H, s, 
CH3), 7.15-7.20 (2H, m, H-3’ and H-5’), 7.37-7.40 (2H, m, H-3 and CH-pyridine), 7.43 (1H, 
ddd, J = 6.2, 8.3 and 8.4 Hz, H-4’), 7.47 (1H, br s, H-5), 8.14 (1H, ddd, J = 1.5, 2.5 and 8.3 
Hz, CH-pyridine), 8.30 (1H, dd, J = 1.5 and 4.7 Hz, N-CH-pyridine), 8.89 (1H, d, J = 2.5 Hz, 
N-CH-pyridine), 10.23 (1H, s, CO-NH), 12.60 (1H, s, NH-pyrrole); 
13
C NMR (125 MHz, 
DMSO-d6) δ ppm 18.4 (CH3), 111.6 (C-Ar), 112.9 (d, JCF = 21.6 Hz, C-Ar), 123.5 (C-Ar), 
126.1 (C-Ar), 126.3 (d, JCF = 2.4 Hz, C-Ar), 127.0 (C-Ar), 127.8 (C-Ar), 128.5 (d, JCF = 18.5 
Hz, C-Ar), 128.7 (C-Ar), 130.5 (d, JCF = 8.7 Hz, C-Ar), 135.5 (C-Ar), 136.9 (d, JCF = 3.3 Hz, 
C-Ar), 141.6 (C-Ar), 144.4 (C-Ar), 158.4 (d, JCF = 243.1 Hz, C-F), 158.8 (CO), 187.8 (CO); 
HRMS calcd for C18H14FN3O2 [M+H]
+
 324.1143, found 324.1147. 
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4-(2-Fluoro-6-methylbenzoyl)-N-(pyridin-4-ylmethyl)-1H-pyrrole-2-carboxamide, 268 
 
General procedure M: 4-(2-fluoro-6-methylbenzoyl)-1H-pyrrole-2-carboxylic acid (50 mg, 
0.20 mmol), PCl3 (17 µL, 0.20 mmol), and 4-picolylamine (51 µL, 0.50 mmol). Purification 
via column chromatography (silica; 0-8% MeOH/DCM) gave 268 as a white solid (35 mg, 
52%). Rf 0.30 (95:5 DCM/MeOH); m.p. 209-210 
o
C; λmax (EtOH/nm) 284.0, 234.5; IR 
υmax/cm
-1
 3278, 3124, 3080, 2971, 2927, 2865, 1634, 1568, 1538; 
1
H NMR (500 MHz, 
DMSO-d6) δ ppm 2.18 (3H, s, CH3), 4.45 (2H, d, J = 6.0 Hz, NH-CH2), 7.13-7.18 (2H, m, H-
3’ and H-5’), 7.22 (1H, br s, H-3), 7.26 (1H, br s, H-5), 7.29 (2H, d, J = 6.1 Hz, CH-
pyridine), 7.41 (1H, ddd, J = 6.2, 8.3 and 8.4 Hz, H-4’), 8.50 (2H, d, J = 6.1 Hz, N-CH-
pyridine), 8.95 (1H, t, J = 6.0 Hz, CO-NH), 12.39 (1H, s, NH-pyrrole); 
13
C NMR (125 MHz, 
DMSO-d6) δ ppm 18.4 (CH3), 41.1 (CH2), 110.2 (C-Ar), 112.9 (d, JCF = 21.6 Hz, C-Ar), 
122.1 (C-Ar), 126.0 (C-Ar), 126.2 (d, JCF = 2.2 Hz, C-Ar), 127.8 (C-Ar), 128.2 (C-Ar), 128.6 
(d, JCF = 18.8 Hz, C-Ar), 130.3 (d, JCF = 8.7 Hz, C-Ar), 136.9 (d, JCF = 3.5 Hz, C-Ar), 148.5 
(C-Ar), 149.5 (C-Ar), 158.4 (d, JCF = 242.5 Hz, C-F), 160.2 (CO), 187.7 (CO); HRMS calcd 
for C19H16FN3O2 [M+H]
+
 338.1299, found 338.1303. 
4-(2-Fluoro-6-methylbenzoyl)-N-(pyridin-3-ylmethyl)-1H-pyrrole-2-carboxamide, 269 
 
General procedure M:  4-(2-fluoro-6-methylbenzoyl)-1H-pyrrole-2-carboxylic acid (50 mg, 
0.20 mmol), PCl3 (17 µL, 0.20 mmol), and 3-picolylamine (51 µL, 0.50 mmol). Purification 
via column chromatography (silica; 0-8% MeOH/DCM) gave 269 as a white solid (39 mg, 
58%). Rf 0.28 (95:5 DCM/MeOH); m.p. 233-234 
o
C; λmax (EtOH/nm) 287.0, 235.0; IR 
υmax/cm
-1
 3358, 3117, 2953, 2809, 1635, 1564, 1531, 1428, 1283, 1240; 
1
H NMR (500 MHz, 
DMSO-d6) δ ppm 2.17 (3H, s, CH3), 4.45 (2H, d, J = 6.0 Hz, NH-CH2), 7.12-7.18 (2H, m, H-
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3, H-3’ and H-5’), 7.25 (1H, br s, H-5), 7.36 (1H, dd, J = 4.8 and 7.9 Hz, CH-pyridine), 7.40 
(1H, ddd, J = 6.2, 8.3 and 8.4 Hz, H-4’), 7.70 (1H, dd, J = 1.5 and 7.9 Hz, CH-pyridine), 8.46 
(1H, dd, J = 1.5 and 4.8 Hz, N-CH-pyridine), 8.53 (1H, d, J = 2.5 Hz, N-CH-pyridine), 8.90 
(1H, t, J = 6.0 Hz, CO-NH), 12.37 (1H, s, NH-pyrrole); 
13
C NMR (125 MHz, DMSO-d6) δ 
ppm 18.4 (CH3), 39.8 (CH2), 110.1 (C-Ar), 112.9 (d, JCF = 21.6 Hz, C-Ar), 123.5 (C-Ar), 
125.9 (C-Ar), 126.2 (d, JCF = 2.3 Hz, C-Ar), 127.7 (C-Ar), 128.2 (C-Ar), 128.6 (d, JCF = 18.7 
Hz, C-Ar), 130.3 (d, JCF = 8.7 Hz, C-Ar), 134.9 (C-Ar), 135.1 (C-Ar), 136.8 (d, JCF = 3.7 Hz, 
C-Ar), 148.1 (C-Ar), 148.8 (C-Ar), 158.3 (d, JCF = 242.4 Hz, C-F), 160.0 (CO), 187.7 (CO); 
HRMS calcd for C19H16FN3O2 [M+H]
+
 338.1299, found 338.1302. 
Methyl 4-(2-chloro-6-fluorobenzoyl)-1H-pyrrole-2-carboxylate, 270 
 
General procedure F:  methyl 1H-pyrrole-2-carboxylate (2.00 g, 15.98 mmol), 2-chloro, 6-
fluorobenzoyl chloride (4.30 mL, 31.96 mmol) and AlCl3 (5.35 g, 39.95 mmol). Purification 
via column chromatography (silica; 0-50% EtOAc/petrol) gave 270 as a white solid (3.99 g, 
89%). Rf 0.20 (8:2 Petrol/EtOAc); m.p. 145-146 
oC; ˚C λmax (EtOH/nm) 280.5, 231.5; IR 
υmax/cm
-1 
3225, 3141, 3006, 1731, 1639, 1603, 1563, 1508; 
1
H NMR (500 MHz, DMSO-d6) δ 
ppm 3.80 (3H, s, O-CH3), 7.01 (1H, br s, H-3), 7.37-7.40 (1H, m, H-5’), 7.46 (1H, d, J = 8.3 
Hz, H-3’), 7.53 (1H, dd, J = 1.6 and 3.4 Hz, H-5), 7.58 (1H, ddd, J = 6.4, 8.3 and 14.6 Hz, H-
4’), 12.89 (1H, s, NH); 13C NMR (125 MHz, DMSO-d6) δ ppm 51.7 (O-CH3), 114.6 (C-Ar), 
115.0 (d, JCF = 21.4 Hz, C-Ar), 124.5 (C-Ar), 125.4 (C-Ar), 125.8 (d, JCF = 3.1 Hz, C-Ar), 
127.7 (d, JCF = 23.1 Hz, C-Ar), 130.1 (C-Ar), 130.3 (d, JCF = 6.1 Hz, C-Ar), 131.9 (d, JCF = 
9.2 Hz, C-Ar), 158.6 (d, JCF = 247.3 Hz, C-F), 160.3 (CO), 183.7 (CO); HRMS calcd for 
C13H9
35
ClFNO3 [M+H]
+
 282.0328, found 282.0331. 
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4-(2-Chloro-6-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid, 271 
 
General procedure G: methyl 4-(2-chloro-6-fluorobenzoyl)-1H-pyrrole-2-carboxylate (3.98 
g, 14.16 mmol), and LiOH monohydrate (11.89 g, 283.27 mmol) gave 271 as a white solid 
(3.74 g, 99%). Rf 0.36 (95:5 DCM/MeOH); m.p. 209-210 
oC; ˚C λmax (EtOH/nm) 281.0, 
233.5; IR υmax/cm
-1 
3306, 1638, 1556; 
1
H NMR (500 MHz, DMSO-d6) δ ppm 6.95 (1H, br s, 
H-3), 7.36-7.39 (1H, m, H-5’), 7.44-7.45 (2H, m, H-5 and H-3’), 7.56 (1H, ddd, J = 6.3, 8.3 
and 8.4 Hz, H-4’), 12.69 (1H, s, NH-pyrrole), 13.15 (1H, br s, COOH); 13C NMR (125 MHz, 
DMSO-d6) δ ppm 114.0 (C-Ar), 114.9 (d, JCF = 21.6 Hz, C-Ar), 125.2 (C-Ar), 125.8 (d, JCF = 
3.1 Hz, C-Ar), 126.2 (C-Ar), 127.9 (d, JCF = 23.0 Hz, C-Ar), 129.6 (C-Ar), 130.3 (d, JCF = 
6.1 Hz, C-Ar), 131.8 (d, JCF = 9.1 Hz, C-Ar), 158.6 (d, JCF = 246.4 Hz, C-F), 161.4 (CO), 
183.7 (CO); 
4-(2-Chloro-6-fluorobenzoyl)-N-(pyridin-4-yl)-1H-pyrrole-2-carboxamide, 272 
 
General procedure M:  4-(2-chloro-6-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (75 mg, 
0.28 mmol), PCl3 (25 µL, 0.28 mmol) and 4-aminopyridine (66 mg, 0.70 mmol). Purification 
via column chromatography (silica; 0-8% MeOH/DCM) gave 272 as a white solid (59 mg, 
61%). Rf 0.31 (95:5 DCM/MeOH); m.p. Degrades >270 
o
C; λmax (EtOH/nm) 341.0, 291.0, 
271.5; IR υmax/cm
-1
 3416, 3354, 1682, 1632, 1586, 1552, 1506; 
1
H NMR (500 MHz, DMSO-
d6) δ ppm 7.40-7.43 (1H, m, H-5’), 7.47-7.48 (1H, m, H-3’), 7.51 (1H, br s, H-3), 7.55 (1H, 
br s, H-5), 7.59 (1H, ddd, J = 6.2, 8.3 and 8.4 Hz, H-4’), 7.74 (2H, d, J = 6.3 Hz, CH-
pyridine), 8.47 (2H, d, J = 6.3 Hz, N-CH-pyridine), 10.36 (1H, s, CO-NH), 12.76 (1H, s, NH-
pyrrole); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 112.1 (C-Ar), 113.7 (C-Ar), 115.0 (d, JCF = 
21.8 Hz, C-Ar), 125.3 (C-Ar), 125.9 (d, JCF = 2.7 Hz, C-Ar), 127.9 (d, JCF = 23.1 Hz, C-Ar), 
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128.0 (C-Ar), 129.8 (C-Ar), 130.4 (d, JCF = 6.1 Hz, C-Ar), 131.9 (d, JCF = 9.2 Hz, C-Ar), 
145.6 (C-Ar), 150.3 (C-Ar), 158.6 (d, JCF = 247.3 Hz, C-F), 159.0 (CO), 183.9 (CO); HRMS 
calcd for C17H11
35
ClFN3O2 [M+H]
+
 344.0597, found 344.0592. 
4-(2-Chloro-6-fluorobenzoyl)-N-(pyridin-3-yl)-1H-pyrrole-2-carboxamide, 273 
 
General procedure M:  4-(2-chloro-6-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (75 mg, 
0.28 mmol), PCl3 (25 µL, 0.28 mmol) and 3-aminopyridine (66 mg, 0.70 mmol). Purification 
via column chromatography (silica; 0-8% MeOH/DCM) gave 273 as a white solid (62 mg, 
64%). Rf 0.29 (95:5 DCM/MeOH); m.p. Degrades >260 
o
C; λmax (EtOH/nm) 350.0, 248.5; IR 
υmax/cm
-1
 3122, 2963, 1635, 1602, 1535; 
1
H NMR (500 MHz, DMSO-d6) δ ppm 7.38-7.43 
(2H, m, H-3 and H-5’), 7.47-7.50 (3H, m, H-5, H-3’ and CH-pyridine), 7.59 (1H, ddd, J = 
6.2, 8.3 and 8.4 Hz, H-4’), 8.14 (1H, ddd, J = 1.5, 2.5 and 8.3 Hz, CH-pyridine), 8.30 (1H, 
dd, J = 1.5 and 4.7 Hz, N-CH-pyridine), 8.89 (1H, d, J = 2.5 Hz, N-CH-pyridine), 10.24 (1H, 
s, CO-NH), 12.71 (1H, s, NH-pyrrole); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 111.6 (C-Ar), 
115.0 (d, JCF = 21.2 Hz, C-Ar), 123.5 (C-Ar), 125.3 (C-Ar), 125.9 (d, JCF = 3.0 Hz, C-Ar), 
127.0 (C-Ar), 128.0 (d, JCF = 23.1 Hz, C-Ar), 128.2 (C-Ar), 129.3 (C-Ar), 130.4 (d, JCF = 6.1 
Hz, C-Ar), 131.8 (d, JCF = 9.1 Hz, C-Ar), 135.5 (C-Ar), 141.6 (C-Ar), 144.4 (C-Ar), 158.6 (d, 
JCF = 247.2 Hz, C-F), 158.7 (CO), 183.9 (CO); HRMS calcd for C17H11
35
ClFN3O2 [M+H]
+
 
344.0597, found 344.0592. 
4-(2-Chloro-6-fluorobenzoyl)-N-(pyridin-4-ylmethyl)-1H-pyrrole-2-carboxamide, 274 
 
General procedure M:  4-(2-chloro-6-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (75 mg, 
0.28 mmol), PCl3 (25 µL, 0.28 mmol) and 4-picolylamine (71 µL, 0.70 mmol). Purification 
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via column chromatography (silica; 0-8% MeOH/DCM) gave 274 as a pink solid (50 mg, 
50%). Rf 0.24 (95:5 DCM/MeOH); m.p. 200-202 
o
C; λmax (EtOH/nm) 281.5, 235.5; IR 
υmax/cm
-1
 3385, 3182, 1622, 1570, 1535; 
1
H NMR (500 MHz, DMSO-d6) δ ppm 4.44 (2H, d, 
J = 5.9 Hz, NH-CH2), 7.13 (1H, br s, H-3), 7.29 (2H, d, J = 6.0 Hz, CH-pyridine), 7.31 (1H, 
br s, H-5), 7.36-7.39 (1H, m, H-5’), 7.43-7.44 (1H, m, H-3’), 7.55 (1H, ddd, J = 6.2, 8.3 and 
8.4 Hz, H-4’), 8.49 (2H, d, J = 6.0 Hz, N-CH-pyridine), 9.12 (1H, br s, CO-NH), 13.07 (1H, 
br s, NH-pyrrole); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 41.1 (CH2), 110.2 (C-Ar), 114.9 
(d, JCF = 21.8 Hz, C-Ar), 122.1 (C-Ar), 125.1 (C-Ar), 125.8 (d, JCF = 2.2 Hz, C-Ar), 128.1 (d, 
JCF = 23.4 Hz, C-Ar), 128.4 (C-Ar), 128.5 (C-Ar), 130.4 (d, JCF = 5.9 Hz, C-Ar), 131.7 (d, 
JCF = 9.0 Hz, C-Ar), 148.4 (C-Ar), 149.5 (C-Ar), 158.6 (d, JCF = 246.3 Hz, C-F), 160.0 (CO), 
183.9 (CO); HRMS calcd for C18H13
35
ClFN3O2 [M+H]
+
 358.0753, found 358.0749. 
4-(2-Chloro-6-fluorobenzoyl)-N-(pyridin-3-ylmethyl)-1H-pyrrole-2-carboxamide, 275 
 
General procedure M: 4-(2-chloro-6-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (75 mg, 
0.28 mmol), PCl3 (25 µL, 0.28 mmol), and 3-picolylamine (71 µL, 0.70 mmol). Purification 
via column chromatography (silica; 0-8% MeOH/DCM) gave 275 as a white solid (68 mg, 
68%). Rf 0.26 (95:5 DCM/MeOH); m.p. 258-261 
o
C; λmax (EtOH/nm) 350.0, 284.0, 236.0; IR 
υmax/cm
-1
 3366, 3185, 3129, 3087, 1627, 1569, 1537; 
1
H NMR (500 MHz, DMSO-d6) δ ppm 
4.46 (2H, d, J = 6.0 Hz, NH-CH2), 7.22 (1H, br s, H-3), 7.35-7.39 (3H, m, H-3, H-5’ and CH-
pyridine), 7.44-7.45 (1H, m, H-3’), 7.56 (1H, ddd, J = 6.2, 8.3 and 8.4 Hz, H-4’),  7.70-7.72 
(1H, m, CH-pyridine), 8.47 (1H, dd, J = 1.5 and 4.7 Hz, N-CH-pyridine), 8.54 (1H, d, J = 2.5 
Hz, N-CH-pyridine), 8.92 (1H, t, J = 6.0 Hz, CO-NH), 12.48 (1H, s, NH-pyrrole); 
13
C NMR 
(125 MHz, DMSO-d6) δ ppm 39.8 (CH2), 110.1 (C-Ar), 114.9 (d, JCF = 21.4 Hz, C-Ar), 
123.5 (C-Ar), 125.1 (C-Ar), 125.8 (d, JCF = 2.8 Hz, C-Ar), 128.1 (d, JCF = 22.9 Hz, C-Ar), 
128.4 (C-Ar), 128.5 (C-Ar), 130.4 (d, JCF = 6.1 Hz, C-Ar), 131.7 (d, JCF = 9.2 Hz, C-Ar), 
134.9 (C-Ar), 135.1 (C-Ar), 148.1 (C-Ar), 148.8 (C-Ar), 158.5 (d, JCF = 246.7 Hz, C-F), 
159.9 (CO), 183.8 (CO); HRMS calcd for C18H13
35
ClFN3O2 [M+H]
+
 358.0753, found 
358.0749. 
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Methyl 4-(2-bromo-6-fluorobenzoyl)-1H-pyrrole-2-carboxylate, 276 
 
General procedure E: 2-bromo, 6-fluorobenzoic acid (3.00 g, 13.70 mmol), SOCl2 (1.50 
mL, 20.55 mmol) and DMF (10 mol%) gave 2-bromo, 6-fluorobenzoyl chloride as a 
colourless oil. The crude material was used directly in the next step. General procedure F:  
methyl 1H-pyrrole-2-carboxylate (0.86 g, 6.85 mmol), 2-bromo,6-fluorobenzoyl chloride 
(3.25 g,  13.70 mmol) and AlCl3 (2.30g, 17.13 mmol). Purification via column 
chromatography (silica; 0-50% EtOAc/petrol) gave 276 as a white solid (1.78 g, 80%). Rf 
0.21 (8:2 Petrol/EtOAc); m.p. 142-144 
oC; ˚C λmax (EtOH/nm) 286.5, 231.5; IR υmax/cm
-1 
3230, 3002, 2953, 1730, 1637, 1599, 1564, 1508; 
1
H NMR (500 MHz, DMSO-d6) δ ppm 
3.80 (3H, s, O-CH3), 6.99 (1H, br s, H-3), 7.40 (1H, dd, J = 8.3 and 8.9 Hz, H-5’), 7.48-7.53 
(2H, m, H-4’ and H-5), 7.59 (1H, d, J = 8.3 Hz, H-3’), 12.88 (1H, s, NH-pyrrole); 13C NMR 
(125 MHz, DMSO-d6) δ ppm 51.7 (CH3), 114.7 (C-Ar), 115.3 (d, JCF = 22.1 Hz, C-Ar), 118.9 
(d, JCF = 5.2 Hz, C-Ar), 124.5 (C-Ar), 125.0 (C-Ar), 128.8 (d, JCF = 2.9 Hz, C-Ar), 129.7 (d, 
JCF = 22.8 Hz, C-Ar), 130.1 (C-Ar), 132.3 (d, JCF = 9.0 Hz, C-Ar), 158.5 (d, JCF = 245.9 Hz, 
C-F), 160.2 (CO), 184.6 (CO); HRMS calcd for C13H9
79
BrFNO3 [M+H]
+
 325.9823, found 
325.9830. 
4-(2-Bromo-6-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid, 277 
 
General procedure G: methyl 4-(2-bromo-6-fluorobenzoyl)-1H-pyrrole-2-carboxylate (2.88 
g, 10.86 mmol), LiOH monohydrate (9.13 g, 217.40 mmol) gave 277 as white solid (2.46 g, 
90%). Rf 0.15 (9:1 DCM/MeOH); m.p. 210-211 
oC; λmax (EtOH/nm) 281.0; IR υmax/cm
-1 
3342, 1690, 1648, 1561; 
1
H NMR (500 MHz, DMSO-d6) δ ppm 6.94 (1H, br s, H-3), 7.39-
7.43 (2H, m, H-5 and H-5’), 7.50 (1H, ddd, J = 6.3, 8.3 and 8.4 Hz, H-4’), 7.59 (1H, d, J = 
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8.3 Hz, H-3’), 12.68 (1H, s, NH), 12.90 (1H, s, COOH); 13C NMR (125 MHz, DMSO-d6) δ 
ppm 114.2 (C-Ar), 115.3 (d, JCF = 21.7 Hz, C-Ar), 118.9 (d, JCF = 5.2 Hz, C-Ar), 124.9 (C-
Ar), 125.8 (C-Ar), 128.8 (d, JCF = 3.1 Hz, C-Ar), 129.7 (C-Ar), 129.9 (C-Ar), 132.2 (d, JCF = 
8.7 Hz, C-Ar), 158.4 (d, JCF = 249.9 Hz, C-F), 161.3 (CO), 184.6 (CO); HRMS calcd for 
C12H7
79
BrFNO3 [M-H]
-
 309.9521, found 309.9512. 
4-(2-Bromo-6-fluorobenzoyl)-N-(pyridin-4-yl)-1H-pyrrole-2-carboxamide, 263 
 
General procedure M: 4-(2-bromo-6-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (50 mg, 
0.16 mmol), PCl3 (14 µL, 0.16 mmol) and 4-aminopyridine (38 mg, 0.40 mmol). Purification 
via column chromatography (silica; 0-8% MeOH/DCM) gave 263 as a white solid (52 mg, 
84%). Rf 0.32 (95:5 DCM/MeOH); m.p. Degrades >150 
o
C; λmax (EtOH/nm) 291.5, 270.5; IR 
υmax/cm
-1
 3344, 3112, 2958, 1627, 1591, 1557, 1506; 
1
H NMR (500 MHz, DMSO-d6) δ ppm 
7.42-7.46 (1H, m, H-5’), 7.49-7.54 (3H, m, H-3, H-4’ and H-5), 7.61-7.62 (1H, m, H-3’), 
7.73 (2H, d, J = 6.4 Hz, CH-pyridine), 8.46 (2H, d, J = 6.4 Hz, N-CH-pyridine), 10.35 (1H, s, 
CO-NH), 12.74 (1H, s, NH-pyrrole); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 112.1 (C-Ar), 
113.7 (C-Ar), 115.4 (d, JCF =  21.6 Hz, C-Ar), 119.0 (d, JCF = 5.1 Hz, C-Ar), 125.0 (C-Ar), 
128.0 (C-Ar), 128.9 (d, JCF = 2.9 Hz, C-Ar), 129.8 (C-Ar), 132.2 (d, JCF = 8.9 Hz, C-Ar), 
145.6 (C-Ar), 150.3 (C-Ar), 158.5 (d, JCF = 247.8 Hz, C-F), 159.0 (CO), 184.9 (CO), one C-
Ar not visualised; HRMS calcd for C17H11
79
BrFN3O2 [M+H]
+
 388.0091, found 388.0088. 
4-(2-Bromo-6-fluorobenzoyl)-N-(pyridin-3-yl)-1H-pyrrole-2-carboxamide, 278 
 
General procedure M: 4-(2-bromo-6-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (50 mg, 
0.16 mmol), PCl3 (14 µL, 0.16 mmol) and 3-aminopyridine (38 mg, 0.40 mmol). Purification 
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via column chromatography (silica; 0-8% MeOH/DCM) gave 278 as a white solid (47 mg, 
76%). Rf 0.31 (95:5 DCM/MeOH); m.p. 138-140 
o
C; λmax (EtOH/nm) 288.0; IR υmax/cm
-1
 
3127, 2960, 1635, 1599, 1534; 
1
H NMR (500 MHz, DMSO-d6) δ ppm 7.39 (1H, dd, J = 4.7 
and 8.4 Hz, CH-pyridine), 7.42-7.48 (3H, m, H-3, H-5’ and H-5), 7.52 (1H, ddd, J = 6.2, 8.3 
and 8.4 Hz, H-4’), 7.61-7.63 (1H, m, H-3’), 8.14 (1H, ddd, J = 1.5, 2.5 and 8.4 Hz, CH-
pyridine), 8.30 (1H, dd, J = 1.5 and 4.7 Hz, N-CH-pyridine), 8.89 (1H, d, J = 2.5 Hz, N-CH-
pyridine), 10.24 (1H, s, CO-NH), 12.70 (1H, s, NH-pyrrole); 
13
C NMR (125 MHz, DMSO-
d6) δ ppm 111.7 (C-Ar), 115.4 (d, JCF = 21.7 Hz, C-Ar), 119.0 (d, JCF = 5.2 Hz, C-Ar), 123.6 
(C-Ar), 124.9 (C-Ar), 127.0 (C-Ar), 128.8 (d, JCF = 2.5 Hz, C-Ar), 129.4 (C-Ar), 130.0 (C-
Ar), 132.1 (d, JCF = 8.7 Hz, C-Ar), 135.5 (C-Ar), 141.6 (C-Ar), 144.4 (C-Ar), 158.5 (d, JCF = 
245.6 Hz, C-F), 158.7 (CO), 184.9 (CO), one C-Ar not visualised; HRMS calcd for 
C17H11
79
BrFN3O2 [M+H]
+
 388.0091, found 388.0090. 
4-(2-Bromo-6-fluorobenzoyl)-N-(pyridin-4-ylmethyl)-1H-pyrrole-2-carboxamide, 279 
 
General procedure M: 4-(2-bromo-6-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (55 mg, 
0.18 mmol), PCl3 (16 µL, 0.18 mmol) and tert-butyl 4-picolylamine (46 µL, 0.45 mmol). 
Purification via column chromatography (silica; 0-8% MeOH/DCM) gave 279 as a white 
solid (40 mg, 55%). Rf 0.66 (9:1 DCM/MeOH); m.p. 141-143 
o
C; λmax (EtOH/nm) 384.5, 
236.0; IR υmax/cm
-1
 3076, 2922, 2861, 1628, 1601, 1567, 1535; 
1
H NMR (500 MHz, DMSO-
d6) δ ppm 4.46 (2H, d, J = 6.0 Hz, NH-CH2), 7.25 (1H, br s, H-3), 7.29 (2H, d, J = 6.0 Hz, 
CH-pyridine), 7.34 (1H, br s, H-5), 7.41-7.43 (1H, m, H-5’), 7.50 (1H, ddd, J = 6.2, 8.3 and 
8.4 Hz, H-4’), 7.58-7.59 (1H, m, H-3’), 8.51 (2H, d, J = 6.0 Hz, N-CH-pyridine), 8.90 (1H, t, 
J = 6.0 Hz, CO-NH), 12.48 (1H, s, NH-pyrrole); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 41.1 
(CH2), 110.3 (C-Ar), 115.3 (d, JCF = 21.5 Hz, C-Ar), 119.0 (d, JCF = 5.2 Hz, C-Ar), 122.1 (C-
Ar), 124.8 (C-Ar), 128.4 (C-Ar), 128.5 (C-Ar), 128.8 (d, JCF = 2.6 Hz, C-Ar), 130.0 (d, JCF = 
22.9 Hz, C-Ar), 132.1 (d, JCF = 8.5 Hz, C-Ar), 148.4 (C-Ar), 149.5 (C-Ar), 158.4 (d, JCF = 
246.9 Hz, C-F), 160.1 (CO), 184.8 (CO); HRMS calcd for C18H13
79
BrFN3O2 [M+H]
+
 
402.0248, found 402.0242. 
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4-(2-Bromo-6-fluorobenzoyl)-N-(pyridin-3-ylmethyl)-1H-pyrrole-2-carboxamide, 280 
 
General procedure M:  4-(2-bromo-6-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (56 mg, 
0.18 mmol), PCl3 (16 µL, 0.18 mmol) and tert-butyl 3-picolylamine (46 µL, 0.45 mmol). 
Purification via column chromatography (silica; 0-8% MeOH/DCM) gave 280 as a white 
solid (49 mg, 68%). Rf 0.65 (9:1 DCM/MeOH); m.p. 128-130 
o
C; λmax (EtOH/nm) 290.5, 
238.0; IR υmax/cm
-1
 3121, 2867, 1626, 1566, 1534; 
1
H NMR (500 MHz, DMSO-d6) δ ppm 
2.44 (2H, d, J = 6.0 Hz, NH-CH2), 7.19 (1H, br s, H-3), 7.32 (1H, br s, H-5), 7.35 (1H, dd, J 
= 4.7 and 7.8 Hz, CH-pyridine), 7.39-7.41 (1H, m, H-5’), 7.48 (1H, ddd, J = 6.2, 8.3 and 8.4 
Hz, H-4’), 7.57-7.58 (1H, m, H-3’), 7.69 (1H, dd, J = 1.5 and 7.8 Hz, CH-pyridine), 8.45 
(1H, dd, J = 1.5 and 4.7 Hz, N-CH-pyridine), 8.53 (1H, d, J = 2.5 Hz, N-CH-pyridine), 8.91 
(1H, t, J = 6.0 Hz, CO-NH), 12.45 (NH-pyrrole); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 
40.1 (CH2), 110.2 (C-Ar), 115.3 (d, JCF = 22.3 Hz, C-Ar), 119.0 (d, JCF = 5.4 Hz, C-Ar), 
123.5 (C-Ar), 124.7 (C-Ar), 128.4 (C-Ar), 128.5 (C-Ar), 128.7 (d, JCF = 2.8 Hz, C-Ar), 130.0 
(d, JCF = 23.1 Hz, C-Ar), 132.0 (d, JCF = 8.7 Hz, C-Ar), 134.9 (C-Ar), 135.1 (C-Ar), 148.1 
(C-Ar), 148.8 (C-Ar), 158.4 (d, JCF = 248.5 Hz, C-F), 159.9 (CO), 184.8 (CO); HRMS calcd 
for C18H13
79
BrFN3O2 [M+H]
+
 402.0248, found 402.0243.  
tert-Butyl 4-(4-(2-fluoro-6-methylbenzoyl)-1H-pyrrole-2-carboxamido)piperidine-1-
carboxylate, 282 
 
General procedure M:  4-(2-fluoro-6-methylbenzoyl)-1H-pyrrole-2-carboxylic acid (100 
mg, 0.40 mmol), PCl3 (35 µL, 0.20 mmol) and tert-butyl 4-aminopiperidine-1-carboxylate 
(200 mg, 1.00 mmol). Purification via column chromatography (silica; 30-70% 
EtOAc/petrol) gave 282 as a colourless oil (64 mg, 37%). Rf 0.67 (9:1 DCM/MeOH); λmax 
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(EtOH/nm) 284.0, 234.0; IR υmax/cm
-1
 3126, 2976, 2935, 2867, 1616, 1568, 1534, 1464, 
1429, 1394, 1366, 1316, 1276, 1238; 
1
H NMR (500 MHz, DMSO-d6) δ ppm 1.31-1.40 (2H, 
m, CH-piperidine), 1.41 (9H, s, C-CH3), 1.74-1.77 (2H, m, CH-piperidine), 2.17 (3H, s, 
CH3), 2.84 (2H, br s, N-CH-piperidine), 3.89-3.96 (3H, m, N-CH-piperidine), 7.12-7.17 (3H, 
m, H-3, H-3’ and H-5’), 7.22 (1H, br s, H-5), 7.41 (1H, ddd, J = 6.2, 8.3 and 8.4 Hz, H-4’), 
8.11 (1H, d, J = 7.8 Hz, CO-NH), 12.31 (1H, s, NH-pyrrole); 
13
C NMR (125 MHz, CDCl3) δ 
ppm 19.0 (d, JCF = 2.0 Hz, CH3), 28.4 (C-CH3), 32.1 (C-piperidine), 42.7 (C-piperidine), 47.1 
(C-piperidine), 79.8 (C-CH3), 108.8 (C-Ar), 113.0 (d, JCF = 21.8 Hz, C-Ar), 126.1 (d, JCF = 
2.5 Hz, C-Ar), 127.5 (C-Ar), 127.8 (C-Ar), 130.4 (d, JCF = 8.7 Hz, C-Ar), 137.8 (d, JCF = 3.2 
Hz, C-Ar), 154.7 (CO), 159.7 (CO), 188.8 (CO), 2 C-Ar and C-F not visualised; HRMS calcd 
for C23H28FN3O4 [M+H]
+ 
430.2137, found 430.2138. 
4-(2-Fluoro-6-methylbenzoyl)-N-(piperidin-4-yl)-1H-pyrrole-2-carboxamide, 291 
 
General procedure K: tert-butyl 4-(4-(2-fluoro-6-methylbenzoyl)-1H-pyrrole-2-
carboxamido)piperidine-1-carboxylate (40 mg, 0.09 mmol), TFA (11 µL, 0.14 mmol). 
Purification via column chromatography (NH silica; 0-5% MeOH/DCM) gave 291 as a white 
solid (30 mg, 100%). Rf 0.45 (9:1 DCM/MeOH, NH silica); m.p. 251-252 
o
C; λmax 
(EtOH/nm) 235.0, 210.0; IR υmax/cm
-1
 3295, 2949, 2852, 1626, 1568, 1532; 
1
H NMR (500 
MHz, DMSO-d6) δ ppm 1.35 (2H, m, CH-piperidine), 1.68-1.71 (2H, m, CH-piperidine), 
2.17 (3H, s, CH3), 2.46-2.51 (2H, m, N-CH-piperidine), 2.92-2.96 (2H, m, N-CH-piperidine), 
3.72-3.80 (1H, m, N-CH-piperidine), 7.12-7.20 (4H, m, H-3, H-3’, H-5’ and H-5), 7.41 (1H, 
ddd, J = 6.2, 8.3 and 8.4 Hz, H-4’), 8.08 (1H, d, J = 8.0 Hz, CO-NH), 12.33 (1H, br s, NH-
pyrrole); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 18.4 (CH3), 33.1 (C-piperidine), 45.3 (C-
piperidine), 46.9 (N-C-piperidine), 109.8 (C-Ar), 112.9 (d, JCF = 21.4 Hz, C-Ar), 125.8 (C-
Ar), 126.2 (d, JCF = 2.4 Hz, C-Ar), 127.4 (C-Ar), 128.6 (C-Ar), 128.8 (C-Ar), 130.3 (d, JCF = 
8.6 Hz, C-Ar), 136.8 (d, JCF = 3.7 Hz, C-Ar), 158.4 (d, JCF = 243.2 Hz, C-F), 158.9 (CO), 
187.8 (CO); HRMS calcd for C18H20FN3O2 [M+H]
+
 330.1612, found 330.1615. 
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4-(2-Chloro-6-fluorobenzoyl)-N-(1-methylpiperidin-4-yl)-1H-pyrrole-2-carboxamide, 
283 
 
General procedure D: 4-(2-chloro-6-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (200 mg, 
0.75 mmol), CDI (243 mg, 1.50 mmol), and 4-amino-1-methyl piperidine (235 µL, 1.88 
mmol). Purification via column chromatography (NH silica; 0-8% MeOH/DCM) gave 283 as 
a white solid (212 mg, 78%). 
Rf 0.17 (9:1 DCM/MeOH); m.p. Degrades above 260 
o
C; λmax (EtOH/nm) 285.5, 236.5; IR 
υmax/cm
-1
 3358, 3122, 2937, 2854, 2788, 1614, 1570, 1535; 
1
H NMR (500 MHz, DMSO-d6) δ 
ppm 1.48-1.56 (2H, m, CH-piperidine), 1.71-1.74 (2H, m, CH-piperidine), 1.88-1.95 (2H, m, 
N-CH-piperidine), 2.16 (3H, s, CH3), 2.74-2.77 (2H, m, N-CH-piperidine), 3.64-3.70 (1H, m, 
N-CH-piperidine), 7.20 (1H, br s, H-3), 7.32 (1H, br s, H-5), 7.37-7.40 (1H, m, H-5’), 7.45-
7.46 (1H, m, H-3’), 7.57 (1H, ddd, J  = 6.4, 8.2 and 8.3 Hz, H-4’),  8.10 (1H, d, J = 8.0 Hz, 
CO-NH), 12.40 (1H, s, NH-pyrrole); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 31.5 (C-
piperidine), 45.9 (C-piperidine), 54.4 (CH3), 109.9 (C-Ar), 114.9 (d, JCF = 21.6 Hz, C-Ar), 
125.0 (C-Ar), 125.8 (d, JCF = 2.7 Hz, C-Ar), 128.0 (C-Ar), 128.2 (d, JCF = 23.7 Hz, C-Ar), 
128.9 (C-Ar), 130.4 (d, JCF = 6.2 Hz, C-Ar), 131.7 (d, JCF = 9.2 Hz, C-Ar), 158.7 (d, JCF = 
246.8 Hz, C-F), 159.0 (CO), 183.9 (CO); HRMS calcd for C18H19
35
ClFN3O2 [M+H]
+
 
364.1223, found 364.1226. 
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tert-Butyl 4-(4-(2-chloro-6-fluorobenzoyl)-1H-pyrrole-2-carboxamido)piperidine-1-
carboxylate, 284 
 
General procedure M: 4-(2-chloro-6-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (100 mg, 
0.37 mmol), PCl3 (31 µL, 0.37 mmol) and tert-butyl 4-aminopiperidine-1-carboxylate (185 
mg, 0.93 mmol). Purification via column chromatography (silica; 30-70% EtOAc/petrol) 
gave 284 as a white solid (77 mg, 46%). Rf 0.69 (9:1 DCM/MeOH); m.p. 153-155 
o
C; λmax 
(EtOH/nm) 283.5, 235.5; IR υmax/cm
-1
 3130, 2976, 2932, 2862, 1623, 1569, 1535; 
1
H NMR 
(500 MHz, DMSO-d6) δ ppm 1.31-1.39 (2H, m, CH-piperidine), 1.41 (9H, s, C-CH3), 1.75-
1.78 (2H, m, CH-piperidine), 2.84 (2H, br s, N-CH-piperidine), 3.89-3.96 (3H, m, N-CH-
piperidine), 7.18 (1H, br s, H-3), 7.33 (1H, br s, H-5), 7.37-7.39 (1H, m, H-5’), 7.45-7.46 
(1H, m, H-3’), 7.57 (1H, ddd, J = 6.2, 8.3 and 8.4 Hz, H-4’), 8.11 (1H, d, J = 7.8 Hz, CO-
NH), 12.42 (1H, s, NH-pyrrole); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 28.1 (C-CH3), 31.4 
(C-piperidine), 45.9 (C-piperidine), 78.6 (C-CH3), 109.9 (C-Ar), 114.9 (d, JCF = 21.6 Hz, C-
Ar), 125.0 (C-Ar), 125.8 (d, JCF = 2.7 Hz, C-Ar), 128.1 (C-Ar), 128.2 (d, JCF = 23.0 Hz, C-
Ar), 128.8 (C-Ar), 130.4 (d, JCF = 5.9 Hz, C-Ar), 131.7 (d, JCF = 9.1 Hz, C-Ar), 153.9 (CO), 
158.5 (d, JCF = 246.8 Hz, C-F), 159.0 (CO), 183.9 (CO); HRMS calcd for 
C22H25
35
ClFN3O4.NH4 [M+NH4]
+
 467.1856, found 467.1855. 
4-(2-Chloro-6-fluorobenzoyl)-N-cyclohexyl-1H-pyrrole-2-carboxamide, 285 
 
General procedure D: 4-(2-chloro-6-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (200 mg, 
0.75 mmol), CDI (243 mg, 1.50 mmol), and cyclohexylamine (0.22 mL, 1.88 mmol). 
Purification via column chromatography (silica; 30-70% EtOAc/petrol) gave 285 with 
cyclohexylamine contamination. The crude sample was redissolved in DCM (10 mL) and 
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passed through a MP-TsOH isolute cartridge to give 285 as a white solid (170 mg, 65%). Rf 
0.45 (95:5 DCM/MeOH); m.p. 288-290 
o
C; λmax (EtOH/nm) 287.0, 236.5; IR υmax/cm
-1
 3361, 
3161, 3123, 2929, 2854, 1617, 1570, 1533; 
1
H NMR (500 MHz, DMSO-d6) δ ppm 1.07-1.15 
(1H, m, CH-cyclohexane), 1.21-1.34 (4H, m, CH-cyclohexane), 1.59-1.62 (1H, m, CH-
cyclohexane), 1.71-1.80 (4H, m, CH-cyclohexane), 3.67-3.75 (1H, m, N-CH-cyclohexane), 
7.20 (1H, br s, H-3), 7.31 (1H, br s, H-5), 7.37-7.40 (1H, m, H-5’), 7.45-7.46 (1H, m, H-3’), 
7.57 (1H, ddd, J = 6.3, 8.3 and 8.4 Hz, H-4’), 8.07 (1H, d, J = 8.0 Hz, CO-NH), 12.38 (1H, s, 
NH-pyrrole); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 24.9 (C-cyclohexane), 25.2 (C-
cyclohexane), 32.5 (C-cyclohexane), 47.7 (N-C-cyclohexane), 109.8 (C-Ar), 114.9 (d, JCF = 
21.8 Hz, C-Ar), 124.9 (C-Ar), 125.8 (d, JCF = 2.6 Hz, C-Ar), 128.0 (C-Ar), 128.2 (d, JCF = 
23.4 Hz, C-Ar), 129.1 (C-Ar), 130.4 (d, JCF = 6.2 Hz, C-Ar), 131.7 (d, JCF = 9.0 Hz, C-Ar), 
158.6 (d, JCF = 247.1 Hz, C-F), 158.8 (CO), 183.9 (CO); HRMS calcd for C18H18
35
ClFN2O2 
[M+H]
+
 349.1114, found 349.1118. 
4-(2-Chloro-6-fluorobenzoyl)-N-(tetrahydro-2H-pyran-4-yl)-1H-pyrrole-2-carboxamide, 
286 
 
General procedure D: 4-(2-chloro-6-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (200 mg, 
0.75 mmol), CDI (243 mg, 1.50 mmol) and 4-aminotetrahydro-2H-pyran (0.19 mL, 1.88 
mmol). Purification via column chromatography (silica; 30-70% EtOAc/petrol) gave 286 as a 
white solid (172 mg, 65%). Rf 0.42 (95:5 DCM/MeOH); m.p. 246-248 
o
C; λmax (EtOH/nm) 
285.5, 238.0; IR υmax/cm
-1
 3356, 3129, 2951, 2849, 1622, 1570, 1535; 
1
H NMR (500 MHz, 
DMSO-d6) δ ppm 1.48-1.57 (2H, m, CH-THP), 1.72-1.75 (2H, m, CH-THP), 3.34-3.40 (2H, 
m, O-CH-THP), 3.35-3.88 (2H, m, O-CH-THP), 3.91-3.99 (1H, m, N-CH-THP), 7.21 (1H, br 
s, H-3), 7.33 (1H, br s, H-5), 7.37-7.41 (1H, m, H-5’), 7.45-7.47 (1H, m, H-3’), 7.57 (1H, 
ddd, J = 6.3, 8.3 and 8.4 Hz, H-4’), 8.17 (1H, d, J = 8.0 Hz, CO-NH), 12.43 (1H, s, NH-
pyrrole); 
13
C MR (125 MHz, DMSO-d6) δ ppm 32.5 (C-THP), 45.2 (C-THP), 66.1 (N-C-
THP), 109.9 (C-Ar), 114.9 (d, JCF = 21.7 Hz, C-Ar), 125.0 (C-Ar), 125.8 (d, JCF = 2.8 Hz, C-
Ar), 128.1 (C-Ar), 128.2 (d, JCF = 20.0 Hz, C-Ar), 128.9 (C-Ar), 130.4 (d, JCF = 6.1 Hz, C-
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Ar), 131.7 (d, JCF = 8.7 Hz, C-Ar), 158.7 (d, JCF = 246.4 Hz, C-F), 159.0 (CO), 183.9 (CO); 
HRMS calcd for C17H16
35
ClFN2O3 [M+H]
+
 351.0906, found 351.0910. 
4-(2-Chloro-6-fluorobenzoyl)-N-(piperidin-4-yl)-1H-pyrrole-2-carboxamide, 292 
 
General procedure K: tert-butyl 4-(4-(2-chloro-6-fluorobenzoyl)-1H-pyrrole-2-
carboxamido)piperidine-1-carboxylate (310 mg, 0.69 mmol), triethylsilane (0.27 mL, 1.73 
mmol) and TFA (2 mL/mmol) gave 292 as a white solid (238 mg, 99%). Rf 0.42 (9:1 
DCM/MeOH, NH silica); m.p. 177-179 
o
C; λmax (EtOH/nm) 287.0, 237.0; IR υmax/cm
-1
 3300, 
2944, 2848, 1628, 1571, 1532; 
1
H NMR (500 MHz, CDCl3) δ ppm 1.39-1.47 (2H, m, CH-
piperidine), 2.01-2.05 (2H, m, CH-piperidine), 2.74-2.79 (2H, m, N-CH-piperidine), 3.12-
3.16 (2H, m, N-CH-piperidine), 4.01-4.09 (1H, m, N-CH-piperidine), 6.98 (1H, d, J = 1.5 Hz, 
H-3), 7.11-7.12 (1H, m, H-5’), 7.30-7.32 (2H, m, H-5 and H-3’), 3.39 (1H, ddd, J = 6.2, 8.3 
and 8.4 Hz, H-4’), 9.66 (1H, br s, CO-NH), 12.62 (1H, br s, NH-pyrrole); 13C NMR (125 
MHz, DMSO-d6) δ ppm 32.3 (C-piperidine), 44.8 (C-piperidine), 46.3 (C-piperidine), 109.9 
(C-Ar), 114.9 (d, JCF = 21.7 Hz, C-Ar), 124.9 (C-Ar), 125.8 (d, JCF = 2.6 Hz, C-Ar), 128.1 
(C-Ar), 128.3 (C-Ar), 128.9 (C-Ar), 130.4 (d, JCF = 6.1 Hz, C-Ar), 131.7 (d, JCF = 8.9 Hz, C-
Ar), 158.6 (d, JCF = 247.5 Hz, C-Ar), 158.9 (CO), 183.9 (CO); HRMS calcd for 
C17H17
35
ClFN3O2 [M+H]
+
 350.1066, found 350.1071. 
4-(2-Bromo-6-fluorobenzoyl)-N-(1-methylpiperidin-4-yl)-1H-pyrrole-2-carboxamide, 
287 
 
General procedure D: 4-(2-bromo-6-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (200 mg, 
0.64 mmol), CDI (207 mg, 1.28 mmol) and 4-amino-1-methyl piperidine (200 µL, 1.60 
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mmol). Purification via column chromatography (NH silica; 0-8% MeOH/DCM) gave 287 as 
a white solid (214 mg, 82%). Rf 0.15 (9:1 DCM/MeOH); m.p. Degrades above 250 
o
C; λmax 
(EtOH/nm) 288.5, 234.5; IR υmax/cm
-1
 3558, 3180, 3127, 2941, 2851, 2797, 1658, 1615, 
1569, 1546; 
1
H NMR (500 MHz, DMSO-d6) δ ppm 1.48-1.56 (2H, m, CH-piperidine), 1.72-
1.74 (2H, m, CH-piperidine), 1.90-1.94 (2H, N-CH-piperidine), 2.15 (3H, s, CH3), 2.74-2.77 
(2H, m, N-CH-piperidine), 3.64-3.70 (1H, m, N-CH-piperidine), 7.19 (1H, br s, H-3), 7.30 
(1H, br s, H-5), 7.40-7.43 (1H, m, H-5’), 7.49 (1H, ddd, J = 6.3, 8.3 and 8.4 Hz, H-4’), 7.58-
7.60 (1H, m, H-3’), 8.10 (1H, d, J = 7.8 Hz, CO-NH), 12.39 (1H, s, NH-pyrrole); 13C NMR 
(125 MHz, DMSO-d6) δ ppm 31.6 (C-piperidine), 45.9 (C-piperidine), 54.4 (CH3), 110.0 (C-
Ar), 115.3 (d, JCF = 21.4 Hz, C-Ar), 119.0 (d, JCF = 4.8 Hz, C-Ar), 124.6 (C-Ar), 128.1 (C-
Ar), 128.8 (d, JCF = 2.7 Hz, C-Ar), 129.0 (C-Ar), 130.1 (d, JCF = 22.7 Hz, C-Ar), 132.0 (d, 
JCF = 8.3 Hz, C-Ar), 158.5 (d, JCF = 248.0 Hz, C-F), 159.1 (CO), 184.8 (CO); HRMS calcd 
for C18H19
79
BrFN3O2 [M+H]
+
 408.0717, found 408.0719. 
tert-Butyl 4-(4-(2-bromo-6-fluorobenzoyl)-1H-pyrrole-2-carboxamido)piperidine-1-
carboxylate, 288 
 
General procedure D: 4-(2-bromo-6-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (100 mg, 
0.32 mmol), CDI (103 mg, 0.64 mmol), and tert-butyl 4-aminopiperidine-1-carboxylate (160 
mg, 0.80 mmol). Purification via column chromatography (silica; 30-70% EtOAc/petrol) 
gave 288 as a white solid (141 mg, 89%). Rf 0.66 (9:1 DCM/MeOH); m.p. 205-207 
o
C; λmax 
(EtOH/nm) 286.5, 236.5; IR υmax/cm
-1
 3359, 3177, 3121, 2976, 2934, 2859, 1693, 1660, 
1618, 1567, 1535; 
1
H NMR (500 MHz, DMSO-d6) δ ppm 1.31-1.40 (2H, m, CH-piperidine), 
1.41 (9H, s, C-CH3), 1.75-1.78 (2H, m, CH-piperidine), 2.84 (2H, br s, N-CH-piperidine), 
3.89-3.97 (3H, m, N-CH-piperidine), 7.18 (1H, br s, H-3), 7.30 (1H, br s, H-5), 7.39-7.43 
(1H, m, H-5’), 7.49 (1H, ddd, J = 6.2, 8.3 and 8.4 Hz, H-4’), 7.58-7.60 (1H, m, H-3’), 8.12 
(1H, d, J = 8.0 Hz, CO-NH), 12.40 (1H, s, NH-pyrrole); 
13
C NMR (125 MHz, DMSO-d6) δ 
ppm 28.1 (C-CH3), 31.4 (C-piperidine), 45.9 (C-piperidine), 78.6 (C-CH3), 110.0 (C-Ar), 
115.3 (d, JCF = 21.7 Hz, C-Ar), 119.0 (d, JCF = 5.1 Hz, C-Ar), 124.7 (C-Ar), 128.1 (C-Ar), 
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128.8 (C-Ar), 130.1 (d, JCF = 23.2 Hz, C-Ar), 132.0 (d, JCF = 8.9 Hz, C-Ar), 153.9 (CO), 
158.5 (d, JCF = 246.8 Hz, C-F), 159.0 (CO), 184.8 (CO), one F split C-Ar not visualised; 
HRMS calcd for C22H25
79
BrFN3O4 [M+H]
+
 494.1085, found 494.1082. 
4-(2-Bromo-6-fluorobenzoyl)-N-cyclohexyl-1H-pyrrole-2-carboxamide, 289 
 
General procedure D: 4-(2-bromo-6-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (200 mg, 
0.64 mmol), CDI (207 mg, 1.28 mmol and cyclohexylamine (180 µL, 1.60 mmol). 
Purification via column chromatography (silica; 30-70% EtOAc/petrol) gave 289 with 
cyclohexylamine contamination. The crude sample was redissolved in DCM (10 mL) and 
passed through a MP-TsOH isolute cartridge to give 289 as a white solid (169 mg, 67%). Rf 
0.43 (95:5 DCM/MeOH); m.p. 296-298 
o
C; λmax (EtOH/nm) 286.5, 236.5; IR υmax/cm
-1
 3356, 
3118, 3055, 2928, 2854, 1615, 1569, 1537; 
1
H NMR (500 MHz, DMSO-d6) δ ppm 1.07-1.15 
(1H, m, CH-cyclohexane), 1.12-1.34 (4H, m, CH-cyclohexane), 1.58-1.62 (1H, m, CH-
cyclohexane), 1.71-1.80 (4H, m, CH-cyclohexane), 3.68-3.75 (1H, m, N-CH-cyclohexane), 
7.20 (1H, br s, H-3), 7.29 (1H, br s, H-5), 7.40-7.43 (1H, m, H-5’), 7.49 (1H, ddd, J = 6.3, 8.3 
and 8.4 Hz, H-4’), 7.58-7.60 (1H, m, H-3’), 8.07 (1H, d, J = 8.0 Hz, CO-NH), 12.37 (1H, s, 
NH-pyrrole); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 24.9 (C-cyclohexane), 25.2 (C-
cyclohexane), 32.5 (C-cyclohexane), 47.7 (N-C-cyclohexane), 109.8 (C-Ar), 115.3 (d, JCF = 
21.5 Hz, C-Ar), 119.1 (d, JCF = 5.1 Hz, C-Ar), 124.6 (C-Ar), 128.0 (C-Ar), 128.8 (d, JCF = 
2.5 Hz, C-Ar), 129.0 (C-Ar), 130.1 (d, JCF = 22.8 Hz, C-Ar), 132.0 (d, JCF = 8.8 Hz, C-Ar), 
158.6 (d, JCF = 247.4 Hz, C-F), 158.8 (CO), 184.8 (CO); HRMS calcd for C18H18
79
BrFN2O2 
[M+H]
+ 
393.0608, found 393.0612. 
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4-(2-Bromo-6-fluorobenzoyl)-N-(tetrahydro-2H-pyran-4-yl)-1H-pyrrole-2-carboxamide, 
290 
 
General procedure D: 4-(2-bromo-6-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (200 mg, 
0.64 mmol), CDI (207 mg, 1.28 mmol), and 4-aminotetrahydro-2H-pyran (170 µL, 1.60 
mmol). Purification via column chromatography (silica; 30-70% EtOAc/petrol) gave 290 as a 
white solid (180 mg, 71%). Rf 0.39 (95:5 DCM/MeOH); m.p. 250-251 
o
C; λmax (EtOH/nm) 
287.0, 236.0; IR υmax/cm
-1
 3352, 3179, 3122, 2956, 2852, 1734, 1619, 1568, 1536; 
1
H NMR 
(500 MHz, DMSO-d6) δ ppm 1.48-1.56 (2H, m, CH-THP), 1.72-1.75 (2H, m, CH-THP), 
3.35-3.40 (2H, m, O-CH-THP), 3.85-3.88 (2H, m, O-CH-THP), 3.91-3.99 (1H, m, N-CH-
THP), 7.20 (1H, br s, H-3), 7.31 (1H, br s, H-5), 7.40-7.44 (1H, m, H-5’), 7.49 (1H, ddd, J = 
6.3, 8.2 and 8.3 Hz, H-4’), 7.59-7.60 (1H, m, H-3’), 8.17 (1H, d, J = 8.0 Hz, CO-NH), 12.42 
(1H, s, NH-pyrrole); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 32.5 (C-THP), 45.2 (C-THP), 
66.1 (N-C-THP), 110.0 (C-Ar), 115.3 (d, JCF = 21.8 Hz, C-Ar), 119.0 (d, JCF = 5.3 Hz, C-Ar), 
124.6 (C-Ar), 128.1 (C-Ar), 128.7 (C-Ar), 128.8 (d, JCF = 2.7 Hz, C-Ar), 130.1 (d, JCF = 22.9 
Hz, C-Ar), 132.0 (d, JCF = 9.0 Hz, C-Ar), 158.6 (d, JCF = 247.4 Hz, C-F), 159.0 (CO), 184.8 
(CO); HRMS calcd for C17H16
79
BrFN2O3 [M+H]
+ 
395.0401, found 395.0403. 
4-(2-Bromo-6-fluorobenzoyl)-N-(piperidin-4-yl)-1H-pyrrole-2-carboxamide, 293 
 
General procedure K: tert-butyl 4-(4-(2-bromo-6-fluorobenzoyl)-1H-pyrrole-2-
carboxamido)piperidine-1-carboxylate (130 mg, 0.26 mmol), triethylsilane (0.10 mL, 0.65 
mmol) and TFA (2 mL/mmol) gave 293 as a white solid (102 mg, 100%). Rf 0.50 (9:1 
DCM/MeOH, NH silica); m.p. 250-252 
o
C; λmax (EtOH/nm) 281.0, 236.0; IR υmax/cm
-1
 3301, 
2945, 2844, 1626, 1600, 1568, 1530; 
1
H NMR (500 MHz, DMSO-d6) δ ppm 1.33-1.41 (2H, 
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m, CH-piperidine), 1.69-1.73 (2H, m, CH-piperidine), 2.48-2.54 (2H, m, N-CH-piperidine), 
2.94-2.98 (2H, m, N-CH-piperidine), 3.74-3.81 (1H, m, N-CH-piperidine), 7.21 (1H, br s, H-
3), 7.29 (1H, br s, H-5), 7.39-7.43 (1H, m, H-5’), 7.49 (1H, ddd, J = 6.2, 8.2 and 8.3 Hz, H-
4’), 7.58-7.60 (1H, m, H-3’), 8.10 (1H, d, J = 8.0 Hz, CO-NH), NH-pyrrole not observed; 13C 
NMR (125 MHz, DMSO-d6) δ ppm 32.8 (C-piperidine), 45.1 (C-piperidine), 46.7 (C-
piperidine), 109.9 (C-Ar), 115.3 (d, JCF = 21.7 Hz, C-Ar), 119.0 (d, JCF = 5.3 Hz, C-Ar), 
124.6 (C-Ar), 128.1 (C-Ar), 128.8 (d, JCF = 2.9 Hz, C-Ar), 129.0 (C-Ar), 130.1 (d, JCF = 22.5 
Hz, C-Ar), 132.0 (d, JCF = 8.6 Hz, C-Ar), 158.5 (d, JCF = 246.9 Hz, C-F), 158.8 (CO), 184.8 
(CO); HRMS calcd for C17H17
79
BrFN3O2 [M+H]
+
 394.0561, found 394.0564. 
Methyl 2-bromo-6-fluorobenzoate, 313 
 
To a solution of methyl 2-bromo-6-fluorobenzoic acid (1.00 g, 4.56 mmol) in MeCN (2 
mL/mmol) was added O-methyl-N,N’-diisopropylisourea (1.00 mL, 5.48 mmol). The 
resulting solution was heated at 120 
o
C with microwave irradiation for 5 min. The crude 
mixture was filtered under suction, washing with diethyl ether (2 x 10 mL) and the precipitate 
discarded. Purification via column chromatography (silica; 0-10% EtOAc/petrol) gave 313 as 
a colourless oil (0.92 g, 87%). Rf 0.42 (8:2 Petrol/EtOAc); λmax (EtOH/nm) 272.0; IR 
υmax/cm
-1
 2954, 1738, 1605, 1573, 1449, 1282; 
1
H NMR (500 MHz, CDCl3) δ ppm 3.90 (3H, 
s, O-CH3), 7.00-7.03 (1H, m, H-5), 7.19 (1H, ddd, J = 5.8, 8.2 and 8.3 Hz, H-4), 7.31-7.33 
(1H, m, H-3); 
13
C NMR (125 MHz, CDCl3) δ ppm 53.0 (CH3), 115.0 (d, JCF = 21.4 Hz, C-
Ar), 120.3 (d, JCF = 4.1 Hz, C-Ar), 124.6 (d, JCF = 19.9 Hz, C-Ar), 128.6 (d, JCF = 3.5 Hz, C-
Ar), 132.0 (d, JCF = 8.9 Hz, C-Ar), 159.6 (d, JCF = 254.0 Hz, C-F), 164.4 (CO); MS (ES+) 
m/z = 233.2 [(
79
BrM)+H]
+
. 
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Methyl 2-ethyl-6-fluorobenzoate, 314 
 
General procedure N: methyl 2-bromo-6-fluorobenzoate (250 mg, 1.07 mmol), ethylboronic 
acid (237 mg, 3.21 mmol), Cs2CO3 (522 mg, 1.61 mmol), and Pd(dtbf)Cl2 (10 mol%). 
Purification via column chromatography (silica; 0-15% EtOAc/petrol) gave 314 as a 
colourless oil (129 mg, 66%). Rf 0.52 (8:2 Petrol/EtOAc); λmax (EtOH/nm) 269.5; IR υmax/cm
-
1
 1736, 1616, 1581; 
1
H NMR (500 MHz, CDCl3) δ ppm 1.14 (3H, t, J = 7.4 Hz, CH3), 2.63 
(2H, q, J = 7.4 Hz, CH2), 3.86 (3H, s, O-CH3), 6.85-6.89 (1H, m, H-5), 6.95-6.97 (1H, m, H-
3), 7.25 (1H, ddd, J = 5.8, 8.2 and 8.3 Hz, H-4); 
13
C NMR (125 MHz, CDCl3) δ ppm 15.5 
(CH3), 26.6 (CH2), 52.4 (O-CH3), 113.2 (d, JCF = 21.6 Hz, C-Ar), 121.2 (d, JCF = 16.0 Hz, C-
Ar), 124.4 (d, JCF = 2.8 Hz, C-Ar), 131.4 (d, JCF = 8.9 Hz, C-Ar), 144.8 (d, JCF = 1.8 Hz, C-
Ar), 159.8 (d, JCF = 250.4 Hz, C-F), 166.4 (CO); HRMS calcd for C10H11FO2 [M+H]
+ 
183.0816, found 183.0813. 
2-Ethyl-6-fluorobenzoic acid, 318 
 
A microwave vial was charged with methyl 2-ethyl-6-fluorobenzoate (1.14 g, 6.26 mmol), 
LiCl (1.33 g, 31.30 mmol) and DMF (5 mL). The resulting mixture was heated at 150 
o
C with 
microwave irradiation for 1 h. Water was added (50 mL) and adjusted to pH10 with a 1M 
aqueous solution of NaOH, and washed with EtOAc (50 mL). The aqueous phase was then 
acidified (pH2-3) with a 1M aqueous solution of HCl and the product extracted into EtOAc 
(2 x 50 mL). Combined organic layers were washed with brine, dried over Na2SO4 and 
concentrated in vacuo to give 318 as a colourless oil (0.79 g, 75%). Rf 0.15 (9:1 
DCM/MeOH); λmax (EtOH/nm) 268.5; IR υmax/cm
-1
 2970, 2877, 2651, 2541, 1690, 1616, 
1579; 
1
H NMR (500 MHz, CDCl3) δ ppm 1.29 (3H, t, J = 7.5 Hz, CH3), 2.86 (2H, q, J = 7.5 
Hz, CH2), 7.00-7.03 (1H, m, H-5), 7.10-7.11 (1H, m, H-3), 7.40 (1H, ddd, J = 5.8, 8.2 and 
8.3 Hz, H-4), 10.73 (1H, br s, COOH); 
13
C NMR (125 MHz, CDCl3) δ ppm 15.7 (CH3), 26.8 
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(CH2), 113.5 (d, JCF = 22.3 Hz, C-Ar), 119.8 (d, JCF = 14.4 Hz, C-Ar), 124.8 (d, JCF = 3.1 Hz, 
C-Ar), 132.2 (d, JCF = 9.2 Hz, C-Ar), 145.6 (C-Ar), 160.4 (d, JCF = 252.7 Hz, C-F), 170.7 
(CO); HRMS calcd for C9H9FO2 [M-H]
- 
167.0514, found 167.0514. 
Methyl 4-(2-ethyl-6-fluorobenzoyl)-1H-pyrrole-2-carboxylate, 320 
 
General procedure E: 2-ethyl-6-fluorobenzoic acid (486 mg, 2.89 mmol), SOCl2 (316 µL, 
4.34 mmol) and DMF (10 mol%) gave 2-ethyl-6-fluorobenzoyl chloride  as a yellow oil 
which was used directly in the next step. General procedure F: methyl 1H-pyrrole-2-
carboxylate (242 mg, 1.93 mmol) and AlCl3 (0.65 g, 4.84 mmol). Purification via column 
chromatography (silica; 0-50% EtOAc/petrol) gave 320 as a colourless oil (441 mg, 83%). Rf 
0.25 (8:2 Petrol/EtOAc); λmax (EtOH/nm) 283.0, 231.5; IR υmax/cm
-1
 3259, 3136, 2972, 2879, 
1709, 1613, 1635, 1558; 
1
H NMR (500 MHz, CDCl3) δ ppm 1.17 (3H, t, J = 7.5 Hz, CH3), 
2.62 (2H, q, J = 7.5 Hz, CH2), 3.90 (3H, s, O-CH3), 6.97-7.00 (1H, m, H-5’), 7.10-7.12 (1H, 
m, H-3’), 7.22 (1H, br s, H-3), 7.36 (1H, ddd, J = 5.9, 8.2 and 8.3 Hz, H-4’), 7.44 (1H, dd, J 
= 1.3 and 3.2 Hz, H-5), 9.54 (1H, s, NH-pyrrole); 
13
C NMR (125 MHz, CDCl3) δ ppm 15.7 
(CH3), 26.0 (CH2), 52.0 (O-CH3), 113.0 (d, JCF = 21.6 Hz, C-Ar), 115.5 (C-Ar), 124.4 (C-
Ar), 124.5 (d, JCF = 2.7 Hz, C-Ar), 127.9 (C-Ar), 128.2 (C-Ar), 130.6 (d, JCF = 8.4 Hz, C-Ar), 
144.2 (d, JCF = 2.8 Hz, C-Ar), 159.0 (d, JCF = 244.5 Hz, C-F), 161.2 (CO), 188.8 (CO), one 
C-Ar not visualised; HRMS calcd for C15H14FNO3 [M+H]
+ 
276.1030, found 276.1035. 
4-(2-Ethyl-6-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid, 321 
 
General procedure G: methyl 4-(2-ethyl-6-fluorobenzoyl)-1H-pyrrole-2-carboxylate (400 
mg, 1.45 mmol), and LiOH monohydrate (1.22 g, 29.00 mmol) gave 321 as a white solid 
(378 mg, 100%). Rf 0.21 (9:1 DCM/MeOH); m.p. 179-181 
o
C; λmax (EtOH/nm) 275.5, 230.5; 
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IR υmax/cm
-1
 3338, 2961, 2921, 2852, 2705, 2625, 1688, 1641, 1560; 
1
H NMR (500 MHz, 
DMSO-d6) δ ppm 1.07 (3H, t, J = 7.5 Hz, CH3), 2.48 (2H, q, J = 7.5 Hz, CH2), 6.91 (1H, br s, 
H-3), 7.13-7.17 (1H, m, H-5’), 7.19-7.21 (1H, m, H-3’), 7.34 (1H, br s, H-5), 7.45 (1H, ddd, J 
= 6.2, 8.3 and 8.4 Hz, H-4’), 12.61 (1H, s, NH-pyrrole), 12.86 (1H, s, COOH); 13C NMR 
(125 MHz, DMSO-d6) δ ppm 15.6 (CH3), 25.3 (CH2), 112.9 (d, JCF = 21.5 Hz, C-Ar), 114.2 
(C-Ar), 124.8 (d, JCF = 2.2 Hz, C-Ar), 125.5 (C-Ar), 126.5 (C-Ar), 127.9 (d, JCF = 18.2 Hz, 
C-Ar), 128.9 (C-Ar), 130.7 (d, JCF = 8.4 Hz, C-Ar), 143.2 (d, JCF = 2.9 Hz, C-Ar), 158.2 (d, 
JCF = 243.5 Hz, C-F), 161.3 (CO), 187.6 (CO); HRMS calcd for C14H12FNO3 [M-H]
- 
260.0728, found 260.0718. 
4-(2-Ethyl-6-fluorobenzoyl)-N-(pyridin-3-yl)-1H-pyrrole-2-carboxamide, 300 
 
General procedure M: 4-(2-ethyl-6-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (50 mg, 
0.19 mmol), PCl3 (16 µL, 0.19 mmol), and 3-aminopyridine (45 mg, 0.48 mmol). Purification 
via column chromatography (silica; 0-8% MeOH/DCM) gave 300 as a white solid (41 mg, 
64%). Rf 0.29 (95:5 DCM/MeOH); m.p. 197-200 
o
C; λmax (EtOH/nm) 292.5, 248.5; IR 
υmax/cm
-1
 3295, 3117, 2969, 2937, 2876, 1641, 1535; 
1
H NMR (500 MHz, DMSO-d6) δ ppm 
1.10 (3H, t, J = 7.5 Hz, CH3), 2.49 (2H, t, J = 7.5 Hz, CH2), 7.16-7.19 (1H, m, H-5’), 7.22-
7.24 (1H, m, H-3’), 7.37 (1H, br s, H-3), 7.39 (1H, dd, J = 4.7 and 8.4 Hz, CH-pyridine), 
7.45-7.50 (2H, m, H-5 and H-4’), 3.14 (1H, ddd, J = 1.5, 2.5, and 8.4 Hz, CH-pyridine), 8.30 
(1H, dd, J = 1.5 and 4.7 Hz, N-CH-pyridine), 8.89 (1H, d, J = 2.5 Hz, N-CH-pyridine), 10.24 
(1H, s, CO-NH), 12.62 (1H, s, NH-pyrrole); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 15.6 
(CH3), 25.4 (CH2), 111.6 (C-Ar), 113.0 (d, JCF = 21.5 Hz, C-Ar), 123.5 (C-Ar), 124.8 (d, JCF 
= 2.5 Hz, C-Ar), 126.5 (C-Ar), 127.0 (C-Ar), 127.8 (C-Ar), 128.0 (d, JCF = 18.7 Hz, C-Ar), 
128.6 (C-Ar), 130.7 (d, JCF = 8.8 Hz, C-Ar), 135.5 (C-Ar), 141.6 (C-Ar), 143.6 (d, JCF = 3.3 
Hz, C-Ar), 144.4 (C-Ar), 158.3 (d, JCF = 242.4 Hz, C-F), 158.8 (CO), 187.8 (CO); HRMS 
calcd for  C19H16FN3O2 [M+H]
+ 
338.1300, found 338.1304. 
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tert-Butyl 4-(4-(2-ethyl-6-fluorobenzoyl)-1H-pyrrole-2-carboxamido)piperidine-1-
carboxylate, 322 
 
General procedure D: 4-(2-ethyl-6-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (86 mg, 
0.33 mmol), CDI (107 mg, 0.66 mmol) and tert-butyl 4-aminopiperidine-1-carboxylate (166 
mg, 0.83 mmol). Purification via column chromatography (silica; 30-70% EtOAc/petrol) 
gave 322 as a white solid (126 mg, 86%).  Rf 0.66 (9:1 DCM/MeOH); m.p. 133-135 
o
C; λmax 
(EtOH/nm) 282.5, 235.0; IR υmax/cm
-1
 3194, 3127, 2973, 2933, 2873, 1614, 1568, 1533; 
1
H 
NMR (500 MHz, DMSO-d6) δ ppm 1.07 (3H, t, J = 7.5 Hz, CH3), 1.31-1.39 (2H, m, CH-
piperidine), 1.41 (9H, s, C-CH3), 1.74-1.77 (2H, m, CH-piperidine), 2.49 (2H, q, J = 7.5 Hz, 
CH2), 2.84 (2H, br s, N-CH-piperidine), 3.88-3.96 (3H, m, N-CH-piperidine), 7.13-7.21 (4H, 
m, H-3, H-5, H-3’ and H-5’), 7.45 (1H, ddd, J = 6.3, 8.3 and 8.4 Hz, H-4’), 8.11 (1H, d, J = 
8.0 Hz, CO-NH), 12.31 (1H, s, NH-pyrrole); 
13
C NMR (125 MHz, CDCl3) δ ppm 15.7 (CH3), 
26.0 (CH2), 28.4 (C-CH3),  32.1 (C-piperidine), 42.7 (C-piperidine), 47.0 (C-piperidine), 79.8 
(C-CH3), 108.8 (C-Ar), 113.0 (d, JCF = 21.4 Hz, C-Ar), 127.7 (C-Ar), 127.8 (d, JCF = 13.8 
Hz, C-Ar), 130.6 (d, JCF = 8.5 Hz, C-Ar), 144.1 (C-Ar), 154.7 (CO), 159.7 (CO), 188.9 (CO), 
three C-Ar and C-F not visualised; HRMS calcd for  C24H30FN3O4 [M+H]
+ 
444.2293, found 
444.2289. 
4-(2-Ethyl-6-fluorobenzoyl)-N-(piperidin-4-yl)-1H-pyrrole-2-carboxamide smm435-001 
 
General procedure K: tert-butyl 4-(4-(2-ethyl-6-fluorobenzoyl)-1H-pyrrole-2-
carboxamido)piperidine-1-carboxylate (100 mg, 0.23 mmol), triethylsilane (92 µL, 0.58 
mmol) and TFA (2 mL/mmol) gave 301 as a white solid (73 mg 93%). Rf 0.60 (9:1 
DCM/MeOH, NH silica); m.p. 172-174 
oC; λmax (EtOH/nm) 234.0, 206.5; IR υmax/cm
-1
 3377, 
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2978, 2855, 2748, 1778, 1664, 1614, 1564, 1533, 1501; 
1
H NMR (500 MHz, DMSO-d6) δ 
ppm 1.03 (3H, t, J = 7.5 Hz, CH3), 1.58-1.67 (2H, m, CH-piperidine), 1.89-1.93 (2H, m, CH-
piperidine), 2.45 (2H, q, J = 7.5 Hz, CH2), 2.95-3.01 (2H, m, N-CH-piperidine), 3.26-3.29 
(2H, m, N-CH-piperidine), 3.95-4.02 (1H, m, N-CH-piperidine), 7.09-7.12 (1H, m, H-5’), 
7.15-7.16 (1H, m, H-3’), 7.41 (1H, ddd, J = 6.3, 8.3 and 8.4 Hz, H-4’), 8.24 (1H, d, J = 8.0 
Hz, CO-NH), 8.33 (1H, br s, H-3), 8.56 (1H, br s, H-5), 12.30 (1H, s, NH); 
13
C NMR (125 
MHz, DMSO-d6) δ ppm 15.6 (CH3), 25.3 (CH2), 28.3 (C-piperidine), 42.3 (C-piperidine), 
43.7 (C-piperidine), 110.1 (C-Ar), 112.9 (d, JCF = 21.6 Hz, C-Ar), 124.7 (d, JCF = 2.2 Hz, C-
Ar), 126.2 (C-Ar), 127.7 (C-Ar), 128.1 (d, JCF = 18.7 Hz, C-Ar), 128.3 (C-Ar), 130.6 (d, JCF 
= 8.5 Hz, C-Ar), 143.2 (d, JCF = 2.8 Hz, C-Ar), 158.2 (d, JCF = 243.0 Hz, C-F), 159.4 (CO), 
187.8 (CO); HRMS calcd for C19H22FN3O2 [M+H]
+
 344.1769, found 344.1771. 
4-(2-Ethyl-6-fluorobenzoyl)-N-(1-methylpiperidin-4-yl)-1H-pyrrole-2-carboxamide, 302 
 
General procedure D: 4-(2-ethyl-6-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (50 mg, 
0.19 mmol), CDI (62 mg, 0.38 mmol), and 4-amino-1-methyl piperidine (60 µL, 0.48 mmol). 
Purification via column chromatography (NH silica; 0-8% MeOH/DCM) gave 302 as a white 
solid (54 mg, 79%). Rf 0.16 (9:1 DCM/MeOH); m.p. 183-186 
o
C; λmax (EtOH/nm) 283.0, 
237.0, 207.0; IR υmax/cm
-1
 3354, 3120, 2935, 2863, 2792, 2684, 1614, 1571, 1537; 
1
H NMR 
(500 MHz, DMSO-d6) δ ppm 1.07 (3H, t, J = 7.5 Hz, CH3), 1.48-1.56 (2H, m, CH-
piperidine), 1.71-1.75 (2H, m, CH-piperidine), 1.89-1.95 (2H, m, N-CH-piperidine), 2.16 
(3H, s, N-CH3), 2.49 (2H, q, J = 7.5 Hz, CH2), 2.74-2.76 (2H, m, N-CH-piperidine), 3.63-
3.71 (1H, m, N-CH-piperidine), 6.92 (1H, br s, H-3), 7.12-7.21 (3H, m, H-5, H-3’, H-5’), 
7.45 (1H, ddd, J = 6.3, 8.3 and 8.4 Hz, H-4’), 8.09 (1H, d, J = 8.0 Hz, CO-NH), 12.01 (1H, s, 
NH-pyrrole); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 15.6 (CH3), 25.3 (CH2), 31.5 (C-
piperidine), 45.9 (N-CH3), 46.0 (C-piperidine), 54.4 (C-piperidine), 109.9 (C-Ar), 112.9 (d, 
JCF = 21.8 Hz, C-Ar), 126.2 (C-Ar), 127.3 (C-Ar), 128.2 (d, JCF = 18.8 Hz, C-Ar), 128.6 (C-
Ar), 130.5 (d, JCF = 8.6 Hz, C-Ar), 135.1 (C-Ar), 143.2 (C-Ar), 158.1 (d, JCF = 243.2 Hz, C-
F), 159.2 (CO), 187.8 (CO); HRMS calcd for  C20H24FN3O2 [M+H]
+ 
358.1925, found 
358.1929. 
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Methyl 4-(2-bromo-6-fluorobenzoyl)-1-tosyl-1H-pyrrole-2-carboxylate, 325 
 
To a solution of methyl 4-(2-bromo-6-fluorobenzoyl)-1H-pyrrole-2-carboxylate (1.23 g, 3.77 
mmol), in THF (1 mL/mmol) was added KO
t
Bu (0.51 g, 4.52 mmol) at 0 
o
C. The resulting 
mixture was warmed to RT and stirred for 15 min. TsCl (0.86 g, 4.52 mmol) was then added, 
and the solution stirred for 16 h. The product was extracted with EtOAc (3 x 100 mL), and 
washed with brine (100 mL). Combined organic layers were dried over Na2SO4 and 
concentrated in vacuo.  Purification via column chromatography (silica; 0-50% 
EtOAc/petrol) gave 325 as a white solid (1.60 g, 89%). Rf 0.20 (8:2 Petrol/EtOAc); m.p. 158-
160 
o
C; λmax (EtOH/nm) 236.5; IR υmax/cm
-1
 3140, 2956, 1733, 1660, 1598, 1549; 
1
H NMR 
(500 MHz, DMSO-d6) δ ppm 2.43 (3H, s, CH3), 3.73 (3H, s, O-CH3), 7.27 (1H, d, J = 2.0 Hz, 
H-3), 7.47-7.50 (1H, m, H-5), 7.52 (2H, d, J = 8.3 Hz, CH-tosyl), 7.58 (1H, ddd, J = 6.3, 8.3 
and 8.4 Hz, H-4’), 7.65-7.67 (1H, m, H-3’), 8.05 (2H, d, J = 8.3 Hz, CH-tosyl), 8.32 (1H, d, J 
= 2.0 Hz, H-5); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 26.4 (CH3), 57.7 (O-CH3), 120.9 (d, 
JCF = 21.4 Hz, C-Ar), 124.2 (d, JCF = 4.7 Hz, C-Ar), 125.2 (C-Ar), 129.5 (C-Ar), 131.6 (C-
Ar), 133.6 (d, JCF = 21.6 Hz, C-Ar), 133.8 (C-Ar), 133.9 (C-Ar), 134.4 (d, JCF = 3.2 Hz, C-
Ar), 135.2 (C-Ar), 138.3 (d, JCF = 8.6 Hz, C-Ar), 138.7 (C-Ar), 139.3 (C-Ar), 151.7 (CO), 
163.5 (CO), 163.8 (d, JCF = 245.9 Hz, C-F); HRMS calcd for C20H15
79
BrFNO5S [M+H]
+
 
479.9911, found 479.9908. 
4-(2-Cyclopropyl-6-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid, 326 
 
General procedure N: methyl 4-(2-bromo-6-fluorobenzoyl)-1-tosyl-1H-pyrrole-2-
carboxylate (286 mg, 0.59 mmol), cyclopropylboronic acid (152 mg, 1.77 mmol), Cs2CO3 
(290 mg, 0.89 mmol), and Pd(dtbf)Cl2 (10 mol%). The crude material was used directly in 
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the next step. General procedure G: LiOH monohydrate (496 mg, 11.80 mmol) gave 326 as a 
white solid (161 mg, 76%). Rf 0.20 (9:1 DCM/MeOH); m.p. Degrades >150 
o
C; λmax 
(EtOH/nm) 282.5, 227.0; IR υmax/cm
-1
 3360, 3005, 2793, 2705, 2629, 1682, 1650, 1617, 
1561; 
1H NMR (500 MHz, MeOD) δ ppm 0.58-0.61 (2H, m, CH-cyclopropane), 0.75-0.79 
(2H, m, CH-cyclopropane), 1.66-1.71 (1H, m, CH-cyclopropane), 6.74-6.75 (1H, m, H-3’), 
6.88-6.92 (1H, m, H-5’), 7.03 (1H, d, J = 1.5 Hz, H-3), 7.23 (1H, d, J = 1.5 Hz, H-5), 7.27 
(1H, ddd, J = 6.3, 8.3 and 8.4 Hz, H-4’), NH-pyrrole and COOH not visualised; 13C NMR 
(125 MHz, MeOD) δ ppm 12.2 (C-cyclopropane), 16.4 (d, JCF = 2.8 Hz, C-cyclopropane), 
116.1 (d, JCF = 21.6 Hz, C-Ar), 118.7 (C-Ar), 123.8 (d, JCF = 2.8 Hz, C-Ar), 129.6 (C-Ar), 
131.1 (C-Ar), 132.8 (d, JCF = 18.4 Hz, C-Ar), 133.2 (C-Ar), 134.5 (d, JCF = 8.7 Hz, C-Ar), 
147.3 (d, JCF = 3.7 Hz, C-Ar), 162.6 (d, JCF = 245.0 Hz, C-F), 166.1 (CO), 193.8 (CO); 
HRMS calcd for C15H12FNO3 [M-H]
- 
272.0728, found 272.0718. 
4-(2-Cyclopropyl-6-fluorobenzoyl)-N-(pyridin-3-yl)-1H-pyrrole-2-carboxamide, 306 
 
General procedure M: 4-(2-cyclopropyl-6-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (21 
mg, 0.08 mmol), PCl3 (7 µL, 0.08 mmol), and 3-aminopyridine (18 mg, 0.19 mmol). 
Purification via column chromatography (silica; 0-8% MeOH/DCM) gave 306 as a white 
solid (8 mg, 30%). Rf 0.27 (95:5 DCM/MeOH); m.p. Degrades >250 
o
C; λmax (EtOH/nm) 
264.5; IR υmax/cm
-1
 3417, 3123, 2957, 2923, 1633, 1556, 1534; 
1
H NMR (500 MHz, MeOD) 
δ ppm 0.59-0.62 (2H, m, CH-cyclopropane), 0.75-0.79 (2H, m, CH-cyclopropane), 1.69-1.75 
(1H, m, CH-cyclopropane), 6.75-6.77 (1H, m, H-3’), 6.90-6.93 (1H, m, H-5’), 7.26-7.34 (4H, 
m, H-4’, H-3, H-5 and CH-pyridine), 8.11 (1H, ddd, J = 1.5, 2.5 and 8.3 Hz, CH-pyridine), 
8.16 (1H, dd, J = 1.5 and 4.7 Hz, N-CH-pyridine), 8.77 (1H, d, J = 2.5 Hz, N-CH-pyridine), 
CO-NH and NH-pyrrole not visualised; 
13
C NMR (125 MHz, MeOD) δ ppm Insufficient 
quantity of material obtained to perform analysis; Insufficient quantity of material to perform 
HRMS analysis. 
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tert-Butyl 4-(4-(2-cyclopropyl-6-fluorobenzoyl)-1H-pyrrole-2-carboxamido)piperidine-
1-carboxylate, 328 
 
General procedure D: 4-(2-cyclopropyl-6-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (47 
mg, 0.17 mmol), CDI (55 mg, 0.34 mmol), and tert-butyl 4-aminopiperidine-1-carboxylate 
(86 mg, 0.43 mmol). Purification via column chromatography (silica; 30-70% EtOAc/petrol) 
gave 328 as a white solid (57 mg, 74%). Rf 0.68 (9:1 DCM/MeOH); m.p. 145-146 
o
C; λmax 
(EtOH/nm) 285.5, 234.0; IR υmax/cm
-1
 3332, 3126, 2973, 2928, 2858, 1691, 1619, 1567, 
1534; 
1
H NMR (500 MHz, CDCl3) δ ppm 0.69-0.72 (2H, m, CH-cyclopropane), 0.85-0.89 
(2H, m, CH-cyclopropane), 1.35-1.43 (2H, m, CH-piperidine), 1.49 (9H, s, C-CH3), 1.84-
1.89 (1H, m, CH-cyclopropane), 1.95-1.98 (2H, m, N-CH-piperidine), 2.85-2.90 (2H, m, N-
CH-piperidine), 4.04-4.11 (3H, m, N-CH-piperidine), 6.25 (1H, d, J = 7.9 Hz, CO-NH), 6.76-
6.77 (1H, m, H-3’), 6.94-6.97 (1H, m, H-5’), 7.21 (1H, br s, H-3), 7.30-7.34 (2H, m, H-5 and 
H-4’), 9.96 (1H, s, NH-pyrrole); 13C NMR (125 MHz, CDCl3) δ ppm 9.4 (C-cyclopropane), 
13.0 (d, JCF = 2.3 Hz, C-cyclopropane), 28.5 (C-CH3), 32.0 (C-piperidine), 42.6 (C-
piperidine), 47.0 (C-piperidine), 79.7 (C-CH3), 108.8 (C-Ar), 112.7 (d, JCF = 21.5 Hz, C-Ar), 
120.0 (C-Ar), 127.8 (C-Ar), 127.9 (d, JCF = 9.1 Hz, C-Ar), 128.9 (d, JCF = 18.6 Hz, C-Ar), 
130.1 (C-Ar), 130.6 (d, JCF = 8.4 Hz, C-Ar), 143.7 (CO), 154.6 (CO),  158.9 (d, JCF = 243.6 
Hz, C-F), 188.9 (CO), one C-Ar not visualised; HRMS calcd for C25H30FN3O4 [M+H]
+
 
456.2293, found 456.2293. 
4-(2-Cyclopropyl-6-fluorobenzoyl)-N-(piperidin-4-yl)-1H-pyrrole-2-carboxamide, 307 
 
General procedure K: tert-Butyl 4-(4-(2-cyclopropyl-6-fluorobenzoyl)-1H-pyrrole-2-
carboxamido)piperidine-1-carboxylate (50 mg, 0.11 mmol), triethylsilane (45 µL, 0.28 
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mmol) and TFA (2 mL/mmol) gave 307 as a white solid (26 mg, 65%). Rf 0.58 (9:1 
DCM/MeOH, NH silica); m.p. Degrades >250 
o
C; λmax (EtOH/nm) 234.0; IR υmax/cm
-1
 3266, 
2951, 2851, 1623, 1566, 1532; 
1
H NMR (500 MHz, DMSO-d6) δ ppm 0.67-0.68 (2H, m, CH-
cyclopropane), 0.83-0.86 (2H, m, CH-cyclopropane), 1.31-1.39 (2H, m, CH-piperidine), 
1.67-1.72 (3H, m, CH-cyclopropane and CH-piperidine), 2.46-2.50 (2H, m, N-CH-
piperidine), 2.92-2.96 (2H, m, N-CH-piperidine), 3.72-3.80 (1H, m, N-CH-piperidine), 6.83-
6.84 (1H, m, H-3’), 7.08-7.11 (1H, m, H-5’), 7.20 (1H, br s, H-3), 7.22 (1H, br s, H-5), 7.39 
(1H, ddd, J = 6.3, 8.3 and 8.4 Hz, H-4’), 8.10 (1H, d, J = 8.0 Hz, CO-NH), 12.26 (1H, br s, 
NH-pyrrole); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 9.3 (C-cyclopropane), 12.6 (C-
cyclopropane), 32.9 (C-piperidine), 45.1 (C-piperidine), 46.7 (C-piperidine), 109.9 (C-Ar), 
112.4 (d, JCF = 21.3 Hz, C-Ar), 119.8 (C-Ar), 126.3 (C-Ar), 127.5 (C-Ar), 128.7 (C-Ar), 
129.0 (d, JCF = 19.0 Hz, C-Ar), 130.5 (d, JCF = 8.6 Hz, C-Ar), 142.9 (d, JCF = 3.8 Hz, C-Ar), 
158.0 (d, JCF = 242.6 Hz, C-F), 159.0 (CO), 187.8 (CO); HRMS calcd for C20H22FN3O2 
[M+H]
+
 56.1769, found 356.1774. 
4-(2-Cyclopropyl-6-fluorobenzoyl)-N-(1-methylpiperidin-4-yl)-1H-pyrrole-2-
carboxamide, 308 
 
General procedure D: 4-(2-cyclopropyl-6-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (20 
mg, 0.07 mmol), CDI (24 mg, 0.15 mmol), and 4-amino-1-methyl piperidine (23 µL, 0.18 
mmol). Semi-preparative HPLC gave 308 as a white solid (15 mg, 58%). Rf 0.17 (9:1 
DCM/MeOH); m.p. Degrades >250 
o
C; λmax (EtOH/nm) 234.5; IR υmax/cm
-1
 3357, 2781, 
1619, 1568, 1534; 
1
H NMR (500 MHz, MeOD) δ ppm 0.57-0.60 (2H, m, CH-cyclopropane), 
0.74-0.76 (2H, m, CH-cyclopropane), 1.51-1.59 (2H, m, CH-piperidine), 1.66-1.72 (1H, m, 
CH-cyclopropane), 1.79-1.84 (2H, m, CH-piperidine), 2.06-2.11 (2H, m, N-CH-piperidine), 
2.21 (3H, s, N-CH3), 2.80-2.84 (2H, m, N-CH-piperidine), 3.70-3.76 (1H, m, N-CH-
piperidine), 6.73-6.75 (1H, m, H-3’), 6.87-6.91 (1H, m, H-5’), 7.02 (1H, d, J = 1.3 Hz, H-3), 
7.23-7.28 (2H, m, H-5 and H-4’), NH peaks not observed; 13C NMR (125 MHz, MeOD) δ 
ppm 9.7 (C-cyclopropane), 13.9 (C-cyclopropane), 32.2 (C-piperidine), 46.0 (N-CH3), 47.5 
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(C-piperidine), 55.6 (C-piperidine), 111.8 (C-Ar), 113.6 (d, JCF = 21.5 Hz, C-Ar), 121.3 (C-
Ar), 128.4 (C-Ar), 129.6 (C-Ar), 130.4 (C-Ar), 131.8 (d, JCF = 8.6 Hz, C-Ar), 144.8 (C-Ar), 
160.1 (d, JCF = 244.2 Hz, C-F), 162.1 (CO), 191.4 (CO), one C-Ar not visualised; Insufficient 
quantity of material to perform HRMS analysis. 
4-(2-Ethynyl-6-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid, 327 
 
General procedure N: methyl 4-(2-bromo-6-fluorobenzoyl)-1-tosyl-1H-pyrrole-2-
carboxylate (237 mg, 0.49 mmol), tert-butyldimethyl((4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)ethynyl)silane (333 mg, 1.47 mmol), Cs2CO3 (240 mg, 0.74 mmol), 
Pd(dtbf)Cl2 (10 mol%). The crude material was used directly in the next step. General 
procedure G: LiOH monohydrate (411 mg, 9.80 mmol) gave 327 as a white solid following 
purification via semi-preparative HPLC (33 mg, 26%). Rf 0.24 (9:1 DCM/MeOH); m.p. 
Degrades >250 
o
C; λmax (EtOH/nm) 285.5, 232.0; IR υmax/cm
-1
 3280, 3136, 1687, 1632, 1605, 
1560; 
1
H NMR (500 MHz, DMSO-d6) δ ppm 4.28 (1H, s, C-CH), 6.89 (1H, br s, H-3), 7.33 
(1H, br s, H-5), 7.40-7.46 (2H, m, H-3’ and H-5’), 7.52-7.56 (1H, m, H-4’), 12.57 (1H, s, 
NH-pyrrole), 12.92 (1H, s, COOH); 
13
C NMR (125 MHz, DMSO-d6) δ ppm Insufficient 
quantity of material obtained to perform analysis; HRMS calcd for C14H8FNO3 [M+H]
+ 
258.0561, found 258.0559. 
4-(2-Ethynyl-6-fluorobenzoyl)-N-(1-methylpiperidin-4-yl)-1H-pyrrole-2-carboxamide, 
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General procedure D with exceptions to the method: 4-(2-ethynyl-6-fluorobenzoyl)-1H-
pyrrole-2-carboxylic acid (21 mg, 0.08 mmol), CDI (26 mg, 0.16 mmol) and 4-amino-1-
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methyl piperidine (25 µL, 0.20 mmol) at RT. Purification via semi-preparative HPLC (1:1 
0.1% NH3 (aq)/MeCN) gave 311 as a white solid (20 mg, 71%). Rf 0.18 (9:1 DCM/MeOH); 
m.p. Degrades >130 
o
C; λmax (EtOH/nm) 286.5, 235.5; IR υmax/cm
-1
 3568, 3198, 3128, 2923, 
2851, 2796, 1620, 1570, 1545; 
1
H NMR (500 MHz, DMSO-d6) δ ppm 1.53-1.60 (2H, m, CH-
piperidine), 1.75-1.77 (2H, m, CH-piperidine), 2.07-2.12 (2H, m, N-CH-piperidine), 2.24 
(1H, s, C-CH-alkyne), 2.84-2.86 (2H, m, N-CH-piperidine), 3.68-3.76 (1H, m, N-CH-
piperidine), 7.20 (1H, br s, H-3), 7.25 (1H, br s, H-5), 7.40-7.45 (2H, m, H-3’ and H-5’), 
7.51-7.56 (1H, m, H-4’), 8.14 (1H, d, J = 7.7 Hz, CO-NH), 12.34 (1H, s, NH-pyrrole); 13C 
NMR (125 MHz, DMSO-d6) δ ppm 31.1 (C-piperidine), 45.4 (N-CH3), 45.6 (C-piperidine), 
54.1 (C-piperidine), 79.9 (d, JCF = 3.7 Hz, C-alkyne), 85.2 (CH-alkyne), 110.0 (C-Ar), 116.8 
(d, JCF = 21.8 Hz, C-Ar), 120.9 (d, JCF = 6.0 Hz, C-Ar), 125.3 (C-Ar), 127.9 (C-Ar), 128.6 
(C-Ar), 128.9 (d, JCF = 2.5 Hz, C-Ar), 131.0 (d, JCF = 8.8 Hz, C-Ar), 131.5 (d, JCF = 21.2 Hz, 
C-Ar), 158.0 (d, JCF = 244.2 Hz, C-F), 159.2 (CO), 185.5 (CO); HRMS calcd for 
C20H20FN3O2 [M+H]
+ 
354.1612, found 354.1610. 
Methyl 4-(2,3,6-trifluorobenzoyl)-1H-pyrrole-2-carboxylate, 330 
 
General procedure F: methyl 1H-pyrrole-2-carboxylate (322 mg, 2.57 mmol), 2,3,6-
trifluorobenzoyl chloride (1.00 g, 5.14 mmol), and AlCl3 (0.86 g, 6.43 mmol). Purification 
via column chromatography (silica; 0-50% EtOAc/petrol) gave 330 as a white solid (0.69 g, 
95%). Rf 0.23 (8:2 Petrol/EtOAc); m.p. 168-170 
o
C; λmax (EtOH/nm) 281.5, 234.5; IR 
υmax/cm
-1
 3280, 3118, 1683, 1640, 1560; 
1
H NMR (500 MHz, DMSO-d6) δ ppm 3.81 (3H, s, 
O-CH3), 7.13 (1H, d, J = 1.5 Hz, H-3), 7.28-7.32 (1H, m, H-5’), 7.65-7.72 (1H, m, H-4’), 
7.78 (1H, d, J = 1.5 Hz, H-5), 12.96 (1H, s, NH-pyrrole); 
13
C NMR (125 MHz, CDCl3) δ ppm 
52.1 (O-CH3), 111.7 (ddd, JCF = 4.5, 4.9 and 24.3 Hz, C-Ar), 115.6 (C-Ar), 118.5 (dd, JCF = 
9.6 and 19.5 Hz, C-Ar), 124.7 (C-Ar), 127.0 (C-Ar), 128.3 (C-Ar), 147.1 (m, C-F), 151.5 (m, 
C-F), 154.7 (m, C-F), 161.1 (CO), 181.0 (CO); HRMS calcd for C13H8F3NO3 [M+H]
+
 
284.0529, found 284.0529. 
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4-(2,3,6-Trifluorobenzoyl)-1H-pyrrole-2-carboxylic acid, 331 
 
General procedure G: Methyl 4-(2,3,6-trifluorobenzoyl)-1H-pyrrole-2-carboxylate (0.66 g, 
2.33 mmol) and LiOH monohydrate (1.96 g, 46.60 mmol) gave 331 as a white solid (0.62 g, 
100%). Rf 0.32 (9:1 DCM/MeOH); m.p. 205-207 
o
C; λmax (EtOH/nm) 285.5, 232.0; IR 
υmax/cm
-1
 3358, 3141, 3083, 1692, 1654, 1627, 1594, 1562; 
1
H NMR (500 MHz, DMSO-d6) δ 
ppm 7.07 (1H, br s, H-3), 7.27-7.32 (1H, m, H-5’), 7.64-7.71 (2H, m, H-5 and H-4’), 12.76 
(1H, s, NH-pyrrole), 12.98 (1H, s, COOH); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 112.5 
(ddd, JCF = 4.4, 6.0 and 25.5 Hz, C-Ar), 114.1 (C-Ar), 119.0 (dd, JCF = 9.6 and 19.6 Hz, C-
Ar), 125.4 (C-Ar), 126.1 (C-Ar), 146.4 (d, JCF = 252.4 Hz, C-F), 153.9 (d, JCF = 248.5 Hz, C-
F), 161.3 (CO), 180.2 (CO), one C-F and one C-Ar not visualised; HRMS calcd for 
C12H6F3NO3 [M+H]
+
 270.0373, found 270.0373. 
N-(Pyridin-3-yl)-4-(2,3,6-trifluorobenzoyl)-1H-pyrrole-2-carboxamide, 332 
 
General procedure M: 4-(2,3,6-trifluorobenzoyl)-1H-pyrrole-2-carboxylic acid (100 mg, 
0.37 mmol), PCl3 (32 µL, 0.37 mmol), and 3-aminopyridine (88 mg, 0.93 mmol). Purification 
via column chromatography (NH silica; 0-8% MeOH/DCM) gave 332 as a white solid (52 
mg, 41%). Rf 0.31 (95:5 DCM/MeOH); m.p. Degrades >250 
o
C; λmax (EtOH/nm) 292.0, 
260.0; IR υmax/cm
-1
 3350, 3239, 3121, 3013, 1628, 1599, 1558, 1533; 
1
H NMR (500 MHz, 
DMSO-d6) δ ppm 7.31-7.35 (1H, m, H-5’), 7.40 (1H, dd, J = 4.7 and 8.3 Hz, CH-pyridine), 
7.58 (1H, d, J = 1.4 Hz, H-3), 7.67-7.74 (2H, m, H-5 and H-4’), 8.15 (1H, ddd, J = 1.5, 2.5 
and 8.3 Hz, CH-pyridine), 8.31 (1H, dd, J = 1.5 and 4.7 Hz, N-CH-pyridine), 8.90 (1H, d, J = 
2.5 Hz, N-CH-pyridine), 10.26 (1H, s, CO-NH), 12.00 (1H, br s, NH-pyrrole); 
13
C NMR (125 
MHz, DMSO-d6) δ ppm 111.5 (C-Ar), 112.6 (m, C-Ar), 119.1 (m, C-Ar), 123.6 (C-Ar), 
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125.4 (C-Ar), 127.0 (C-Ar), 128.3 (C-Ar), 130.4 (C-Ar), 135.5 (C-Ar), 141.6 (C-Ar), 144.4 
(C-Ar), 158.7 (CO), 180.4 (CO), one C-Ar and three C-F not visualised; HRMS calcd for 
C17H10F3N3O2 [M+H]
+
 346.0798, found 346.0800. 
N-(Pyrimidin-5-yl)-4-(2,3,6-trifluorobenzoyl)-1H-pyrrole-2-carboxamide, 333 
 
General procedure M with exceptions to the method: 4-(2,3,6-trifluorobenzoyl)-1H-
pyrrole-2-carboxylic acid (52 mg, 0.19 mmol), PCl3 (17 µL, 0.19 mmol), and 5-
aminopyrimidine (46 mg, 0.48 mmol) for 30 min. Purification via column chromatography 
(silica; 0-8% MeOH/DCM) gave 333 as a yellow solid (34 mg, 52%). Rf 0.58 (9:1 
DCM/MeOH); m.p. Degrades >250 
o
C; λmax (EtOH/nm) 242.0; IR υmax/cm
-1
 3331, 3247, 
3119, 3037, 1626, 1590, 1555, 1526; 
1
H NMR (500 MHz, DMSO-d6) δ ppm 7.32-7.35 (1H, 
m, H-5’), 7.58 (1H, br s, H-3), 7.68-7.73 (2H, m, H-4’ and H-5), 8.93 (1H, s, N-CH-
pyrimidine), 9.14 (2H, s, N-CH-pyrimidine), 10.46 (1H, s, CO-NH), 12.89 (1H, s, NH-
pyrrole); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 112.0 (C-Ar), 112.6 (m, C-Ar), 119.0 (m, 
C-Ar), 125.5 (C-Ar), 127.8 (C-Ar), 130.7 (C-Ar), 134.3 (C-Ar), 147.8 (C-Ar), 153.2 (C-Ar), 
158.8 (CO), 180.4 (CO), one C-Ar and three C-F not visualised; HRMS calcd for 
C16H9F3N4O2 [M+H]
+
 347.0750, found 347.0755. 
tert-Butyl 4-(4-(2,3,6-trifluorobenzoyl)-1H-pyrrole-2-carboxamido)piperidine-1-
carboxylate, 334 
 
General procedure D: 4-(2,3,6-trifluorobenzoyl)-1H-pyrrole-2-carboxylic acid (100 mg, 
0.37 mmol), CDI (120 mg, 0.74 mmol), and tert-butyl 4-aminopiperidine-1-carboxylate (186 
mg, 0.93 mmol). Purification via column chromatography (silica; 30-100% EtOAc/petrol) 
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gave 334 as a white solid (155 mg, 93%). Rf 0.70 (9:1 DCM/MeOH); m.p. 148-150 
o
C; λmax 
(EtOH/nm) 285.5, 236.0; IR υmax/cm
-1
 3128, 2976, 2863, 1667, 1624, 1567, 1535; 
1
H NMR 
(500 MHz, CDCl3) δ ppm 1.39-1.45 (2H, m, CH-piperidine), 1.49 (9H, s, C-CH3), 1.98-2.00 
(2H, m, CH-piperidine), 2.87-2.93 (2H, m, N-CH-piperidine), 4.06-4.14 (3H, m, N-CH-
piperidine), 6.12 (1H, d, J = 7.9 Hz, CO-NH), 6.95-7.00 (1H, m, H-5’), 7.11 (1H, dd, J = 1.5 
and 2.4 Hz, H-3), 7.25-7.31 (1H, m, H-4’), 7.39 (1H, br s, H-5), 10.20 (NH-pyrrole); 13C 
NMR (125 MHz, CDCl3) δ ppm 28.4 (C-CH3), 31.9 (C-piperidine), 42.7 (C-piperidine), 47.1 
(C-piperidine), 79.8 (C-CH3), 109.6 (C-Ar), 111.7 (ddd, JCF = 4.5, 5.8 and 24.4 Hz, C-Ar), 
118.4 (dd, JCF = 9.9 and 19.3 Hz, C-Ar), 119.6 (dd, JCF = 18.6 and 24.6 Hz, C-Ar), 126.5 (C-
Ar), 128.5 (C-Ar), 129.0 (C-Ar), 147.0 (dd, JCF = 9.2 and 244.0 Hz, C-F), 147.2 (dd, JCF = 
15.7 and 244.9 Hz, C-F), 154.5 (ddd, JCF = 3.1, 5.5 and 247.6 Hz, C-F), 154.7 (CO), 160.1 
(CO), 181.2 (CO); HRMS calcd for C22H24F3N3O4 [M+H]
+
 452.1792, found 452.1790. 
N-(Piperidin-4-yl)-4-(2,3,6-trifluorobenzoyl)-1H-pyrrole-2-carboxamide, 376 
 
General procedure K: tert-butyl 4-(4-(2,3,6-trifluorobenzoyl)-1H-pyrrole-2-
carboxamido)piperidine-1-carboxylate (140 mg, 0.31 mmol), triethylsilane (124 µL, 0.78 
mmol), and TFA (2 mL/mmol) gave 376 as a white solid (103 mg, 95%). Rf 0.45 (9:1 
DCM/MeOH, NH silica); m.p. 214-216 
o
C; λmax (EtOH/nm) 286.5, 236.5; IR υmax/cm
-1
 3280, 
2943, 2845, 1630, 1568, 1535; 
1
H NMR (500 MHz, DMSO-d6) δ ppm 1.41-1.49 (2H, m, CH-
piperidine), 1.77-1.80 (2H, m, CH-piperidine), 2.62-2.68 (2H, m, N-CH-piperidine), 3.04-
3.07 (2H, m, N-CH-piperidine), 3.81-3.89 (1H, m, N-CH-piperidine), 7.28-7.33 (2H, m, H-3 
and H-5’), 7.51 (1H, d, J = 1.5 Hz, H-5), 7.65-7.72 (1H, m, H-4’), 8.17 (1H, d, J = 7.8 Hz, 
CO-NH); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 31.0 (C-piperidine), 43.9 (C-piperidine), 
45.6 (C-piperidine), 110.0 (C-Ar), 112.5 (ddd, JCF = 3.3, 5.9 and 24.2 Hz, C-Ar), 118.8 (dd, 
JCF = 9.9 and 19.5 Hz, C-Ar), 119.5 (dd, JCF = 19.6 and 25.9 Hz, C-Ar), 125.1 (C-Ar), 129.0 
(C-Ar), 129.1 (C-Ar), 146.2 (m, C-F), 146.4 (m, C-F), 153.8 (dd, JCF = 5.1 and 244.7 Hz, C-
F), 158.9 (CO), 180.3 (CO); HRMS calcd for C17H16F3N3O2 [M+H]
+
 352.1267, found 
352.1268. 
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N-(1-Methylpiperidin-4-yl)-4-(2,3,6-trifluorobenzoyl)-1H-pyrrole-2-carboxamide, 335 
 
General procedure D: 4-(2,3,6-trifluorobenzoyl)-1H-pyrrole-2-carboxylic acid (100 mg, 
0.37 mmol), CDI (120 mg, 0.74 mmol), and 4-amino-1-methyl piperidine (116 µL, 0.93 
mmol). Purification via column chromatography (NH silica; 0-8% MeOH/DCM) gave 335 as 
a white solid (96 mg, 71%). Rf 0.17 (9:1 DCM/MeOH); m.p. Degrades >250 
o
C; λmax 
(EtOH/nm) 236.5; IR υmax/cm
-1
 3368, 2943, 2852, 2798, 1638, 1566, 1517; 
1
H NMR (500 
MHz, DMSO-d6) δ ppm 1.49-1.57 (2H, m, CH-piperidine), 1.72-1.75 (2H, m, CH-
piperidine), 1.90-1.95 (2H, m, N-CH-piperidine), 2.16 (3H, s, N-CH3), 2.74-2.77 (2H, m, N-
CH-piperidine), 3.64-3.72 (1H, m, N-CH-piperidine), 7.28-7.33 (2H, m, H-3 and H-5’), 7.51 
(1H, br s, H-5), 7.65-7.71 (1H, m, H-4’), 8.10 (1H, d, J = 7.8 Hz, CO-NH), 12.47 (1H, s, NH-
pyrrole); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 31.6 (C-piperidine), 45.9 (N-CH3), 46.0 (C-
piperidine), 54.4 (C-piperidine), 109.8 (C-Ar), 112.5 (m, C-Ar), 118.8 (dd, JCF = 9.4 and 19.6 
Hz, C-Ar), 119.5 (m, C-Ar), 125.1 (C-Ar), 129.0 (C-Ar), 129.1 (C-Ar), 146.2 (m, two C-F), 
153.8 (m, C-F), 159.0 (CO), 180.3 (CO); HRMS calcd for C18H18F3N3O2 [M+H]
+
 366.1424, 
found 366.1430. 
Methyl 4-(3-chloro-2,6-difluorobenzoyl)-1H-pyrrole-2-carboxylate, 336 
 
General procedure F: methyl 1H-pyrrole-2-carboxylate (593 mg, 4.74 mmol), 3-chloro, 2,6-
difluorobenzoyl chloride (2.00 g, 9.48 mmol) and AlCl3 (1.59 g, 11.85 mmol). Purification 
via column chromatography (silica; 0-50% EtOAc/petrol) gave 336 as a white solid (1.28 g, 
90%). Rf 0.27 (8:2 Petrol/EtOAc); m.p. 143-145 
o
C; λmax (EtOH/nm) 289.0; IR υmax/cm
-1
 
3256, 3147, 3090, 2998, 2956, 1693, 1650, 1615, 1561; 
1
H NMR (500 MHz, DMSO-d6) δ 
ppm 3.81 (3H, s, O-CH3), 7.12 (1H, br s, H-3), 7.34 (1H, dd, J = 8.9 and 10.2 Hz, H-5’), 7.72 
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(1H, dd, J = 1.5 and 3.4 Hz, H-5), 7.80-7.85 (1H, m, H-4’), 12.95 (1H, s, NH-pyrrole); 13C 
NMR (125 MHz, DMSO-d6) δ ppm 51.7 (O-CH3), 113.6 (dd, JCF = 3.7 and 23.4 Hz, C-Ar), 
114.6 (C-Ar), 116.1 (dd, JCF = 3.8 and 17.9 Hz, C-Ar), 118.8 (t, JCF =24.2 Hz, C-Ar), 124.7 
(C-Ar), 125.5 (C-Ar), 131.0 (C-Ar), 132.2 (d, JCF = 9.8 Hz, C-Ar), 153.7 (dd, JCF = 8.6 and 
249.5 Hz, C-F), 157.2 (dd, JCF = 7.0 and 248.6 Hz, C-F), 160.3 (CO), 180.4 (CO); HRMS 
calcd for C13H8
35
ClF2NO3 [M+H]
+
 300.0234, found 300.0236. 
4-(3-Chloro-2,6-difluorobenzoyl)-1H-pyrrole-2-carboxylic acid, 337 
 
General procedure G: methyl 4-(3-chloro-2,6-difluorobenzoyl)-1H-pyrrole-2-carboxylate 
(1.20 g, 4.00 mmol), and LiOH monohydrate (3.36 g, 80.00 mmol) gave 337 as a white solid 
(1.14 g, 100%). Rf 0.36 (9:1 DCM/MeOH); m.p. 235-237 
o
C; λmax (EtOH/nm) 282.5, 231.5; 
IR υmax/cm
-1
 3358, 3238, 3134, 1676, 1630, 1613, 1555; 
1
H NMR (500 MHz, DMSO-d6) δ 
ppm 7.06 (1H, br s, H-3), 7.33 (1H, dd, J = 8.8 and 10.0 Hz, H-5’), 7.65 (1H, dd, J = 1.5 and 
3.4 Hz, H-5), 7.79-7.84 (1H, m, H-4’), 12.77 (1H, s, NH-pyrrole), 12.95 (1H, s, COOH); 13C 
NMR (125 MHz, DMSO-d6) δ ppm 113.6 (dd, JCF = 3.8 and 23.2 Hz, C-Ar), 114.1 (C-Ar), 
116.1 (dd, JCF = 3.8 and 17.9 Hz, C-Ar), 118.9 (m, C-Ar), 125.4 (C-Ar), 126.0 (C-Ar), 130.6 
(C-Ar), 132.1 (d, JCF = 9.7 Hz, C-Ar), 153.7 (dd, JCF = 8.3 and 248.8 Hz, C-F), 157.2 (dd, JCF 
= 6.9 and 248.2 Hz, C-F), 161.3  (CO), 180.3 (CO); HRMS calcd for C12H6
35
ClF2NO3 [M-H]
-
 
283.9932, found 283.9922. 
4-(3-Chloro-2,6-difluorobenzoyl)-N-(pyridin-3-yl)-1H-pyrrole-2-carboxamide, 338 
 
General procedure M: 4-(3-chloro-2,6-difluorobenzoyl)-1H-pyrrole-2-carboxylic acid (51 
mg, 0.18 mmol), PCl3 (16 µL, 0.18 mmol), and 3-aminopyridine (42 mg, 0.45 mmol). 
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Purification via column chromatography (NH silica; 0-8% MeOH/DCM) gave 338 as a white 
solid (62 mg, 95%). Rf 0.32 (95:5 DCM/MeOH); m.p. 269-272 
o
C; λmax (EtOH/nm) 305.0; IR 
υmax/cm
-1
 3359, 3235, 1642, 1613, 1561, 1535; 
1
H NMR (500 MHz, DMSO-d6) δ ppm 7.35-
7.41 (2H, m, H-5’ and CH-pyridine), 7.57 (1H, br s, H-3), 7.68 (1H, br s, H-5), 7.82-7.86 
(1H, m, H-4’), 8.15 (1H, ddd, J = 1.5, 2.5 and 8.3 Hz, CH-pyridine), 8.31 (1H, dd, J = 1.5 
and 4.6 Hz, N-CH-pyridine), 8.90 (1H, d, J = 2.5 Hz, N-CH-pyridine), 10.26 (1H, s, CO-
NH), 12.80 (1H, s, NH-pyrrole); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 111.5 (C-Ar), 113.6 
(dd, JCF = 3.3 and 23.4 Hz, C-Ar), 116.1 (dd, JCF = 3.5 and 18.4 Hz, C-Ar), 119.0 (t, JCF = 
23.4 Hz, C-Ar), 123.6 (C-Ar), 125.4 (C-Ar), 127.0 (C-Ar), 128.4 (C-Ar), 130.4 (C-Ar), 132.1 
(d, JCF = 9.7 Hz, C-Ar), 135.5 (C-Ar), 141.6 (C-Ar), 144.4 (C-Ar), 153.7 (dd, JCF = 9.1 and 
248.7 Hz, C-F), 157.2 (dd, JCF = 6.8 and 248.5 Hz, C-F), 158.7 (CO), 180.5 (CO); HRMS 
calcd for C17H10
35
ClF2N3O2 [M+H]
+
 362.0502, found 362.0503. 
4-(3-Chloro-2,6-difluorobenzoyl)-N-(pyrimidin-5-yl)-1H-pyrrole-2-carboxamide, 339 
 
General procedure M with exceptions to the method: 4-(3-chloro-2,6-difluorobenzoyl)-
1H-pyrrole-2-carboxylic acid (100 mg, 0.35 mmol), PCl3 (31 µL, 0.35 mmol), and 5-
aminopyrimidine (84 mg, 0.88 mmol) for 15 min. Purification via column chromatography 
(silica; 0-8% MeOH/DCM) gave 339 as a yellow solid (58 mg, 46%). Rf 0.62 (9:1 
DCM/MeOH); m.p. 322-324 
o
C; λmax (EtOH/nm) 267.5; IR υmax/cm
-1
 3076, 2922, 2861, 
1628, 1601, 1567, 1535; 
1
H NMR (500 MHz, DMSO-d6) δ ppm 7.37 (1H, dd, J = 7.6 and 9.0 
Hz, H-5’), 7.57 (1H, br s, H-3), 7.73 (1H, br s, H-5), 7.83-7.87 (1H, m, H-4’), 8.93 (1H, s, 
CH-pyrimidine), 9.14 (2H, s, CH-pyrimidine), 10.45 (1H, s, CO-NH), 12.89 (1H, s, NH-
pyrrole); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 112.0 (C-Ar), 113.7 (dd, JCF = 3.9 and 23.6 
Hz, C-Ar), 116.1 (m, C-Ar), 119.0 (m, C-Ar), 125.4 (C-Ar), 127.8 (C-Ar), 130.6 (C-Ar), 
132.2 (d, JCF = 9.8 Hz, C-Ar), 134.3 (C-Ar), 147.8 (C-Ar), 153.2 (C-Ar), 153.7 (dd, JCF = 9.2 
and 249.4 Hz, C-F), 157.2 ((dd, JCF = 7.5 and 248.2 Hz, C-F), 158.8 (CO), 180.5 (CO); 
HRMS calcd for C16H9
35
ClF2N4O2 [M+H]
+
 363.0455, found 363.0460. 
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tert-Butyl 4-(4-(3-chloro-2,6-difluorobenzoyl)-1H-pyrrole-2-carboxamido)piperidine-1-
carboxylate, 340 
 
General procedure D: 4-(3-chloro-2,6-difluorobenzoyl)-1H-pyrrole-2-carboxylic acid (117 
mg, 0.41 mmol), CDI (133 mg, 0.82 mmol), tert-butyl 4-aminopiperidine-1-carboxylate (206 
mg, 1.03 mmol). Purification via column chromatography (silica; 30-70% EtOAc/petrol) 
gave 340 as a white solid (167 mg, 87%). Rf 0.71 (9:1 DCM/MeOH); m.p. 135-137 
o
C; λmax 
(EtOH/nm) 290.0, 233.5; IR υmax/cm
-1
 2960, 2930, 2865, 1663, 1618, 1567, 1535; 
1
H NMR 
(500 MHz, DMSO-d6) δ ppm 1.40-1.49 (11H, m, CH-piperidine and C-CH3), 1.98-2.01 (2H, 
m, CH-piperidine), 2.87-2.93 (2H, m, N-CH-piperidine), 4.07-4.15 (3H, m, N-CH-
piperidine), 6.10 (1H, d, J = 7.7 Hz, CO-NH), 7.00 (1H, dd, J = 7.9 and 9.0 Hz, H-5’), 7.08 
(1H, br s, H-3), 7.38 (1H, br s, H-5), 7.58-7.52 (1H, m, H-4’), 10.17 (1H, s, NH-pyrrole); 13C 
NMR (125 MHz, DMSO-d6) δ ppm 28.4 (C-CH3), 32.1 (C-piperidine), 42.6 (C-piperidine), 
47.1 (C-piperidine), 79.8 (C-CH3), 108.9 (C-Ar), 112.7 (dd, JCF = 4.2 and 23.3 Hz, C-Ar), 
117.4 (m, C-Ar), 119.3 (t, JCF = 22.6 Hz, C-Ar), 126.8 (C-Ar), 128.0 (C-Ar), 128.1 (C-Ar), 
131.7 (d, JCF = 9.5 Hz, C-Ar), 154.7 (CO), 154.9 (dd, JCF = 8.7 and 253.8 Hz, C-F), 157.8 
(dd, JCF = 6.8 and 251.9 Hz, C-F), 159.5 (CO), 181.1 (CO); HRMS calcd for 
C22H24
35
ClF2N3O4 [M+H]
+
 468.1496, found 468.1495. 
4-(3-Chloro-2,6-difluorobenzoyl)-N-(piperidin-4-yl)-1H-pyrrole-2-carboxamide, 377 
 
General procedure K: tert-butyl 4-(4-(3-chloro-2,6-difluorobenzoyl)-1H-pyrrole-2-
carboxamido)piperidine-1-carboxylate (100 mg, 0.21 mmol), triethylsilane (84 µL, 0.53 
mmol), and TFA (2 mL/mmol) gave 377 as a white solid (98 mg, 97%). Rf 0.01 (9:1 
DCM/MeOH, NH silica); m.p. 185-187 
oC; λmax (EtOH/nm) 286.0, 235.5; IR υmax/cm
-1
 3452, 
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3267, 2829, 2738, 1754, 1699, 1662, 1638, 1616, 1576; 
1
H NMR (500 MHz, DMSO-d6) δ 
ppm 1.65-1.73 (2H, m, CH-piperidine), 1.95-1.98 (2H, m, CH-piperidine), 2.30-2.37 (2H, m, 
N-CH-piperidine), 3.32-3.34 (2H, m, N-CH-piperidine), 4.00-4.07 (1H, m, N-CH-piperidine), 
7.33-7.36 (2H, m, H-3 and H-5’), 7.54 (1H, br s, H-5), 7.78-7.84 (1H, m, H-4’), 8.32 (1H, d, 
J = 7.4 Hz, CO-NH), 8.61 (1H, br s, NH-piperidine), 8.78 (1H, br s, NH-piperidine), 12.52 
(1H, s, NH-pyrrole); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 28.3 (C-piperidine), 42.2 (C-
piperidine), 43.8 (C-piperidine), 110.2 (C-Ar), 113.5 (dd, JCF = 3.1 and 23.3 Hz, C-Ar), 116.0 
(dd, JCF = 3.5 and 17.8 Hz, C-Ar), 116.0 (q, JCF = 293.0 Hz, CF3), 119.3 (d, JCF = 5.8 Hz, C-
Ar), 125.1 (C-Ar), 128.7 (C-Ar), 129.3 (C-Ar), 132.0 (d, JCF = 9.5 Hz, C-Ar), 153.7 (dd, JCF 
= 8.4 and 249.1 Hz, C-F), 157.1 (dd, JCF = 7.0 and 247.9 Hz, C-F), 158.6 (d, JCF = 34.9 Hz, 
CO), 159.2 (CO), 180.4 (CO); HRMS calcd for C17H16
35
ClF2N3O2 [M+H]
+
 368.0972, found 
368.0971. 
4-(3-Chloro-2,6-difluorobenzoyl)-N-(1-methylpiperidin-4-yl)-1H-pyrrole-2-
carboxamide, 341 
 
General procedure D: 4-(3-chloro-2,6-difluorobenzoyl)-1H-pyrrole-2-carboxylic acid (50 
mg, 0.17 mmol), CDI (55 mg, 0.34 mmol), and 4-amino-1-methyl piperidine (54 µL, 0.43 
mmol). Purification via column chromatography (NH silica; 0-8% MeOH/DCM) gave 341 as 
a white solid (57 mg, 88%). Rf 0.20 (9:1 DCM/MeOH); m.p. 200-203 
o
C; λmax (EtOH/nm) 
292.0, 236.5; IR υmax/cm
-1
 3241, 3073, 2940, 2850, 2801, 2689, 1625, 1578, 1518; 
1
H NMR 
(500 MHz, DMSO-d6) δ ppm 1.49-1.56 (2H, m, CH-piperidine), 1.73-1.75 (2H, m, CH-
piperidine), 1.90-1.95 (2H, m, N-CH-piperidine), 2.16 (3H, m, N-CH3), 2.74-2.78 (2H, m, N-
CH-piperidine), 3.64-3.72 (1H, m, N-CH-piperidine), 7.27 (1H, br s, H-3), 7.35 (1H, dd, J = 
7.9 and 9.2 Hz, H-5’), 7.51 (1H, br s, H-5), 7.79-7.84 (1H, m, H-4’), 8.10 (1H, d, J = 7.9 Hz, 
CO-NH), 12.47 (1H, s, NH-pyrrole); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 31.5 (C-
piperidine), 45.9 (N-CH3), 46.0 (C-piperidine), 54.4 (C-piperidine), 109.8 (C-Ar), 113.6 (dd, 
JCF = 3.3 and 22.9 Hz, C-Ar), 115.9 (dd, JCF = 3.5 and 17.8 Hz, C-Ar), 125.1 (C-Ar), 129.0 
(C-Ar), 129.1 (C-Ar), 132.0 (d, JCF = 9.5 Hz, C-Ar), 159.0 (CO), 180.4 (CO) one C-Ar and 
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two C-F not visualised; HRMS calcd for C18H18
35
ClF2N3O2 [M+H]
+
 382.1128, found 
382.1130. 
Methyl 4-(2-chloro-3,6-difluorobenzoyl)-1H-pyrrole-2-carboxylate, 342 
 
General procedure F: methyl 1H-pyrrole-2-carboxylate (297 mg, 2.37 mmol), 2-chloro, 3, 
6-difluorobenzoyl chloride (1.00 g, 4.74 mmol), and AlCl3 (0.76 g, 5.93 mmol). Purification 
via column chromatography (silica; 0-50% EtOAc/petrol) gave 342 as a white solid (0.67 g, 
94%). 
Rf 0.25 (8:2 Petrol/EtOAc); m.p. 123-125 
o
C; λmax (EtOH/nm) 279.5, 232.5; IR υmax/cm
-1
 
3257, 3106, 2994, 2952, 1697, 1659, 1561; 
1
H NMR (500 MHz, DMSO-d6) δ ppm 3.81 (3H, 
s, O-CH3), 7.08 (1H, d, J = 1.6 Hz, H-3), 7.44-7.48 (1H, m, H-5’), 7.61-7.66 (2H, m, H-4’ 
and H-5), 12.94 (NH-pyrrole); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 51.7 (O-CH3), 114.6 
(C-Ar), 116.4 (dd, JCF = 7.8 and 24.3 Hz, C-Ar), 118.3 (dd, JCF = 9.1 and 23.7 Hz, C-Ar), 
124.9 (d, JCF = 26.7 Hz, C-Ar), 129.0 (d, JCF = 25.1 Hz, C-Ar), 130.9 (C-Ar), 154.1 (d, JCF = 
244.0 Hz, C-F), 154.3 (d, JCF = 247.6 Hz, C-F), 160.3 (CO), 182.4 (CO), two C-Ar not 
visualised; HRMS calcd for C13H8
35
ClF2NO3 [M+H]
+
 300.0234, found 300.0237. 
4-(2-Chloro-3,6-difluorobenzoyl)-1H-pyrrole-2-carboxylic acid, 343 
 
General procedure G: methyl 4-(2-chloro-3,6-difluorobenzoyl)-1H-pyrrole-2-carboxylate 
(0.60 g, 2.01 mmol), and LiOH monohydrate (1.69 g, 40.20 mmol) gave 343 as a white solid 
(0.56 g, 98%). Rf 0.32 (9:1 DCM/MeOH); m.p. 226-228 
o
C; λmax (EtOH/nm) 276.5, 233.0; IR 
υmax/cm
-1
 3368, 3137, 3093, 1682, 1650, 1559; 
1
H NMR (500 MHz, DMSO-d6) δ ppm 7.03 
(1H, br s, H-3), 7.43-7.48 (1H, m, H-5’), 7.58 (1H, br s, H-5), 7.60-7.65 (1H, m, H-4’), 12.75 
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(1H, s, NH-pyrrole), 12.95 (1H, s, COOH); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 114.1 (C-
Ar), 116.3 (dd, JCF = 7.7 and 24.3 Hz, C-Ar), 117.5 (dd, JCF = 6.9 and 21.3 Hz, C-Ar), 118.2 
(dd, JCF = 9.2 and 23.7 Hz, C-Ar), 124.9 (C-Ar), 126.1 (C-Ar), 129.1 (d, JCF = 25.5 Hz, C-
Ar), 130.4 (C-Ar), 154.0 (dd, JCF = 1.5 and 243.1 Hz, C-F), 154.2 (dd, JCF = 5.6 and 240.8 
Hz, C-F), 161.3 (CO), 182.4 (CO); HRMS calcd for C12H6
35
ClF2NO3 [M-H]
-
 283.9932, 
found 283.9921. 
4-(2-Chloro-3,6-difluorobenzoyl)-N-(pyridin-3-yl)-1H-pyrrole-2-carboxamide, 344 
 
General procedure M: 4-(2-chloro-3,6-difluorobenzoyl)-1H-pyrrole-2-carboxylic acid (100 
mg, 0.35 mmol), PCl3 (31 µL, 0.35 mmol), and 3-aminopyridine (83 mg, 0.88 mmol). 
Purification via column chromatography (silica; 0-8% MeOH/DCM) gave 344 as a white 
solid (73 mg, 58%). Rf 0.34 (95:5 DCM/MeOH); m.p. 177-178 
o
C; λmax (EtOH/nm) 292.0, 
268.0; IR υmax/cm
-1
 3120, 2817, 2708, 1639, 1593, 1557, 1530, 1501; 
1
H NMR (500 MHz, 
DMSO-d6) δ ppm 7.39 (1H, dd, J = 4.7 and 8.4 Hz, CH-pyridine), 7.47-7.51 (1H, m, H-5’), 
7.54 (1H, br s, H-3), 7.61 (1H, br s, H-5), 7.63-7.68 (1H, m, H-4’), 8.14 (1H, ddd, J = 1.5, 2.5 
and 8.4 Hz, CH-pyridine), 8.31 (1H, dd, J = 1.5 and 4.7 Hz, N-CH-pyridine), 8.99 (1H, d, J = 
2.5 Hz, N-CH-pyridine), 10.25 (1H, s, CO-NH), 12.79 (1H, s, NH-pyrrole); 
13
C NMR (125 
MHz, DMSO-d6) δ ppm 111.5 (C-Ar), 116.4 (dd, JCF = 7.5 and 24.4 Hz, C-Ar), 118.2 (dd, 
JCF = 9.4 and 23.9 Hz, C-Ar), 119.6 (C-Ar), 123.6 (C-Ar), 124.8 (C-Ar), 127.0 (C-Ar), 128.4 
(C-Ar), 129.2 (d, JCF = 25.7 Hz, C-Ar), 130.1 (C-Ar), 135.5 (C-Ar), 141.6 (C-Ar), 144.4 (C-
Ar), 154.1 (d, JCF = 241.9 Hz, C-F), 154.4 (d, JCF = 241.9 Hz, C-F), 158.7 (CO), 182.6 (CO); 
HRMS calcd for C17H10
35
ClF2N3O2 [M+H]
+
 362.0502, found 362.0508. 
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tert-Butyl 4-(4-(2-chloro-3,6-difluorobenzoyl)-1H-pyrrole-2-carboxamido)piperidine-1-
carboxylate, 345 
 
General procedure D: 4-(2-chloro-3,6-difluorobenzoyl)-1H-pyrrole-2-carboxylic acid (104 
mg, 0.36 mmol), CDI (117 mg, 0.72 mmol), and tert-butyl 4-aminopiperidine-1-carboxylate 
(180 mg, 0.90 mmol). Purification via column chromatography (silica; 30-70% 
EtOAc/petrol) gave 345 as a white solid (143 mg, 85%). Rf 0.71 (9:1 DCM/MeOH); m.p. 
159-161 
o
C; λmax (EtOH/nm) 281.0, 236.0; IR υmax/cm
-1
 3190, 2976, 2935, 2865, 1666, 1622, 
1565, 1535; 
1
H NMR (500 MHz, CDCl3) δ ppm 1.38-1.46 (2H, m, CH-piperidine), 1.49 (9H, 
s, C-CH3), 1.97-2.00 (2H, m, CH-piperidine), 2.87-2.92 (2H, m, N-CH-piperidine), 4.05-4.12 
(3H, m, N-CH-piperidine), 6.14 (1H, d, J = 8.0 Hz, CO-NH), 7.07-7.13 (2H, m, H-3 and H-
5’), 7.22-7.27 (1H, m, H-4’), 7.33 (1H, br s, H-5), 10.20 (1H, s, NH-pyrrole); 13C NMR (125 
MHz, CDCl3) δ ppm 28.4 (C-CH3), 31.9 (C-piperidine), 42.7 (C-piperidine), 47.1 (C-
piperidine), 79.8 (C-CH3), 109.5 (C-Ar), 115.4 (dd, JCF = 7.1 and 24.1 Hz, C-Ar), 117.6 (dd, 
JCF = 8.9 and 23.9 Hz, C-Ar), 119.2 (dd, JCF = 6.4 and 21.2 Hz, C-Ar), 126.0 (C-Ar), 128.6 
(C-Ar), 128.9 (C-Ar), 129.4 (d, JCF = 24.4 Hz, C-Ar), 154.6 (CO), 154.7 (dd, JCF = 2.8 and 
244.0 Hz, C-F), 154.8 (d, JCF = 244.0 Hz, C-F), 160.1 (CO), 183.5 (CO); HRMS calcd for 
C22H24
35
ClF2N3O4 [M+H]
+
 468.1496, found 468.1495. 
4-(2-Chloro-3,6-difluorobenzoyl)-N-(piperidin-4-yl)-1H-pyrrole-2-carboxamide, 378 
 
General procedure K: tert-butyl 4-(4-(2-chloro-3,6-difluorobenzoyl)-1H-pyrrole-2-
carboxamido)piperidine-1-carboxylate (130 mg, 0.28 mmol), triethylsilane (112 µL, 0.70 
mmol), and TFA (2 mL/mmol) gave 378 as a white solid (97 mg, 94%). Rf 0.53 (9:1 
DCM/MeOH, NH silica); m.p. 223-225 
o
C; λmax (EtOH/nm) 283.5, 237.0; IR υmax/cm
-1
 3280, 
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2955, 2842, 1629, 1566, 1535; 
1
H NMR (500 MHz, DMSO-d6) δ ppm 1.48-1.56 (2H, m, CH-
piperidine), 1.82-1.86 (2H, m, CH-piperidine), 2.74-2.80 (2H, m, N-CH-piperidine), 3.12-
3.16 (2H, m, N-CH-piperidine), 3.87-3.95 (1H, m, N-CH-piperidine), 7.27 (1H, br s, H-3), 
7.45-7.49 (2H, m, H-3 and H-5’), 7.61-7.66 (1H, m, H-4’), 8.20 (1H, d, J = 7.8 Hz, CO-NH), 
NH-pyrrole not observed. 
13
C NMR (125 MHz, DMSO-d6) δ ppm 30.2 (C-piperidine), 43.4 
(C-piperidine), 45.1 (C-piperidine), 110.0 (C-Ar), 116.3 (dd, JCF = 7.6 and 24.4 Hz, C-Ar), 
117.5 (dd, JCF = 7.0 and 21.1 Hz, C-Ar), 118.0 (dd, JCF = 9.0 and 23.6 Hz, C-Ar), 124.6 (C-
Ar), 129.0 (C-Ar), 129.4 (d, JCF =  25.7 Hz, C-Ar), 154.1 (d, JCF = 242.5 Hz, C-F), 154.2 (d, 
JCF = 242.5 Hz, C-Ar), 159.0 (CO), 182.5 (CO), one C-Ar not visualised; HRMS calcd for 
C17H16
35
ClF2N3O2 [M+H]
+
 368.0972, found 368.0977. 
4-(2-Chloro-3,6-difluorobenzoyl)-N-(1-methylpiperidin-4-yl)-1H-pyrrole-2-
carboxamide, 346 
 
General procedure D: 4-(2-chloro-3,6-difluorobenzoyl)-1H-pyrrole-2-carboxylic acid (109 
mg, 0.38 mmol), CDI (123 mg, 0.76 mmol), and 4-amino-1-methyl piperidine (119 µL, 0.95 
mmol). Purification via column chromatography (NH silica; 0-8% MeOH/DCM) gave 346 as 
a white solid (142 mg, 98%). Rf 0.20 (9:1 DCM/MeOH); m.p. Degrades >250 
o
C; λmax 
(EtOH/nm) 281.5, 237.0; IR υmax/cm
-1
 3196, 3124, 2945, 2852, 2796, 1668, 1620, 1566, 
1529; 
1
H NMR (500 MHz, DMSO-d6) δ ppm 1.49-1.56 (2H, m, CH-piperidine), 1.72-1.75 
(2H, m, CH-piperidine), 1.90-1.95 (2H, m, N-CH-piperidine), 2.16 (3H, s, N-CH3), 2.74-2.77 
(2H, m, N-CH-piperidine), 3.64-3.72 (1H, m, N-CH-piperidine), 7.24 (1H, br s, H-3), 7.44-
7.48 (2H, m, H-5 and H-5’), 7.61-7.65 (1H, m, H-4’), 8.09 (1H, d, J = 7.8 Hz, CO-NH), 
12.46 (1H, s, NH-pyrrole); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 31.5 (C-piperidine), 45.9 
(N-CH3), 46.0 (C-piperidine), 54.4 (C-piperidine), 109.8 (C-Ar), 116.3 (dd, JCF = 7.5 and 
24.5 Hz, C-Ar), 117.5 (dd, JCF = 7.2 and 21.4 Hz, C-Ar), 118.0 (dd, JCF = 8.9 and 23.7 Hz, C-
Ar), 124.6 (C-Ar), 128.7 (C-Ar), 129.1 (C-Ar), 129.4 (d, JCF = 25.6 Hz, C-Ar), 154.0 (d, JCF 
= 244.5 Hz, C-F), 154.2 (d, JCF = 242.4 Hz, C-F), 159.0 (CO), 182.5 (CO); HRMS calcd for 
C18H18
35
ClF2N3O2 [M+H]
+
 382.1128, found 382.1134. 
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Methyl 4-(2,6-difluoro-3-methylbenzoyl)-1H-pyrrole-2-carboxylate, 347 
 
General procedure F: methyl 1H-pyrrole-2-carboxylate (330 mg, 2.63 mmol), 2,6- difluoro, 
3- methylbenzoyl chloride (1.00 g, 5.25 mmol), and AlCl3 (0.88 g, 6.58 mmol). Purification 
via column chromatography (silica; 0-50% EtOAc/petrol) gave 347 as a colourless oil (0.69 
g, 94%). Rf 0.25 (8:2 Petrol/EtOAc); λmax (EtOH/nm) 277.5, 233.5; IR υmax/cm
-1
 3277, 2955, 
2923, 1709, 1643, 1625, 1559; 
1
H NMR (500 MHz, CDCl3) δ ppm 2.30 (3H, s, CH3), 3.90 
(3H, s, O-CH3), 6.90 (1H, dd, J = 8.6 and 9.7 Hz, H-5’), 7.24-7.27 (2H, m, H-3 and H-4’), 
7.51 (1H, dd, J = 1.5 and 3.3 Hz, H-5), 9.63 (1H, s, NH-pyrrole); 
13
C NMR (125 MHz, 
CDCl3) δ ppm 14.1 (d, JCF = 2.9 Hz, CH3), 52.0 (O-CH3), 111.2 (dd, JCF = 3.9 and 21.5 Hz, 
C-Ar), 115.8 (C-Ar), 117.4 (t, JCF = 22.2 Hz, C-Ar), 121.3 (dd, JCF = 3.5 and 17.6 Hz, C-Ar), 
124.4 (C-Ar), 127.5 (C-Ar), 128.3 (C-Ar), 132.6 (dd, JCF = 6.8 and 9.1 Hz, C-Ar), 157.5 (dd, 
JCF = 7.8 and 250.0 Hz, C-F), 157.7 (dd, JCF = 7.3 and 248.8 Hz, C-F), 161.2 (CO), 183.1 
(CO); HRMS calcd for C14H11F2NO3 [M+H]
+
 280.0780, found 280.0780. 
4-(2,6-Difluoro-3-methylbenzoyl)-1H-pyrrole-2-carboxylic acid, 348 
 
General procedure G: methyl 4-(2,6-difluoro-3-methylbenzoyl)-1H-pyrrole-2-carboxylate 
(0.60 g, 2.15 mmol), and LiOH monohydrate (1.81 g, 43.00 mmol) gave 348 as a white solid 
(0.55 g, 98%). Rf 0.27 (9:1 DCM/MeOH); m.p. 222-224 
o
C; λmax (EtOH/nm) 282.0, 231.5; IR 
υmax/cm
-1
 3294, 2882, 2703, 2623, 2546, 1626, 1552, 1506; 
1
H NMR (500 MHz, DMSO-d6) δ 
ppm 2.26 (3H, s, CH3), 6.99 (1H, br s, H-3), 7.14 (1H, dd, J = 8.6 and 9.4 Hz, H-5’), 7.45-
7.50 (2H, m, H-5 and H-4’), 12.69 (1H, s, NH-pyrrole), 12.92 (1H, s, COOH); 13C NMR (125 
MHz, DMSO-d6) δ ppm 13.6 (d, JCF = 2.7 Hz, CH3), 111.5 (dd, JCF = 3.5 and 21.2 Hz, C-Ar), 
114.2 (C-Ar), 117.2 (t, JCF = 23.6 Hz, C-Ar), 121.1 (dd, JCF = 3.5 and 17.8 Hz, C-Ar), 125.7 
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(C-Ar), 125.9 (C-Ar), 129.7 (C-Ar), 132.9 (dd, JCF = 6.8 and 9.4 Hz, C-Ar), 156.6 (dd, JCF = 
7.6 and 246.7 Hz, C-F), 156.7 (dd, JCF = 7.6 and 245.1 Hz, C-F), 161.3 (CO), 182.0 (CO); 
HRMS calcd for C13H9F2NO3 [M-H]
-
 264.0478, found 264.0466. 
4-(2,6-Difluoro-3-methylbenzoyl)-N-(pyridin-3-yl)-1H-pyrrole-2-carboxamide, 349 
 
General procedure M: 4-(2,6-difluoro-3-methylbenzoyl)-1H-pyrrole-2-carboxylic acid (55 
mg, 0.21 mmol), PCl3 (18 µL, 0.21 mmol), and 3-aminopyridine (50 mg, 0.53 mmol). 
Purification via column chromatography (NH silica; 0-8% MeOH/DCM) gave 349 as a white 
solid (66 mg, 92%). Rf 0.31 (95:5 DCM/MeOH); m.p. 254-256 
o
C; λmax (EtOH/nm) 293.5, 
253.5; IR υmax/cm
-1
 3356, 3254, 3118, 1705, 1631, 1599, 1533; 
1
H NMR (500 MHz, DMSO-
d6) δ ppm 2.27 (3H, s, CH3), 7.17 (1H, dd, J = 8.6 and 8.7 Hz, H-5’), 7.39 (1H, dd, J = 4.7 
and 8.2 Hz, CH-pyridine), 4.47-4.53 (3H, m, H-3, H-5 and H-4’), 8.14-8.16 (1H, m, CH-
pyridine), 8.30 (1H, dd, J = 1.5 and 4.7 Hz, N-CH-pyridine), 8.90 (1H, d, J = 2.5 Hz, N-CH-
pyridine), 10.25 (1H, s, CO-NH), 12.71 (1H, s, NH-pyrrole); 
13
C NMR (125 MHz, DMSO-
d6) δ ppm 13.7 (CH3), 111.5 (C-Ar), 111.6 (C-Ar), 117.4 (m, C-Ar), 121.1 (dd, JCF = 3.0 and 
18.6 Hz, C-Ar), 123.6 (C-Ar), 125.9 (C-Ar), 127.0 (C-Ar), 132.9 (m, C-Ar), 135.5 (C-Ar), 
141.6 (C-Ar), 144.4 (C-Ar), 156.5 (dd, JCF = 7.5 and 245.9 Hz, C-F), 156.6 (dd, JCF = 7.1 and 
244.5 Hz, C-F), 158.7 (CO), 182.2 (CO), two C-Ar not visualised; HRMS calcd for 
C18H13F2N3O2 [M+H]
+
 342.1049, found 342.1049. 
4-(2,6-Difluoro-3-methylbenzoyl)-N-(pyrimidin-5-yl)-1H-pyrrole-2-carboxamide, 350 
 
General procedure M with exceptions to the method: 4-(2,6-difluoro-3-methylbenzoyl)-
1H-pyrrole-2-carboxylic acid (85 mg, 0.32 mmol), PCl3 (28 µL, 0.32 mmol), and 5-
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aminopyrimidine (76 mg, 0.80 mmol) for 15 min. Purification via column chromatography 
(silica; 0-8% MeOH/DCM) gave 350 as a yellow solid (56 mg, 51%). Rf 0.60 (9:1 
DCM/MeOH); m.p. 317-319 
o
C; λmax (EtOH/nm) 290.0; IR υmax/cm
-1
 3331, 3257, 3118, 
2982, 1666, 1626, 1589, 1554, 1525; 
1
H NMR (500 MHz, DMSO-d6) δ ppm 2.27 (3H, s, 
CH3), 7.17 (1H, dd, J = 8.6 and 8.7 Hz, H-5’), 7.57-7.53 (2H, m, H-3 and H-4’), 7.58 (1H, br 
s, H-5), 8.92 (1H, s, CH-pyrimidine), 9.13 (2H, s, CH-pyrimidine), 10.44 (1H, s, CO-NH), 
12.81 (1H, s, NH-pyrrole); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 13.7 (CH3), 111.6 (dd, JCF 
= 2.9 and 20.5 Hz, C-Ar), 112.2 (C-Ar), 117.3 (t, JCF = 23.9 Hz, C-Ar), 121.1 (dd, JCF = 2.8 
and 17.5 Hz, C-Ar), 125.9 (C-Ar), 127.5 (C-Ar), 129.7 (C-Ar), 133.0 (dd, JCF = 6.1 and 8.1 
Hz, C-Ar), 134.3 (C-Ar), 147.8 (C-Ar), 153.2 (C-Ar), 156.6 (m, C-F), 158.8 (CO), 182.2 
(CO), one C-F not visualised; HRMS calcd for C17H12F2N4O2 [M+H]
+
 343.1001, found 
343.1003. 
tert-Butyl 4-(4-(2,6-difluoro-3-methylbenzoyl)-1H-pyrrole-2-carboxamido)piperidine-1-
carboxylate, 351 
 
General procedure D: 4-(2,6-difluoro-3-methylbenzoyl)-1H-pyrrole-2-carboxylic acid (101 
mg, 0.38 mmol), CDI (123 mg, 0.76 mmol), and tert-butyl 4-aminopiperidine-1-carboxylate 
(190 mg, 0.95 mmol). Purification via column chromatography (silica; 30-100% 
EtOAc/petrol) gave 351 as a white solid (115 mg, 68%). Rf 0.71 (9:1 DCM/MeOH); m.p. 
231-232 
o
C; λmax (EtOH/nm) 288.0, 237.0; IR υmax/cm
-1
 3355, 3167, 3125, 2973, 2931, 2864, 
1696, 1621, 1568, 1531; 
1
H NMR (500 MHz, CDCl3) δ ppm 1.38-1.46 (2H, m, CH-
piperidine), 1.49 (9H, s, C-CH3), 1.97-1.80 (2H, m, CH-piperidine), 2.30 (3H, s, CH3), 2.86-
2.92 (2H, m, N-CH-piperidine), 4.05-4.12 (3H, m, N-CH-piperidine), 6.15 (1H, br s, CO-
NH), 6.91 (1H, dd, J = 7.6 and 8.6 Hz, H-5’), 7.14 (1H, br s, H-3), 7.24-7.28 (1H, m, H-4’), 
7.36 (1H, d, J = 2.5 Hz, H-5), 10.02 (1H, s, NH-pyrrole); 
13
C NMR (125 MHz, CDCl3) δ ppm 
14.1 (d, JCF = 2.9 Hz, CH3), 28.4 (C-CH3), 32.0 (C-piperidine), 42.8 (C-piperidine), 47.1 (C-
piperidine), 79.8 (C-CH3), 109.2 (C-Ar), 111.2 (dd, JCF = 3.8 and 21.2 Hz, C-Ar), 117.5 (t, 
JCF =22.7 Hz, C-Ar), 121.3 (dd, JCF = 3.4 and 17.9 Hz, C-Ar), 127.3 (C-Ar), 128.0 (C-Ar), 
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128.3 (C-Ar), 132.6 (dd, JCF = 6.9 and 8.8 Hz, C-Ar), 154.7 (CO), 157.5 (dd, JCF = 7.5 and 
249.2 Hz, C-F), 157.6 (dd, JCF = 7.1 and 248.3 Hz, C-F), 159.9 (CO), 183.1 (CO); HRMS 
calcd for C23H27F2N3O4 [M+H]
+
 448.2042, found 448.2043. 
4-(2,6-Difluoro-3-methylbenzoyl)-N-(piperidin-4-yl)-1H-pyrrole-2-carboxamide, 379 
 
General procedure K: tert-butyl 4-(4-(2,6-difluoro-3-methylbenzoyl)-1H-pyrrole-2-
carboxamido)piperidine-1-carboxylate (80 mg, 0.17 mmol), triethylsilane (69 µL, 0.43 
mmol) and TFA ( 2 mL/mmol) gave 379 as a white solid (55 mg, 93%). Rf 0.61 (9:1 
DCM/MeOH, NH silica); m.p. 212-213 
o
C; λmax (EtOH/nm) 283.0, 234.5; IR υmax/cm
-1
 2935, 
2862, 1624, 1566, 1535; 
1
H NMR (500 MHz, DMSO-d6) δ ppm 1.46-1.53 (2H, m, CH-
piperidine), 1.79-1.82 (2H, m, CH-piperidine), 2.25 (3H, s, CH3), 2.69-2.74 (2H, m, N-CH-
piperidine), 3.09-3.12 (2H, m, N-CH-piperidine), 3.85-3.91 (1H, m, N-CH-piperidine), 7.12-
7.16 (1H, dd, J = 7.6 and 8.6 Hz, H-5’), 7.26 (1H, br s, H-3), 7.37 (1H, br s, H-5), 7.43-7.49 
(1H, m, H-4’), 8.20 (1H, d, J = 7.9 Hz, CO-NH); 13C NMR (125 MHz, DMSO-d6) δ ppm 
13.6 (d, JCF = 2.3 Hz, CH3), 31.0 (C-piperidine), 43.9 (C-piperidine), 45.5 (C-piperidine), 
110.1 (C-Ar), 111.5 (dd, JCF = 3.1 and 21.3 Hz, C-Ar), 117.5 (t, JCF = 23.3 Hz, C-Ar), 121.0 
(dd, JCF = 3.0 and 17.5 Hz, C-Ar), 125.6 (C-Ar), 128.2 (C-Ar), 128.7 (C-Ar), 132.7 (dd, JCF = 
6.4 and 8.4 Hz, C-Ar), 156.5 (dd, JCF = 8.2 and 246.5 Hz, C-F), 156.7 (dd, JCF = 7.8 and 
244.8 Hz, C-F), 159.0 (CO), 182.2 (CO); HRMS calcd for C18H19F2N3O2 [M+H]
+
 348.1518, 
found 348.1520. 
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4-(2,6-Difluoro-3-methylbenzoyl)-N-(1-methylpiperidin-4-yl)-1H-pyrrole-2-
carboxamide, 352 
 
General procedure D: 4-(2,6-difluoro-3-methylbenzoyl)-1H-pyrrole-2-carboxylic acid (50 
mg, 0.17 mmol), CDI (55 mg, 0.34 mmol), and 4-amino-1-methyl piperidine (54 µL, 0.43 
mmol). Purification via column chromatography (NH silica; 0-8% MeOH/DCM) gave 352 as 
a white solid (57 mg, 88%). Rf 0.19 (9:1 DCM/MeOH); m.p. 275-278 
o
C; λmax (EtOH/nm) 
295.0, 235.5; IR υmax/cm
-1
 3243, 2940, 2803, 1622, 1582; 
1
H NMR (500 MHz, DMSO-d6) δ 
ppm 1.48-1.56 (2H, m, CH-piperidine), 1.72-1.75 (2H, m, CH-piperidine), 1.90-1.95 (2H, m, 
N-CH-piperidine), 2.16 (3H, s, N-CH3), 2.26 (3H, s, CH3), 2.74-2.77 (2H, m, N-CH-
piperidine), 3.64-3.72 (1H, m, N-CH-piperidine), 7.14 (1H, dd, J = 8.6 and 9.1 Hz, H-5’), 
7.24 (1H, br s, H-3), 7.36 (1H, br s, H-5), 7.44-7.49 (1H, m, H-4’), 8.09 (1H, d, J = 7.9 Hz, 
CO-NH), 12.37 (1H, s, NH-pyrrole); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 13.7 (d, JCF = 
2.3 Hz, CH3), 31.6 (C-piperidine), 45.9 (N-CH3), 46.0 (C-piperidine), 54.4 (C-piperidine), 
109.9 (C-Ar), 111.5 (dd, JCF = 3.8 and 20.7 Hz, C-Ar), 121.0 (dd, JCF = 3.4 and 17.5 Hz, C-
Ar), 125.6 (C-Ar), 128.1 (C-Ar), 128.8 (C-Ar), 132.7 (m, C-Ar), 156.5 (m, two C-F), 159.1 
(CO), 182.2 (CO), one C-F not visualised; HRMS calcd for C19H21F2N3O2 [M+H]
+
 362.1675, 
found 362.1674. 
Methyl 4-(6-chloro-2,3-difluorobenzoyl)-1H-pyrrole-2-carboxylate, 353 
 
General procedure E: 6-chloro, 2,3-difluorobenzoic acid (1.12 g, 5.83 mmol), SOCl2 (0.64 
mL, 8.75 mmol) and DMF (10 mol%) gave 6-chloro, 2,3-difluorobenzoyl chloride as a 
yellow oil which was used directly in the next step. General procedure F: methyl 1H-
pyrrole-2-carboxylate (365 mg, 2.92 mmol), and AlCl3 (0.98 g, 7.30 mmol). Purification via 
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column chromatography (silica; 0-50% EtOAc/petrol) gave 353 as a white solid (0.51 g, 
59%). Rf 0.19 (8:2 Petrol/EtOAc); m.p. 176-178 
o
C; λmax (EtOH/nm) 281.0, 232.5, 211.5; IR 
υmax/cm
-1
 3260, 3162, 3037, 2967, 1691, 1656, 1557; 
1
H NMR (500 MHz, CDCl3) δ ppm 
3.91 (3H, s, O-CH3), 7.21-7.25 (3H, m, H-3, H-4’ and H-5’), 7.49 (1H, dd, J = 1.6 and 2.4 
Hz, H-5), 9.79 (1H, s, NH-pyrrole); 
13
C NMR (125 MHz, CDCl3) δ ppm 52.1 (O-CH3), 115.6 
(C-Ar), 118.5 (d, JCF = 18.5 Hz, C-Ar), 124.8 (C-Ar), 125.7 (dd, JCF = 4.3 and 5.0 Hz, C-Ar), 
126.1 (dd, JCF = 3.4 and 3.5 Hz, C-Ar), 126.4 (C-Ar), 128.4 (C-Ar), 129.9 (d, JCF = 18.6 Hz, 
C-Ar), 147.4 (dd, JCF = 12.9 and 248.9 Hz, C-F), 149.2 (dd, JCF =  12.8 and 249.5 Hz, C-F), 
161.1 (CO), 183.2 (CO); HRMS calcd for C13H8
35
ClF2NO3 [M+H]
+
 300.0234, found 
300.0240. 
4-(6-Chloro-2,3-difluorobenzoyl)-1H-pyrrole-2-carboxylic acid, 354 
 
General procedure G: methyl 4-(6-chloro-2,3-difluorobenzoyl)-1H-pyrrole-2-carboxylate 
(480 mg, 1.61 mmol), and LiOH monohydrate (1.35 g, 32.2 mmol) gave 354 as a white solid 
(459 mg, 100%). Rf 0.21 (9:1 DCM/MeOH); m.p. 253-255 
o
C; λmax (EtOH/nm) 283.0, 234.5; 
IR υmax/cm
-1
 3334, 2674, 2626, 2605, 1685, 1651, 1558; 
1
H NMR (500 MHz, DMSO-d6) δ 
ppm 7.05 (1H, br s, H-3), 7.48 (1H, ddd, J = 1.8, 4.0 and 9.1 Hz, H-5’), 7.60-7.67 (2H, m, H-
5 and H-4’), 12.76 (1H, s, NH-pyrrole), 12.93 (1H, s, COOH); 13C NMR (125 MHz, DMSO-
d6) δ ppm 114.1 (C-Ar), 119.1 (d, JCF = 19.0 Hz, C-Ar), 124.8 (C-Ar), 125.0 (dd, JCF = 3.4 
and 3.5 Hz, C-Ar), 126.1 (C-Ar), 126.4 (dd, JCF = 4.1 and 6.8 Hz, C-Ar), 129.5 (d, JCF = 19.4 
Hz, C-Ar), 130.6 (C-Ar), 146.6 (dd, JCF = 12.7 and 247.5 Hz, C-F), 148.6 (dd, JCF =  13.0 and 
247.9 Hz, C-F), 161.3 (CO), 182.3 (CO); HRMS calcd for C12H6
35
ClF2NO3 [M+H]
+
 
286.0077, found 286.0082. 
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4-(6-Chloro-2,3-difluorobenzoyl)-N-(pyridin-3-yl)-1H-pyrrole-2-carboxamide, 355 
 
General procedure M: 4-(6-chloro-2,3-difluorobenzoyl)-1H-pyrrole-2-carboxylic acid  (54 
mg, 0.19 mmol), PCl3 (17 µL, 0.19 mmol), and 3-aminopyridine (45 mg, 0.48 mmol). 
Purification via column chromatography (silica; 0-8% MeOH/DCM) gave 355 as a white 
solid (39 mg, 57%). Rf 0.31 (95:5 DCM/MeOH); m.p. 228-229 
o
C; λmax (EtOH/nm) 290.5, 
253.5; IR υmax/cm
-1 
3319, 3123, 3095, 2979, 2930, 2875, 1647, 1593, 1516; 
1
H NMR (500 
MHz, DMSO-d6) δ ppm 7.40 (1H, dd, J = 4.7 and 8.4 Hz, CH-pyridine), 7.52 (1H, ddd, J = 
1.8, 4.1 and 9.1 Hz, H-5’), 7.55 (1H, br s, H-3), 7.64-7.70 (2H, m, H-5 and H-4’), 8.14 (1H, 
ddd, J = 1.5, 2.5 and 8.3 Hz, CH-pyridine), 8.31 (1H, dd, J = 1.5 and 4.7 Hz, N-CH-
pyridine), 8.90 (1H, d, J = 2.5 Hz, N-CH-pyridine), 10.25 (1H, s, CO-NH), 12.79 (1H, s, NH-
pyrrole); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 111.5 (C-Ar), 119.1 (d, JCF = 18.0 Hz, C-
Ar), 123.6 (C-Ar), 124.8 (C-Ar), 125.1 (dd, JCF = 4.6 and 5.7 Hz, C-Ar), 126.4 (dd, JCF = 3.7 
and 5.9 Hz, C-Ar), 127.0 (C-Ar), 128.4 (C-Ar), 129.7 (d, JCF = 20.1 Hz, C-Ar), 130.4 (C-Ar), 
135.5 (C-Ar), 141.6 (C-Ar), 158.7 (CO), 182.4 (CO), two C-F and one C-Ar not visualised; 
HRMS calcd for C17H10
35
ClF2N3O2 [M+H]
+
 362.0502, found 362.0503. 
4-(6-Chloro-2,3-difluorobenzoyl)-N-(pyrimidin-5-yl)-1H-pyrrole-2-carboxamide, 356 
 
General procedure M with exceptions to the method: 4-(6-chloro-2,3-difluorobenzoyl)-
1H-pyrrole-2-carboxylic acid  (59 mg, 0.21 mmol), PCl3 (18 µL, 0.21 mmol), and 5-
aminopyrimidine (50 mg, 0.53 mmol) for 30 min. Purification via column chromatography 
(silica; 0-8% MeOH/DCM) gave 356 as a yellow solid (42 mg, 55%). Rf 0.58 (9:1 
DCM/MeOH); m.p. 277-279 
o
C; λmax (EtOH/nm) 291.0, 267.5; IR υmax/cm
-1 
3309, 3125, 
3079, 2868, 1644, 1588, 1555, 1533; 
1
H NMR (500 MHz, DMSO-d6) δ ppm 7.51-7.54 (2H, 
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m, H-5’ and H-3), 7.65-7.70 (2H, m, H-4’ and H-5), 8.93 (1H, s, N-CH-pyrimidine), 9.13 
(2H, s, N-CH-pyrimidine), 10.45 (1H, s, CO-NH), 12.88 (1H, s, NH-pyrrole); 
13
C NMR (125 
MHz, DMSO-d6) δ ppm 112.0 (C-Ar), 119.2 (d, JCF = 18.6 Hz, C-Ar), 124.9 (C-Ar), 125.1 
(dd, JCF = 3.8 and 4.0 Hz, C-Ar), 126.5 (dd, JCF = 3.6 and 5.9 Hz, C-Ar), 127.9 (C-Ar), 129.6 
(d, JCF = 19.2 Hz, C-Ar), 130.6 (C-Ar), 134.3 (C-Ar), 146.5 (dd, JCF = 14.4 and 248.3 Hz, C-
F), 147.8 (C-Ar), 148.8 (dd, JCF = 11.6 and 235.6 Hz, C-F), 153.2 (C-Ar), 158.8 (CO), 182.4 
(CO); HRMS calcd for C16H9
35
ClF2N4O2 [M+H]
+
 363.0455, found 363.0472. 
tert-Butyl 4-(4-(6-chloro-2,3-difluorobenzoyl)-1H-pyrrole-2-carboxamido)piperidine-1-
carboxylate, 357 
 
General procedure D: 4-(6-chloro-2,3-difluorobenzoyl)-1H-pyrrole-2-carboxylic acid  (100 
mg, 0.35 mmol), CDI (113 mg, 0.70 mmol), and tert-butyl 4-aminopiperidine-1-carboxylate  
(176 mg, 0.88 mmol). Purification via column chromatography (silica; 30-100% 
EtOAc/petrol) gave 357 as a colourless oil (150 mg, 91%). Rf 0.65 (9:1 DCM/MeOH); λmax 
(EtOH/nm) 288.0, 236.5; IR υmax/cm
-1 
1662, 1619, 1568, 1534; 
1
H NMR (500 MHz, CDCl3) 
δ ppm 1.37-1.45 (2H, m, CH-piperidine), 1.48 (9H, s, C-CH3), 1.97-2.00 (2H, m, CH-
piperidine), 2.86-2.92 (2H, m, N-CH-piperidine), 4.04-4.12 (3H, m, N-CH-piperidine), 5.93 
(1H, d, J = 7.9 Hz, CO-NH), 7.00 (1H, br s, H-3), 7.22-7.24 (2H, m, H-4’ and H-5’), 7.33 
(1H, br s, H-5), 9.90 (1H, s, NH-pyrrole); 
13
C NMR (125 MHz, CDCl3) δ ppm 28.4 (C-CH3), 
32.1 (C-piperidine), 42.7 (C-piperidine), 47.1 (C-piperidine), 79.8 (C-CH3), 108.8 (C-Ar), 
118.5 (d, JCF = 18.8 Hz, C-Ar), 125.8 (dd, JCF = 4.2 and 5.8 Hz, C-Ar), 126.2 (d, JCF = 6.8 
Hz, C-Ar), 128.0 (C-Ar), 128.2 (C-Ar), 154.7 (CO), 159.4 (CO), two C-F, two C-Ar and one 
CO not visualised; HRMS calcd for C22H24
35
ClF2N3O4 [M+NH4]
+
 485.1762, found 485.1754.   
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4-(6-Chloro-2,3-difluorobenzoyl)-N-(piperidin-4-yl)-1H-pyrrole-2-carboxamide, 380 
 
General procedure K: tert-butyl 4-(4-(6-chloro-2,3-difluorobenzoyl)-1H-pyrrole-2-
carboxamido)piperidine-1-carboxylate (140 mg, 0.30 mmol), triethylsilane (120 µL, 0.75 
mmol) and TFA (2 mL/mmol) gave 380 as a white solid (105 mg, 95%). Rf 0.43 (9:1 
DCM/MeOH, NH silica); m.p. 154-156 
o
C; λmax (EtOH/nm) 286.5, 236.5; IR υmax/cm
-1 
3123, 
2941, 2854, 1620, 1566, 1533; 
1
H NMR (500 MHz, DMSO-d6) δ ppm 1.32-1.39 (2H, m, CH-
piperidine), 1.69-1.72 (2H, m, CH-piperidine), 2.46-2.51 (2H, m, N-CH-piperidine), 2.93-
2.96 (2H, m, N-CH-piperidine), 3.73-3.81 (1H, m, N-CH-piperidine), 7.25 (1H, br s, H-3), 
7.46 (1H, br s, H-5), 7.49 (1H, ddd, J = 1.7, 4.0 and 9.1 Hz, H-5’), 7.62-7.67 (1H, m, H-4’), 
8.10 (1H, d, J = 7.7 Hz, CO-NH), NH-piperidine and NH-pyrrole not visualised; 
13
C NMR 
(125 MHz, CDCl3) 33.0 (C-piperidine), 45.2 (C-piperidine), 46.8 (C-piperidine), 109.8 (C-
Ar), 118.9 (d, JCF = 18.6 Hz, C-Ar), 124.5 (C-Ar), 125.1 (C-Ar), 126.4 (dd, JCF = 3.6 and 5.7 
Hz, C-Ar), 129.1 (m, C-Ar), 129.4 (C-Ar), 129.9 (d, JCF = 19.6 Hz, C-Ar), 146.5 (dd, JCF = 
14.8 and 247.5 Hz, C-F), 148.7 (dd, JCF = 11.9 and 248.5 Hz, C-F), 158.8 (CO), 182.3 (CO); 
HRMS calcd for C17H16
35
ClF2N3O2 [M+H]
+ 
368.0972, found 368.0976. 
4-(6-Chloro-2,3-difluorobenzoyl)-N-(1-methylpiperidin-4-yl)-1H-pyrrole-2-
carboxamide, 358 
 
General procedure D: 4-(6-chloro-2,3-difluorobenzoyl)-1H-pyrrole-2-carboxylic acid  (71 
mg, 0.25 mmol), CDI (81 mg, 0.50 mmol), and 4-amino-1-methyl piperidine  (79 µL, 0.63 
mmol). Purification via column chromatography (NH silica; 0-5% MeOH/DCM) gave 358 as 
a white solid (65 mg, 68%). 
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Rf 0.17 (9:1 DCM/MeOH); m.p. 188-190 
o
C; λmax (EtOH/nm) 286.0, 238.0; IR υmax/cm
-1 
3562, 3200, 3131, 2947, 2852, 2801, 1665, 1616, 1579, 1549; 
1
H NMR (500 MHz, DMSO-
d6) δ ppm 1.49-1.57 (2H, m, CH-piperidine), 1.72-1.75 (2H, m, CH-piperidine), 1.90-1.95 
(2H, m, N-CH-piperidine), 2.16 (3H, s, N-CH3), 2.74-2.78 (2H, m, N-CH-piperidine), 3.64-
3.72 (1H, m, N-CH-piperidine), 7.25 (1H, br s, H-3), 7.47-7.51 (2H, m, H-5 and H-5’), 7.62-
7.67 (1H, m, H-4’), 8.10 (1H, d, J = 7.9 Hz, CO-NH), 12.47 (1H, s, NH-pyrrole); 13C NMR 
(125 MHz, DMSO-d6) δ ppm 31.5 (C-piperidine), 45.9 (N-CH3), 46.0 (C-piperidine), 54.4 
(C-piperidine), 109.8 (C-Ar), 119.0 (d, JCF = 18.3 Hz, C-Ar), 124.5 (C-Ar), 125.1 (dd, JCF = 
3.8 and 3.9 Hz, C-Ar), 126.4 (dd, JCF = 3.0 and 5.6 Hz, C-Ar), 129.0 (C-Ar), 129.2 (C-Ar), 
129.8 (d, JCF = 19.8 Hz, C-Ar), 146.4 (dd, JCF = 14.4 and 247.2 Hz, C-F), 148.7 (dd, JCF = 
12.2 and 248.3 Hz, C-F), 159.0 (CO), 182.3 (CO); HRMS calcd for C18H18
35
ClF2N3O2 
[M+H]
+
 382.1128, found 382.1130. 
Methyl 4-(2,5-difluorobenzoyl)-1H-pyrrole-2-carboxylate, 359 
 
General procedure F: methyl 1H-pyrrole-2-carboxylate (0.51 g, 4.05 mmol), 2,5-
difluorobenzoyl chloride (1.43 mL, 8.10 mmol, and AlCl3 (1.36 g, 10.13 mmol). Purification 
via column chromatography (silica; 0-50% EtOAc/petrol) gave 359 as a white solid (0.97 g, 
93%). Rf 0.17 (8:2 Petrol/EtOAc); m.p. 151-153 
o
C; λmax (EtOH/nm) 284.5, 234.5.; IR 
υmax/cm
-1
 3321, 3090, 2957, 1719, 1630, 1590, 1557, 1508; 
1
H NMR (500 MHz, DMSO-d6) δ 
ppm 3.81 (3H, s, O-CH3), 7.09 (1H, br s, H-3), 7.40-7.49 (3H, m, H-3’, H-4’ and H-6’), 7.58 
(1H, br s, H-5), 12.84 (1H, s, NH-pyrrole); 
13
C NMR (125 MHz, CDCl3) δ ppm 52.1 (O-
CH3), 116.1 (C-Ar), 116.5 (dd, JCF = 3.7 and 25.2 Hz, C-Ar), 117.8 (dd, JCF = 8.3 and 25.1 
Hz, C-Ar), 119.1 (dd, JCF = 8.5 and 24.1 Hz, C-Ar), 124.3 (C-Ar), 126.4 (C-Ar), 128.4 (C-
Ar), 129.0 (dd, JCF = 6.5 and 18.0 Hz, C-Ar), 155.5 (dd, JCF = 2.3 and 247.6 Hz, C-F), 160.3 
(d, JCF = 232.9 Hz, C-F), 161.2 (CO), 185.5 (CO); HRMS calcd for C13H9F2NO3 [M+H]
+
 
266.0623, found 266.0628. 
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4-(2,5-Difluorobenzoyl)-1H-pyrrole-2-carboxylic acid, 360 
 
General procedure G: methyl 4-(2,5-difluorobenzoyl)-1H-pyrrole-2-carboxylate (0.90 g, 
3.40 mmol), and LiOH monohydrate (2.86 g, 68.00 mmol) gave 360 as a white solid (0.85 g, 
100%). Rf 0.30 (9:1 DCM/MeOH); m.p. 209-210 
o
C; λmax (EtOH/nm) 285.0, 233.0; IR 
υmax/cm
-1
 3672, 3447, 3360, 3317, 3074, 1676, 1630, 1558; 
1
H NMR (500 MHz, DMSO-d6) δ 
ppm 7.04 (1H, br s, H-3), 7.39-7.48 (3H, m, H-3’, H-4’ and H-6’), 7.50 (1H, br s, H-5), 12.65 
(1H, s, NH-pyrrole), 12.90 (1H, s, COOH); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 114.7 (C-
Ar), 116.0 (dd, JCF = 3.7 and 25.4 Hz, C-Ar), 118.1 (dd, JCF = 8.4 and 24.9 Hz, C-Ar), 118.9 
(dd, JCF = 8.7 and 24.1 Hz, C-Ar), 124.9 (C-Ar), 125.4 (C-Ar), 129.2 (dd, JCF = 7.0 and 19.2 
Hz, C-Ar), 129.9 (C-Ar), 154.8 (d, JCF  = 243.8 Hz, C-F), 157.8 (d, JCF  = 241.8 Hz, C-F), 
161.4 (CO), 184.6 (CO); HRMS calcd for C12H7F2NO3 [M+H]
+
 252.0467, found 252.0467. 
4-(2,5-Difluorobenzoyl)-N-(pyridin-3-yl)-1H-pyrrole-2-carboxamide, 361 
 
General procedure M: 4-(2,5-difluorobenzoyl)-1H-pyrrole-2-carboxylic acid (100 mg, 0.37 
mmol), PCl3 (32 µL, 0.37 mmol), and 3-aminopyridine (88 mg, 0.93 mmol). Purification via 
column chromatography (NH silica; 0-8% MeOH/DCM) gave 361 as a white solid (52 mg, 
41%). Rf 0.25 (95:5 DCM/MeOH); m.p. 276-277 
o
C; λmax (EtOH/nm) 265.5; IR υmax/cm
-1
 
3238, 3079, 1668, 1635, 1562, 1545; 
1
H NMR (500 MHz, DMSO-d6) δ ppm 7.40 (1H, dd, J 
= 4.7 and 8.3 Hz, CH-pyridine), 7.42-7.50 (3H, m, H-3’, H-4’ and H-6’), 7.54 (1H, br s, H-3), 
7.58 (1H, br s, H-5), 8.15 (1H, ddd, J = 1.5, 2.5 and 8.3 Hz, CH-pyridine), 8.30 (1H, dd, J = 
1.5 and 4.7 Hz, N-CH-pyridine), 8.91 (1H, d, J = 2.5 Hz, N-CH-pyridine), 10.25 (1H, s, CO-
NH), 12.68 (1H, s, NH-pyrrole); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 112.1 (C-Ar), 116.0 
(dd, JCF = 3.4 and 25.2 Hz, C-Ar), 118.1 (dd, JCF = 8.5 and 25.1 Hz, C-Ar), 118.9 (dd, JCF = 
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8.8 and 24.2 Hz, C-Ar), 123.6 (C-Ar), 124.9 (C-Ar), 126.9 (C-Ar), 127.8 (C-Ar), 129.4 (dd, 
JCF = 6.4 and 19.1 Hz, C-Ar), 129.6 (C-Ar), 135.5 (C-Ar), 141.6 (C-Ar), 144.4 (C-Ar), 154.8 
(d, JCF = 243.8 Hz, C-F), 157.8 (d, JCF = 243.5 Hz, C-F), 158.8 (CO), 184.8 (CO); HRMS 
calcd for C17H11F2N3O2 [M+H]
+
 328.0892, found 328.0897. 
tert-Butyl 4-(4-(2,5-difluorobenzoyl)-1H-pyrrole-2-carboxamido)piperidine-1-
carboxylate, 362 
 
General procedure D: 4-(2,5-difluorobenzoyl)-1H-pyrrole-2-carboxylic acid (102 mg, 0.41 
mmol), CDI (133 mg, 0.82 mmol), and tert-butyl 4-aminopiperidine-1-carboxylate (206 mg, 
1.03 mmol). Purification via column chromatography (silica; 30-100% EtOAc/petrol) gave 
362 as a white solid (154 mg, 87%). Rf 0.69 (9:1 DCM/MeOH); m.p. 133-135 
o
C; λmax 
(EtOH/nm) 286.0, 238.0; IR υmax/cm
-1
 3127, 2975, 2932, 2866, 1623, 1565, 1533; 
1
H NMR 
(500 MHz, CDCl3) δ ppm 1.39-1.47 (2H, m, CH-piperidine), 1.49 (9H, s, C-CH3), 1.97-2.00 
(2H, m, CH-piperidine), 2.87-2.92 (2H, m, N-CH-piperidine), 4.06-4.14 (3H, m, N-CH-
piperidine), 6.25 (1H, d, J = 7.9 Hz, CO-NH), 7.14-7.23 (3H, m, H-3, H-3’, H-6’), 7.26 (1H, 
dddd, J = 3.4, 3.5, 8.0 and 8.1 Hz, Hz, H-4’), 7.40 (1H, br s, H-5), 10.41 (1H, s, NH-pyrrole); 
13
C NMR (125 MHz, CDCl3) δ ppm 28.4 (C-CH3), 32.1 (C-piperidine), 42.7 (C-piperidine), 
47.1 (C-piperidine), 79.8 (C-CH3), 109.6 (C-Ar), 116.4 (dd, JCF = 3.1 and 24.9 Hz, C-Ar), 
117.8 (dd, JCF = 8.1 and 25.0 Hz, C-Ar), 119.0 (dd, JCF = 8.4 and 23.9 Hz, C-Ar), 126.0 (C-
Ar), 127.8 (C-Ar), 128.2 (C-Ar), 129.1 (dd, JCF = 6.1 and 18.7 Hz, C-Ar), 154.7 (CO), 155.5 
(d, JCF = 248.0 Hz, C-F), 158.3 (d, JCF = 244.8 Hz, C-F), 159.8 (CO), 185.6 (CO); HRMS 
calcd for C22H25F2N3O4 [M+H]
+
 434.1886, found 434.1888. 
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4-(2,5-Difluorobenzoyl)-N-(piperidin-4-yl)-1H-pyrrole-2-carboxamide, 381 
 
General procedure K: tert-butyl 4-(4-(2,5-difluorobenzoyl)-1H-pyrrole-2-
carboxamido)piperidine-1-carboxylate (140 mg, 0.32 mmol), triethylsilane (127 µL, 0.73 
mmol), and TFA (2 mL/mmol) gave 381 as a white solid (101 mg, 95%). Rf 0.45 (9:1 
DCM/MeOH, NH silica); m.p. 198-200 
o
C; λmax (EtOH/nm) 289.0, 238.0; IR υmax/cm
-1
 3124, 
2940, 2834, 2742, 1675, 1628, 1567, 1535; 
1
H NMR (500 MHz, DMSO-d6) δ ppm 1.46-1.54 
(2H, m, CH-piperidine), 1.80-1.84 (2H, m, CH-piperidine), 2.70-2.75 (2H, m, N-CH-
piperidine), 3.09-3.13 (2H, m, N-CH-piperidine), 3.86-3.92 (1H, m, N-CH-piperidine), 7.30 
(1H, d, J = 1.5 Hz, H-3), 7.38 (1H, br s, H-5), 7.39-7.49 (3H, m, H-2’, H-4’ and H-5’), 8.19 
(1H, d, J = 7.8 Hz, CO-NH), 12.35 (1H, br s, NH-pyrrole); 
13
C NMR (125 MHz, DMSO-d6) 
δ ppm 30.8 (C-piperidine), 43.8 (C-piperidine), 45.4 (C-piperidine), 110.6 (C-Ar), 115.9 (dd, 
JCF = 2.9 and 25.6 Hz, C-Ar), 118.0 (dd, JCF = 8.6 and 24.9 Hz, C-Ar), 118.7 (dd, JCF = 8.3 
and 23.8 Hz, C-Ar), 124.6 (C-Ar), 128.4 (C-Ar), 129.5 (m, C-Ar), 154.8 (d, JCF = 243.2 Hz, 
C-F), 157.8 (d, JCF = 224.3 Hz, C-F), 159.1 (CO), 184.9 (CO), one C-Ar not visualised; 
HRMS calcd for C17H17F2N3O2 [M+H]
+
 334.1362, found 334.1364. 
4-(2,5-Difluorobenzoyl)-N-(1-methylpiperidin-4-yl)-1H-pyrrole-2-carboxamide, 363 
 
General procedure D: 4-(2,5-difluorobenzoyl)-1H-pyrrole-2-carboxylic acid (108 mg, 0.43 
mmol), CDI (139 mg, 0.86 mmol), and 4-amino-1-methyl piperidine (135 µL, 1.08 mmol). 
Purification via column chromatography (NH silica; 0-8% MeOH/DCM) gave 363 as a white 
solid (149 mg, 100%). Rf 0.15 (9:1 DCM/MeOH); m.p. 211-213 
o
C; λmax (EtOH/nm) 288.0, 
238.0; IR υmax/cm
-1
 2934, 2798, 1637, 1563, 1516; 
1
H NMR (500 MHz, DMSO-d6) δ ppm 
1.49-1.57 (2H, m, CH-piperidine), 1.72-1.75 (2H, m, CH-piperidine), 1.90-1.95 (2H, m, N-
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CH-piperidine), 2.16 (3H, s, N-CH3), 2.75-2.77 (2H, m, N-CH-piperidine), 3.64-3.72 (1H, m, 
N-CH-piperidine), 7.27 (1H, d, J = 1.5 Hz, H-3), 7.37 (1H, br s, H-5), 7.39-7.47 (3H, m, H-
2’, H-4’ and H-5’), 8.10 (1H, d, J = 7.9 Hz, CO-NH), 12.34 (1H, s, NH-pyrrole); 13C NMR 
(125 MHz, DMSO-d6) δ ppm 31.5 (C-piperidine), 45.9 (N-CH3), 46.0 (C-piperidine), 54.4 
(C-piperidine), 110.4 (C-Ar), 115.9 (dd, JCF = 3.9 and 25.4 Hz, C-Ar), 118.0 (dd, JCF = 8.4 
and 25.1 Hz, C-Ar), 118.7 (dd, JCF = 9.0 and 24.2 Hz, C-Ar), 124.6 (C-Ar), 128.3 (C-Ar), 
128.5 (C-Ar), 129.6 (dd, JCF = 6.7 and 19.1 Hz, C-Ar), 154.8 (dd, JCF = 2.0 and 244.2 Hz, C-
F), 157.8 (dd, JCF = 2.0 and 242.0 Hz, C-F), 159.1 (CO), 184.9 (CO); HRMS calcd for 
C18H19F2N3O2 [M+H]
+
 348.1518, found 348.1520. 
Methyl 4-(5-chloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxylate, 364 
 
General procedure F: methyl 1H-pyrrole-2-carboxylate (0.95 g, 7.57 mmol), 5-chloro, 6-
fluorobenzoyl chloride (2.00 mL, 15.13 mmol), and AlCl3 (2.54 g, 18.93 mmol). Purification 
via column chromatography (silica; 0-50% EtOAc/petrol) gave 364 as a white solid (1.85 g, 
87%). Rf 0.17 (8:2 Petrol/EtOAc); m.p. 156-157 
o
C; λmax (EtOH/nm) 283.5, 236.0; IR 
υmax/cm
-1
 3284, 3143, 3074, 2993, 2947, 1720, 1637, 1605, 1561; 
1
H NMR (500 MHz, 
DMSO-d6) δ ppm 3.81 (O-CH3), 7.09 (1H, br s, H-3), 7.42 (1H, dd, J = 8.8 and 9.2 Hz, H-
3’), 7.58 (1H, br s, H-5), 7.60 (1H, dd, J = 2.7 and 5.9 Hz, H-6’), 7.66 (1H, ddd, J = 2.7, 4.4 
and 8.8 Hz, H-4’), 12.84 (1H, s, NH-pyrrole); 13C NMR (125 MHz, DMSO-d6) δ ppm 51.6 
(O-CH3), 115.1 (C-Ar), 118.4 (d, JCF = 24.3 Hz, C-Ar), 124.1 (C-Ar), 125.0 (C-Ar), 128.5 (d, 
JCF = 2.8 Hz, C-Ar), 129.0 (d, JCF = 3.6 Hz, C-Ar), 129.5 (d, JCF = 18.2 Hz, C-Ar), 130.3 (C-
Ar), 132.2 (d, JCF = 8.5 Hz, C-Ar), 157.4 (d, JCF = 248.2 Hz, C-F), 160.4 (CO), 184.4 (CO); 
HRMS calcd for C13H9
35
ClFNO3 [M+H]
+
 282.0328, found 282.0333. 
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4-(5-Chloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid, 365 
 
General procedure G: methyl 4-(5-chloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxylate (1.80 
g, 6.41 mmol), and LiOH monohydrate (5.38 g, 128.20 mmol) gave 365 as a white solid 
(1.68 g, 98%). Rf 0.35 (9:1 DCM/MeOH); m.p. 237-239 
o
C; λmax (EtOH/nm) 281.5, 234.0; IR 
υmax/cm
-1
 3410, 3131, 3027, 2876, 2634, 2555, 1673, 1635, 1604, 1560; 
1
H NMR (500 MHz, 
DMSO-d6) δ ppm 7.03 (1H, br s, H-3), 7.42 (1H, dd, J = 8.8 and 9.2 Hz, H-3’), 7.51 (1H, br 
s, H-5), 7.60 (1H, dd, J = 2.8 and 5.9 Hz, H-6’), 7.66 (1H, ddd, J = 2.8, 4.4 and 8.8 Hz, H-4’), 
12.65 (1H, s, NH-pyrrole), 12.89 (1H, s, COOH); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 
114.7 (C-Ar), 118.3 (d, JCF = 23.9 Hz, C-Ar), 124.9 (C-Ar), 125.5 (C-Ar), 128.5 (d, JCF = 2.4 
Hz, C-Ar), 129.0 (d, JCF = 3.5 Hz, C-Ar), 129.6 (d, JCF = 18.2 Hz, C-Ar), 129.9 (C-Ar), 132.2 
(d, JCF = 8.6 Hz, C-Ar), 157.4 (d, JCF = 248.4 Hz, C-F), 161.4 (CO), 184.5 (CO); HRMS 
calcd for C12H7
35
ClFNO3 [M-H]
-
 266.0026, found 266.0017. 
4-(5-Chloro-2-fluorobenzoyl)-N-(pyridin-3-yl)-1H-pyrrole-2-carboxamide, 366 
 
General procedure M: 4-(5-chloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (69 mg, 
0.26 mmol), PCl3 (23 µL, 0.26 mmol), and 3-aminopyridine (61 mg, 0.65 mmol). Purification 
via column chromatography (NH silica; 0-8% MeOH/DCM) gave 366 as a white solid (81 
mg, 91%). Rf 0.27 (95:5 DCM/MeOH); m.p. 263-265 
o
C; λmax (EtOH/nm) 263.5; IR υmax/cm
-
1
 3230, 3076, 2984, 1668, 1603, 1545; 
1
H NMR (500 MHz, DMSO-d6) δ ppm 7.39-7.47 (2H, 
m, H-6’ and H-3’), 7.54 (1H, br s, H-3), 7.58 (1H, br s, H-5), 7.64-7.69 (2H, m, H-4’ and 
CH-pyridine), 8.16 (1H, ddd, J = 1.5, 2.5 and 8.3 Hz, CH-pyridine), 8.31 (1H, br s, N-CH-
pyridine), 8.92 (1H, br s, N-CH-pyridine), 10.26 (1H, s, CO-NH), 12.69 (1H, s, NH-pyrrole); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 112.1 (C-Ar), 118.4 (d, JCF = 23.6 Hz, C-Ar), 123.6 
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(C-Ar), 124.9 (C-Ar), 127.0 (C-Ar), 127.8 (d, JCF = 2.7 Hz, C-Ar), 129.0 (d, JCF = 3.3 Hz, C-
Ar), 129.7 (C-Ar), 129.8 (C-Ar), 132.1 (d, JCF = 8.5 Hz, C-Ar), 135.6 (C-Ar), 141.5 (C-Ar), 
144.3 (C-Ar), 157.5 (d, JCF = 248.7 Hz, C-F), 158.8 (CO), 184.7 (CO), one C-Ar not 
visualised; HRMS calcd for C17H11
35
ClFN3O2 [M+H]
+
 344.0597, found 344.0599. 
4-(5-Chloro-2-fluorobenzoyl)-N-(pyrimidin-5-yl)-1H-pyrrole-2-carboxamide, 367 
 
General procedure M with exceptios to the method: 4-(5-chloro-2-fluorobenzoyl)-1H-
pyrrole-2-carboxylic acid (106 mg, 0.40 mmol), PCl3 (35 µL, 0.40 mmol), and 5-
aminopyrimidine (95 mg, 1.00 mmol) for 15 min. Purification via column chromatography 
(silica; 0-8% MeOH/DCM) gave 367 as a white solid (58 mg, 42%). Rf 0.59 (9:1 
DCM/MeOH); m.p. Degrades >250 
o
C; λmax (EtOH/nm) 297.5; IR υmax/cm
-1
 3504, 3307, 
3227, 3116, 3051, 2981, 2922, 2860, 1652, 1622, 1584, 1554, 1525; 
1
H NMR (500 MHz, 
DMSO-d6) δ ppm 7.45 (1H, dd, J = 8.9 and 9.1 Hz, H-3’), 7.57 (1H, br s, H-3), 7.59 (1H, br 
s, H-5), 7.64-7.70 (2H, m, H-5’ and H-4’), 8.92 (1H, s, CH-pyrimidine), 9.15 (2H, s, CH-
pyrimidine), 10.51 (1H, s, CO-NH), 12.67 (1H, s, NH-pyrrole); 
13
C NMR (125 MHz, DMSO-
d6) δ ppm 112.7 (C-Ar), 118.4 (d, JCF = 24.3 Hz, C-Ar), 125.0 (C-Ar), 127.3 (C-Ar), 128.5 
(d, JCF = 2.9 Hz, C-Ar), 129.0 (d, JCF = 3.1 Hz, C-Ar), 129.7 (d, JCF = 18.0 Hz, C-Ar), 130.0 
(C-Ar), 132.2 (d, JCF = 8.5 Hz, C-Ar), 134.4 (C-Ar), 147.8 (C-Ar), 153.1 (C-Ar), 157.5 (d, 
JCF = 249.5 Hz, C-F), 158.9 (CO), 184.7 (CO); HRMS calcd for C16H10
35
ClFN4O2 [M+H]
+ 
345.0549, found 345.0555.    
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tert-Butyl 4-(4-(5-chloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxamido)piperidine-1-
carboxylate, 368 
 
General procedure D: 4-(5-chloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (75 mg, 
0.28 mmol), CDI (91 mg, 0.56 mmol), and tert-butyl 4-aminopiperidine-1-carboxylate (140 
mg, 0.95 mmol). Purification via column chromatography (silica; 30-100% EtOAc/petrol) 
gave 368 as a white solid (93 mg, 74%). Rf 0.68 (9:1 DCM/MeOH); m.p. 134-135 
o
C; λmax 
(EtOH/nm) 294.0, 242.5; IR υmax/cm
-1
 3122, 2959, 2869, 1621, 1566, 1534; 
1
H NMR (500 
MHz, CDCl3) δ ppm 1.40-1.49 (11H, m, CH-piperidine and C-CH3), 1.98-2.01 (2H, m, CH-
piperidine), 2.87-2.93 (2H, m, N-CH-piperidine), 4.07-4.13 (3H, m, N-CH-piperidine), 6.18 
(1H, d, J = 7.7 Hz, CO-NH), 7.13-7.17 (2H, m, H-3 and H-3’), 7.40 (1H, br s, H-5), 7.45-
7.48 (1H, m, H-4’), 7.53 (1H, dd, J = 2.6 and 5.7 Hz,  H-6’), 10.31 (1H, s, NH-pyrrole); 13C 
NMR (125 MHz, CDCl3) δ ppm 28.4 (C-CH3), 32.1 (C-piperidine), 42.7 (C-piperidine), 47.1 
(C-piperidine), 79.8 (C-CH3), 109.4 (C-Ar), 117.9 (d, JCF = 24.1 Hz, C-Ar), 126.1 (C-Ar), 
127.8 (C-Ar), 129.6 (C-Ar), 129.7 (d, JCF = 2.9 Hz, C-Ar), 132.2 (d, JCF = 7.8 Hz, C-Ar), 
154.7 (CO), 158.1 (d, JCF = 251.1 Hz, C-F), 159.7 (CO), 185.4 (CO), two C-Ar not 
visualised; HRMS calcd for C22H25
35
ClFN3O4 [M+H]
+
 450.1590, found 450.1590. 
4-(5-Chloro-2-fluorobenzoyl)-N-(piperidin-4-yl)-1H-pyrrole-2-carboxamide, 382 
 
General procedure K: tert-butyl 4-(4-(5-chloro-2-fluorobenzoyl)-1H-pyrrole-2-
carboxamido)piperidine-1-carboxylate (80 mg, 0.17 mmol), triethylsilane (69 µL, 0.43 
mmol) and TFA (2 mL/mmol) gave 382 as a white solid (61 mg, 100%). Rf 0.42 (9:1 
DCM/MeOH, NH silica); m.p. 208-210 
o
C; λmax (EtOH/nm) 238.5; IR υmax/cm
-1
 3299, 2939, 
2824, 2745, 1627, 1568, 1533; 
1
H NMR (500 MHz, DMSO-d6) δ ppm 1.39-1.44 (2H, m, CH-
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piperidine), 1.73-1.76 (2H, m, CH-piperidine), 2.55-2.60 (2H, m, N-CH-piperidine), 2.99-
3.01 (2H, m, N-CH-piperidine), 3.78-3.85 (1H, m, N-CH-piperidine), 7.29 (1H, br s, H-3), 
7.38 (1H, br s, H-5), 7.41-7.45 (1H, m, H-6’), 7.58-7.60 (1H, m, H-3’), 7.65-7.68 (1H, m, H-
4’), 8.14 (1H, d, J = 7.9 Hz, CO-NH); 13C NMR (125 MHz, DMSO-d6) δ ppm 32.3 (C-
piperidine), 44.8 (C-piperidine), 46.4 (C-piperidine), 110.4 (C-Ar), 118.3 (d, JCF = 23.9 Hz, 
C-Ar), 124.6 (C-Ar), 128.3 (C-Ar), 128.4 (C-Ar), 128.6 (C-Ar), 128.9 (d, JCF = 3.1 Hz, C-
Ar), 130.0 (d, JCF = 18.5 Hz, C-Ar), 131.9 (d, JCF = 8.6 Hz, C-Ar), 157.4 (d, JCF = 248.9 Hz, 
C-F), 159.0 (CO), 184.7 (CO); HRMS calcd for C17H17
35
ClFN3O2 [M+H]
+
 350.1066, found 
350.1073. 
4-(5-Chloro-2-fluorobenzoyl)-N-(1-methylpiperidin-4-yl)-1H-pyrrole-2-carboxamide, 
369 
 
General procedure D: 4-(5-chloro-2-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (63 mg, 
0.24 mmol), CDI (78 mg, 0.48 mmol), and 4-amino-1-methyl piperidine (75 µL, 0.60 mmol). 
Purification via column chromatography (NH silica; 0-8% MeOH/DCM) gave 369 as a white 
solid (76 mg, 87%). Rf 0.17 (9:1 DCM/MeOH); m.p. Degrades >250 
o
C; λmax (EtOH/nm) 
290.0, 238.0; IR υmax/cm
-1
 3104, 2935, 2848, 2794, 2689, 1637, 1564, 1516; 
1
H NMR (500 
MHz, DMSO-d6) δ ppm 1.49-1.57 (2H, m, CH-piperidine), 1.72-1.75 (2H, m, CH-
piperidine), 1.90-1.95 (2H, m, N-CH-piperidine), 2.16 (3H, s, N-CH3), 2.74-2.77 (2H, m, N-
CH-piperidine), 3.64-3.72 (1H, m, N-CH-piperidine), 7.27 (1H, br s, H-3), 7.37 (1H, br s, H-
5), 7.42 (1H, dd, J = 9.0 and 9.1 Hz, H-3’), 7.58 (1H, dd, J = 2.7 and 5.8 Hz, H-6’), 7.64-7.67 
(1H, m, H-4’), 8.09 (1H, d, J = 7.9 Hz, CO-NH), 12.35 (1H, s, NH-pyrrole); 13C NMR (125 
MHz, DMSO-d6) δ ppm 31.6 (C-piperidine), 45.9 (N-CH3), 46.0 (C-piperidine), 54.4 (C-
piperidine), 110.4 (C-Ar), 118.3 (d, JCF = 23.5 Hz, C-Ar), 124.6 (C-Ar), 128.3 (C-Ar), 128.4 
(d, JCF = 2.6 Hz, C-Ar), 128.6 (C-Ar), 128.9 (d, JCF = 3.5 Hz, C-Ar), 130.0 (d, JCF = 18.5 Hz, 
C-Ar), 131.9 (d, JCF = 9.0 Hz, C-Ar), 157.4 (d, JCF = 248.2 Hz, C-F), 159.1 (CO), 184.7 
(CO); HRMS calcd for C18H19
35
ClFN3O2 [M+H]
+
 364.1223, found 364.1225. 
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Methyl 4-(2-fluoro-5-methylbenzoyl)-1H-pyrrole-2-carboxylate, 370 
 
General procedure E: 2-fluoro, 6-methylbenzoic acid (2.00 g, 13.07 mmol), SOCl2 (1.43 
mL, 19.61 mmol), and DMF (10 mol%) gave 2-fluoro, 6-methylbenzoyl chloride as a yellow 
oil which was used directly in the next step. General procedure F: methyl 1H-pyrrole-2-
carboxylate (0.82 g, 6.54 mmol), and AlCl3 (2.19 g, 16.35 mmol). Purification via column 
chromatography (silica; 0-50% EtOAc/petrol) gave 370 as a white solid (1.47 g, 86%). Rf 
0.19 (8:2 Petrol/EtOAc); m.p. 115-117 
o
C; λmax (EtOH/nm) 286.0, 233.5; IR υmax/cm
-1
 3296, 
3139, 3067, 2998, 2955, 1794, 1701, 1645, 1611, 1561; 
1
H NMR (500 MHz, DMSO-d6) δ 
ppm 2.34 (3H, s, CH3), 3.81 (3H, s, O-CH3), 7.06 (1H, br s, H-3), 7.23 (1H, dd, J = 8.6 and 
10.0 Hz, H-3’), 7.34 (1H, dd, J = 2.0 and 6.5 Hz, H-6’), 7.38-7.41 (1H, m, H-4’), 7.50 (1H, br 
s, H-5), 12.78 (1H, s, NH-pyrrole); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 20.0 (CH3), 51.6 
(O-CH3), 115.2 (C-Ar), 115.9 (d, JCF = 21.8 Hz, C-Ar), 123.9 (C-Ar), 125.5 (C-Ar), 127.5 (d, 
JCF = 15.9 Hz, C-Ar), 129.7 (d, JCF = 2.7 Hz, C-Ar), 129.8 (C-Ar), 132.9 (d, JCF = 8.0 Hz, C-
Ar), 133.8 (d, JCF = 3.0 Hz, C-Ar), 157.0 (d, JCF = 245.7 Hz, C-F), 160.4 (CO), 186.1 (CO); 
HRMS calcd for C14H12FNO3 [M+H]
+
 262.0874, found 262.0878. 
4-(2-Fluoro-5-methylbenzoyl)-1H-pyrrole-2-carboxylic acid, 371 
 
General procedure G: methyl 4-(2-fluoro-5-methylbenzoyl)-1H-pyrrole-2-carboxylate (1.40 
g, 5.36 mmol), and LiOH monohydrate (4.50 g, 107.20 mmol) gave 371 as a white solid 
(1.31 g, 99%). Rf 0.27 (9:1 DCM/MeOH); m.p. 189-190 
o
C; λmax (EtOH/nm) 285.0, 233.0; IR 
υmax/cm
-1
 3302, 2978, 2877, 2701, 2618, 2550, 1668, 1629, 1553; 
1
H NMR (500 MHz, 
DMSO-d6) δ ppm 2.34 (3H, s, CH3), 7.01 (1H, br s, H-3), 7.22 (1H, dd, J = 8.5 and 9.9 Hz, 
H-3’), 7.33 (1H, dd, J = 1.8 and 6.6 Hz, H-6’), 7.37-7.40 (1H, m, H-4’), 7.43 (1H, br s, H-5), 
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12.58 (1H, s, NH-pyrrole), 12.84 (1H, s, COOH); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 
20.0 (CH3), 114.8 (C-Ar), 115.9 (d, JCF = 21.8 Hz, C-Ar), 125.1 (C-Ar), 125.4 (C-Ar), 127.6 
(d, JCF = 16.1 Hz, C-Ar), 129.3 (C-Ar), 129.7 (d, JCF = 2.6 Hz, C-Ar), 132.8 (d, JCF = 7.9 Hz, 
C-Ar), 133.7 (d, JCF = 2.9 Hz, C-Ar), 157..0 (d, JCF = 245.1 Hz, C-F), 161.4 (CO), 186.2 
(CO); HRMS calcd for C13H10FNO3 [M-H]
- 
246.0572, found 246.0562. 
4-(2-Fluoro-5-methylbenzoyl)-N-(pyridin-3-yl)-1H-pyrrole-2-carboxamide, 372 
 
General procedure M: 4-(2-fluoro-5-methylbenzoyl)-1H-pyrrole-2-carboxylic acid (65 mg, 
0.26 mmol), PCl3 (23 µL, 0.26 mmol), and 3-aminopyridine (61 mg, 0.65 mmol). ). 
Purification via column chromatography (NH silica; 0-8% MeOH/DCM) gave 372 as a white 
solid (75 mg, 89%). Rf 0.28 (95:5 DCM/MeOH); m.p. 251-253 
o
C; λmax (EtOH/nm) 303.5; IR 
υmax/cm
-1
 3334, 3238, 3117, 3038, 2977, 1625, 1557, 1532; 
1
H NMR (500 MHz, DMSO-d6) δ 
ppm 2.36 (3H, s, CH3), 7.25 (1H, dd, J = 8.2 and 8.3 Hz, H-3’), 7.36-7.41 (3H, m, H-6’, H’4’ 
and CH-pyridine), 7.46 (1H, br s, H-3), 7.57 (1H, br s, H-5), 8.15-8.17 (1H, m, CH-pyridine), 
8.30 (1H, br s, N-CH-pyridine), 8.92 (1H, br s, N-CH-pyridine), 10.24 (1H, s, CO-NH), 
12.61 (1H, s, NH-pyrrole); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 20.0 (CH3), 112.2 (C-Ar), 
115.9 (d, JCF = 21.7 Hz, C-Ar), 123.6 (C-Ar), 125.4 (C-Ar), 126.9 (C-Ar), 127.5 (C-Ar), 
127.8 (d, JCF = 15.7 Hz, C-Ar), 129.1 (C-Ar), 129.7 (C-Ar), 132.8 (d, JCF = 8.0 Hz, C-Ar), 
133.8 (d, JCF = 2.6 Hz, C-Ar), 135.6 (C-Ar), 141.5 (C-Ar), 144.3 (C-Ar), 157.0 (d, JCF = 
245.8 Hz, C-F), 158.9 (CO), 186.4 (CO); HRMS calcd for C18H14FN3O2 [M+H]
+
 324.1143, 
found 324.1145. 
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4-(2-Fluoro-5-methylbenzoyl)-N-(pyrimidin-5-yl)-1H-pyrrole-2-carboxamide, 373 
 
General procedure M with exceptions to the method: 4-(2-fluoro-5-methylbenzoyl)-1H-
pyrrole-2-carboxylic acid (113 mg, 0.46 mmol), PCl3 (40 µL, 0.46 mmol), and 5-
aminopyrimidine (109 mg, 1.15 mmol) for 15 min. Purification via column chromatography 
(silica; 0-8% MeOH/DCM) gave 373 as a yellow solid (73 mg, 49%). Rf 0.61 (9:1 
DCM/MeOH);  m.p. 287-288 
o
C; λmax (EtOH/nm) 294.5, 249.5; IR υmax/cm
-1
 3238, 3115, 
3050, 2979, 2927, 2868, 1622, 1584, 1553, 1525; 
1
H NMR (500 MHz, DMSO-d6) δ ppm 
2.36 (3H, s, CH3), 7.25 (1H, dd, J = 8.6 and 8.7 Hz, H-3’), 7.37-7.41 (2H, m, H-4’ and H-6’), 
7.50 (1H, br s, H-3), 7.56 (1H, br s, H-5), 8.92 (1H, s, CH-pyrimidine), 9.15 (2H, s, CH-
pyrimidine), 10.44 (1H, s, CO-NH), 12.70 (1H, s, NH-pyrrole); 
13
C NMR (125 MHz, DMSO-
d6) δ ppm 20.0 (CH3), 112.7 (C-Ar), 116.0 (d, JCF = 21.9 Hz, C-Ar), 125.5 (C-Ar), 127.0 (C-
Ar), 127.7 (d, JCF = 16.1 Hz, C-Ar), 129.4 (C-Ar), 129.7 (d, JCF =2.2 Hz, C-Ar), 132.9 (d, JCF 
= 8.1 Hz, C-Ar), 133.8 (d, JCF = 2.9 Hz, C-Ar), 134.4 (C-Ar), 147.7 (C-Ar), 153.1 (C-Ar), 
157.0 (d, JCF = 246.0 Hz, C-F), 159.0 (CO), 186.4 (CO); HRMS calcd for C17H13FN4O2 
[M+H]
+
 325.1095, found 325.1098. 
tert-Butyl 4-(4-(2-fluoro-5-methylbenzoyl)-1H-pyrrole-2-carboxamido)piperidine-1-
carboxylate, 374 
 
General procedure D: 4-(2-fluoro-5-methylbenzoyl)-1H-pyrrole-2-carboxylic acid (74 mg, 
0.30 mmol), CDI (97 mg, 0.60 mmol), and tert-butyl 4-aminopiperidine-1-carboxylate (150 
mg, 0.75 mmol). Purification via column chromatography (silica; 30-100% EtOAc/petrol) 
gave 374 as a white solid (70 mg, 54%). Rf 0.70 (9:1 DCM/MeOH); m.p. 127-130 
o
C; λmax 
(EtOH/nm) 288.0, 239.0; IR υmax/cm
-1
 2961, 2927, 2861, 1622, 1566, 1534; 
1
H NMR (500 
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MHz, CDCl3) δ ppm 1.40-1.45 (2H, m, CH-piperidine), 1.47 (9H, s, C-CH3), 1.96-1.99 (2H, 
m, CH-piperidine), 2.37 (3H, s, CH3), 2.85-2.91 (2H, m, N-CH-piperidine), 4.03-4.15 (3H, 
m, N-CH-piperidine), 6.05 (1H, d, J = 7.8 Hz, CO-NH), 7.04 (1H, dd, J = 8.7 and 9.5 Hz, H-
3’), 7.10 (1H, br s, H-3), 7.26-7.29 (1H, m, H-4’), 7.33 (1H, dd, J = 2.2 and 6.7 Hz, H-6’), 
7.39 (1H, br s, H-5), 9.92 (1H, s, NH-pyrrole); 
13
C NMR (125 MHz, CDCl3) δ ppm 20.6 
(CH3), 28.5 (C-CH3), 32.1 (C-piperidine), 42.8 (C-piperidine), 47.0 (C-piperidine), 79.8 (C-
CH3), 109.4 (C-Ar), 116.0 (d, JCF = 21.8 Hz, C-Ar), 126.7 (C-Ar), 127.4 (C-Ar), 127.7 (d, JCF 
= 15.7 Hz, C-Ar), 127.8 (C-Ar), 130.2 (d, JCF = 2.9 Hz, C-Ar), 133.0 (d, JCF = 7.9 Hz, C-Ar), 
133.9 (d, JCF = 3.5 Hz, C-Ar), 154.7 (CO), 157.8 (d, JCF = 248.9 Hz, C-F), 159.8 (CO), 187.4 
(CO); HRMS calcd for C23H28FN3O4 [M+H]
+
 430.2137, found 430.2138. 
4-(2-Fluoro-5-methylbenzoyl)-N-(1-methylpiperidin-4-yl)-1H-pyrrole-2-carboxamide, 
375 
 
General procedure D: 4-(2-fluoro-5-methylbenzoyl)-1H-pyrrole-2-carboxylic acid (75 mg, 
0.30 mmol), CDI (97 mg, 0.60 mmol) and 4-amino-1-methyl piperidine (94 µL, 0.75 mmol). 
Purification via column chromatography (NH silica; 0-8% MeOH/DCM) gave 375 as a white 
solid (91 mg, 88%). Rf 0.18 (9:1 DCM/MeOH); m.p. Degrades > 250 
o
C; λmax (EtOH/nm) 
287.5, 237.5; IR υmax/cm
-1
 3370, 2934, 2850, 2795, 1637, 1562, 1517, 1489, 1432; 
1
H NMR 
(500 MHz, CDCl3) δ ppm 1.49-1.57 (2H, m, CH-piperidine), 1.72-1.75 (2H, m, CH-
piperidine), 1.90-1.95 (2H, m, N-CH-piperidine), 2.16 (3H, s, N-CH3), 2.34 (3H, s, CH3), 
2.74-2.78 (2H, m, N-CH-piperidine), 3.64-3.72 (1H, m, N-CH-piperidine), 7.22 (1H, dd, J = 
9.0 and 9.1 Hz, H-3’), 7.26 (1H, br s, H-3), 7.29-7.32 (2H, m, H-5 and H-6’), 7.36-7.39 (1H, 
m, H-4’), 8.09 (1H, d, J = 7.9 Hz, CO-NH), 12.27 (1H, s, NH-pyrrole); 13C NMR (125 MHz, 
CDCl3) δ ppm 20.0 (CH3), 31.5 (C-piperidine), 45.9 (N-CH3 and C-piperidine), 54.4 (C-
piperidine), 110.4 (C-Ar), 115.9 (d, JCF = 21.9 Hz, C-Ar), 125.1 (C-Ar), 128.0 (d, JCF = 15.8 
Hz, C-Ar), 128.3 (C-Ar), 129.6 (d, JCF = 2.8 Hz, C-Ar), 132.5 (d, JCF = 7.9 Hz, C-Ar), 133.7 
(d, JCF = 2.9 Hz, C-Ar), 157.0 (d, JCF = 244.6 Hz, C-F), 159.2 (CO), 186.5 (CO), one C-Ar 
not visualised; HRMS calcd for C19H22FN3O2 [M+H]
+
 344.1769, found 344.1771. 
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Methyl 4-bromo-1-tosyl-1H-pyrrole-2-carboxylate, 387 
 
To a solution of methyl 4-bromo-1H-pyrrole-2-carboxylate (507 mg, 2.49 mmol) in THF (4 
mL/mmol) was added NaH (72 mg, 2.99 mmol) portionwise at 0 
o
C. The resulting mixture 
was stirred for 15 min, then tosyl chloride (0.95 g, 4.98 mmol) was added and the mixture 
warmed to RT. The mixture was stirred for 16 h. The reaction was quenched with a saturated 
aqueous solution of NaHCO3 then extracted with DCM (2 x 50 mL). Combined organic 
layers were washed with brine (50 mL), dried over Na2SO4 and concentrated in vacuo. 
Column chromatography (silica; 0-20% EtOAc/petrol) gave 387 as a white solid (0.96 g, 
55%). Rf 0.41 (9:1 Petrol/EtOAc); m.p. 123-124 ˚C; λmax (EtOH/nm) 271.0, 237.0; IR 
υmax/cm
-1 
3157, 2945, 1730, 1595;  
1
H NMR (500 MHz, DMSO-d6) δ ppm: 2.41 (3H, s, CH3), 
3.70 (3H, s, O-CH3), 7.17 (1H, d, J = 1.6 Hz, H-3), 7.50 (2H, d, J = 8.1 Hz, H-3 and H-5 
tosyl), 7.96 (2H, d, J = 8.1 Hz, H-2 and H-6 tosyl), 8.04 (1H, d, J = 1.6 Hz, H-5); 
13
C NMR 
(125 MHz, DMSO-d6) δ ppm; 21.1 (CH3), 52.2 (O-CH3), 98.7 (C-Ar), 123.9 (C-Ar), 124.8 
(C-Ar), 128.0 (C-Ar), 128.1 (C-Ar), 129.9 (C-Ar), 134.4 (C-Ar), 145.8 (C-Ar), 157.9 (CO); 
MS (ES+) m/z = 358 and 360.1 [M+H]
+
; HRMS calcd for C13H12
79
BrNO4S [M+H]
+ 
357.9743, found 357.9750. 
Methyl 4-(pyridin-2-yl)-1-tosyl-1H-pyrrole-2-carboxylate, 390 
 
General procedure O: methyl 4-bromo-1-tosyl-1H-pyrrole-2-carboxylate  (150 mg, 0.42 
mmol), bis(pinacolato) diboron (160 mg, 0.63 mmol), KOAc (123 mg, 1.26 mmol) and  
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polymer-supported dichloro[1,1'-bis(di-tert-butylphosphino)ferrocene]palladium (II) (10 
mol%). Then 2-bromopyridine (60 μL, 0.63 mmol), Na2CO3 (53 mg, 0.50 mmol) and 
polymer-supported tetrakis(triphenylphosphine)palladium (0) (10 mol%). Column 
chromatography (silica; 10-50% EtOAc/petrol) gave 390 as a white solid (110 mg, 73%). Rf 
0.32 (7:3 Petrol/EtOAc); m.p. Degrades >250 ˚C; λmax (EtOH/nm) 239.5; IR υmax/cm
-1 
2978, 
1721, 1597, 1559, 1464; 
1
H NMR (500 MHz, DMSO-d6) δ ppm 2.43 (3H, s, CH3), 3.73 (3H, 
s, O-CH3), 7.31 (1H, ddd, J = 1.1, 4.9 and 7.4 Hz, CH-pyridine), 7.50 (2H, d, J = 8.1 Hz, H-3 
and H-5 tosyl), 7.67 (1H, d, J = 2.0 Hz, H-3), 7.82-7.86 (1H, m, CH-pyridine), 7.91-7.94 (1H, 
m, N-CH-pyridine). 7.98 (2H, d, J = 8.1 Hz,  H-2 and H-6 tosyl), 8.44 (1H, d, J = 2.0 Hz, H-
5), 8.59 (1H, ddd, J = 1.1, 1.8 and 4.9 Hz, N-CH-pyridine); 
13
C NMR (125 MHz, DMSO-d6) 
δ ppm 21.1 (CH3), 52.0 (O-CH3), 120.0 (C-Ar), 120.5 (C-Ar), 122.5 (C-Ar), 125.1 (C-Ar), 
126.0 (C-Ar), 126.8 (C-Ar), 128.0 (C-Ar), 129.8 (C-Ar), 134.7 (C-Ar), 137.1 (C-Ar), 145.6 
(C-Ar), 149.5 (C-Ar), 150.5 (C-Ar), 158.6 (CO); MS (ES+) m/z = 357.1 [M+H]
+
; HRMS 
calcd for  C18H16N2O4S [M+H]
+ 
357.0904, found 357.0906. 
4-(Pyridin-2-yl)-1H-pyrrole-2-carboxylic acid, 391 
 
General procedure G: methyl 4-(pyridin-2-yl)-1-tosyl-1H-pyrrole-2-carboxylate (134 mg, 
0.38 mmol), and LiOH monohydrate (315 mg, 7.50 mmol) gave 391 as an off-white solid (34 
mg, 48%). Rf 0.15 (9:1 DCM/MeOH); m.p. Degrades >250 ˚C; λmax (EtOH/nm) 297.0, 234.0; 
IR υmax/cm
-1 
3239, 3131, 1624, 1604, 1554;  
1
H NMR (500 MHz, DMSO-d6) δ ppm 7.01-7.03 
(1H, m, CH-pyridine), 7.15 (1H, br, H-3), 7.48 (1H, br, H-5), 7.59-7.62 (2H, m, CH-pyridine 
and N-CH-pyridine), 8.35-8.37 (1H, m, N-CH-pyridine), 11.88 (1H, s, NH-pyrrole), 12.30 
(1H, s, COOH); 
13
C NMR (125 MHz, MeOD) δ ppm 114.1 (C-Ar), 121.2 (C-Ar), 122.2 (C-
Ar), 123.5 (C-Ar), 139.0 (C-Ar), 149.4 (C-Ar), three C-Ar and CO not visualised; HRMS 
calcd for C10H8N2O2 [M+H]
+ 
189.0659, found 189.0658. 
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4-(Pyridin-2-yl)-N-(pyridin-4-ylmethyl)-1H-pyrrole-2-carboxamide, 393 
 
General procedure D: 4-(pyridin-2-yl)-1H-pyrrole-2-carboxylic acid (25 mg, 0.13 mmol), 
CDI (42 mg, 0.26 mmol) and 4-picolylamine (19 μL, 0.20 mmol). Column chromatography 
(silica; 0-8% MeOH/DCM) gave 393 as a white solid (8 mg, 22%). Rf 0.26 (9:1 
DCM/MeOH); m.p. 195-197 ˚C; λmax (EtOH/nm) 295.0, 239.5; IR υmax/cm
-1 
2936, 2914, 
1619, 1589, 1550;  
1H NMR (500 MHz, MeOD) δ ppm 4.52 (2H, s, CH2), 7.10 (1H, ddd, J = 
1.0, 5.0 and 7.4 Hz, CH-pyridine), 7.23 (1H, d, J = 1.6 Hz, H-3), 7.33 (2H, d, J = 6.3 Hz, CH-
pyridine), 7.48 (1H, d, J = 1.6 Hz, H-5), 7.56-7.58 (1H, m, CH-pyridine), 7.67-7.70 (1H, m, 
N-CH-pyridine), 8.34-8.36 (1H, m, N-CH-pyridine), 8.38 (2H, d, J = 6.3 Hz, N-CH-
pyridine); 
13C NMR (125 MHz, MeOD) δ ppm 42.9 (CH2), 109.7 (C-Ar), 121.1 (C-Ar), 
122.2 (C-Ar), 122.6 (C-Ar), 123.9 (C-Ar), 126.6 (C-Ar), 138.9 (C-Ar), 149.6 (C-Ar), 150.0 
(C-Ar), 151.6 (C-Ar), 155.4 (C-Ar), 163.7 (CO), one C-Ar not visualised; HRMS calcd for 
C16H14N4O [M+H]
+ 
279.1240, found 279.1246. 
Methyl 4-(isoquinolin-1-yl)-1-tosyl-1H-pyrrole-2-carboxylate, 385 
 
General procedure O: methyl 4-bromo-1-tosyl-1H-pyrrole-2-carboxylate (150 mg, 0.42 
mmol), bis(pinacolato) diboron (160 mg, 0.63 mmol), KOAc (123 mg, 1.26 mmol) and  
polymer-supported dichloro[1,1'-bis(di-tert-butylphosphino)ferrocene]palladium (II) (10 
mol%). Then, 2-bromoisoquinoline (131 mg, 0.63 mmol), Na2CO3 (53 mg, 0.50 mmol) and 
polymer-supported tetrakis(triphenylphosphine)palladium (0) (10 mol%). Column 
chromatography (silica; 10-50% EtOAc/petrol) gave 385 as a white solid (105 mg, 62%). Rf 
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0.32 (8:2 Petrol/EtOAc); m.p. Degrades >250 ˚C; λmax (EtOH/nm) 295.0, 231.0; IR υmax/cm
-1 
2977, 1718, 1595, 1563; 
1
H NMR (500 MHz, CDCl3) δ ppm 2.38 (3H, s, CH3), 3.72 (3H, s, 
O-CH3), 7.28 (2H, d, J = 8.2 Hz, H-3 and H-5 tosyl), 7.51 (1H, d, J = 2.0 Hz, H-3), 7.59-7.62 
(2H, m, CH-isoquinoline), 7.67-7.69 (1H, m, CH-isoquinoline), 7.83 (1H, d, J = 8.0 Hz, CH-
isoquinoline), 7.93 (2H, d, J = 8.2 Hz, H-2 and H-6 tosyl), 8.20 (1H, br, H-5), 8.29 (1H, d, J 
= 8.0 Hz, CH-isoquinoline), 8.50 (1H, d, J = 5.9 Hz, N-CH-isoquinoline); 
13
C NMR (125 
MHz, CDCl3) δ ppm 21.8 (CH3), 51.9 (O-CH3), 120.2 (C-Ar), 124.2 (C-Ar), 124.7 (C-Ar), 
126.5 (C-Ar), 126.7 (C-Ar), 127.3 (C-Ar), 127.8 (C-Ar), 128.5 (C-Ar), 128.9 (C-Ar), 129.5 
(C-Ar), 130.3 (C-Ar), 135.5 (C-Ar), 136.8 (C-Ar), 142.3 (C-Ar), 145.3 (C-Ar), 153.0 (C-Ar), 
159.2 (CO); MS (ES+) m/z = 407.3 [M+H]
+
; HRMS calcd for C22H18N2O4S  
[M+H]
+ 
407.1060, found 407.1059. 
4-(Isoquinolin-1-yl)-1H-pyrrole-2-carboxylic acid, 392 
 
General procedure G: methyl 4-(isoquinolin-1-yl)-1-tosyl-1H-pyrrole-2-carboxylate (91 
mg, 0.22 mmol), and LiOH monohydrate (188 mg, 4.48 mmol) gave 392 as an off-white solid 
(33 mg, 57%). Rf 0.17 (9:1 DCM/MeOH); m.p. Degrades >250 ˚C; λmax (EtOH/nm) 339.5, 
218.0; IR υmax/cm
-1 
3197, 1644, 1537, 1499, 1429;  
1
H NMR (500 MHz, DMSO-d6) δ ppm 
7.25 (1H, br, H-3), 7.53 (1H, dd, J = 1.7 and 2.9 Hz, H-5), 7.67-7.70 (2H, m, CH-
isoquinoline), 7.77-7.80 (1H, m, CH-isoquinoline), 7.99 (1H, d, J = 8.4 Hz, CH-
isoquinoline), 8.43 (1H, d, J = 8.4 Hz, CH-isoquinoline), 8.48 (1H, d, J = 5.6 Hz, N-CH-
isoquinoline), 12.22 (1H, s, NH-pyrrole), 12.52 (1H, s, COOH); 
13
C NMR (125 MHz, 
DMSO-d6) δ ppm 115.6 (C-Ar), 118.6 (C-Ar), 124.0 (C-Ar), 124.5 (C-Ar), 125.5 (C-Ar), 
126.5 (C-Ar), 127.1 (C-Ar), 127.6 (C-Ar), 130.0 (C-Ar), 136.3 (C-Ar), 142.1 (C-Ar), 154.3 
(C-Ar), 161.8 (CO), one C-Ar not visualised; HRMS calcd for C14H10N2O2 [M-H]
- 
237.0670, 
found 237.0668. 
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4-(Isoquinolin-1-yl)-N-(pyridin-4-ylmethyl)-1H-pyrrole-2-carboxamide, 384 
 
General procedure D: 4-(isoquinolin-1-yl)-1H-pyrrole-2-carboxylic acid (15 mg, 0.06 
mmol), CDI (21 mg, 0.13 mmol), and 4-picolylamine (16 μL, 0.16 mmol). Column 
chromatography (silica; 0-8% MeOH/DCM) gave 384 as a white solid (10 mg, 51%). Rf 0.29 
(9:1 DCM/MeOH); m.p. 145-147 ˚C; λmax (EtOH/nm) 303.0, 263.5, 218.0; IR υmax/cm
-1 
2934 
1641, 1531; 
1
H NMR (500 MHz, MeOD) δ ppm 4.53 (2H, s, CH2), 7.25 (1H, d, J = 1.6 Hz, 
H-3), 7.33 (2H, d, J = 6.0 Hz, CH-pyridine), 7.37 (1H, d, J = 1.6 Hz, H-5), 7.55-7.59 (1H, m, 
CH-isoquinoline), 7.60 (1H, d, J = 5.9 Hz, CH-isoquinoline), 7.66-7.69 (1H, m, CH-
isoquinoline), 7.85 (1H, d, J = 8.4 Hz, CH-isoquinoline), 8.28 (1H, d, J = 5.9 Hz, CH-
isoquinoline), 8.38-8.40 (3H, m, N-CH-pyridine and N-CH-isoquinoline); 
13
C NMR (125 
MHz, DMSO-d6) δ ppm 42.9 (CH2), 113.1 (C-Ar), 120.8 (C-Ar), 123.9 (C-Ar),  124.6 (C-
Ar), 124.7 (C-Ar), 127.5 (C-Ar), 128.1 (C-Ar), 128.2 (C-Ar), 128.6 (C-Ar), 128.9 (C-Ar), 
131.8 (C-Ar), 138.6 (C-Ar), 142.0 (C-Ar), 150.1 (C-Ar), 151.4 (C-Ar), 156.9 (C-Ar), 163.6 
(CO); MS (ES+) m/z = 327.1 [M+H]
+
; HRMS calcd for C20H16N4O [M+H]
+ 
329.1397, found 
329.1394. 
2,2-Diethoxy-N-(pyridin-4-ylmethyl)ethanamine, 409 
 
To a solution of aminoacetaldehyde diethyl acetal (0.50 mL, 3.44 mmol) in toluene (1 
mL/mmol) was added 4-pyridine carboxaldehyde (0.49 mL, 5.16 mmol) and MgSO4 (300 
mg).  The resulting mixture was heated at 110 
o
C for 16 h. The mixture was cooled, filtered 
and concentrated in vacuo. The resulting yellow oil, (E)-2,2-diethoxy-N-(pyridin-4-
ylmethylene)ethanamine, was used directly in the next step. To a solution of (E)-2,2-
diethoxy-N-(pyridin-4-ylmethylene)ethanamine (0.76 g, 3.44 mmol) in MeOH (2.5 
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mL/mmol) was added NaBH4 (156 mg, 4.13 mmol) portionwise at 0 
o
C. The resulting 
mixture was stirred for 4 h. The reaction was quenched with H2O (20 mL), neutralised with a 
saturated aqueous solution of NaHCO3 and the MeOH removed in vacuo. The resulting 
aqueous solution was extracted with EtOAc (2 x 30 mL). Combined organic layers were 
washed with brine, dried over Na2SO4 and concentrated in vacuo. Purification via column 
chromatography (silica; 0-8% MeOH/DCM) gave 409 as a yellow oil (0.67 g, 87%). Rf 0.35 
(EtOAc); λmax (EtOH/nm) 256-257; IR υmax/cm
-1 
2975, 2897, 1601, 1561;  
1
H NMR (500 
MHz, CDCl3) δ ppm 1.22 (6H, t, J = 7.1 Hz, CH3), 1.76 (1H, s, NH), 2.74 (2H, dd, J = 1.5 
and 5.4 Hz, NH-CH2), 3.52-3.58 (2H, m, CH2), 3.68-3.75 (2H, m, CH2), 3.84 (2H, s, N-CH2-
pyridine), 4.62 (1H, t, J = 5.4 Hz, CH), 7.27 (2H, d, J = 4.5 Hz, CH-pyridine),  8.55 (2H, d, J 
= 4.5 Hz, N-CH-pyridine); 
13
C NMR (125 MHz, CDCl3) δ ppm 15.4 (CH3), 51.6 (NH-CH2), 
52.5 (NH-CH2), 62.6 (CH2), 102.1 (CH), 122.9 (C-Ar), 149.3 (C-Ar), 149.8 (C-Ar); MS 
(ES+) m/z = 225.3 [M+H]
+ 
. 
Methyl 4-(2,6-difluorobenzoyl)-1H-pyrrole-2-carboxylate, 411 
 
General procedure F: methyl 1H-pyrrole-2-carboxylate (1.00 g, 7.99 mmol), 2,6-
difluorobenzoyl chloride (2.00 mL, 15.98 mmol) and AlCl3 (2.68 g, 19.98 mmol). 
Purification via column chromatography (silica; 0-50% EtOAc/petrol) gave 411 as a white 
solid (1.31 g, 62%). Rf 0.17 (8:2 Petrol/EtOAc); m.p. 131-132 
o
C; λmax (EtOH/nm) 281.0, 
232.0; IR υmax/cm
-1 
3335, 2919, 2563, 2224, 2021, 1733;  
1
H NMR (500 MHz, DMSO-d6) δ 
ppm 3.86 (3H, s, O-CH3), 7.13 (1H, br s, H-3), 7.31-7.36 (2H, m, H-3’ and H-5’), 7.67-7.73 
(2H, m, H-5 and H-4’), 12.99 (1H, s, NH); 13C NMR (125 MHz DMSO-d6) δ ppm 51.7 (O-
CH3), 112.2 (d, JCF = 24.7 Hz, C-Ar), 114.6 (C-Ar), 117.5 (C-Ar), 124.5 (C-Ar), 125.9 (C-
Ar), 130.2 (C-Ar), 132.4 (t, JCF = 10.0 Hz, C-Ar), 158.7 (dd, JCF = 8.1 and 247.0 Hz, C-F), 
160.3 (CO), 181.6 (CO); MS (ES+) m/z = 266.1 [M+H]
+ 
. 
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4-(2,6-Difluorobenzoyl)-1H-pyrrole-2-carboxylic acid, 412 
 
General procedure G:  methyl 4-(2,6-difluorobenzoyl)-1H-pyrrole-2-carboxylate (1.30 g, 
4.91 mmol) and LiOH monohydrate (4.12 g, 98.20 mmol) gave 412 as a white solid (1.19 g, 
97%). Rf 0.22 (9:1 DCM/MeOH); m.p. 197-198 
o
C; λmax (EtOH/nm) 283.0, 232.5; IR 
υmax/cm
-1 
3772, 3024, 2779, 2612, 2539, 2105, 1753;  
1
H NMR (500 MHz DMSO-d6) δ ppm 
7.00 (1H, br s, H-3), 7.23-7.28 (2H, m, H-3’ and H-5’), 7.51 (1H, br s, H-5), 7.62 (1H, dddd, 
J = 6.7, 6.8, 8.3 and 8.4 Hz, H-4’), 12.71 (1H, s, NH), 12.94 (1H, s COOH); 13C NMR (125 
MHz, DMSO-d6) δ ppm 112.2 (d, JCF = 25.2 Hz, C-Ar), 114.2 (C-Ar), 117.6 (t, JCF = 24.5 
Hz, C-Ar), 124.3 (C-Ar), 125.8 (C-Ar), 129.7 (C-Ar), 132.3 (t, JCF = 10.0 Hz, C-Ar), 158.6 
(dd, JCF = 8.0 and 248.3 Hz, C-F), 161.3 (CO), 181.6 (CO); MS (ES+) m/z = 252.2 [M+H]
+ 
; 
HRMS calcd for C12H8NF2O3 [M+H]
+
 252.0467, found 252.0470. 
N-(2,2-Diethoxyethyl)-4-(2,6-difluorobenzoyl)-N-(pyridin-4-ylmethyl)-1H-pyrrole-2-
carboxamide, 413 
 
General procedure E: 4-(2,6-difluorobenzoyl)-1H-pyrrole-2-carboxylic acid (313 mg, 1.25 
mmol), SOCl2 (140 μL, 1.88 mmol) gave 4-(2,6-difluorobenzoyl)-1H-pyrrole-2-carbonyl 
chloride as a colourless oil and used directly in the next step. To a solution of 4-(2,6-
difluorobenzoyl)-1H-pyrrole-2-carbonyl chloride (336 mg, 1.25 mmol) in DCM (2.5 
mL/mmol) was added 2,2-diethoxy-N-(pyridin-4-ylmethyl)ethanamine (420 mg, 1.88 mmol). 
The resulting mixture was stirred at RT for 16 h. The DCM was removed by rotary 
evaporation and the slurry obtained was diluted with H2O (10 mL) and adjusted to pH 10 
with 1M NaOH (aq). The resulting mixture was extracted with EtOAc (2 x 20 mL). 
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Combined organic layers were dried over Na2SO4 and concentrated in vacuo. Purification via 
column chromatography (silica; 30-100% EtOAc/petrol) gave 413 as a white solid (400 mg, 
70%). Rf 0.32 (20:80 Petrol/EtOAc); m.p. 84-85 ˚C; λmax (EtOH/nm) 290.5, 234.0; IR 
υmax/cm
-1 
2977, 1653, 1620, 1600, 1550;  
1
H NMR (500 MHz DMSO-d6, 353 K) δ ppm 1.09 
(6H, t, J = 7.3 Hz, CH3), 3.43-3.49 (2H, m, O-CH2), 3.60-3.65 (4H, m, O-CH2 and N-CH2), 
4.75 (1H, t,  J = 5.3 Hz, CH), 4.85 (2H, s, N-CH2-pyridine), 6.85 (1H, br s, H-3), 7.18 (2H, 
dd, J = 8.1 and 8.2 Hz, H-3’), 7.25 (2H, d, J = 6.0 Hz, CH-pyridine), 7.40 (1H, br s, H-5), 
7.60 (1H, m, H-4’), 8.52 (2H, d, J = 6.0 Hz, N-CH-pyridine), 12.21 (1H, s, NH-pyrrole); 13C 
NMR (125 MHz, DMSO-d6) δ ppm Use of long VT experiment not possible; MS (ES+) m/z 
= 458.1 [M+H]
+
; HRMS calcd for C24H25F2N3O4 [M+H]
+ 
458.1186, found 458.1187.  
7-(2,6-Difluorobenzoyl)-2-(pyridin-4-ylmethyl)pyrrolo[1,2-a]pyrazin-1(2H)-one, 414 
 
A solution of N-(2,2-diethoxyethyl)-4-(2,6-difluorobenzoyl)-N-(pyridin-4-ylmethyl)-1H-
pyrrole-2-carboxamide (153 mg, 0.40 mmol) in 1:1 TFA:H2O (3 mL/mmol) was heated with 
microwave irradiation for 2 h at 160 
o
C. The mixture was allowed to cool, diluted with H2O 
(10 mL), and adjusted to pH 10 with 2M NaOH (aq). The mixture was extracted with EtOAc 
(2 x 20 mL). Combined organic layers were washed with brine, dried over Na2SO4 and 
concentrated in vacuo. Purification via column chromatography (silica; DCM) gave 414 as a 
greyish solid (133 mg, 90%). Rf 0.34 (DCM); m.p. 77-79 ˚C; λmax (EtOH/nm) 267.0, 223.0; 
IR υmax/cm
-1 
3106, 1640, 1622, 1601, 1532;  
1
H NMR (500 MHz MeOD) δ ppm  5.05 (2H, s, 
N-CH2), 6.01 (1H, d, J = 6.0 Hz, CH-pyridone), 7.01-7.06 (2H, m, H-3’), 7.24-7.29 (4H, m, 
H-3, CH-pyridine and N-CH-pyridone), 7.45-7.51 (1H, m, H-4’), 7.78 (1H, d, J = 1.6 Hz, H-
5), 8.40 (2H, m, N-CH-pyridine); 
13C NMR (125 MHz, MeOD) δ ppm 50.4 (CH2), 110.2 (C-
Ar), 112.2 (C-Ar), 113.0 (C-Ar), 113.2 (d, JCF = 25.0 Hz, C-Ar), 121.6 (C-Ar), 123.9 (C-Ar), 
125.2 (C-Ar), 126.6 (C-Ar), 129.3 (C-Ar), 133.7 (t, JCF = 10.1 Hz, C-Ar), 148.6 (C-Ar), 150.5 
(C-Ar), 158.0 (CO), 184.5 (CO), C-F not visualised; MS (ES+) m/z = 366.2 [M+H]
+
; HRMS 
calcd for  C20H13F2N3O2 [M+H]
+ 
366.1049, found 366.1051. 
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Methyl 4-(2,6-difluorobenzoyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrole-2-
carboxylate, 415 
 
To a solution of methyl 4-(2,6-difluorobenzoyl)-1H-pyrrole-2-carboxylate (400 mg, 1.51 
mmol) in THF (4 mL/mmol) was added KO
t
Bu (203 mg, 1.81 mmol) at 0 
o
C. The resulting 
mixture was stirred for 15 min, and then SEM chloride (0.32 mL, 1.81 mmol) was added 
dropwise. The mixture was warmed to RT and stirred for 2 h. The reaction was quenched 
with H2O (10 mL) and extracted with DCM (2 x 30 mL). Combined organic layers were 
washed with brine, dried over Na2SO4 and concentrated in vacuo. Purification via column 
chromatography (silica; 0-30 % EtOAc/petrol) gave 415 as a colourless oil (554 mg, 93%). Rf 
0.45 (9:1 Petrol/EtOAc); λmax (EtOH/nm) 279.5, 234.0; IR υmax/cm
-1 
2954, 2895, 1716, 1659, 
1622, 1545; 
1
H NMR (500 MHz CDCl3) δ ppm 
 
0.00 (9H, s, CH3), 0.92-0.96 (2H, m, CH2-
Si), 3.58-3.62 (2H, m, O-CH2), 3.87 (3H, s, O-CH3), 5.73 (2H, s, N-CH2-O), 6.99-7.04 (2H, 
m, H-3’ and H-5’), 7.35 (1H, d, J = 1.6 Hz, H-3), 7.44 (1H, dddd, J = 6.7, 6.8, 8.3 and 8.4 
Hz, H-4’), 7.56 (1H, d, J = 1.6 Hz, H-5); 13C NMR (125 MHz, CDCl3) δ ppm 17.8 (Si-CH3), 
22.2 (CH2-Si), 51.7 (O-CH3), 67.0 (O-CH2), 78.0 (N-CH2-O), 111.9 (d, JCF = 25.2 Hz, C-Ar), 
117.2 (t, JCF = 22.2 Hz, C-Ar) 119.1 (C-Ar), 124.0 (C-Ar), 125.1 (C-Ar), 131.6 (t, JCF = 10.2 
Hz, C-Ar), 132.8 (C-Ar), 159.7 (dd, JCF = 7.0 and 251.5 Hz, C-F), 161.0 (CO), 182.2 (CO); 
MS (ES+) m/z = 394.2 [M-H]
-
; HRMS calcd for C19H23F2NO4Si [M+H]
+ 
396.1437, found 
396.1437. 
 
 
 
360 
 
4-(2,6-Difluorobenzoyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrole-2-carboxylic 
acid, 416 
 
General procedure G: methyl 4-(2,6-difluorobenzoyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-
1H-pyrrole-2-carboxylate (540 mg, 1.37 mmol) and LiOH monohydrate (1.15 g, 27.30 mmol) 
gave 416 as a colourless oil which solidified as a white solid upon cooling (501 mg, 96%). Rf 
0.25 (9:1 Petrol/EtOAc); m.p. 125-126 
oC; λmax (EtOH/nm) 279.0, 233.0; IR υmax/cm
-1 
2952, 
1663, 1624, 1589, 1547; 
1
H NMR (500 MHz CDCl3) δ ppm 
 
0.00 (9H, s, Si-CH3), 0.93-0.96 
(2H, m, CH2-Si), 3.58-3.62 (2H, m, O-CH2), 5.71 (2H, s, N-CH2-O), 6.99-7.04 (2H, m, H-3’ 
and H-5’), 7.45 (1H, dddd, J = 6.7, 6.8, 8.3 and 8.4 Hz, H-4’), 7.49 (1H, d, J = 1.6 Hz, H-3), 
7.61 (1H, d, J = 1.6 Hz, H-5), COOH not visualised; 
13
C NMR (125 MHz, CDCl3) δ ppm 
17.8 (Si-CH3), 21.1 (CH2-Si), 67.2 (O-CH2), 78.2 (N-CH2-O), 112. (d, JCF = 24.7 Hz, C-Ar), 
117.7 (t, JCF = 22.0 Hz, C-Ar), 121.3 (C-Ar), 123.1 (C-Ar), 125.3 (C-Ar), 131.7 (t, JCF = 10.4 
Hz, C-Ar), 133.5 (C-Ar), 159.7 (dd, JCF = 7.0 and 251.7 Hz, C-F), 164.5 (CO), 182.2 (CO); 
MS (ES+) m/z = 382.2 [M+H]
+
; HRMS calcd for C18H21F2NO4Si [M+H]
+ 
382.1281, found 
382.1283. 
 
 
 
 
 
 
361 
 
N-(2,2-Diethoxyethyl)-4-(2,6-difluorobenzoyl)-N-(pyridin-4-ylmethyl)-1-((2-
(trimethylsilyl)ethoxy)methyl)-1H-pyrrole-2-carboxamide, 417 
 
General procedure E: 4-(2,6-difluorobenzoyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-
pyrrole-2-carboxylic acid (490  mg, 1.29 mmol), and SOCl2 (140  μL, 1.94 mmol) gave 4-
(2,6-difluorobenzoyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrole-2-carbonyl chloride as 
a colourless oil which was used directly in the next step. To a solution of 4-(2,6-
difluorobenzoyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrole-2-carbonyl chloride (0.51 
g, 1.29 mmol) in DCM (3 mL/mmol) was added 2,2-diethoxy-N-(pyridin-4-
ylmethyl)ethanamine (347 mg, 1.55 mmol) at RT. The resulting mixture was stirred for 16 h. 
The reaction was quenched with H2O, and adjusted to pH 10 with 1M NaOH (aq). The 
mixture was extracted with DCM (2 x 30 mL). Combined organic layers were washed with 
brine, dried over Na2SO4 and concentrated in vacuo. Purification via column chromatography 
(silica; 0-50% EtOAc/petrol) gave 417 as a pale yellow oil (389 mg, 51%). Rf 0.45 (1:1 
Petrol/EtOAc); λmax (EtOH/nm) 236.0; IR υmax/cm
-1
 2896, 1736, 1622, 1546, 1497, 1463;  
1
H 
NMR (500 MHz, DMSO-d6, 353 K) δ ppm 0.04 (s, 9H, Si-CH3), 0.81 (2H, t, J = 8 Hz, CH2-
Si), 1.10 (6H, t, J = 7.3 Hz, CH3), 3.43-3.47 (4H, m, CH2 and O-CH2), 3.51 (2H, d, J = 5.5 
Hz, N-CH2), 3.59-3.62 (2H, m, CH2), 4.73 (1H, t,  J = 5.5 Hz, CH), 4.80 (2H, s, CH2-
pyridine), 5.47 (2H, s, N-CH2-O), 6.90 (1H, br s, H-3), 7.17-7.21 (2H, m, H-3’ and H-5’), 
7.28 (2H, d, J = 6 Hz, CH-pyridine), 7.60 (1H, dddd, J = 6.7, 6.8, 8.3 and 8.4 Hz, H-4’), 7.71 
(1H, d, J = 1.5 Hz, H-5), 8.52 (2H, d, J = 6 Hz, CH-N-pyridine); 
13
C NMR (125 MHz,  
DMSO-d6) δ ppm Use of long VT experiment not possible; MS (ES+) m/z = 588.3 [M+H]
+
; 
HRMS calcd for C30H39F2N3O5Si [M+H]
+ 
588.2700, found 588.2694.  
 
362 
 
3-(2,6-Difluorobenzoyl)-6-(pyridin-4-ylmethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-
pyrrolo[2,3-c]pyridin-7(6H)-one, 418 
 
N-(2,2-Diethoxyethyl)-4-(2,6-difluorobenzoyl)-N-(pyridin-4-ylmethyl)-1-
((2(trimethylsilyl)ethoxy)methyl)-1H-pyrrole-2-carboxamide (350 mg, 0.60 mmol) was 
dissolved in a 5% TFA solution in DME (6 mL/mmol). The resulting solution was heated at 
120 
o
C for 1.5 h under microwave irradiation. The reaction mixture was diluted with water 
(10 mL), and adjusted to pH 10 with 1M NaOH (aq). The mixture was extracted with EtOAc 
(2 x 30 mL). Combined organic layers were washed with brine, dried over Na2SO4 and 
concentrated in vacuo. Purification via column chromatography (silica; 0-5% DCM/MeOH 
then NH silica; 30-100% EtOAc/petrol) gave 418 as a colourless oil (103 mg, 35%). Rf 0.37 
(8:2 Petrol/EtOAc); λmax (EtOH/nm) 260.0, 223.5; IR υmax/cm
-1
2954, 2899, 1648, 1623, 1590, 
1519;  
1
H NMR (500 MHz DMSO-d6) δ ppm 0.00 (9H, s, Si-CH3), 0.90 (2H, t, J = 8 Hz, 
CH2-Si), 3.65 (2H, t, J = 8 Hz, O-CH2), 5.41 (2H, s, CH2-pyridine), 5.97 (2H, s, N-CH2-O), 
7.22 (1H, d, J = 7 Hz, CH), 7.34 (2H, d, J = 6 Hz, CH-pyridine), 8.41-8.45 (2H, m, H-3’ and 
H-5’), 7.79-7.83 (2H, m, H-4’ and N-CH), 8.23 (1H, s, H-5), 8.65 (2H, d, J = 6.1 Hz, CH-N-
pyridine);
 13
C NMR (125 MHz, DMSO-d6) δ ppm 17.2 (Si-CH3), 49.9 (CH2-Si), 65.3 (O-
CH2), 76.5 (N-CH2-O), 100.5 (C-Ar), 112.3 (dd, JCF = 4.3 and 20.7 Hz, C-Ar), 117.5 (C-Ar), 
122.1 (C-Ar), 123.5 (C-Ar), 130.7 (C-Ar), 132.5 (t, JCF = 10.3 Hz, C-Ar), 134.0 (C-Ar), 
140.1 (C-Ar), 146.5 (C-Ar), 149.7 (C-Ar), 154.0 (CO), 158.7 (dd, JCF = 7.8 and 247.7 Hz, C-
F), 181.8 (CO), one C-Ar and N-CH2 not visualised; MS (ES+) m/z = 496.3 [M+H]
+
; HRMS 
calcd for C26H27F2N3O3Si [M+H]
+ 
496.1863, found 496.1855. 
 
 
 
363 
 
3-(2,6-Difluorobenzoyl)-6-(pyridin-4-ylmethyl)-1H-pyrrolo[2,3-c]pyridin-7(6H)-one, 394 
 
General procedure H: 3-(2,6-difluorobenzoyl)-6-(pyridin-4-ylmethyl)-1-((2-
(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-c]pyridin-7(6H)-one (90 mg, 0.18 mmol). 
Purification via column chromatography (silica; 0-8% DCM/MeOH) followed by 
recrystallisation from a minimum amount of hot ethanol gave 394 as a white solid (55 mg, 
83%). Rf 0.30 (95:5 DCM/MeOH); m.p 271-272 
o
C; λmax (EtOH/nm) 393.5, 258.5, 222.5; IR 
υmax/cm
-1
 3040, 2916, 1649, 1619, 1587, 1518; 
1
H NMR (500 MHz DMSO-d6) δ ppm 5.34 
(2H, s, CH2), 7.03 (1H, d, J = 7.1 Hz, CH), 7.25 (2H, d, J = 6.0 Hz, CH-pyridine), 7.29-7.34 
(2H, m, H-3’ and H-5’), 7.61 (1H, d, J = 7.1 Hz, N-CH), 7.68 (1H, m, H-4’),  7.84 (1H, s, H-
5), 8.56 (2H, d, J = 6.0 Hz, N-CH-pyridine), 13.2 (1H, s, NH-pyrrole); 
13
C NMR (125 MHz, 
DMSO-d6) δ ppm 49.6 (CH2), 100.8 (C-Ar), 112.3 (dd, JCF = 4.7 and 21.3 Hz, C-Ar), 117.9 
(t, JCF = 22.3 Hz, C-Ar), 118.6 (C-Ar), 122.0 (C-Ar), 125.2 (C-Ar), 129.3 (C-Ar), 132.2 (t, 
JCF = 9.8 Hz, C-Ar), 133.0 (C-Ar), 135.9 (C-Ar), 146.6 (C-Ar), 149.8 (C-Ar), 154.0 (CO), 
158.6 (dd, JCF = 7.8 and 247.8 Hz, C-F), 181.7 (CO); MS (ES+) m/z = 366.2 [M+H]
+
; HRMS 
calcd for C20H13F2N3O2 [M+H]
+ 
366.1049, found 366.1051.  
N-(2,2-Diethoxyethyl)-4-(2,6-difluorobenzoyl)-1H-pyrrole-2-carboxamide, 428 
 
General procedure D:  4-(2,6-Difluorobenzoyl)-1H-pyrrole-2-carboxylic acid (0.50 g, 1.99 
mmol), CDI (0.65 g, 3.98 mmol) and aminoacetaldehyde diethyl acetal (0.72 mL, 4.98 
mmol). Purification via column chromatography (10-70% EtOAc/petrol) gave 428 as a white 
solid (0.63 g, 87%). Rf 0.47 (9:1 DCM/MeOH); m.p. 144-146 
oC; ˚C λmax (EtOH/nm) 285.5, 
235.0; IR υmax/cm
-1 
3379, 3191, 2976, 2888, 1621, 1572, 1536; 
1
H NMR (500 MHz, DMSO-
d6) δ ppm 1.12 (6H, t, J = 7.1 Hz, CH3), 3.29 (2H, dd, J = 5.5 and 5.8 Hz, NH-CH2), 3.46-
364 
 
3.52 (2H, m, CH2), 3.60-3.66 (2H, m, CH2), 4.58 (1H, t, J = 5.5 Hz, CH), 7.23-7.28 (3H, m, 
H-3, H-3’ and H-5’), 7.38 (1H, br s, H-5), 7.61 (1H, dddd, J = 6.7, 6.8, 8.3 and 8.4  Hz, H-
4’), 8.42 (1H, t, J = 5.8 Hz, CO-NH),  12.42 (1H, s, NH-pyrrole); 13C NMR (125 MHz, 
DMSO-d6) δ ppm 15.3 (CH3), 41.6 (NH-CH2), 61.5 (CH2), 100.2 (CH), 112.2 (d, JCF = 24.7 
Hz, C-Ar), 117.9 (t, JCF = 23.5 Hz, C-Ar), 125.6 (C-Ar), 128.4 (C-Ar), 128.6 (C-Ar), 132.1 (t, 
JCF = 9.8 Hz, C-Ar), 158.6 (dd, JCF = 8.0 and 247.6 Hz, C-F), 159.9 (CO), 181.8 (CO); 
HRMS calcd for C18H20F2N2O4 [M-H]
-
 365.1318, found 365.1308 
3-(2,6-Difluorobenzoyl)-1H-pyrrolo[2,3-c]pyridin-7(6H)-one, 429 
 
General procedure P: N-(2,2-diethoxyethyl)-4-(2,6-difluorobenzoyl)-1H-pyrrole-2-
carboxamide (1.30 g, 3.56 mmol). Purification via column chromatography (silica; 0-5% 
MeOH/DCM) gave 429 as a white solid (450 mg, 46%). Rf 0.41 (9:1 DCM/MeOH); m.p. 
289-290 
oC; ˚C λmax (EtOH/nm) 259.0, 217.0; IR υmax/cm
-1 
2911, 1772, 1622, 1531; 
1
H NMR 
(500 MHz, DMSO-d6) δ ppm 6.88 (1H, d, J = 6.8 Hz, CH-pyridone), 7.14 (1H, dd, J = 5.9 
and 6.8 Hz, NH-CH-pyridone), 7.24-7.28 (2H, m, H-3’ and H-5’), 7.62 (1H, dddd, J = 6.7, 
6.8, 8.3 and 8.4 Hz, H-4’), 7.72 (1H, s, H-5), 11.37 (1H, br s, CO-NH), 13.02 (1H, s, NH-
pyrrole); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 99.9 (C-pyridone), 112.2 (d, JCF = 24.8 Hz, 
C-Ar), 118.0 (t, JCF = 23.0 Hz, C-Ar), 118.6 (C-pyridone), 125.6 (C-Ar), 128.6 (C-Ar), 129.8 
(C-Ar), 132.1 (t, JCF = 9.8 Hz, C-Ar), 135.3 (C-Ar), 154.6 (CO), 158.6 (dd, JCF = 8.1 and 
247.3 Hz, C-F), 181.6 (CO); HRMS calcd for C14H8F2N2O2 [M+H]
+
 275.0627, found 
275.0631. 
 
 
 
 
365 
 
3-(2,6-Difluorobenzoyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-c]pyridin-
7(6H)-one, 430 
 
General procedure Q:  3-(2,6-difluorobenzoyl)-1H-pyrrolo[2,3-c]pyridin-7(6H)-one (0.59 
g, 2.15 mmol), SEMCl (0.46 mL, 0.94 mmol), Et3N (0.36 mL, 2.58 mmol) and DMAP (10 
mol%). Purification via column chromatography (silica; 0-70% EtOAc/petrol) gave 430 as a 
colourless oil (0.50 g, 58%). Rf 0.37 (8:2 Petrol/EtOAc); λmax (EtOH/nm) 260.0, 219.5; IR 
υmax/cm
-1 
2957, 2900, 1642, 1622, 1588, 1521, 1463, 1374, 1309, 1246; 
1
H NMR (500 MHz, 
CDCl3) δ ppm 0.01 (9H, s, CH3), 0.90-0.0.94 (2H, m, Si-CH2), 3.63-3.66 (2H, m, O-CH2), 
5.98 (2H, s, N-CH2-O), 7.00-7.04 (2H, m, H-3’ and H-5’), 7.14 (1H, dd, J = 5.9 and 7.2 Hz, 
NH-CH-pyridone), 7.33 (1H, d, J = 7.2 Hz, CH-pyridone), 7.45 (1H, dddd, J = 6.7, 6.8, 8.3 
and 8.4 Hz, H-4’), 7.56 (1H, s, H-5), 10.28 (1H, s, CO-NH); 13C NMR (125 MHz, CDCl3) δ 
ppm 17.8 (CH2), 66.8 (O-CH2), 74.7 (N-CH2-O), 102.5 (C-pyridone), 112.0 (d, JCF = 24.9 
Hz, C-Ar), 119.3 (C-pyridone), 124.3 (C-Ar), 127.8 (C-Ar), 129.8 (C-Ar), 132.1 (t, JCF = 9.8 
Hz, C-Ar), 134.7 (C-Ar), 156.1 (CO), 159.6 (dd, JCF = 7.6 and 251.1 Hz, C-F), 182.1 (CO), 
one F split C-Ar not visualised; HRMS calcd for C20H22F2N2O3Si [M+H]
+
 405.1441, found 
405.1442. 
 
 
 
 
 
 
366 
 
3-(2,6-Difluorobenzoyl)-6-(pyridin-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-
pyrrolo[2,3-c]pyridin-7(6H)-one, 431 
 
General procedure R:  3-(2,6-difluorobenzoyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-
pyrrolo[2,3-c]pyridin-7(6H)-one (200 mg, 0.50 mmol), 4-bromopyridine (126 mg, 0.65 
mmol), K2CO3 (228 mg, 1.65 mmol and CuI (10 mol%). Purification via column 
chromatography (silica; 20-100% EtOAc/petrol) gave 431 as a colourless oil (50 mg, 21%).  
Rf 0.18 (8:2 Petrol/EtOAc); λmax (EtOH/nm) 309.5, 284.0; IR υmax/cm
-1 
2964, 1651, 1623, 
1581, 1517, 1464, 1380, 1274; 
1
H NMR (500 MHz, CDCl3) δ ppm 0.04 (9H, s, CH3), 0.90-
0.93 (2H, m, Si-CH2), 3.64-3.67 (2H, m, O-CH2), 5.95 (2H, s, N-CH2-O), 7.02-7.06 (2H, m, 
H-3’ and H-5’), 7.21 (1H, d, J = 7.3 Hz, CH-pyridone), 7.43 (1H, d, J = 7.3 Hz, N-CH-
pyridone), 7.45-7.50 (3H, m, H-4’ and CH-pyridine), 7.60 (1H, s, H-5), 8.80 (2H, br s, N-
CH-pyridine); 
13
C NMR (125 MHz, CDCl3) δ ppm 17.9 (CH2), 67.0 (O-CH2), 77.4 (N-CH2-
O), 103.4 (C-pyridone), 112.0 (d, JCF = 25.2 Hz, C-Ar), 119.2 (C-pyridone), 121.7 (m, C-Ar), 
124.0 (C-Ar), 131.1 (C-Ar), 131.6 (C-Ar), 131.8 (t, JCF = 9.7 Hz, C-Ar), 137.6 (C-Ar), 148.0 
(C-Ar), 151.0 (C-Ar), 154.4 (CO), 159.7 (dd, JCF = 7.1 and 250.7 Hz, C-F), 182.1 (CO) one 
C-Ar not visualised; HRMS calcd for C25H25F2N3O3Si [M+H]
+
 482.1706, found 482.1701. 
 
 
 
 
 
 
367 
 
3-(2,6-Difluorobenzoyl)-6-(pyridin-4-yl)-1H-pyrrolo[2,3-c]pyridin-7(6H)-one, 432 
 
General procedure H: 3-(2,6-difluorobenzoyl)-6-(pyridin-4-yl)-1-((2-
(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-c]pyridin-7(6H)-one (50 mg, 0.10 mmol), 1M 
TBAF in THF (0.15 mL, 0.15 mmol). Purification via column chromatography (silica; 0-8% 
MeOH/DCM) gave 432 as a white solid (21 mg, 60%). Rf 0.23 (9:1 DCM/MeOH); m.p. 
Degrades >200 
oC; λmax (EtOH/nm) 256.5, 223.5; IR υmax/cm
-1 
3055, 2986, 2917, 1668, 1641, 
1620, 1579, 1518, 1479, 1457;
 1
H NMR (500 MHz, DMSO-d6) δ ppm 7.03 (1H, d, J = 7.1 
Hz, CH-pyridone), 7.27-7.30 (2H, m, H-3’ and H-5’), 7.50 (1H, d, J = 7.1 Hz, N-CH-
pyridone), 7.61-7.67 (3H, m, CH-pyridine and H-4’), 7.87 (1H, s, H-5), 8.76 (2H, d, J = 6.1 
Hz, N-CH-pyridine), 13.28 (1H, s, NH-pyrrole); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 
101.4 (C-pyridone), 112.3 (d, JCF = 24.7 Hz, C-Ar), 118.7 (C-pyridone), 121.9 (C-Ar), 125.0 
(C-Ar), 129.3 (C-Ar), 132.0 (C-Ar), 132.5 (t, JCF = 9.6 Hz, C-Ar), 147.6 (C-Ar), 150.7 (C-
Ar), 153.4 (CO), 158.6 (dd, JCF = 8.1 and 247.6 Hz, C-F), 181.8 (CO), one F split C-Ar not 
visualised; HRMS calcd for C19H11F2N3O2 [M+H]
+
 352.0892, found 352.0895. 
3-(2,6-Difluorobenzoyl)-6-(pyridin-3-yl)-1H-pyrrolo[2,3-c]pyridin-7(6H)-one, 433 
 
General procedure R:  3-(2,6-difluorobenzoyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-
pyrrolo[2,3-c]pyridin-7(6H)-one (110 mg, 0.27 mmol), 3-bromopyridine HCl (68 mg, 0.35 
mmol), K2CO3 (123 mg, 0.89 mmol) and CuI (10 mol%) gave 3-(2,6-difluorobenzoyl)-6-
(pyridin-3-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-c]pyridin-7(6H)-one 
which was used directly in the next step. General procedure H:  1M TBAF in THF (0.41 mL, 
0.41 mmol). Purification via column chromatography (silica; 0-5% MeOH/DCM) gave 433 
as a white solid (35 mg, 37%).Rf 0.22 (9:1 DCM/MeOH); m.p Degrades >200 
oC; λmax 
368 
 
(EtOH/nm) 262.5, 221.5; IR υmax/cm
-1 
3111, 3045, 1651, 1620, 1594, 1573; 
1
H NMR (500 
MHz, DMSO-d6) δ ppm 7.01 (1H, d, J = 7.1 Hz, CH-pyridone), 7.27-7.30 (2H, m, H-3’ and 
H-5’), 7.50 (1H, d, J = 7.1 Hz, N-CH-pyridone), 7.60-7.68 (2H, m, CH-pyridine and H-4’), 
7.87 (1H, s, H-5), 7.99 (1H, ddd, J = 1.5, 2.5 and 8.1 Hz, CH-pyridine), 8.67 (1H, dd, J = 1.5 
and 4.5 Hz, N-CH-pyridine), 8.72 (1H, d, J = 2.5 Hz, N-CH-pyridine), 13.27 (1H, s, NH-
pyrrole); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 100.6 (C-pyridone), 112.3 (d, JCF = 24.7 
Hz, C-Ar), 118.8 (C-pyridone), 123.9 (C-Ar), 125.0 (C-Ar), 129.4 (C-Ar), 132.3 (t, JCF = 9.8 
Hz, C-Ar), 132.8 (C-Ar), 134.9 (C-Ar), 136.0 (C-Ar), 137.2 (C-Ar), 147.9 (C-Ar), 148.8 (C-
Ar), 153.9 (CO), 158.6 (dd, JCF = 8.1 and 247.3 Hz, C-F), 181.7 (CO); HRMS calcd for 
C19H11F2N3O2 [M+H]
+
 352.0892, found 352.0896. 
Methyl 4-(2,3-dichlorobenzoyl)-1H-pyrrole-2-carboxylate, 434 
 
General procedure F: methyl 1H-pyrrole-2-carboxylate (1.50 g, 11.99 mmol), 2,3-
dichlorobenzoyl chloride (5.00 g, 23.98 mmol), and AlCl3 (4.02 g, 29.98 mmol). Purification 
via column chromatography (silica; 0-50% EtOAc/petrol) gave 434 as a white solid (2.25 g, 
79%). Rf 0.18 (8:2 Petrol/EtOAc); m.p. 188-190 
oC; ˚C λmax (EtOH/nm) 282.5, 228.0; IR 
υmax/cm
-1 
3281, 3118, 2956, 1687, 1655, 1560; 
1
H NMR (500 MHz, DMSO-d6) δ ppm 3.80 
(3H, s, O-CH3), 7.02 (1H, br s, H-3), 7.44-7.50 (3H, m, H-6’, H-5 and H-5’), 7.78 (1H, dd, J 
= 1.7 and 7.8 Hz, H-4’), 12.84 (1H, s, NH); 13C NMR (125 MHz, DMSO-d6) δ ppm 51.6 (O-
CH3), 115.0 (C-Ar), 124.3 (C-Ar), 124.8 (C-Ar), 126.9 (C-Ar), 127.5 (C-Ar), 128.6 (C-Ar), 
130.4 (C-Ar), 131.5 (C-Ar), 132.3 (C-Ar), 141.3 (C-Ar), 160.3 (CO), 187.2 (CO); HRMS 
calcd for C13H9
35
Cl2NO3 [M+H]
+
 298.0032, found 298.0037. 
 
 
 
 
369 
 
4-(2,3-Dichlorobenzoyl)-1H-pyrrole-2-carboxylic acid, 435 
 
General procedure G:  methyl 4-(2,3-dichlorobenzoyl)-1H-pyrrole-2-carboxylate (2.20 g, 
7.38 mmol) and LiOH monohydrate (6.20 g, 147.60 mmol) gave 435 as a white solid (2.04 g, 
97%). Rf 0.25  (9:1 DCM/MeOH); m.p. Degrades >150 
o
C; ˚C λmax (EtOH/nm) 282.5, 230.0; 
IR υmax/cm
-1 
3300, 3128, 2786, 2685, 2619, 2412, 1672, 1639, 1550, 1501; 
1
H NMR (500 
MHz, DMSO-d6) δ ppm 6.97 (1H, dd, J = 1.8 and 2.2 Hz, H-3), 7.38 (1H, dd, J = 1.8 and 3.4 
Hz, H-5), 7.44 (1H, dd, J = 1.8 and 7.6 Hz, H-6’), 7.48 (1H, dd, J = 7.7 and 7.8 Hz, H-5’), 
7.78 (1H, dd, J = 1.8 and 7.8 Hz, H-4’), 12.64 (1H, s, NH), 12.90 (1H, s, COOH); 13C NMR 
(125 MHz, DMSO-d6) δ ppm 114.6 (C-Ar), 124.6 (C-Ar), 125.6 (C-Ar), 126.9 (C-Ar), 127.5 
(C-Ar), 128.5 (C-Ar), 130.0 (C-Ar), 131.4 (C-Ar), 132.3 (C-Ar), 141.5 (C-Ar), 161.3 (CO), 
187.2 (CO); HRMS calcd for C12H7
35
Cl2NO3 [M+H]
+
 283.9876, found 283.9880. 
4-(2,3-Dichlorobenzoyl)-N-(2,2-diethoxyethyl)-1H-pyrrole-2-carboxamide, 436 
 
General procedure D:  4-(2,3-Dichlorobenzoyl)-1H-pyrrole-2-carboxylic acid (2.00 g, 7.04 
mmol), CDI (2.28 g, 14.08 mmol) and aminoacetaldehyde diethyl acetal (2.56 mL, 17.60 
mmol). Purification via column chromatography (silica; 10-70% EtOAc/petrol) gave 436 as a 
white solid (2.36 g, 84%). Rf 0.50 (9:1 DCM/MeOH); m.p. 160-162 
oC; λmax (EtOH/nm) 
295.0; IR υmax/cm
-1 
3365, 3180, 3130, 2975, 2931, 2894, 1617, 1573, 1534; 
1
H NMR (500 
MHz, DMSO-d6) δ ppm 1.12 (6H, t, J = 7.0 Hz, CH3), 3.29 (2H, dd, J = 5.4 and 5.8 Hz, NH-
CH2), 3.46-3.52 (2H, m, CH2), 3.60-3.67 (2H, m, CH2), 4.58 (1H, t, J = 5.4 Hz, CH), 7.21 
(1H, d, J = 1.5 Hz, H-3), 7.27 (1H, d, J = 1.5 Hz, H-5), 7.44 (1H, dd, J = 1.6 and 7.5 Hz, H-
6’), 7.49 (1H, dd, J = 7.5 and 7.8 Hz, H-5’), 7.78 (1H, dd, J = 1.6 and 7.8 Hz, H-4’), 8.41 
(1H, t, J = 5.8 Hz, NH), 12.37 (1H, s, NH-pyrrole); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 
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15.3 (CH3), 41.6 (NH-CH2), 61.4 (CH2), 100.2 (CH), 110.6 (C-Ar), 124.3 (C-Ar), 126.9 (C-
Ar), 127.5 (C-Ar), 128.5 (C-Ar), 128.6 (C-Ar), 131.2 (C-Ar), 132.2 (C-Ar), 141.8 (C-Ar), 
160.0 (CO), 187.4 (CO); HRMS calcd for C18H20
35
Cl2N2O4 [M+H]
+
 399.0873, found 
399.0875. 
3-(2,3-Dichlorobenzoyl)-1H-pyrrolo[2,3-c]pyridin-7(6H)-one, 437 
 
General procedure P: 4-(2,3-Dichlorobenzoyl)-N-(2,2-diethoxyethyl)-1H-pyrrole-2-
carboxamide (2.30 g, 5.76 mmol). Purification via column chromatography (silica; 0-5% 
MeOH/DCM) gave 437 as a white solid (0.97 g, 55%). Rf 0.44 (9:1 DCM/MeOH); m.p. 
Degrades >200 
oC; ˚C λmax (EtOH/nm) 259.0, 216.5; IR υmax/cm
-1 
3087, 2956, 2915, 2869, 
1774, 1633, 1527; 
1
H NMR (500 MHz, DMSO-d6) δ ppm 6.86 (1H, d, J = 6.9 Hz, CH-
pyridone), 7.13 (1H, dd, J = 5.9 and 6.5 Hz, N-CH-pyridone), 7.48-7.50 (2H, m, H-6’ and H-
5’), 7.57 (1H, s, H-5), 7.79 (1H, dd, J = 3.8 and 5.8 Hz, H-4’), 11.34 (1H, s, CO-NH), 12.81 
(1H, s, NH-pyrrole); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 100.1 (C-pyridone), 117.2 (C-
pyridone), 125.6 (C-Ar), 127.0 (C-Ar), 127.6 (C-Ar), 128.4 (C-Ar), 128.6 (C-Ar), 130.2 (C-
Ar), 131.3 (C-Ar), 132.3 (C-Ar), 135.3 (C-Ar), 141.8 (C-Ar), 154.7 (CO), 187.5 (CO); 
HRMS calcd for C14H8
35
Cl2N2O2 [M+H]
+
 307.0036, found 307.0042. 
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3-(2,3-Dichlorobenzoyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-c]pyridin-
7(6H)-one, 438 
 
General procedure Q:  3-(2,3-Dichlorobenzoyl)-1H-pyrrolo[2,3-c]pyridin-7(6H)-one (0.61 
g, 1.99 mmol), SEMCl (0.42 mL, 2.39 mmol), Et3N (0.33 mL, 2.39 mmol), and DMAP (10 
mol%). Purification via column chromatography (silica; 0-70% EtOAc/petrol) gave 438 as a 
colourless oil (0.63 g, 72%). Rf 0.39 (8:2 Petrol/EtOAc); λmax (EtOH/nm) 260.5, 218.0; IR 
υmax/cm
-1 
2956, 1646, 1611, 1525; 
1
H NMR (500 MHz, CDCl3) δ ppm 0.01 (9H, s, CH3), 
0.91-0.94 (2H, m, Si-CH2), 3.63-3.67 (2H, m, O-CH2), 5.96 (2H, s, N-CH2-O), 7.12 (1H, dd, 
J = 6.1 and 6.9 Hz, N-CH-pyridone), 7.29 (1H, d, J = 6.9 Hz, CH-pyridone), 7.33-7.34 (2H, 
m, H-6’ and H-5’), 7.44 (1H, s, H-5), 7.61 (1H, dd, J = 3.4 and 6.1 Hz, H-4’), 9.87 (1H, s, 
CO-NH); 
13
C NMR (125 MHz, CDCl3) δ ppm 0.00 (CH3), 19.3 (CH2), 68.2 (O-CH2), 76.1 
(N-CH2-O), 103.9 (C-pyridone), 104.6 (C-Ar), 119.3 (C-pyridone), 125.5 (C-Ar), 127.9 (C-
Ar), 129.0 (C-Ar), 133.0 (C-Ar), 134.1 (C-Ar), 134.5 (C-Ar), 135.5 (C-Ar), 139.1 (C-Ar), 
143.0 (C-Ar), 157.4 (CO), 189.6 (CO); HRMS calcd for C20H22
35
Cl2N2O3Si [M+H]
+
 
437.0850, found 437.0854. 
3-(2,3-Dichlorobenzoyl)-6-(pyridin-4-yl)-1H-pyrrolo[2,3-c]pyridin-7(6H)-one, 439 
 
General procedure R:   3-(2,3-Dichlorobenzoyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-
pyrrolo[2,3-c]pyridin-7(6H)-one (210 mg, 0.48 mmol), 4-bromopyridine HCl (122 mg, 0.63 
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mmol), K2CO3 (220 mg, 1.59 mmol) and CuI (10 mol%) gave 3-(2,3-dichlorobenzoyl)-6-
(pyridin-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-c]pyridin-7(6H)-one 
which was used directly in the next step. General procedure H: 1M TBAF in THF (0.72 mL, 
0.72 mmol). Purification via column chromatography (silica; 0-8% MeOH/DCM) gave 439 
as a white solid (127 mg, 69%). Rf 0.26 (9:1 DCM/MeOH); m.p. Degrades >200 
o
C; λmax 
(EtOH/nm) 253.0, 219.5; IR υmax/cm
-1 
3116, 3040, 2985, 1663, 1619, 1577;
 1
H NMR (500 
MHz, DMSO-d6) δ ppm 7.01 (1H, d, J = 7.1 Hz, CH-pyridone), 7.49-7.52 (3H, m, N-CH-
pyridone, H-4’ and H-6’), 7.61 (2H, d, J = 6.1 Hz, CH-pyridine), 7.72 (1H, s, H-5), 7.81 (1H, 
dd, J = 4.8 and 4.9 Hz, H-5’), 8.76 (2H, d, J = 6.1 Hz, N-CH-pyridine), 13.23 (1H, s, NH-
pyrrole); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 101.6 (C-pyridone), 117.5 (C-pyridone), 
121.9 (C-Ar), 124.9 (C-Ar), 127.0 (C-Ar), 127.6 (C-Ar), 128.7 (C-Ar), 129.6 (C-Ar), 131.5 
(C-Ar), 131.8 (C-Ar), 132.4 (C-Ar), 136.2 (C-Ar), 141.7 (C-Ar), 147.6 (C-Ar), 150.6 (C-Ar), 
153.4 (CO), 187.6 (CO); HRMS calcd for C19H11
35
Cl2N3O2 [M+H]
+
 384.0301, found 
384.0304. 
3-(2,3-Dichlorobenzoyl)-6-(pyridin-3-yl)-1H-pyrrolo[2,3-c]pyridin-7(6H)-one, 440 
 
General procedure R: 3-(2,3-Dichlorobenzoyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-
pyrrolo[2,3-c]pyridin-7(6H)-one (250 mg, 0.59 mmol), 3-bromopyridine HCl (150 mg, 0.77 
mmol), K2CO3 (270 mg, 1.95 mmol) and CuI (10 mol%) gave 3-(2,3-Dichlorobenzoyl)-6-
(pyridin-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-c]pyridin-7(6H)-one 
which was used directly in the next step. General procedure H: 1M TBAF in THF (0.89 mL, 
0.89 mmol). Purification via column chromatography (silica; 0-8% MeOH/DCM) gave 440 
as a white solid (90 mg, 40%). Rf 0.25 (9:1 DCM/MeOH); m.p. Degrades >200 
o
C; λmax 
(EtOH/nm) 262.0, 219.5; IR υmax/cm
-1 
3079, 2935, 1653, 1591, 1573, 1517; 
1
H NMR (500 
MHz, DMSO-d6) δ ppm 6.99 (1H, d, J = 6.9 Hz, CH-pyridone), 7.48-7.54 (3H, m, N-CH-
pyridone, H-6’ and H-4’), 7.60 (1H, dd, J = 4.7 and 8.0 Hz, CH-pyridine), 7.71 (1H, s, H-5), 
7.81 (1H, dd, J = 4.7 and 4.8 Hz, H-5’), 7.98 (1H, ddd, J = 1.5, 2.5 and 8.0 Hz, CH-pyridine), 
8.66 (1H, dd, J = 1.5 and 4.7 Hz, N-CH-pyridine), 8.72 (1H, d, J = 2.5 Hz, N-CH-pyridine), 
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13.21 (1H, s, NH-pyrrole); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 101.2 (C-pyridone), 117.5 
(C-pyridone), 123.9 (C-Ar), 124.9 (C-Ar), 127.0 (C-Ar), 127.6 (C-Ar), 128.7 (C-Ar), 129.7 
(C-Ar), 131.5 (C-Ar), 132.4 (C-Ar), 132.6 (C-Ar), 134.9 (C-Ar), 136.0 (C-Ar), 137.2 (C-Ar), 
141.7 (C-Ar), 147.9 (C-Ar), 148.8 (C-Ar), 153.9 (CO), 187.6 (CO); HRMS calcd for 
C19H11
35
Cl2N3O2 [M+H]
+
 384.0301, found 384.0304. 
4-(2-Chloro-6-fluorobenzoyl)-N-(2,2-diethoxyethyl)-1H-pyrrole-2-carboxamide, 441 
 
General procedure D: 4-(2-Chloro-6-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (0.74 g, 
2.77 mmol), CDI (0.90 mg, 5.54 mmol) and aminoacetaldehyde diethyl acetal (1.01 mL, 6.93 
mmol). Purification via column chromatography (silica; 10-70% EtOAc/petrol) gave 441 as a 
white solid (1.17 g, 64%). Rf 0.48 (9:1 DCM/MeOH); m.p. 142-145 
oC; ˚C λmax (EtOH/nm) 
290.0, 236.0; IR υmax/cm
-1 
3372, 3182, 3132, 2976, 2884, 1621, 1571, 1534; 
1
H NMR (500 
MHz, DMSO-d6) δ ppm 1.12 (6H, t, J = 7.0 Hz, CH3), 3.29 (2H, dd, J = 5.5 and 6.1 Hz, NH-
CH2), 3.46-3.52 (2H, m, CH2), 3.60-3.67 (2H, m, CH2), 4.58 (1H, t, J = 5.5 Hz, CH), 7.21 
(1H, br s, H-3), 7.33 (1H, br s, H-5), 7.38 (1H, dd, J = 8.3 and 8.9 Hz, H-5’), 7.45 (1H, d, J = 
8.3 Hz, H-3’), 7.57 (1H, ddd, J = 6.3, 8.3 and 8.4 Hz, H-4’), 8.42 (1H, t, J = 6.1 Hz, CO-NH), 
12.41 (1H, s, NH-pyrrole); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 15.3 (CH3), 41.6 (NH-
CH2), 61.4 (CH2), 100.2 (CH), 110.1 (C-Ar), 114.9 (d, JCF = 21.7 Hz, C-Ar), 125.0 (C-Ar), 
125.8 (d, JCF = 2.8 Hz, C-Ar), 128.1 (C-Ar), 128.3 (C-Ar), 128.7 (C-Ar), 130.4 (d, JCF = 6.4 
Hz, C-Ar), 131.7 (d, JCF = 9.1 Hz, C-Ar), 158.6 (d, JCF = 246.7 Hz, C-F), 159.9 (CO), 183.8 
(CO); HRMS calcd for C18H20
35
ClFN2O4 [M+H]
+
 383.1168, found 383.1172. 
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3-(2-Chloro-6-fluorobenzoyl)-1H-pyrrolo[2,3-c]pyridin-7(6H)-one, 442 
 
General procedure P: 4-(2-Chloro-6-fluorobenzoyl)-N-(2,2-diethoxyethyl)-1H-pyrrole-2-
carboxamide (1.10 g, 2.88 mmol). Purification via column chromatography (silica; 0-5% 
MeOH/DCM) gave 442 as a white solid (0.44 g, 53%). Rf 0.43 (9:1 DCM/MeOH); m.p. 
Degrades >200 
oC; ˚C λmax (EtOH/nm) 260.0, 215.5; IR υmax/cm
-1 
3132, 3097, 2973, 1773, 
1646, 1605, 1570, 1530; 
1
H NMR (500 MHz, DMSO-d6) δ ppm 6.80 (1H, br s, CH-
pyridone), 7.14 (1H, dd, J = 6.5 and 6.9 Hz, N-CH-pyridone), 7.39 (1H, dd, J = 8.3 and 8.9 
Hz, H-5’), 7.46 (1H, d, J = 8.3 Hz, H-3’), 7.58 (1H, ddd, J = 6.3, 8.3 and 8.4 Hz, H-4’), 7.66 
(1H, d, J = 3.3 Hz, H-5), 11.37 (1H, br s, CO-NH), 13.02 (1H, s, NH-pyrrole); 
13
C NMR (125 
MHz, DMSO-d6) δ ppm 99.8 (C-pyridone), 115.0 (d, JCF = 21.8 Hz, C-Ar), 118.0 (C-
pyridone), 125.6 (C-Ar), 125.8 (d, JCF = 3.0 Hz, C-Ar), 128.2 (d, JCF = 22.6 Hz, C-Ar), 128.6 
(C-Ar), 129.8 (C-Ar), 130.5 (d, JCF = 6.2 Hz, C-Ar), 131.8 (d, JCF = 9.3 Hz, C-Ar), 135.0 (C-
Ar), 154.6 (CO), 158.6 (d, JCF = 247.8 Hz, C-F), 183.7 (CO); HRMS calcd for 
C14H8
35
ClFN2O2 [M+H]
+
 291.0331, found 291.0336. 
3-(2-Chloro-6-fluorobenzoyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-
c]pyridin-7(6H)-one, 443 
 
General procedure Q: 3-(2-Chloro-6-fluorobenzoyl)-1H-pyrrolo[2,3-c]pyridin-7(6H)-one 
(430 mg, 1.48 mmol), SEMCl (0.32 mL, 1.78 mmol), Et3N (0.25 mL, 1.78 mmol) and DMAP 
(10 mol%). Purification via column chromatography (silica; 0-70% EtOAc/petrol) gave 443 
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as a colourless oil (298 mg, 48%). Rf 0.39 (8:2 Petrol/EtOAc); λmax (EtOH/nm) 259.5, 217.5; 
IR υmax/cm
-1 
2953, 2890, 1649, 1605, 1571, 1521; 
1
H NMR (500 MHz, CDCl3) δ ppm 0.02 
(9H, s, CH3), 0.86-0.90 (2H, m, Si-CH2), 3.54-3.57 (2H, m, O-CH2), 5.77 (2H, s, N-CH2-O), 
7.11-7.14 (1H, m, H-5’), 7.30 (1H, d, J = 8.2 Hz, H-3’), 7.40 (1H, ddd, J = 6.3, 8.3 and 8.4 
Hz, H-4’), 7.54 (1H, s, H-5), 7.78 (1H, d, J = 5.6 Hz, CH-pyridone), 7.96 (1H, d, J = 5.6 Hz, 
N-CH-pyridone); 
13
C NMR (125 MHz, CDCl3) δ ppm 0.00 (CH3), 19.5 (CH2), 69.1 (O-CH2), 
79.6 (N-CH2-O), 104.0 (C-pyridone), 113.0 (C-pyridone), 116.0 (d, JCF = 21.7 Hz, C-Ar), 
127.1 (d, JCF = 3.3 Hz, C-Ar), 128.9 (C-Ar), 132.4 (d, JCF = 9.1 Hz, C-Ar), 133.5 (d, JCF = 5.8 
Hz, C-Ar), 135.7 (C-Ar), 140.1 (C-Ar), 140.7 (C-Ar), 151.5 (CO), 160.8 (d, JCF = 250.9 Hz, 
C-F), 185.3 (CO), one F split C-Ar not observed; HRMS calcd for C20H22
35
ClFN2O3Si 
[M+H]
+
 421.1145, found 421.1148. 
3-(2-Chloro-6-fluorobenzoyl)-6-(pyridin-4-yl)-1H-pyrrolo[2,3-c]pyridin-7(6H)-one, 444 
 
General procedure R:  3-(2-Chloro-6-fluorobenzoyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-
1H-pyrrolo[2,3-c]pyridin-7(6H)-one (100 mg, 0.24 mmol), 4-bromopyridine HCl (61 mg, 
0.31 mmol), K2CO3 (109 mg, 0.79 mmol) and CuI (10 mol%) gave 3-(2-chloro-6-
fluorobenzoyl)-6-(pyridin-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-
c]pyridin-7(6H)-one which was used directly in the next step. General procedure H: 1M 
TBAF in THF (0.36 mL, 0.36 mmol). Purification via column chromatography (silica; 0-8% 
MeOH/DCM) gave 444 as a white solid (45 mg, 51%). Rf 0.26 (9:1 DCM/MeOH); m.p. 
Degrades >200 
o
C; λmax (EtOH/nm) 254.0; IR υmax/cm
-1 
3121, 3035, 2971, 1636, 1599, 1577, 
1518; 
1
H NMR (500 MHz, DMSO-d6) δ ppm 6.95 (1H, br s, CH-pyridone), 7.42 (1H, dd, J = 
8.6 and 8.9 Hz, H-5’), 7.48-7.50 (2H, m, N-CH-pyridone and H-3’), 7.58-7.62 (3H, m, CH-
pyridine and H-4’), 7.81 (1H, s, H-5), 8.76 (2H, d, J = 6.1 Hz, N-CH-pyridine), 13.29 (1H, s, 
NH-pyrrole); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 101.3 (C-pyridone), 115.1 (d, JCF = 
21.5 Hz, C-Ar), 118.2 (C-pyridone), 121.9 (C-Ar), 125.0 (C-Ar), 125.9 (d, JCF = 2.7 Hz, C-
Ar), 129.2 (C-Ar), 130.4 (d, JCF = 6.1 Hz, C-Ar), 132.0 (C-Ar), 132.1 (C-Ar), 136.0 (C-Ar), 
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147.6 (C-Ar), 150.7 (C-Ar), 153.3 (CO), 158.6 (JCF = 246.8 Hz, C-F), 183.9 (CO), one C-Ar 
not visualised; HRMS calcd for C19H11
35
ClFN3O2 [M+H]
+
 368.0597, found 368.0600. 
3-(2-Chloro-6-fluorobenzoyl)-6-(pyridin-3-yl)-1H-pyrrolo[2,3-c]pyridin-7(6H)-one, 445 
 
General procedure R: 3-(2-Chloro-6-fluorobenzoyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-
1H-pyrrolo[2,3-c]pyridin-7(6H)-one (120 mg, 0.29 mmol), 3-bromopyridine HCl (74 mg, 
0.38 mmol), K2CO3 (138 mg, 1.00 mmol) and CuI (10 mol%) gave 3-(2-chloro-6-
fluorobenzoyl)-6-(pyridin-3-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-
c]pyridin-7(6H)-one which was used directly in the next step. General procedure H:  1M 
TBAF in THF (0.44 mL, 0.44 mmol). Purification via column chromatography (silica; 0-8% 
MeOH/DCM) gave 445 as a white solid (20 mg, 19%). Rf 0.26 (9:1 DCM/MeOH); m.p. 
Degrades >200 
o
C λmax (EtOH/nm) 262.5, 217.5; IR υmax/cm
-1 
3057, 2816, 1645, 1560, 1568, 
1528; 
1
H NMR (500 MHz, DMSO-d6) δ ppm 6.93 (1H, br s, CH-pyridone), 7.42 (1H, dd, J = 
8.7 and 8.9 Hz, H-5’), 7.48-7.50 (2H, m, N-CH-pyridone and H-3’), 7.58-7.63 (2H, m, H-4’ 
and CH-pyridine), 7.80 (1H, s, H-5), 7.99 (1H, ddd, J = 1.5, 2.4 and 8.2 Hz, CH-pyridine), 
8.66 (1H, dd, J = 1.5 and 4.7 Hz, N-CH-pyridine), 8.72 (1H, d, J = 2.4 Hz, N-CH-pyridine), 
13.27 (1H, s, NH-pyrrole); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 100.8 (C-pyridone), 115.1 
(d, JCF = 21.4 Hz, C-Ar), 118.2 (C-pyridone), 123.9 (C-Ar), 125.1 (C-Ar), 125.9 (d, JCF = 3.0 
Hz, C-Ar), 129.4 (C-Ar), 130.4 (d, JCF = 7.8 Hz, C-Ar), 132.0 (d, JCF = 9.5 Hz, C-Ar), 132.9 
(C-Ar), 135.0 (C-Ar), 135.9 (C-Ar), 137.2 (C-Ar), 147.9 (C-Ar), 148.8 (C-Ar), 153.8 (CO), 
158.7 (d, JCF = 247.8 Hz, C-F), 183.8 (CO), one C-Ar not visualised; HRMS calcd for 
C19H11
35
ClFN3O2 [M+H]
+
 368.0597, found 368.0600. 
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4-(2-Bromo-6-fluorobenzoyl)-N-(2,2-diethoxyethyl)-1H-pyrrole-2-carboxamide, 446 
 
General procedure D: 4-(2-bromo-6-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (1.90 g, 
6.09 mmol), CDI (1.97 g, 12.18 mmol) and aminoacetaldehyde diethyl acetal (2.21 mL, 
15.33 mmol). Purification via column chromatography (silica; 10-70% EtOAc/petrol) gave 
446 as a white solid (1.42 g, 57%). Rf  0.49 (9:1 DCM/MeOH); m.p. 152-154 
o
C; ˚C λmax 
(EtOH/nm) 285.0, 234.0; IR υmax/cm
-1 
3368, 3174, 3130, 2979, 2899, 1620; 
1
H NMR (500 
MHz, DMSO-d6) δ ppm 1.12 (6H, t, J = 7.0 Hz, CH3), 3.28 (2H, dd, J = 5.5 and 5.8 Hz, NH-
CH2), 3.46-3.52 (2H, m, CH2), 3.60-3.66 (2H, m, CH2), 4.58 (1H, t, J = 5.5 Hz, CH), 7.20 
(1H, br s, H-3), 7.30 (1H, br s, H-5), 7.41 (1H, dd, J = 8.3 and 8.9 Hz, H-5’), 7.49 (1H, ddd, J 
= 6.3, 8.3 and 8.4 Hz, H-4’), 7.59 (1H, d, J = 8.3 Hz, H-3’), 8.42 (1H, t, J = 5.8 Hz, CO-NH), 
12.40 (1H, s, NH-pyrrole); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 15.3 (CH3), 41.6 (NH-
CH2), 61.4 (CH2), 100.2 (CH), 110.2 (C-Ar), 115.3 (d, JCF = 21.7 Hz, C-Ar), 119.0 (d, JCF = 
5.2 Hz, C-Ar), 124.7 (C-Ar), 125.8 (C-Ar), 128.3 (C-Ar), 128.8 (C-Ar), 130.1 (d, JCF = 22.7 
Hz, C-Ar), 132.0 (d, JCF = 8.5 Hz, C-Ar), 158.5 (d, JCF = 249.1 Hz, C-F), 159.9 (CO), 184.8 
(CO); HRMS calcd for C18H20
79
BrFN2O4 [M+H]
+
 427.0663, found 427.0666. 
3-(2-Bromo-6-fluorobenzoyl)-1H-pyrrolo[2,3-c]pyridin-7(6H)-one, 447 
 
General procedure P: 4-(2-bromo-6-fluorobenzoyl)-N-(2,2-diethoxyethyl)-1H-pyrrole-2-
carboxamide (1.40 g, 3.28 mmol). Purification via column chromatography (silica; 0-5% 
MeOH/DCM) gave 447 as a white solid (0.65 g, 59%). Rf 0.44 (9:1 DCM/MeOH); m.p. 301-
302 
oC; ˚C λmax (EtOH/nm) 261.0, 215.5; IR υmax/cm
-1 
3117, 3094, 2916, 1729, 1650, 1602, 
1568, 1530; 
1
H NMR (500 MHz, DMSO-d6) δ ppm 6.78 (1H, br s, CH-pyridone), 7.13 (1H, 
dd, J = 6.4 and 6.9 Hz, N-CH-pyridone), 7.42 (1H, dd, J = 8.5 and 9.1 Hz, H-5’), 7.51 (1H, 
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ddd, J = 6.3, 8.3 and 8.4  Hz, H-4’), 7.60 (1H, d, J = 8.3 Hz, H-3’), 7.63 (1H, s, H-5), 11.36 
(1H, br s, CO-NH), 13.01 (1H,s, NH-pyrrole); 
13
C NMR (125 MHz, DMSO-d6) δ ppm 99.8 
(C-pyridone), 115.4 (d, JCF = 21.8 Hz, C-Ar), 117.7 (C-pyridone), 119.2 (d, JCF = 5.1 Hz, C-
Ar), 125.7 (C-Ar), 128.5 (C-Ar), 128.8 (d, JCF = 2.8 Hz, C-Ar), 129.9 (C-Ar), 130.1 (d, JCF = 
22.6 Hz, C-Ar), 132.1 (d, JCF = 8.7 Hz, C-Ar), 134.9 (C-Ar), 154.6 (CO), 158.6 (d, JCF = 
247.8 Hz, C-F), 184.7 (CO); HRMS calcd for C14H8
79
BrFN2O2 [M-H]
-
 334.9826, found 
334.9833. 
3-(2-Bromo-6-fluorobenzoyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-
c]pyridin-7(6H)-one, 448 
 
General procedure Q: 3-(2-bromo-6-fluorobenzoyl)-1H-pyrrolo[2,3-c]pyridin-7(6H)-one 
(450 mg, 1.34 mmol), SEMCl (0.28 mL, 1.61 mmol), Et3N (0.22 mL, 1.61 mmol) and DMAP 
(10 mol%). Purification via column chromatography (silica; 0-70% EtOAc/petrol) gave 448 
as a colourless oil (400 mg, 64%). Rf 0.40 (8:2 Petrol/EtOAc); λmax (EtOH/nm) 260.5, 218.0; 
IR υmax/cm
-1 
2952, 2894, 1646, 1602, 1570, 1521; 
1
H NMR (500 MHz, CDCl3) δ ppm 0.01 
(9H, s, CH3), 0.89-0.82 (2H, m, Si-CH2), 3.62-3.65 (2H, m, O-CH2), 5.96 (2H, s, N-CH2-O), 
7.10 (1H, dd, J = 5.5 and 5.9 Hz, N-CH-pyridone), 7.14-7.18 (1H, m, H-5’),  7.21 (1H, d, J = 
5.5 Hz, CH-pyridone), 7.32-7.36 (1H, m, H-4’), 7.46-7.48 (2H, m, H-5 and H-3’), 9.47 (1H, 
s, CO-NH); 
13
C NMR (125 MHz, CDCl3) δ ppm 0.01 (C-CH3), 19.3 (CH2), 68.3 (O-CH2), 
76.0 (N-CH2-O), 104.6 (C-pyridone), 116.6 (d, JCF = 21.6 Hz, C-Ar), 119.7 (C-pyridone), 
121.5 (d, JCF = 4.8 Hz, C-Ar), 125.6 (d, JCF = 2.8 Hz, C-Ar), 129.3 (C-Ar), 130.3 (C-Ar), 
131.7 (d, JCF = 22.0 Hz, C-Ar), 133.0 (d, JCF = 8.7 Hz, C-Ar), 134.3 (C-Ar), 138.9 (C-Ar), 
157.4 (CO), 160.8 (d, JCF = 252.1 Hz, C-F), 186.6 (CO); HRMS calcd for C20H22
79
BrFN2O3Si 
[M+H]
+
 465.0640, found 465.0635. 
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3-(2-Bromo-6-fluorobenzoyl)-6-(pyridin-4-yl)-1H-pyrrolo[2,3-c]pyridin-7(6H)-one, 449 
 
General procedure R: 3-(2-bromo-6-fluorobenzoyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-
1H-pyrrolo[2,3-c]pyridin-7(6H)-one (190 mg, 0.41 mmol), 4-bromopyridine HCl (86 mg, 
0.44 mmol), K2CO3 (155 mg, 1.12 mmol), and CuI (10 mol%) gave 3-(2-bromo-6-
fluorobenzoyl)-6-(pyridin-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-
c]pyridin-7(6H)-one which was used directly in the next step. General procedure H: 1M 
TBAF in THF (0.62 mL, 0.62 mmol). Semi-preparative chromatography gave 449 as a white 
solid (16 mg, 9%). Rf 0.24 (9:1 DCM/MeOH); m.p. Degrades >200 
oC; λmax (EtOH/nm) 
260.0; IR υmax/cm
-1
 3115, 3088, 2935, 1637, 1600, 1579, 1516; 
1
H NMR (500 MHz, DMSO-
d6) δ ppm 6.92 (1H, br s, CH-pyridone), 7.44 (1H, dd, J = 8.7 and 9.1 Hz, H-5’), 7.48 (1H, d, 
J = 7.5 Hz, N-CH-pyridone), 7.52 (1H, ddd, J = 6.3, 8.3 and 8.4 Hz, H-4’), 7.61-7.63 (3H, m, 
CH-pyridine and H-3’), 7.78 (1H, s, H-5), 8.75 (2H, s, J = 6.1 Hz, N-CH-pyridine), 13.25 
(1H, s, NH-pyrrole); HRMS calcd for C19H11
79
BrFN3O2 [M+H]
+
 412.0091, found 412.0091. 
  
380 
 
Chapter 8: References 
1. Hanahan, D.; Weinberg, R. A. The Hallmarks of Cancer. Cell. 2000, 100, 57-70. 
2. http://info.cancerresearchuk.org/cancerstats/incidence/all-cancers-combined/. 
(25/07/2012). 
3. Jemal, A.; Siegel, R.; Ward, E.; Hao, Y.; Xu, J.; Murray, T.; Thun, M. J. Cancer 
Statistics, 2008. CA. Cancer J. Clin. 2008, 58, 71-96. 
4. http://info.cancerresearchuk.org/cancerstats/incidence/commoncancers/. 
http://info.cancerresearchuk.org/cancerstats/incidence/commoncancers/ (25/07/2012). 
5. DeVita, V. T., Jr.; Chu, E. A history of cancer chemotherapy. Cancer Res. 2008, 68, 
8643-53. 
6. Farber, S.; Diamond, L. K.; Mercer, R. D.; Sylvester, R. F.; Wolff, J. A. Temporary 
Remissions in Acute Leukemia in Children Produced by Folic Acid Antagonist, 4-
Aminopteroyl-Glutamic Acid (Aminopterin). N. Engl. J. Med. 1948, 238, 787-793. 
7. Capdeville, R.; Buchdunger, E.; Zimmermann, J.; Matter, A. Glivec (STI571, imatinib), 
a rationally developed, targeted anticancer drug. Nat. Rev. Drug Discov. 2002, 1, 493-
502. 
8. Drews, J. Drug Discovery: A Historical Perspective. Science. 2000, 287, 1960-1964. 
9. Jordan, V. C. Tamoxifen: a most unlikely pioneering medicine. Nat. Rev. Drug Discov. 
2003, 2, 205-213. 
10. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and 
computational approaches to estimate solubility and permeability in drug discovery and 
development settings. Adv. Drug Delivery Rev. 1997, 23, 3-25. 
11. Ertl, P.; Rohde, B.; Selzer, P. Fast Calculation of Molecular Polar Surface Area as a Sum 
of Fragment-Based Contributions and Its Application to the Prediction of Drug Transport 
Properties. J. Med. Chem. 2000, 43, 3714-3717. 
12. Kramer, J. A.; Sagartz, J. E.; Morris, D. L. The application of discovery toxicology and 
pathology towards the design of safer pharmaceutical lead candidates. Nat. Rev. Drug 
Discov. 2007, 6, 636-649. 
13. Manning, G.; Whyte, D. B.; Martinez, R.; Hunter, T.; Sudarsanam, S. The Protein Kinase 
Complement of the Human Genome. Science. 2002, 298, 1912-1934. 
14. Manley, P. W.; Cowan-Jacob, S. W.; Buchdunger, E.; Fabbro, D.; Fendrich, G.; Furet, 
P.; Meyer, T.; Zimmermann, J. Imatinib: a selective tyrosine kinase inhibitor. Eur. J. 
Cancer. 2002, 38, S19-S27. 
381 
 
15. Rask-Andersen, M.; Almén, M. S.; Schiöth, H. B. Trends in the exploitation of novel 
drug targets. Nat. Rev. Drug Discov. 2011, 10, 579-590. 
16. http://www.fda.gov/Drugs/default.htm. (26/07/2012). 
17. Shepherd, F. A.; Rodrigues Pereira, J.; Ciuleanu, T.; Tan, E. H.; Hirsh, V.; Thongprasert, 
S.; Campos, D.; Maoleekoonpiroj, S.; Smylie, M.; Martins, R.; van Kooten, M.; Dediu, 
M.; Findlay, B.; Tu, D.; Johnston, D.; Bezjak, A.; Clark, G.; Santabárbara, P.; Seymour, 
L. Erlotinib in Previously Treated Non–Small-Cell Lung Cancer. N. Engl. J. Med. 2005, 
353, 123-132. 
18. http://www.ukmi.nhs.uk. (28/08/2012). 
19. Wells, S. A., Jr.; Gosnell, J. E.; Gagel, R. F.; Moley, J.; Pfister, D.; Sosa, J. A.; Skinner, 
M.; Krebs, A.; Vasselli, J.; Schlumberger, M. Vandetanib for the treatment of patients 
with locally advanced or metastatic hereditary medullary thyroid cancer. J. Clin. Oncol. 
2010, 28, 767-72. 
20. Engelman, J. A.; Zejnullahu, K.; Mitsudomi, T.; Song, Y.; Hyland, C.; Park, J. O.; 
Lindeman, N.; Gale, C.-M.; Zhao, X.; Christensen, J.; Kosaka, T.; Holmes, A. J.; Rogers, 
A. M.; Cappuzzo, F.; Mok, T.; Lee, C.; Johnson, B. E.; Cantley, L. C.; Janne, P. A. MET 
Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 
Signaling. Science. 2007, 316, 1039-1043. 
21. Balak, M. N.; Gong, Y.; Riely, G. J.; Somwar, R.; Li, A. R.; Zakowski, M. F.; Chiang, 
A.; Yang, G.; Ouerfelli, O.; Kris, M. G.; Ladanyi, M.; Miller, V. A.; Pao, W. Novel 
D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor 
Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors. 
Clin. Cancer Res. 2006, 12, 6494-6501. 
22. Gazdar, A. F. Activating and resistance mutations of EGFR in non-small-cell lung 
cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene. 2009, 28, 
S24-S31. 
23. Chapman, P. B.; Hauschild, A.; Robert, C.; Haanen, J. B.; Ascierto, P.; Larkin, J.; 
Dummer, R.; Garbe, C.; Testori, A.; Maio, M.; Hogg, D.; Lorigan, P.; Lebbe, C.; Jouary, 
T.; Schadendorf, D.; Ribas, A.; O'Day, S. J.; Sosman, J. A.; Kirkwood, J. M.; 
Eggermont, A. M. M.; Dreno, B.; Nolop, K.; Li, J.; Nelson, B.; Hou, J.; Lee, R. J.; 
Flaherty, K. T.; McArthur, G. A. Improved Survival with Vemurafenib in Melanoma 
with BRAF V600E Mutation. N. Engl. J. Med. 2011, 364, 2507-2516. 
24. Dhillon, A. S.; Hagan, S.; Rath, O.; Kolch, W. MAP kinase signalling pathways in 
cancer. Oncogene. 26, 3279-3290. 
382 
 
25. Turjanski, A. G.; Vaque, J. P.; Gutkind, J. S. MAP kinases and the control of nuclear 
events. Oncogene. 26, 3240-3253. 
26. Cargnello, M.; Roux, P. P. Activation and function of the MAPKs and their substrates, 
the MAPK-activated protein kinases. Microbiol. Mol. Biol. Rev. 2011, 75, 50-83. 
27. Lee, J. T., Jr.; McCubrey, J. A. The Raf/MEK/ERK signal transduction cascade as a 
target for chemotherapeutic intervention in leukemia. Leukemia. 2002, 16, 486-507. 
28. Drew, B. A.; Burow, M. E.; Beckman, B. S. MEK5/ERK5 pathway: The first fifteen 
years. Biochim. Biophys. Acta, Rev. Cancer. 2012, 1825, 37-48. 
29. Robinson, M. J.; Cobb, M. H. Mitogen-activated protein kinase pathways. Curr. Opin.  
Cell Biol. 1997, 9, 180-186. 
30. Wu, X.; Noh, S. J.; Zhou, G.; Dixon, J. E.; Guan, K. L. Selective activation of MEK1 but 
not MEK2 by A-Raf from epidermal growth factor-stimulated Hela cells. J. Biol. Chem. 
1996, 271, 3265-71. 
31. Friday, B. B.; Adjei, A. A. Advances in targeting the Ras/Raf/MEK/Erk mitogen-
activated protein kinase cascade with MEK inhibitors for cancer therapy. Clin. Cancer 
Res. 2008, 14, 342-6. 
32. Thompson, N.; Lyons, J. Recent progress in targeting the Raf/MEK/ERK pathway with 
inhibitors in cancer drug discovery. Curr. Opin. Pharmacol. 2005, 5, 350-356. 
33. Kloog, Y.; Cox, A. D. RAS inhibitors: potential for cancer therapeutics. Mol. Med. 
Today. 2000, 6, 398-402. 
34. Barrett, S. D.; Bridges, A. J.; Dudley, D. T.; Saltiel, A. R.; Fergus, J. H.; Flamme, C. M.; 
Delaney, A. M.; Kaufman, M.; LePage, S.; Leopold, W. R.; Przybranowski, S. A.; 
Sebolt-Leopold, J.; Van Becelaere, K.; Doherty, A. M.; Kennedy, R. M.; Marston, D.; 
Howard Jr, W. A.; Smith, Y.; Warmus, J. S.; Tecle, H. The discovery of the 
benzhydroxamate MEK inhibitors CI-1040 and PD 0325901. Bioorg. Med. Chem. Lett. 
2008, 18, 6501-6504. 
35. Sebolt-Leopold, J. S.; Merriman, R.; Omer, C.; Tecle, H.; Bridges, A.; Klohs, W.; Loi, 
C.-M.; Valik, H.; Przybranowski, S.; Meyer, M.; Leopold, W. R. The biological profile 
of PD 0325901: A second generation analog of CI-1040 with improved pharmaceutical 
potential. AACR Meeting Abstracts 2004, 2004, 925. 
36. Davies, B. R.; Logie, A.; McKay, J. S.; Martin, P.; Steele, S.; Jenkins, R.; Cockerill, M.; 
Cartlidge, S.; Smith, P. D. AZD6244 (ARRY-142886), a potent inhibitor of mitogen-
activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: 
383 
 
mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and 
potential for combination in preclinical models. Mol. Cancer Ther. 2007, 6, 2209-2219. 
37. Yeh, T. C.; Marsh, V.; Bernat, B. A.; Ballard, J.; Colwell, H.; Evans, R. J.; Parry, J.; 
Smith, D.; Brandhuber, B. J.; Gross, S.; Marlow, A.; Hurley, B.; Lyssikatos, J.; Lee, P. 
A.; Winkler, J. D.; Koch, K.; Wallace, E. Biological Characterization of ARRY-142886 
(AZD6244), a Potent, Highly Selective Mitogen-Activated Protein Kinase Kinase 1/2 
Inhibitor. Clin. Cancer Res. 2007, 13, 1576-1583. 
38. Leijen, S. M., M.R; Tresca, P; Kraeber-Bodere, F; Dieras, V; Scheulen, M; Gupta, A; 
Lopez-Valverde, V; Xu, Z-X; Rueger, R; Tessier, J; Shochat, E; Blotner, S; Naegelen, 
V.M; Schellens, J.H.M; Eberhardt W.E.E. Phase I Dose-escalation Study of the Safety, 
Pharmacokinetics and Pharmacodynamics of the MEK Inhibitor RO4987655 
(CH4987655) in Patients with Advanced Solid Tumours. Clin. Cancer Res. 2012. 
39. Ohori, M.; Kinoshita, T.; Okubo, M.; Sato, K.; Yamazaki, A.; Arakawa, H.; Nishimura, 
S.; Inamura, N.; Nakajima, H.; Neya, M.; Miyake, H.; Fujii, T. Identification of a 
selective ERK inhibitor and structural determination of the inhibitor–ERK2 complex. 
Biochem. Biophys. Res. Commun. 2005, 336, 357-363. 
40. Kim, M. H.; Chung, J. Y.; Ryu, J. S.; Hah, J. M. Structure tuning of pyrazolylpyrrole 
derivatives as ERK inhibitors utilizing dual tools; 3D-QSAR and side-chain hopping. 
Bioorg. Med. Chem. Lett. 2011, 21, 4900-4. 
41. Johnson, G. L.; Lapadat, R. Mitogen-Activated Protein Kinase Pathways Mediated by 
ERK, JNK, and p38 Protein Kinases. Science. 2002, 298, 1911-1912. 
42. Herlaar, E.; Brown, Z. p38 MAPK signalling cascades in inflammatory disease. Mol. 
Med. Today. 1999, 5, 439-47. 
43. Bradham, C.; McClay, D. R. p38 MAPK in development and cancer. Cell Cycle. 2006, 5, 
824-8. 
44. Losa, J. H.; Cobo, C. P.; Viniegra, J. G.; Lobo, V. J. S.-A.; Cajal, S. R. y.; Sanchez-
Prieto, R. Role of the p38 MAPK pathway in cisplatin-based therapy. Oncogene. 2003, 
22, 3998-4006. 
45. Davis, R. J. Signal Transduction by the JNK Group of MAP Kinases. Cell. 2000, 103, 
239-252. 
46. Hope, H. R.; Anderson, G. D.; Burnette, B. L.; Compton, R. P.; Devraj, R. V.; Hirsch, J. 
L.; Keith, R. H.; Li, X.; Mbalaviele, G.; Messing, D. M.; Saabye, M. J.; Schindler, J. F.; 
Selness, S. R.; Stillwell, L. I.; Webb, E. G.; Zhang, J.; Monahan, J. B. Anti-inflammatory 
384 
 
properties of a novel N-phenyl pyridinone inhibitor of p38 mitogen-activated protein 
kinase: preclinical-to-clinical translation. J. Pharmacol. Exp. Ther. 2009, 331, 882-95. 
47. M. Bello, A.; K. Purohit, M.; Jun Yang Cui, T.; Brandon Stead, S.; P. Kotra, L. 
Immunological Targets in Inflammation from the Small Molecule Perspective. Curr. 
Med. Chem.: Anti-Inflammatory Anti-Allergy Agents. 2011, 10, 121-131. 
48. Yong, H. Y.; Koh, M. S.; Moon, A. The p38 MAPK inhibitors for the treatment of 
inflammatory diseases and cancer. Expert. Opin. Investig. Drugs. 2009, 18, 1893-905. 
49. Navas, T.; Hideshima, T.; Nguyen, A.; Henson, M.; Stebbins, L.; Kapoun, A. M.; 
O'Young, G.; Chakravarty, S.; Mavunkel, B.; Perumattam, J.; Luedtke, G.; Dugar, S.; 
Schreiner, G.; Anderson, K.; Higgins, L. S. The p38α MAPK inhibitor SCIO-469 
enhances the apoptotic and anti-proliferative effects of proteasome inhibitors MG132 and 
PS341 (Velcade) in multiple myeloma cells. AACR Meeting Abstracts. 2004, 2004, 775-
776. 
50. Manning, A. M.; Davis, R. J. Targeting JNK for therapeutic benefit: from junk to gold? 
Nat. Rev. Drug Discov. 2003, 2, 554-565. 
51. Pearson, G.; English, J. M.; White, M. A.; Cobb, M. H. ERK5 and ERK2 Cooperate to 
Regulate NF-kappa B and Cell Transformation. J. Biol. Chem. 2001, 276, 7927-7931. 
52. Wang, X.; Tournier, C. Regulation of cellular functions by the ERK5 signalling pathway. 
Cell. Signalling. 2006, 18, 753-760. 
53. Hayashi, M.; Lee, J.-D. Role of the BMK1/ERK5 signaling pathway: lessons from 
knockout mice. J. Mol. Med. 2004, 82, 800-808. 
54. English, J. M.; Pearson, G.; Hockenberry, T.; Shivakumar, L.; White, M. A.; Cobb, M. 
H. Contribution of the ERK5/MEK5 Pathway to Ras/Raf Signaling and Growth Control. 
J. Biol. Chem. 1999, 274, 31588-31592. 
55. Zhou, G.; Bao, Z. Q.; Dixon, J. E. Components of a New Human Protein Kinase Signal 
Transduction Pathway. J. Biol. Chem. 1995, 270, 12665-12669. 
56. Sun, W.; Wei, X.; Kesavan, K.; Garrington, T. P.; Fan, R.; Mei, J.; Anderson, S. M.; 
Gelfand, E. W.; Johnson, G. L. MEK Kinase 2 and the Adaptor Protein Lad Regulate 
Extracellular Signal-Regulated Kinase 5 Activation by Epidermal Growth Factor via Src. 
Mol. Cell. Biol. 2003, 23, 2298-2308. 
57. Dhanasekaran, D. N.; Kashef, K.; Lee, C. M.; Xu, H.; Reddy, E. P. Scaffold proteins of 
MAP-kinase modules. Oncogene. 2007, 26, 3185-202. 
58. Roberts, O. L.; Holmes, K.; Muller, J.; Cross, D. A.; Cross, M. J. ERK5 and the 
regulation of endothelial cell function. Biochem. Soc. Trans. 2009, 37, 1254-9. 
385 
 
59. Nishimoto, S. MAPK Signalling: ERK5 versus ERK1/2. EMBO reports. 2006, 7, 782-
786. 
60. Wada, T.; Penninger, J. M. Mitogen-activated protein kinases in apoptosis regulation. 
Oncogene. 23, 2838-2849. 
61. Ranganathan, A.; Pearson, G. W.; Chrestensen, C. A.; Sturgill, T. W.; Cobb, M. H. The 
MAP kinase ERK5 binds to and phosphorylates p90 RSK. Arch. Biochem. Biophys. 
2006, 449, 8-16. 
62. Carriere, A. R., H; Blenis, J; Roux, P. P. The RSK factors of activating the Ras/MAPK 
signaling cascade. Front. Biosci. 2008, 13, 4258-4275. 
63. Yang, Q.; Deng, X.; Lu, B.; Cameron, M.; Fearns, C.; Patricelli, M. P.; Yates Iii, J. R.; 
Gray, N. S.; Lee, J.-D. Pharmacological Inhibition of BMK1 Suppresses Tumor Growth 
through Promyelocytic Leukemia Protein. Cancer Cell. 2010, 18, 258-267. 
64. Kato, Y.; Tapping, R. I.; Huang, S.; Watson, M. H.; Ulevitch, R. J.; Lee, J.-D. 
Bmk1/Erk5 is required for cell proliferation induced by epidermal growth factor. Nature. 
1998, 395, 713-716. 
65. Cude, K.; Wang, Y.; Choi, H.-J.; Hsuan, S.-L.; Zhang, H.; Wang, C.-Y.; Xia, Z. 
Regulation of the G2–M cell cycle progression by the ERK5–NFκB signaling pathway. 
J. Cell Biol. 2007, 177, 253-264. 
66. Girio, A.; Montero, J. C.; Pandiella, A.; Chatterjee, S. Erk5 is activated and acts as a 
survival factor in mitosis. Cell Signal. 2007, 19, 1964-72. 
67. Gilley, R.; Lochhead, P. A.; Balmanno, K.; Oxley, D.; Clark, J.; Cook, S. J. CDK1, not 
ERK1/2 or ERK5, is required for mitotic phosphorylation of BIMEL. Cell Signal. 2012, 
24, 170-80. 
68. Sohn, S. J.; Sarvis, B. K.; Cado, D.; Winoto, A. ERK5 MAPK regulates embryonic 
angiogenesis and acts as a hypoxia-sensitive repressor of vascular endothelial growth 
factor expression. J. Biol. Chem. 2002, 277, 43344-51. 
69. Hayashi, M.; Fearns, C.; Eliceiri, B.; Yang, Y.; Lee, J.-D. Big Mitogen-Activated Protein 
Kinase 1/Extracellular Signal-Regulated Kinase 5 Signaling Pathway Is Essential for 
Tumor-Associated Angiogenesis. Cancer Res. 2005, 65, 7699-7706. 
70. Doebele, R. C.; Schulze-Hoepfner, F. T.; Hong, J.; Chlenski, A.; Zeitlin, B. D.; Goel, K.; 
Gomes, S.; Liu, Y.; Abe, M. K.; Nor, J. E.; Lingen, M. W.; Rosner, M. R. A novel 
interplay between Epac/Rap1 and mitogen-activated protein kinase kinase 5/extracellular 
signal-regulated kinase 5 (MEK5/ERK5) regulates thrombospondin to control 
angiogenesis. Blood. 2009, 114, 4592-4600. 
386 
 
71. Reddy, K. B.; Nabha, S. M.; Atanaskova, N. Role of MAP kinase in tumor progression 
and invasion. Cancer Metastasis Rev. 2003, 22, 395-403. 
72. Westermarck, J.; Kahari, V. M. Regulation of matrix metalloproteinase expression in 
tumor invasion. Faseb J. 1999, 13, 781-92. 
73. Mehta, P. B.; Jenkins, B. L.; McCarthy, L.; Thilak, L.; Robson, C. N.; Neal, D. E.; 
Leung, H. Y. MEK5 overexpression is associated with metastatic prostate cancer, and 
stimulates proliferation, MMP-9 expression and invasion. Oncogene. 22, 1381-1389. 
74. Sawhney, R. S.; Liu, W.; Brattain, M. G. A novel role of ERK5 in integrin-mediated cell 
adhesion and motility in cancer cells via Fak signaling. J Cell Physiol 2009, 219, 152-61. 
75. Bawn, R. Development of Small-Molecule Inhibitors of ERK5 for the Treatment of 
Cancer. Newcastle University, 2011. 
76. www.moleculardevices.com/pages/reagents/imap_intro.html. (28/08/2012). 
77.. http://info.cancerresearchuk.org/cancerstats/. (02/07/2012). 
78. Consortium, T. B. C. L. Cancer Risks in BRCA2 Mutation Carriers. J. Natl. Cancer Inst. 
1999, 91, 1310-1316. 
79. Stamey, T. A.; McNeal, J. E.; Yemoto, C. M.; Sigal, B. M.; Johnstone, I. M. Biological 
Determinants of Cancer Progression in Men With Prostate Cancer. JAMA. 1999, 281, 
1395-1400. 
80. http://www.stjohnprovidence.org/InnerPage.aspx?PageID=1446. (02/07/2012). 
81. Heidenreich, A.; Aus, G.; Bolla, M.; Joniau, S.; Matveev, V. B.; Schmid, H. P.; Zattoni, 
F. EAU Guidelines on Prostate Cancer. Eur. Urol. 2008, 53, 68-80. 
82. Heinlein, C. A.; Chang, C. Androgen receptor in prostate cancer. Endocr. Rev. 2004, 25, 
276-308. 
83. Sharifi N, G. J. L. D. W. L. ANdrogen deprivation therapy for prostate cancer. JAMA. 
2005, 294, 238-244. 
84. Emami, K. H.; Corey, E. When prostate cancer meets bone: Control by wnts. Cancer 
Lett. 2007, 253, 170-179. 
85. Wirth, M. P.; Hakenberg, O. W.; Froehner, M. Antiandrogens in the Treatment of 
Prostate Cancer. Eur. Urol. 2007, 51, 306-314. 
86. Tannock, I. F.; de Wit, R.; Berry, W. R.; Horti, J.; Pluzanska, A.; Chi, K. N.; Oudard, S.; 
Theodore, C.; James, N. D.; Turesson, I.; Rosenthal, M. A.; Eisenberger, M. A.; the, T. 
A. X. I. Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced 
Prostate Cancer. N. Engl. J. Med. 2004, 351, 1502-1512. 
387 
 
87. O'Donnell, A.; Judson, I.; Dowsett, M.; Raynaud, F.; Dearnaley, D.; Mason, M.; 
Harland, S.; Robbins, A.; Halbert, G.; Nutley, B.; Jarman, M. Hormonal impact of the 
17[alpha]-hydroxylase//C17,20-lyase inhibitor abiraterone acetate (CB7630) in patients 
with prostate cancer. Br. J. Cancer. 2004, 90, 2317-2325. 
88. McPhaul, M. J. Mechanisms of prostate cancer progression to androgen independence. 
Best Pract. Res. Clin. Endocrinol. Metab. 2008, 22, 373-388. 
89. Vasaitis, T. S.; Bruno, R. D.; Njar, V. C. O. CYP17 inhibitors for prostate cancer 
therapy. J. Steroid Biochem. Mol. Biol. 2011, 125, 23-31. 
90. Kaku, T.; Hitaka, T.; Ojida, A.; Matsunaga, N.; Adachi, M.; Tanaka, T.; Hara, T.; 
Yamaoka, M.; Kusaka, M.; Okuda, T.; Asahi, S.; Furuya, S.; Tasaka, A. Discovery of 
orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-
lyase inhibitor with potential utility in the treatment of prostate cancer. Bioorg. Med. 
Chem. 2011, 19, 6383-6399. 
91. Tran, C.; Ouk, S.; Clegg, N. J.; Chen, Y.; Watson, P. A.; Arora, V.; Wongvipat, J.; 
Smith-Jones, P. M.; Yoo, D.; Kwon, A.; Wasielewska, T.; Welsbie, D.; Chen, C. D.; 
Higano, C. S.; Beer, T. M.; Hung, D. T.; Scher, H. I.; Jung, M. E.; Sawyers, C. L. 
Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate 
Cancer. Science. 2009, 324, 787-790. 
92. Scher, H. I.; Beer, T. M.; Higano, C. S.; Anand, A.; Taplin, M.-E.; Efstathiou, E.; 
Rathkopf, D.; Shelkey, J.; Yu, E. Y.; Alumkal, J.; Hung, D.; Hirmand, M.; Seely, L.; 
Morris, M. J.; Danila, D. C.; Humm, J.; Larson, S.; Fleisher, M.; Sawyers, C. L. 
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 
study. The Lancet. 375, 1437-1446. 
93. So, A.; Gleave, M.; Hurtado-Col, A.; Nelson, C. Mechanisms of the development of 
androgen independence in prostate cancer. World J. Urol. 2005, 23, 1-9. 
94. McDonnell, T. J.; Troncoso, P.; Brisbay, S. M.; Logothetis, C.; Chung, L. W. K.; Hsieh, 
J.-T.; Tu, S.-M.; Campbell, M. L. Expression of the Protooncogene bcl-2 in the Prostate 
and Its Association with Emergence of Androgen-independent Prostate Cancer. Cancer 
Res. 1992, 52, 6940-6944. 
95. McCracken, S. R. C.; Ramsay, A.; Heer, R.; Mathers, M. E.; Jenkins, B. L.; Edwards, J.; 
Robson, C. N.; Marquez, R.; Cohen, P.; Leung, H. Y. Aberrant expression of 
extracellular signal-regulated kinase 5 in human prostate cancer. Oncogene. 2007, 27, 
2978-2988. 
388 
 
96. McPherson, K.; Steel, C. M.; Dixon, J. M. Breast cancer—epidemiology, risk factors, 
and genetics. BMJ. 2000, 321, 624-628. 
97. King, M.-C.; Marks, J. H.; Mandell, J. B.; Group, T. N. Y. B. C. S. Breast and Ovarian 
Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2. Science. 2003, 302, 
643-646. 
98. Song, H.; Jin, X.; Lin, J. Stat3 upregulates MEK5 expression in human breast cancer 
cells. Oncogene. 2004, 23, 8301-8309. 
99. Kamath, S.; Buolamwini, J. K. Targeting EGFR and HER-2 receptor tyrosine kinases for 
cancer drug discovery and development. Med. Res. Rev. 2006, 26, 569-594. 
100. Montero, J. C.; Ocaña, A.; Abad, M.; Ortiz-Ruiz, M. J.; Pandiella, A.; Esparís-Ogando, 
A. Expression of Erk5 in Early Stage Breast Cancer and Association with Disease Free 
Survival Identifies this Kinase as a Potential Therapeutic Target. PLoS. ONE. 2009, 4, 
e5565. 
101. Zen, K. Y., K.; Nakajima, T. et al. ERK5 is a target for gene amplification at 17p11 and 
promotes cell growth in hepatocellular carcinoma by regulating mitotic entry. Genes, 
chromosomes. cancer. 2009, 48, 109-120. 
102. Angtuaco, E. J. C.; Fassas, A. B. T.; Walker, R.; Sethi, R.; Barlogie, B. Multiple 
Myeloma: Clinical Review and Diagnostic Imaging. Radiology. 2004, 231, 11-23. 
103. Carvajal-Vergara, X.; Tabera, S.; Montero, J. C.; Esparís-Ogando, A.; López-Pérez, R.; 
Mateo, G.; Gutiérrez, N.; Parmo-Cabañas, M.; Teixidó, J.; San Miguel, J. F.; Pandiella, 
A. Multifunctional role of Erk5 in multiple myeloma. Blood. 2005, 105, 4492-4499. 
104. Tatake, R. J.; O'Neill, M. M.; Kennedy, C. A.; Wayne, A. L.; Jakes, S.; Wu, D.; Kugler 
Jr, S. Z.; Kashem, M. A.; Kaplita, P.; Snow, R. J. Identification of pharmacological 
inhibitors of the MEK5/ERK5 pathway. Biochem. Biophys. Res. Commun. 2008, 377, 
120-125. 
105. Roth, J., G.; Heckel, A.; Walter, R.; Van Meel, J.; Redemann, N.; Tontsch-Grunt, U.; 
Spevak, W.; Hilberg, F.; Substituted indolines which inhibit receptor tyrosine kinases. 
2004. 
106. Lovric, M.; Cepanec, I.; Litvic, M.; Bartolincic, A.; Vinkovic, V. Scope and limitations 
of sodium and potassium trimethylsilanolate as reagents for conversion of esters to 
carboxylic acids. Croat. Chem. Acta. 2007, 80, 109-115. 
107. Shestopalov, A. M.; Nikishin, K. G.; Gromova, A. V.; Rodinovskaya, L. A. One-pot 
synthesis of 4,6-diaryl-3-cyanopyridine-2(1H)-thiones and their transformation to 
389 
 
substituted thieno[2,3-b;4,5-b]dipyridines and pyrido[3",2":4,5]thieno[3,2-d]pyrimidines. 
Russ. Chem. Bull. 2003, 52, 2203-2206. 
108. Krauze, A.; Germane, S.; Eberlins, O.; Sturms, I.; Klusa, V.; Duburs, G. Derivatives of 
3-cyano-6-phenyl-4-(3'-pyridyl)-pyridine-2(1H)-thione and their neurotropic activity. 
Eur. J. Med. Chem. 1999, 34, 301-310. 
109. Fan, H.; Peng, J.; Hamann, M. T.; Hu, J.-F. Lamellarins and Related Pyrrole-Derived 
Alkaloids from Marine Organisms. Chem. Rev. 2007, 108, 264-287. 
110. Ferreira, V. F.; De Souza, M. C. B.; Cunha, A. C.; Pereira, L. O. R.; Ferreira, M. L. G. 
Recent Advances in the Synthesis of Pyrroles. ChemInform. 2001, 32. 
111. Paal, C. Synthese von Thiophen und Pyrrolderivaten. Chem. Ber. 1885, 18, 367. 
112. Amarnath, V.; Anthony, D. C.; Amarnath, K.; Valentine, W. M.; Wetterau, L. A.; 
Graham, D. G. Intermediates in the Paal-Knorr synthesis of pyrroles. J. Org. Chem. 
1991, 56, 6924-6931. 
113. Trautwein, A. W.; Süßmuth, R. D.; Jung, G. Hantzsch pyrrole synthesis on solid support. 
Bioorg. Med. Chem. Lett. 1998, 8, 2381-2384. 
114. Williams, S. P.; Kuyper, L. F.; Pearce, K. H. Recent applications of protein 
crystallography and structure-guided drug design. Curr. Opin. Chem. Biol. 2005, 9, 371-
380. 
115. Fox, T.; Coll, J. T.; Xie, X.; Ford, P. J.; Germann, U. A.; Porter, M. D.; Pazhanisamy, S.; 
Fleming, M. A.; Galullo, V.; Su, M. S.; Wilson, K. P. A single amino acid substitution 
makes ERK2 susceptible to pyridinyl imidazole inhibitors of p38 MAP kinase. Protein 
Sci. 1998, 7, 2249-55. 
116. Gramstad, T. Studies of hydrogen bonding—part VII: Hydrogen-bond association of 
phenol and pentachlorophenol with carbonyl compounds and ethers. Spectrochim. Acta. 
1963, 19, 497-508. 
117. Kakushima, M.; Hamel, P.; Frenette, R.; Rokach, J. Regioselective synthesis of 
acylpyrroles. J. Org. Chem. 1983, 48, 3214-3219. 
118. Karplus, M. Vicinal proton coupling in nuclear magnetic resonance. Am. Chem. Soc. 
1963, 85, 2870-2871. 
119. Mattsson, S.; Dahlström, M.; Karlsson, S. A mild hydrolysis of esters mediated by 
lithium salts. Tet. Lett. 2007, 48, 2497-2499. 
120. Hanessian, S.; Guindon, Y. Cleavage of methyl and benzyl ethers with 
thiotrimethylsilanes. Tet. Lett. 1980, 21, 2305-2308. 
390 
 
121. Rebelo, R. A.; Rezende, M. C.; Nome, F.; Zucco, C. The Use of 2,2,2-Trichloro-1-
Arylethanones as Benzoylating Agents. Synth. Commun. 1987, 17, 1741-1748. 
122. Shadnia, H.; Wright, J. S. Understanding the Toxicity of Phenols: Using Quantitative 
Structure−Activity Relationship and Enthalpy Changes To Discriminate between 
Possible Mechanisms. Chem. Res. Toxicol. 2008, 21, 1197-1204. 
123. Ethell, B. T.; Ekins, S.; Wang, J.; Burchell, B. Quantitative structure activity 
relationships for the glucuronidation of simple phenols by expressed human UGT1A6 
and UGT1A9. Drug Metab. Dispos. 2002, 30, 734-8. 
124. Katritzky, A. R.; Suzuki, K.; Singh, S. K.; He, H.-Y. Regiospecific C-Acylation of 
Pyrroles and Indoles Using N-Acylbenzotriazoles. J. Org. Chem. 2003, 68, 5720-5723. 
125. Colombo, M.; Bossolo, S.; Aramini, A. Phosphorus Trichloride-Mediated and 
Microwave-Assisted Synthesis of a Small Collection of Amides Bearing Strong 
Electron-Withdrawing Group Substituted Anilines. J. Comb. Chem. 2009, 11, 335-337. 
126. Mehta, A.; Jaouhari, R.; Benson, T. J.; Douglas, K. T. Improved efficiency and 
selectivity in peptide synthesis: Use of triethylsilane as a carbocation scavenger in 
deprotection of t-butyl esters and t-butoxycarbonyl-protected sites. Tet. Lett. 1992, 33, 
5441-5444. 
127. Down, K.; Bamborough, P.; Alder, C.; Campbell, A.; Christopher, J. A.; Gerelle, M.; 
Ludbrook, S.; Mallett, D.; Mellor, G.; Miller, D. D.; Pearson, R.; Ray, K.; Solanke, Y.; 
Somers, D. The discovery and initial optimisation of pyrrole-2-carboxamides as 
inhibitors of p38α MAP kinase. Bioorg. Med. Chem. Lett. 2010, 20, 3936-3940. 
128. Herberich, B.; Cao, G.-Q.; Chakrabarti, P. P.; Falsey, J. R.; Pettus, L.; Rzasa, R. M.; 
Reed, A. B.; Reichelt, A.; Sham, K.; Thaman, M.; Wurz, R. P.; Xu, S.; Zhang, D.; Hsieh, 
F.; Lee, M. R.; Syed, R.; Li, V.; Grosfeld, D.; Plant, M. H.; Henkle, B.; Sherman, L.; 
Middleton, S.; Wong, L. M.; Tasker, A. S. Discovery of Highly Selective and Potent p38 
Inhibitors Based on a Phthalazine Scaffold. J. Med.Chem. 2008, 51, 6271-6279. 
129. Adams, J. L.; Boehm, J. C.; Kassis, S.; Gorycki, P. D.; Webb, E. F.; Hall, R.; Sorenson, 
M.; Lee, J. C.; Ayrton, A.; Griswold, D. E.; Gallagher, T. F. Pyrimidinylimidazole 
inhibitors of CSBP/P38 kinase demonstrating decreased inhibition of hepatic cytochrome 
P450 enzymes. Bioorg. Med. Chem. Lett. 1998, 8, 3111-3116. 
130. Leeson, P. Drug discovery: Chemical beauty contest. Nature. 2012, 481, 455-456. 
131. Veber, D. F.; Johnson, S. R.; Cheng, H. Y.; Smith, B. R.; Ward, K. W.; Kopple, K. D. 
Molecular properties that influence the oral bioavailability of drug candidates. J. Med. 
Chem. 2002, 45, 2615-23. 
391 
 
132. Hitchcock, S. A. Structural Modifications that Alter the P-Glycoprotein Efflux Properties 
of Compounds. J. Med. Chem. 2012, 55, 4877-4895. 
133. Auerbach, R.; Lewis, R.; Shinners, B.; Kubai, L.; Akhtar, N. Angiogenesis assays: a 
critical overview. Clin. Chem. 2003, 49, 32-40. 
134. Knapp, D. M.; Gillis, E. P.; Burke, M. D. A General Solution for Unstable Boronic 
Acids: Slow-Release Cross-Coupling from Air-Stable MIDA Boronates. J. Am. Chem. 
Soc. 2009, 131, 6961-6963. 
135. Payne, S. L. Small-molecule inhibitors of mTOR and DNA-PK. Newcastle University, 
2010. 
136. Rose, J. D.; Secrist, J. A.; Montgomery, J. A. Certain 3,9-Dideazapurines as Inhibitors of 
Purine Nucleoside Phosphorylase. Nucleos. Nucleot. 1999, 18, 2443-2461. 
137. Sahoo, S. P. C., M-H; Dykstra, K.D; Koyama, H; Meinke, P.T; O'Keefe, S.J; Yang, G, 
X-Q;. Pyrrolo[2, 3-C]pyridine derivatives as p38 kinase inhibiting agents. 2009. 
138. Wang, P.-S.; Liang, C.-K.; Leung, M.-k. An improved Ullmann–Ukita–Buchwald–Li 
conditions for CuI-catalyzed coupling reaction of 2-pyridones with aryl halides. 
Tetrahedron. 2005, 61, 2931-2939. 
139. Andrews, S. P.; Ladlow, M. Convenient Preparation and Use of a New Analytical 
Construct for the Analysis and Development of Solid-Phase Chemistries. J. Org. Chem. 
2003, 68, 5525-5533. 
140. Stroba, A.; Schaeffer, F.; Hindie, V.; Lopez-Garcia, L.; Adrian, I.; Fr hner, W.; 
Hartmann, R. W.; Biondi, R. M.; Engel, M. 3,5-Diphenylpent-2-enoic Acids as 
Allosteric Activators of the Protein Kinase PDK1: Structure−Activity Relationships and 
Thermodynamic Characterization of Binding as Paradigms for PIF-Binding Pocket-
Targeting Compounds†† PDB code of 2Z with PDK1: 3HRF. J. Med. Chem. 2009, 52, 
4683-4693. 
141. Edwards, M. L.; Stemerick, D. M.; Sabol, J. S.; Diekema, K. A.; Dinerstein, R. J. 
Inhibition of Myeloperoxidase Release from Rat Polymorphonuclear Leukocytes by a 
Series of Azachalcone Derivatives. J. Med. Chem. 1994, 37, 4357-4362. 
142. Mroczkiewicz, M.; Ostaszewski, R. A new and general method for the synthesis of 
tripeptide aldehydes based on the multi-component Ugi reaction. Tetrahedron. 2009, 65, 
4025-4034. 
143. Anderson, H. J.; Riche, C. R.; Costello, T. G.; Loader, C. E.; Barnett, G. H. Pyrrole 
chemistry. XIX. Reactions of 2-pyrrolecarbonitrile and its 4-substituted derivatives. Can. 
J. Chem. 1978, 56, 654-657. 
392 
 
 
 
